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Abstract 
 
Daily oral tenofovir-based pre-exposure prophylaxis (PrEP) has recently been shown 
to be an efficacious HIV prevention strategy for key populations at high risk of acquiring 
HIV-1, including serodiscordant couples. This thesis addresses the following research 
question: what is the projected impact and cost-effectiveness of PrEP for serodiscordant 
couples in sub-Saharan Africa, and would it be a worthwhile intervention? By using 
statistical analysis and mathematical modelling, I answer this question and provide 
recommendations for the optimisation of antiretroviral-based HIV prevention this population. 
In this thesis, I begin by exploring the effect of the reduced risk of herpes simplex 
virus type 2 (HSV-2) acquisition by means of PrEP on the outcomes of an intervention, but 
conclude that the supplementary benefit is unlikely to substantially alter the cost-
effectiveness. I also perform statistical analysis of daily adherence patterns to PrEP, 
according to electronic monitoring, from the Partners PrEP Study and the Partners 
Demonstration Project in Kenya and Uganda and find that adherence was high in both 
settings. Finally, I adapt a microsimulation model of serodiscordant couples in Africa to 
include realistic PrEP adherence patterns, HIV-1 transmission, external partnerships, and 
empirical costs. Using this model, I simulate the likely impact and cost-effectiveness of a 
PrEP intervention according to characteristics and behaviours of couples in the context of a 
clinical trial and a demonstration project. Overall, I conclude that a PrEP intervention could 
be cost-effective or cost-saving when targeted to high-risk couples, but is unlikely to be cost-
effective if expected incidence is low. In addition, the utility of PrEP for serodiscordant 
couples could be compromised if the resources needed to find high-risk couples are 
expensive or if couples are not found easily. 
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1      Introduction 
1.1  Background 
 
In 1981, the first cases of Acquired Immunodeficiency Syndrome (AIDS) were 
diagnosed among five young gay men with pneumocystis pneumonia in Los Angeles [1]. 
Two years later, scientists discovered that the condition was caused by a virus now known as 
Human Immunodeficiency Virus Type 1 (HIV-1) [2,3]. Though the disease was originally 
associated with homosexual men, it soon became apparent that the virus did not discriminate 
when it came to those it infected, and that heterosexual populations were also at risk [4]. In 
the early years of the epidemic, pervasive stigma and a lack of knowledge about transmission 
impeded prevention efforts, and the disease was allowed to spread rapidly amongst key 
populations in the West and, most importantly, morph into a full-blown generalized epidemic 
in sub-Saharan Africa. 
In 1987, a randomized controlled trial of an antiretroviral drug, zidovudine (AZT), 
demonstrated safety and efficacy of the drug for decreasing AIDS mortality and opportunistic 
infections [5]. Soon afterwards, the United States Food and Drug Administration (FDA) 
approved AZT as the first antiretroviral therapy (ART) for the treatment of HIV/AIDS [6], a 
major breakthrough in the fight against the virus. However, drug-resistant mutations arose 
quickly in response to monotherapy and AZT failed to slow progression to AIDS beyond the 
short-term [7]. In 1996, the concept of highly active antiretroviral therapy (HAART) was 
introduced, comprising a combination 3-drug regimen of two non-nucleoside reverse 
transciptase inhibitors (NNRTIs) and a protease inhibitor (PI). In contrast to the slow gains of 
the previous decade, the introduction of HAART changed the meaning of a positive HIV 
diagnosis: it was no longer considered a death sentence, but a manageable chronic condition.  
In spite of monumental advances in antiretroviral treatment, broad-scale public 
awareness campaigns, and intensive efforts to promote HIV prevention, new infections 
continue to occur. After over 30 years of the epidemic, more than 35 million people are living 
with HIV-1 globally. The majority of HIV-infected individuals are concentrated in Africa [8], 
where heterosexual transmission makes up the greatest proportion of incidence [9]. In 2012 
alone, an estimated 1.6 million new infections occurred in sub-Saharan Africa, accounting for 
70% of global incidence. Although overall incidence rates have declined in a number of 
countries over the past decade, the epidemic is not yet under control. In hyper-endemic 
	  
	  
21 
southern Africa, young women face a disproportionate proportion of HIV incidence [10], and 
globally, men who have sex with men (MSM), female sex workers (FSW), and injecting drug 
users (IDU) bear the burden of new infections [11-13]. Serodiscordant couples, in which one 
partner is HIV-infected and the other HIV-uninfected, are also an important contributor to 
incidence [14], and will be discussed in detail throughout this thesis. 
There is currently no vaccine to prevent infection – though advances are being made 
[15] – and averting new infections remains the greatest challenge to controlling the epidemic. 
Both treatment and prevention programs are in need of economic resources in low- and 
middle-income countries (LMIC), with the vast majority of spending directed towards 
treatment and care [8]. In the context of decreasing international funding and rising country 
ownership of HIV budgets, maximizing restricted resources and prioritizing efficient 
distribution of treatment and effective prevention interventions to high-risk populations are 
increasingly imperative goals [16]. 
In this chapter, I cover background information relevant to the research described in 
Chapters 2-6. I will discuss HIV epidemiology and development of behavioural, biomedical, 
and structural HIV prevention methods, including trials of treatment as prevention (TasP) and 
pre-exposure prophylaxis (PrEP). I also cover the importance of a key population for HIV 
prevention – heterosexual HIV-serodiscordant couples – and provide a detailed account of the 
contribution of adherence to the effectiveness of PrEP. Finally, I conclude with guideline and 
policy implications of antiretroviral-based prevention interventions and the utility of 
mathematical modelling for decision-making in this respect. 
 
1.1.1   Antiretroviral Therapy 
 
Antiretroviral therapy is highly effective at preventing HIV replication, thereby 
lowering the viral load of HIV-1 in infected persons and prolonging survival. Six groups of 
antiretrovirals (ARVs) are currently used as treatment – nucleoside reverse-transcriptase 
inhibitors (NRTIs), non-nucleoside reverse-transcriptase inhibitors, protease inhibitors, fusion 
inhibitors, entry inhibitors, and integrase inhibitors [17]. As a first-line treatment regimen, a 
combination of three drugs from at least two classes is normally used, usually composed of 
two NRTIs and one NNRTI and often including the drugs tenofovir disoproxil fumarate 
	  
	  
22 
(TDF) and emtricitabine (FTC). Second-line therapy is recommended to be composed of two 
NRTIs (at least one of which must be new to the patient) and a PI including ritonavir. 
HIV-infected individuals are started on treatment based on the number of cluster of 
differentiation 4 (CD4) cells – a type of lymphocyte that supports the immune system – in the 
blood. Normal CD4 counts in healthy individuals vary from 500 to 1,500 cells per cubic 
millimetre of blood (µl) [18]. HIV attacks and destroys CD4 cells, leading to depletion over 
time; infected individuals become immunocompromised and susceptible to opportunistic 
infections, including tuberculosis, candidiasis, herpes simplex viruses, and cancers, among 
others [19]. A CD4 count <200 cells/µl is one of the criteria for an AIDS diagnosis. When 
ART is initiated, HIV is prevented from replicating within cells, and patients experience viral 
suppression and a CD4 cell count rebound [20]. Prior to 2010, the World Health Organization 
(WHO) recommended that only people with a CD4 count of less than 200 cells/µl initiate 
treatment [21], a threshold that was then lifted to less than 350 cells/µl [22]. In 2013, the 
WHO advocated treatment for those with a CD4 count of less than 500 cells/µl, increasing 
the number of people eligible for treatment in LMIC to a total of 25.9 million [23], and in 
September 2015 issued updated treatment guidelines to recommend ART for all HIV-infected 
individuals [24]. 
Scale-up of ART has accelerated dramatically over the past five years. In 2010, the 
WHO announced the “Treatment 2.0” strategy to optimize ART regimens, scale-up treatment 
programs, and capitalize on prevention benefits [25], and in 2011, the United Nations (UN) 
announced a target of delivering ART to 15 million people in need by the end of 2015 [26]. 
At the turn of the millennium, fewer than 1 million people were being treated; by 2013, 12.9 
million people were taking ART, with 90% of individuals on treatment located in low- and 
middle-income countries [27], and in July 2015, the UN goal was achieved ahead of schedule 
[28]. This impressive accomplishment showed that a combination of political will, funding, 
advocacy, and local response could and did change access to life-saving drugs, and that 
delivery of programs was possible even in resource-poor settings. In light of recent successes, 
the Joint United Nations Programme on HIV/AIDS (UNAIDS) has declared an ambitious 
three-pronged target of getting 90% of HIV-infected individuals diagnosed, 90% of those 
diagnosed on ART, and 90% of those treated also virally suppressed [29]. Expanding 
resources for treatment will be a critical step towards ending the epidemic, but immediate 
efforts are also needed to stem the tide of new infections and prevent the burden of 
maintaining individuals on lifelong treatment from growing too large. 
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1.1.2 Combination Prevention: Biomedical, Behavioural, and     
Structural Approaches 
 
In order to tackle different HIV epidemics effectively, a strategy of location-specific 
combination prevention is essential [30]. Combination prevention programs incorporate 
evidence-based behavioural, biomedical, and structural approaches to address those most 
susceptible to acquiring HIV while also working to change cultural or institutional factors 
that contribute to risk (Figure 1.1) [31,32]. The optimal portfolio of combination prevention 
interventions differs greatly depending on the context of the epidemic and the budget 
available for HIV prevention. For example, a strategy pioneered by UNAIDS called “know 
your epidemic, know your response” promotes individual country ownership of epidemics to 
tailor programs for treatment and prevention effectively and efficiently [33]. 
 
	  
Figure 1.1: Components of combination prevention. Text and layout from [32]. 
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Behavioural strategies seek to minimize risk behaviour, primarily through education 
and promotion of testing, counselling, and safe sex. The earliest prevention successes centred 
on behaviour change; in the 1980s and 1990s, Uganda’s National AIDS Control Program 
(NACP) actively promoted community mobilisation to reduce new infections [34]. The 
central pillar of the policy was the ABC strategy – abstinence, be faithful, and use condoms – 
and the NACP and local non-governmental organizations (NGOs) vigorously encouraged 
“zero grazing,” or partner reduction. Though this program succeeded in curbing incidence in 
Uganda [35], behaviour change interventions have had mixed results [36,37]. Nevertheless, 
provision of counselling, testing, and promotion of condoms remain essential components of 
any HIV prevention intervention. 
Biomedical approaches offer biologically efficacious ways to impede HIV infection 
or decrease infectiousness [38]. Condoms, voluntary medical male circumcision (VMMC), 
and provision of clean needles for injection drug users have all been demonstrated to lower 
the rate of HIV transmission [39-43]. Antiretroviral drugs can decrease the risk of vertical 
transmission from mother to child [44,45], reduce the risk of horizontal transmission through 
treatment of infected persons [46,47], and serve as prophylaxis for high-risk individuals [48-
54]. 
Structural interventions are some of the broadest and most difficult to target 
accurately, as they attempt to address a range of political, legal, economic, social, cultural, 
and contextual issues that contribute to underlying vulnerability to HIV [55]. These issues 
can include gender inequality, distribution of wealth and political power, stigma against HIV-
infected individuals, and human rights. Structural approaches are by nature long-term 
investments, but can suffer from lack of clarity and operational direction. In order to address 
drivers of HIV risk fully, however, structural approaches must be incorporated into 
prevention packages. 
Successful policies to suppress HIV incidence will also rely upon a maximally 
efficient allocation of resources. In 2011, Schwartlander et al. proposed a new Investment 
Framework for HIV/AIDS funding that aims to develop more strategic and targeted programs 
to reduce risk of transmission and decrease morbidity and mortality [16]. In the framework, 
behavioural and biomedical interventions are supported by social enablers (e.g. political 
advocacy, laws, and mass media) and program enablers (e.g. community-based delivery and 
distribution of interventions, research, and innovation), and integrating structural 
interventions across all activities provides a foundation for the approach. Determining the 
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most efficient, effective, and cost-effective strategies for country-specific program will rely 
on understanding the complexities of contributing factors to HIV incidence, modelling their 
effect on epidemics, and implementing these optimal combination prevention interventions, 
prioritized for high-risk populations using a country-specialized version of the Investment 
Framework. 
 
1.1.2.1 Prevention Successes 
 
One of the most successful HIV prevention strategies to date has been the prevention 
of mother-to-child transmission (PMTCT). In the 1990s, several studies demonstrated that 
providing antiretroviral drugs, such as zidovudine or nevirapine, to expectant mothers during 
gestation, labour and delivery, and to the infant for six weeks after birth greatly reduced the 
risk of transmitting HIV-1 to the child [44,45]. Since 2001, PMTCT programs have been 
initiated in countries globally and have severely curtailed the transmission of HIV from 
mother to infant. The 2013 WHO guidelines recommend the Option B+ strategy through 
which pregnant women are offered ART for life, regardless of CD4 cell count, or Option B – 
in which pregnant women take antiretrovirals while pregnant and breastfeeding only – if 
implementation of Option B+ is not feasible [23]. This strategy simplifies distribution of 
ARVs, can prevent transmission of HIV to an uninfected partner, and is increasingly possible 
due to the decreasing cost of antiretroviral drugs. The UN target of reducing 90% of mother-
to-child transmission globally by the end of 2015 is fast approaching [56], with the ultimate 
goal of creating an “AIDS-free Generation” [57]. Between 2000-2009, a 24% reduction was 
observed in mother-to-child transmission, and a projected 1 million new infections in 
children would have been averted through scaling up PMTCT [58]. In addition, in June 2015, 
Cuba became the first country to eliminate mother-to-child transmission of HIV completely 
[59]. However, challenges are still present, as coverage remains low in countries like Nigeria, 
where the burden of paediatric HIV is high [60]. In addition, studies have shown that ART 
initiation may be lower for individuals with CD4 counts >350 cells/µl, and that lack of 
education, stigma, and discrimination are barriers to starting treatment [61]. 
A number of population-level HIV prevention interventions have also achieved 
success in controlling new infections. In Thailand during the 1990s, the 100% Condom 
Program, which required condoms to be used in commercial sex and featured an extensive 
advertisement campaign promoting and enforcing condom use, helped to curb transmission 
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nationally [62]. A second example is Avahan, a program launched by the Bill & Melinda 
Gates Foundation in 2003 as a combination prevention initiative to decrease HIV incidence 
within six high-prevalence states in India [63]. The intervention provides prevention services 
for FSW, MSM, IDU, and truck drivers by offering condoms, clean needles, risk-reduction 
counselling, treatment for sexually transmitted infections (STIs), and access to HIV testing 
and care. Avahan collaborates with the Indian government and local NGOs, and has worked 
extensively to identify key populations and implement structural interventions. After the first 
five years of the intervention, an analysis determined that areas with greater Avahan funding 
were significantly associated with lower HIV prevalence in three of the states, and an 
estimated 100,178 HIV infections in men and women were averted [64]. A further modelling 
study found that 57% of potential HIV infections were averted during the first ten years of the 
program [65]. The program has now been handed over to the Indian government [66]. The 
Thai 100% Condom Program and Avahan were two very different types of prevention 
interventions – one highly specific in scope and the other ambitious designed to investigate 
HIV prevention at scale. Avahan is, to date, the largest combination prevention program 
globally, and early results have validated the benefits of a directed, country-specific epidemic 
response, while the 100% Condom Program demonstrated the importance of targeting key 
populations. 
Male circumcision has also been shown to reduce the risk of acquiring HIV-1 through 
sexual intercourse. After a wealth of observational studies suggesting that male circumcision 
could reduce acquisition of HIV-1, several clinical trials confirmed the observations. The 
first, in South Africa, found that circumcision reduced HIV-1 incidence by 60% [40], a 
second in Rakai, Uganda reported a 51% risk reduction [41], and a third in Kenya estimated 
53% protection [42]. In 2007, the WHO recommended VMMC as a new HIV prevention 
strategy in the epidemics of East and South Africa [67]. A 2011 modelling study predicted 
that scaling up coverage of VMMC to 80% in 13 sub-Saharan African countries would avert 
3.36 million new infections by 2025 and save $16.5 billion [68]. By 2013, national programs 
had been implemented and VMCC had increased substantially in the prioritized countries 
[27]. Despite this, a much more accelerated pace of scale-up is necessary to achieve the 
targeted coverage of 80% of adult males by 2016, and countries will need to prioritize 
funding for VMMC, increase efficiency, and explore new circumcision technologies [69]. 
Behavioural interventions have had mixed results in randomized controlled trials 
(RCTs), though several notable successes have been achieved. Sexual health education 
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interventions for adolescents [70,71] and integrated peer education, condom distribution, and 
management of STIs did not reduce HIV incidence in African settings. Nevertheless, large-
scale declines in HIV prevalence in Uganda, Kenya, Zimbabwe, and Haiti have been 
associated with decreased sexual risk behaviour [35,72]. In addition, cash transfer programs, 
which have long been used to motivate health outcomes, have shown new promise for HIV 
prevention. One important illustration of effectiveness was seen in a cluster randomised trial 
of young women in Malawi, in which cash incentives were successfully used to encourage 
girls to remain in school and thereby to prevent HIV and other STIs [73]. 
Lastly, antiretrovirals used for treatment also have the potential to be utilized as tools 
for prevention. Since 1998, post-exposure prophylaxis (PEP) has been a standard ARV 
intervention in the United States to prevent infection after exposure to the virus from 
occupational exposures, such as health care workers who have experienced accidental needle-
stick injuries. PEP is commonly used among those accidentally exposed to infection, in the 
health care profession and among female sex workers after unprotected sex [74]. The United 
States Centers for Disease Control and Prevention (CDC) also approved PEP in 2005 for non-
occupational exposures including injecting drug use and sexual contact with a known HIV-
infected individual [75]. Finally, in 2010 the first RCTs testing antiretroviral efficacy for 
prevention in HIV-uninfected individuals released results and ultimately transformed the 
landscape of HIV prevention. 
 
1.2 A New Era of Biomedical Prevention 
 
1.2.1 Treatment as Prevention 
 
Treatment as prevention (TasP) involves treating HIV-infected individuals, regardless 
of CD4 cell count, with the aim of decreasing the risk of transmission [76]. Long before a 
clinical trial investigated the potential of dual treatment and prevention, scientists had 
theorized that treating infected individuals could also reduce HIV transmission [77]. In 2006, 
Montaner et al. argued that expanding ART access globally could slow the spread of the 
epidemic and warranted further investigation [78]. Systematic reviews have found 
transmission reductions of 54-92% [46,79-81] and an observational cohort study in Rakai, 
Uganda saw no HIV transmission among serodiscordant couples in which the HIV-positive 
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partner had initiated ART [82]. In 2011, the many studies of observational data were 
confirmed through the HPTN 052 clinical trial [47], and galvanized the HIV prevention field 
about the potential of ARV-based prevention [83]. 
The HPTN 052 Study compared rates of HIV-1 transmission in 1,763 serodiscordant 
couples in Botswana, Kenya, Malawi, South Africa, Zimbabwe, Brazil, India, Thailand, and 
the United States [47]. At enrolment, the HIV-infected partners were not yet eligible for 
treatment, and all had CD4 counts of 350-500 cells/µl. The HIV-positive partner in each 
couple was randomized to receive either early antiretroviral therapy or delayed treatment at 
CD4 counts <250 cells/µl according to WHO clinical guidelines at the time [21].  For those in 
the early treatment group, ART began at enrolment. At the time of an interim review in 2011, 
39 transmission events had occurred, only 4 of which were in the early treatment group – an 
incidence rate of 0.3 per 100 person-years (PY), as compared to 2.2 per 100 PY in the 
delayed treatment group. Of those 4 infections, only 1 could be virologically linked to the 
study partner, resulting in an estimated 96% relative reduction of risk of HIV-1 transmission 
in the early therapy group [47]. Subsequent analysis also determined that the single linked 
infection in the early ART arm occurred either immediately prior to ART initiation or before 
viral suppression had been achieved [84]. This monumental finding has generated an 
immense amount of optimism about curbing transmission and turning the tide of the epidemic 
[85,86], and in 2011, Science designated treatment as prevention as the scientific 
breakthrough of the year for its “profound implications for the future response to the AIDS 
epidemic” [87]. The decade-long study reported its final results in July 2015; over the full 
course of investigation, ART provided a 93% reduction in transmission within couples [88]. 
This final analysis confirmed that TasP can be a sustainable, highly effective HIV prevention 
strategy for serodiscordant couples and that HIV-1 transmission is unlikely to occur when 
replication of the virus is suppressed.  
Clinical trial results cannot easily be extrapolated to “real-world” settings, however. 
In KwaZulu-Natal in South Africa, areas with 30-40% ART coverage were associated with a 
34% lower individual risk of HIV acquisition compared to a person living in an area with 
<10% ART coverage, demonstrating a strong link between treatment and prevention [89]. 
Conversely, an observational cohort study of ART use in discordant couples in China found a 
26% reduction in transmission in the treatment cohort and protection that was only significant 
for the first year of ART use [90]. This may have been due to a combination of challenges to 
TasP: non-adherence to ART, drug resistance, or new HIV infections from outside 
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partnerships. In addition, a review of preventive benefits of ART in four Western settings 
found little population-level change in transmission, suggesting that effectiveness outside of 
clinical trials will be much lower and face substantial barriers to success [91]. 
A logical extension of the potential of treatment to reduce incidence is to pursue a 
policy of immediate treatment for all HIV-positive people. In 2009, a mathematical model by 
Granich et al. proposed using a universal “test-and-treat” methodology to identify HIV-
infected individuals in generalized epidemics and put them on treatment immediately [92]. 
This test-and-treat strategy would entail universal voluntary testing once a year and 
subsequent initiation of treatment for every HIV-infected individual. The model projections 
indicate that implementation of this strategy would push a generalized epidemic, analogous to 
South Africa, into an “elimination” phase (annual incidence of 0.1% or below) almost 
immediately, assuming that ART coverage would reach 90% within 7 years. While this 
model suggests that test-and-treat could ultimately reduce the epidemic to extremely low 
levels within 10 years of implementation, the reality of access in low- and middle-income 
countries paints a much more daunting picture of success. Given that not all those eligible for 
ART are being treated, it would require a colossal effort to scale up treatment to such an 
extent in the near future and increased financial commitment globally. 
 
1.2.2  Pre-Exposure Prophylaxis 
 
A number of trials have tested the use of antiretrovirals as pre-exposure prophylaxis 
(PrEP) for HIV-uninfected individuals. Similarly to PEP, ARVs in PrEP can prevent the virus 
from replicating, and therefore from establishing an enduring infection. Prior to 2010, a 
number of microbicide trials attempted to find an effective HIV prevention solution for 
women, and none were able to demonstrate a protective effect [93]. The early microbicide 
trials did not include ARVs in their formulation, however, and it has only been since the 
inclusion of antiretroviral drugs that PrEP trials have shown some encouraging results. Since 
2010, there have been seven landmark trials that investigated antiretroviral microbicides and 
oral pills, five of which showed some level of efficacy and two that demonstrated no effect. 
The resulting estimates of efficacy therefore range widely, from 0% [94,95] to 75% [50], 
with even greater estimates for participants with high levels of adherence in some of the trials 
(Table 1.1). These contradictory results require careful analysis to understand the lack of 
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The first positive result came from the CAPRISA 004 Study, a double-blind, 
randomized controlled trial among high risk, sexually active women in Kwazulu-Natal, South 
Africa [48]. The trial compared use of a 1% tenofovir (TFV) gel to placebo, and requested 
participants to use of the gel 12 hours or less prior to sex and 12 hours or less after sex, with 
no more than two doses per 24 hours (dubbed the “BAT24” dosing strategy). Overall, use of 
the tenofovir gel reduced acquisition of HIV-1 by 39% (95% confidence interval [CI] 6-60%, 
p=0.017), rising to 54% amongst those who had over 80% gel adherence. However, the 
FACTS 001 Study, which was intended to confirm the results of CAPRISA 004 for high-risk 
women in South Africa, reported no difference between the TFV gel and placebo arms in 
early 2015 [97]. The study enrolled 2,059 women at nine sites and prescribed the same 
“BAT24” dosing strategy. 61 infections occurred in the PrEP arm, while 62 occurred in the 
placebo arm, yielding 0% efficacy (95% CI -60-30%) overall. 
Shortly after the results of CAPRISA 004, the iPrEx trial established the efficacy of 
daily oral PrEP in populations of MSM and transgender women [49]. Conducted in Peru, 
Ecuador, South Africa, Brazil, Thailand and the United States, the iPrEx Study compared oral 
emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) to placebo. The trial found a 44% 
overall reduction (95% CI 15-63%, p=0.005) in HIV incidence amongst users of FTC/TDF. 
While this reduction was not as high as originally anticipated, measured drug levels indicated 
that a lack of adherence could potentially explain this discrepancy. The iPrEx trial also 
conducted in-depth studies on patient experiences [98], risk compensation [99], and 
adherence [100,101]. 
The Partners PrEP Study examined the efficacy of two formulations of oral 
antiretroviral drugs to reduce HIV-1 acquisition amongst heterosexual serodiscordant couples 
in Kenya and Uganda [50]. The HIV-negative partner in each couple was randomized to one 
of three regimens: daily oral TDF, once-daily co-formulated oral FTC/TDF, or placebo. In 
order for couples to be eligible for enrolment, the HIV-positive partner could not be receiving 
ART for the duration of the study. Out of 82 total HIV infections during the trial, 17 occurred 
in the TDF group, 13 in the FTC/TDF group, and 52 in the placebo group, representing a 
67% reduction in incidence for TDF alone (95% CI 44-81%, p<0.0001) and a 75% reduction 
for combination FTC/TDF (95% CI 55-87%, p<0.0001). In addition to the quantitative 
results, the Partners PrEP Study yielded qualitative data about the acceptability of PrEP [102] 
and behavioural factors that can affect adherence to an oral PrEP regimen among couples 
[103]. 
	  
	  
32 
At the same time as Partners PrEP, the TDF2 trial in Botswana reported the efficacy 
of daily oral PrEP in heterosexual adults [51]. The study recruited 1,219 heterosexual men 
and women aged 18 to 39, who were randomized to receive once-daily oral FTC/TDF or 
placebo. Throughout the study, 33 participants became infected, 9 of whom were in the active 
arm and 24 in the placebo group. Overall efficacy of oral FTC/TDF was 62% (95% CI 22-
83%, p=0.01). 
Concurrent with both the Partners PrEP and TDF2 trials, the FEM-PrEP Study 
reported unexpected null results about the efficacy of daily oral PrEP amongst high-risk 
African women [94]. The FEM-PrEP trial enrolled 2,120 HIV-negative women aged 18 to 35 
at sites in Kenya, South Africa, and Tanzania. The women were randomized to receive either 
once-daily oral FTC/TDF or placebo. In April 2011, the independent Data Safety Monitoring 
Board (DSMB) for the trial reviewed the existing results and determined that the trial would 
not be able to demonstrate efficacy of oral FTC/TDF, and therefore halted the study [104]. In 
the time before the study concluded, 33 infections occurred in the FTC/TDF group and 35 in 
the placebo group. The study estimated a 6% reduction in HIV acquisition for those in the 
FTC/TDF group, but this finding was not significant (95% CI -52-40%, p=0.8). The study 
authors hypothesized several reasons for the contradiction between the FEM-PrEP results and 
those of iPrEx, Partners PrEP, and TDF2: first, adherence to the study drug was low, as less 
than 40% of women who seroconverted had any evidence of recent pill use based on blood 
tests. This behaviour could potentially be explained by inaccurate risk perception: most 
participants believed they had little to no risk of contracting HIV. Secondly, there could be 
biological factors affecting the performance of oral FTC/TDF in the genital tract, though both 
the Partners PrEP and TDF2 Studies showed no significant difference in efficacy between 
men and women. 
In addition to the disappointing findings from FEM-PrEP, the VOICE trial (MTN-
003) also reported no effect of three antiretroviral-based prevention methods to reduce risk of 
HIV-1 acquisition [95]. VOICE recruited 5,029 high risk women at three African sites in 
Uganda, South Africa, and Zimbabwe, and tested the efficacy of daily oral TDF, once-daily 
oral co-formulated FTC/TDF, and a 1% tenofovir gel against placebo, with an additional goal 
of testing preference for oral or gel delivery of PrEP. In September 2011, the trial’s DSMB 
recommended discontinuing the oral TDF arm, and in November 2011, they also stopped the 
tenofovir gel arm, as neither showed any evidence of reducing HIV acquisition. The 
FTC/TDF arm continued actively until the conclusion of the study in April 2012, but also did 
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not find any significant results. In the FTC/TDF arm, 61 women acquired HIV, as compared 
to 60 infections in the placebo group. 52 infections occurred in the oral TDF arm, with 35 
infections among those receiving placebo, and 61 infections occurred with 1% tenofovir gel 
as compared to 70 in the placebo group. As more infections took place in both the oral 
FTC/TDF and TDF groups than in their placebo counterparts, the estimates of effectiveness 
for both drug arms were below zero. For the tenofovir gel, the efficacy estimate was 15% 
(95% CI -20-40%), but this could have been due to chance alone. As with the FEM-PrEP 
trial, adherence was problematic in the study, especially among younger women. Qualitative 
behavioural studies from the VOICE Study found several themes explaining why women had 
not adhered to PrEP: ambivalence and uncertainty about the research, a view of taking ARVs 
as contradictory to being healthy, and the difficulty of managing relationships with partners, 
friends, and family [105]. 
Finally, in 2013, the Bangkok Tenofovir Study found that daily oral tenofovir-based 
PrEP reduced HIV incidence by 48.9% among injecting drug users in Thailand [52]. The 
study recruited 2,413 HIV-uninfected individuals from 17 drug clinics in Bangkok, and 
measured adherence using either daily directly observed therapy or self-reported diaries at 
monthly clinic visits. This finding confirmed that oral PrEP was efficacious across multiple 
key populations. 
In addition, two important pilot studies of oral PrEP for MSM reported results in 
2015. The PROUD Study enrolled 545 MSM in the United Kingdom and individuals were 
randomized to one of two arms: either to receive daily oral FTC/TDF PrEP immediately, or 
after 12 months [54]. The study reported incidence of 1.3/100 PY in the immediate PrEP arm 
and 8.9/100 PY in the delayed PrEP arm, yielding an 86% (95% CI 62-96%, p=0.0002) 
reduction in new infections. In addition, the IPERGAY Study tested coitally-associated 
intermittent oral FTC/TDF PrEP among 400 MSM and transgender women in France and 
Canada [53]. HIV-1 incidence was 6.75/100 PY in the placebo arm and 0.94/100 PY in the 
PrEP arm, also estimating an 86% (95% CI 39-99%, p=0.002) protective effect. 
The findings from these studies solidified the efficacy of oral PrEP across many 
populations at risk of HIV infection, and re-emphasized the importance of adherence for 
achieving effectiveness. They also revealed that acceptability of PrEP gel may be too low to 
demonstrate impact for young women, and that other HIV prevention options for this 
population are urgently needed. 
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1.2.2.1 An Unanticipated Benefit of PrEP 
 
In two of the trials, PrEP also offered an unexpected benefit in addition to preventing 
HIV infection. In CAPRISA 004, 1% TFV gel reduced herpes simplex virus-2 (HSV-2) 
incidence by an estimated 51% (95% CI 23-70%, p=0.003) [106]. In addition, daily oral 
FTC/TDF significantly reduced HSV-2 acquisition by 33% (95% CI 2-54%, p=0.038) in the 
Partners PrEP trial [107]. Genital herpes and HIV-1 are synergistic infections; each infection 
increases both the risk of acquisition and onward transmission of the other [108,109].  Due to 
the lack of effective primary prevention interventions for HSV-2, as well as the role of HSV-
2 in propagating the HIV epidemic [110], there was much enthusiasm about this 
unanticipated result. Previously, a trial of HSV-2 suppressive therapy among serodiscordant 
couples – in which one partner was co-infected with HIV-1 and HSV-2 and the other HIV-
uninfected – hypothesized that reducing the recurrence of herpes outbreaks would 
consequently decrease HIV transmission to a seronegative partner [111]. Though this trial did 
not find any significant decrease in HIV acquisition, findings from the PrEP trials revealed an 
opportunity to reduce incidence of a highly pervasive STI and additionally improve outcomes 
for HIV- and HSV-uninfected individuals. Furthermore, the cost-effectiveness of PrEP may 
be improved by this dual benefit, at no further cost to the health system. 
 Topical PrEP has been shown to exhibit antiviral activity against HSV-2 by actively 
preventing DNA replication, but requires a high drug concentration at the site of exposure in 
order to do so [112]. Given the wide confidence intervals around the efficacy of oral PrEP 
against HSV-2 for discordant couples, and a lack of reduced HSV-2 incidence among MSM 
[113], the degree of the benefit for daily oral PrEP may be smaller than estimated in the 
Partners PrEP Study. Nevertheless, there are few primary prevention options for HSV-2, and 
even a slight additional benefit of PrEP use may be useful. 
 
1.2.2.2 Reconciling the Contradictory Results of the PrEP Trials 
 
PrEP offers an effective means of prevention that can be controlled by HIV-
susceptible individuals themselves, an option that has long been advocated for and is 
necessary for reductions in heterosexual transmission of the virus in Africa [114]. In July 
2012, the United States (U.S.) FDA approved Truvada (co-formulated oral FTC/TDF) for use 
as PrEP within the U.S., the first pill to ever be approved for HIV prevention worldwide 
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[115]. However, the sobering findings from the FEM-PrEP, VOICE, and FACTS 001 trials 
are cautionary tales about the applicability of PrEP to all populations and the critical 
importance of adherence. The lack of efficacy from these trials may suggest a threshold tissue 
concentration for prevention, especially in women, or that adherence is higher within a 
discordant partnership than for individuals [116]. Ultimately, the central conclusion that can 
be deduced from all of the clinical trials thus far is that PrEP is efficacious, but only if it is 
used properly, particularly surrounding times of risk exposure. 
Important considerations for the implementation of PrEP are adherence, biologic 
factors of drug concentration at the site of exposure, and acute infection in the HIV-positive 
partner (during which increased viral load may prevent PrEP from being effective) [96]. In 
order for PrEP to be a viable prevention intervention, several criteria should also be met: 
 
1. The population should be at high risk of acquiring HIV-1. 
2. The population should have high acceptability of and adherence to the product. 
3. The population should be easily identifiable for an intervention. 
 
Now that PrEP efficacy has been established conclusively, attention has turned towards 
understanding how PrEP might be implemented in real-world settings, supporting adherence 
with open-label use, and investigating the potential cost-effectiveness of an intervention for 
key populations. 
 
1.2.2.3 On-going PrEP Trials & Demonstration Projects 
 
Currently, there are several on-going PrEP trials investigating different patterns of 
PrEP dosing, alternative forms of antiretroviral delivery, and testing the efficacy of different 
ARVs for PrEP. The ADAPT Study is examining three dosing regimens – daily, twice per 
week, and before and after sex – among MSM, transgender women, and women who have 
sex with men in the U.S., South Africa, and Thailand [117]. Preliminary results have 
indicated greater adherence among those in the daily dosing arm, but completed results are 
yet to be reported. There are also several Phase I-III trials considering different methods of 
delivery for PrEP, such as vaginal rings and injectables, as well as testing the efficacy of 
alternative ARVs like maraviroc, rilpivirine, and dapivirine [118]. 
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In addition, there are several on-going demonstration projects testing PrEP regimens 
in settings with less clinical oversight than in trials, in order to investigate the potential 
success of real-world implementation. A number of open label extensions and demonstration 
projects are continuing to seek out detailed information about how PrEP operates in key 
populations [119]. The iPrEx, TDF2, and Partners PrEP extensions are investigating post-trial 
access to PrEP, while several demonstration projects in the United States and Africa are 
examining important factors to PrEP success. In September 2014, the iPrEx demonstration 
project reported high uptake and effectiveness of oral PrEP among MSM and transgender 
women in the United States, Brazil, Peru, Ecuador, South Africa and Thailand [120]. There 
was a strong association between drug concentration from dried blood spots (DBS) and risk 
of infection; for participants with drug concentrations consistent with taking four or more 
pills per week, there were 0.0 infections per 100 PY, as compared to 4.7 infections per 100 
PY with no detectable tenofovir. For serodiscordant couples, the Partners Demonstration 
Project in Kenya and Uganda is investigating approximately 1,000 couples over two years, 
and will report finalized results in 2016. The study is examining targeted enrolment of 
couples, preference for early ART or PrEP, adherence to both PrEP and ART, and outcomes 
related to PrEP use during pregnancy. An interim analysis reported that PrEP had averted 
96% of expected HIV-1 infections in the population as of January 2015; only one new 
infection occurred over 440 PY of follow-up, yielding incidence of 0.2/100 PY as compared 
to predicted incidence of 5.3/100 PY in the absence of PrEP and early ART [121]. Other 
demonstration projects and open label studies are being planned and conducted among FSW 
in Zimbabwe, Benin, Senegal, Kenya, South Africa, India, among MSM and transgender 
women in Belgium, Australia, South Africa, and the U.S., among serodiscordant couples in 
Nigeria and the U.S., among high risk men and women in Australia, Kenya, South Africa, 
and the U.S., and among IDU in Thailand [119]. The full results of the demonstration 
projects will provide essential information about feasibility, scalability, and potential barriers 
to PrEP programs for implementation outside of rigorous clinical trial settings. 
 
1.2.2.4 Challenges Facing PrEP Implementation 
 
A central complexity of developing prevention programs is an existing tension 
between traditional prevention methods, like condom use and behaviour change, and recent 
biomedical developments. Because some biomedical prevention methods now overlap with 
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drugs available for treatment, the ethical quandary of diverting funds to preventing infections 
while currently infected people go untreated presents a challenge for allocating resources 
[122]. In addition, PrEP is highly dependant on adherence to prevent infection, and can be 
much more expensive to provide than other HIV prevention strategies. Furthermore, if PrEP 
users were to practice unsafe sex in all other respects (otherwise known as “risk 
compensation”), the potential benefits could be offset by new infections. Risk compensation 
could open the door to increased transmission of other infections in addition to HIV, as PrEP 
does not provide any or complete protection against other STIs. There is also some concern 
that PrEP could substantially increase transmitted drug resistance [123], particularly if 
adherence is low. Based on predictions of mathematical models, though, PrEP could be cost-
effective or even cost-saving, depending on the assumed level of efficacy, type of epidemic, 
level of adherence, program coverage, and prioritization of rollout to high-risk populations 
[124-127]. 
While most of these fears have been assuaged by positive experiences implementing 
PrEP in the context of demonstration projects thus far, concerns about the delivery of PrEP 
through health systems remain present. For example, in the United States, a high-income 
setting with excellent treatment programs, PrEP uptake has been surprisingly slow since the 
FDA licenced oral Truvada for prevention in 2012 [128]. Lack of awareness about PrEP, 
stigma, and cost have all been cited as barriers to PrEP use [129]. In resource-poor countries 
in Africa, additional challenges – considering affordability, negotiating the burden on the 
health system, and linking individuals to care – will likely present themselves as well. 
 
1.3  Serodiscordant Couples 
 
Serodiscordant couples exemplify a key population for potential HIV prevention 
interventions. At present, though, there is no standardized definition of a “serodiscordant 
couple.” The most basic component of the definition of a serodiscordant couple is an HIV-
infected individual engaging in a sexual partnership with an uninfected individual – a 
definition that could apply to all HIV transmission. However, a number of other factors must 
narrow the definition of a serodiscordant couple – does a couple have to be heterosexual? 
How long must the partnership exist for them to be considered a couple?  Does the couple 
need to be married, or cohabiting? A number of studies also frequently refer to “stable” 
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partnerships, indicating an intention to remain engaged in the partnership. The concept of a 
“stable” couple is also vague, however, given that these couples are not necessarily 
monogamous and a substantial proportion of HIV transmission can originate from external 
partnerships [130]. 
In guidelines for antiretroviral strategies for HIV prevention among couples, the 
WHO simply defines a serodiscordant couple as “two persons in an on-going sexual 
relationship” in which one partner is HIV-positive and the other HIV-negative [131].  Within 
trials, criteria for the definition of a serodiscordant couple are more refined for the objectives 
of the study. In the Partners PrEP and HPTN 052 Studies, recruited couples were required to 
be sexually active (six or more occurrences of vaginal intercourse with the study partner in 
the past three months) and intend to stay in the relationship for the duration of the study 
(normally a period of at least one to two years) [47,50]. The majority of couples in both trials 
were also married and nearly all were heterosexual. 
Because the meaning of a serodiscordant couple has been used in a variety of different 
ways, it is important to settle on concrete definitions in order to prioritize interventions 
appropriately. The definition of a serodiscordant couple also may not be universal: like the 
differentiation between HIV epidemics driven by heterosexual sex, MSM, or IDUs, those 
couples most vulnerable to acquiring HIV will vary widely by the type of epidemic and the 
country they inhabit. While any definition will naturally exclude some partnerships that could 
benefit from antiretroviral-based prevention, it is important to determine location-specific 
definitions categories will identify those at highest risk. In this thesis, a “serodiscordant 
couple” is referred to as a stable, heterosexual couple intending to remain in the relationship 
for the foreseeable future. 
 
1.3.1        Advantages of Prioritizing Couples for HIV Prevention 
 
The rise of serodiscordant couples as a population of interest for HIV interventions is 
somewhat a result of their essential role in prevention trials examining reduction of 
transmission rates, and not because they have always been a priority. However, there are 
clear reasons why couples are important: first, the negative partner is clearly at risk of 
acquiring HIV from their positive partner because of repeated sexual activity over an 
extended period of time, increasing the cumulative probability of transmission. Second, they 
represent a distinct population that potentially can be accessible in multiple ways: via the 
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HIV-infected partner’s linkage to care, couples’ voluntary HIV testing and counselling, or 
through antenatal clinics. Third, both partners are likely to be motivated to prevent infection 
in the uninfected partner, and have been shown to have high adherence to prevention 
programs due to personal motivation [103]. In addition, analyses of ARV-based prevention 
for couples in developing countries have indicated that TasP could be cost-saving in the first 
few years of implementation and very cost-effective over a longer time horizon [132], and 
that PrEP could be more cost-effective than early ART assuming certain levels of PrEP 
efficacy, cost, and behaviour among couples [125]. 
Biomedical prevention methods have the potential to offer couples a means of 
keeping the HIV-negative partner uninfected while accommodating prevention preferences. 
In long-term partnerships, condom use is often very low [133], and couples report disliking 
regular use of condoms for a variety of reasons, including expense, inconvenience, and lack 
of pleasure [103,134]. For women, condom use can also be difficult to negotiate with 
partners, especially after alcohol use [135,136]. Participants interviewed after the Partners 
PrEP Study demonstrated a clear preference for taking PrEP as opposed to using condoms for 
protection [103]. In addition, while the HIV-infected partner in a serodiscordant couple 
should always be offered ART according to the WHO guidelines [137], in reality, ART 
initiation often does not occur immediately, especially for couples in higher categories of 
CD4 cell counts [61]. ART use is also not universally accepted by HIV-infected individuals; 
only half of partners in discordant couples would prefer early ART over other prevention 
measures [102]. Furthermore, adherence to ART may be less than perfect, potentially leaving 
the window open for viral rebound and for transmission to occur. 
Serodiscordant couples may also wish to conceive, and would benefit from 
antiretroviral-based interventions that would permit unprotected sex with a reduced risk of 
transmission [138]. In Kenya, for example, approximately a quarter of women who self-
identified as HIV-positive reported a desire to have a first child or additional children [139]; 
in such situations, TasP could be used for HIV-infected partner, PrEP could be used for the 
HIV-uninfected partner, or a combination of both strategies could be used at different points 
throughout conception and pregnancy. PrEP in serodiscordant partnerships is intended to 
allow couples to use ARVs for the negative partner not on a lifelong basis, as would be the 
case with ART for the positive partner, but for periods of especially high-risk behaviour. 
Though couples are strongly recommended to use other prevention methods like condoms, 
PrEP and TasP can offer either additional protection or a less risky path to fulfilling fertility 
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desires. PrEP also offers individuals – particularly women – the ability to take some control 
over their own negative HIV status without relying on their partner to take responsibility for 
preventing infection. 
 
1.3.2   Identifying Serodiscordant Couples in sub-Saharan Africa 
 
In sub-Saharan African countries, HIV epidemics are typically generalized (i.e. well-
established in the overall population), and the majority of HIV-1 transmission occurs through 
heterosexual sex [131]. While serodiscordant couples are now considered a key target 
population for HIV-1 interventions [137], there is some uncertainty about both the number of 
couples that exist in sub-Saharan African countries and the proportion of new infections that 
originate from within-couple transmission. Serodiscordancy varies with respect to population 
HIV-1 prevalence, but is relatively common in sub-Saharan Africa (Figure 1.2). Across 
countries, there is also substantial variation in the proportion of couples in which the HIV-
positive partner is female, but overall, women are equally as likely to be infected as men 
[140]. 
 The ability to identify and recruit serodiscordant couples will have important 
consequences for both the impact and cost-effectiveness of potential antiretroviral-based 
prevention interventions. A subset of discordant couples can be identified through joint 
couples testing, antenatal clinics, or via partner testing of previously identified HIV-infected 
individuals (i.e. contact tracing) [14,141,142]. However, these methods may suffer from left 
censoring, when the event in question – in this case, partner seroconversion – has already 
occurred before identification. This could result in the recruitment of so-called “survivor 
couples” that have maintained serodiscordancy during the initial and likely riskier phase of 
the relationship. In addition, the couples that present themselves to health systems could be a 
non-random sample of the full population (otherwise known as selection bias) and may not 
represent the entire spectrum of discordancy; potentially, those couples that seek out 
antiretroviral-based prevention are couples that are also motivated by other forms of HIV 
prevention. It is also probable that many more serodiscordant couples exist than the health 
care system can be aware of, as a proportion of couples will not know that they do not share 
the same serostatus as their partner. Rates of testing also vary by country, and women are 
more likely to test than men, due to high rates of antenatal testing. In Kenya, for example, 
only 29% of women and 23% of men took an HIV test and knew their results within the year 
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prior [143]. If a serodiscordant couple is found, the WHO recommends retesting the HIV-
negative partner 4 weeks after the initial discovery of discordancy, and annual tests thereafter 
if the couple continue to be sexually active [144]. A risk score, which includes factors like 
age, marital status, number of children in the partnership, and proportion of unprotected sex 
acts, can also help to identify which couples are most likely to seroconvert [145]. 
Several studies have tried to estimate the numbers of serodiscordant couples in sub-
Saharan African countries (Figure 1.2). In 2007, Guthrie et al. estimated that approximately 
half of all HIV-infected individuals had an uninfected partner [146]. In addition, screening 
for RCTs has captured the approximate proportional distribution of HIV-serodiscordant 
couples out of all couples in a number of countries. For example, recruitment for the Partners 
in Prevention HSV/HIV Transmission Study showed that across all study sites (in Kenya, 
Uganda, Tanzania, South Africa, Zambia, and Botswana), 8-31% of all couples screened 
were discordant [142]. More recently, Chemaitelly et al. produced estimates based on data 
from the Demographic and Health Surveys (DHS) program, which have shown that the 
proportion of serodiscordant couples (defined as married or cohabiting partnerships) can vary 
greatly based on location. Low-prevalence countries tend to experience higher levels of 
discordancy out of all relationships affected by HIV (i.e. partnerships with at least one HIV-
positive individual), but serodiscordant couples are a smaller proportion of all stable 
partnerships (i.e. total married or cohabiting couples). In low-prevalence countries where 
HIV prevalence is below 10%, most stable partnerships affected by HIV were discordant 
(with a mean of 75%), whereas in high-prevalence countries, about 50% of HIV-affected 
couples were discordant [147]. 
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Figure 1.2: Prevalence of HIV-serodiscordant couples relative to all stable partnerships 
according to (A) modelled estimates based on DHS data [147] and (B) data from the Partners 
in Prevention HSV/HIV Transmission Study recruitment [148]. Country estimates for South 
Africa, Botswana, and Uganda were drawn from trial recruitment in specific areas, and may 
not be representative of all areas in the country. 
 
1.3.3  The Contribution of Serodiscordant Couples to HIV-1 
Incidence in Africa 
 
Aside from determining the proportion of stable partnerships that are serodiscordant 
in each country, another critical question is the amount of HIV transmission occurring within 
such couples, which would help determine their relative priority for interventions. As part of 
the Rakai Community Cohort Study, Gray and colleagues estimated the number of infections 
due to identifiable serodiscordant couples, both before and after the introduction of ART 
[149]. The authors found that 18.3% of all new infections occurred within discordant couples 
prior to ART usage, falling to 13.7% post-ART. The largest contribution to incidence came 
from unmarried individuals, with transmission in concordant negative partnerships occurring 
through external relationships making up roughly one quarter of total new infections. In 
Dunkle et al.’s modelling analysis of data on married or cohabiting couples in urban Zambia 
and Rwanda, the authors concluded that 55.1% to 92.7% of heterosexual HIV incidence was 
attributable to transmission within married or cohabiting serodiscordant couples [150]. 
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However, their analysis failed to take into account downward-biased reports of sexual 
transmission originating outside the reported stable partnerships. Several recent studies have 
offered differing estimates suggesting that intra-couple HIV transmission is relatively low, 
and varies substantially by country [130,151]. A model based on DHS data also found that 
across 20 African nations, spanning low- to high-prevalence countries, an average of 29% of 
new infections occurred within couples that were identified as serodiscordant [151]. 
Within a serodiscordant couple, HIV transmission rates can also differ greatly, 
depending on prevention precautions the couple may take [14]. For couples that receive 
regular counselling and free condoms, the incidence rate is around 2.0/100 PY [47,111]. 
However, couples that used condoms infrequently had incidence of 11.8/100 PY prior to the 
introduction of ART [152], and transmission rates among couples unaware of their 
serodiscordant status are as high as 25% per year [153]. If the HIV-positive partner in a 
couple is on ART, there can be up to a 96% reduction in the risk of transmission, though 
reported protection outside of an RCT has been variable [47,79,89,90]. In addition, for 
uninfected men, circumcision can lower transmission by approximately 60% [40-42]. 
Consistent use of condoms is also highly effective at preventing transmission, decreasing the 
risk by 80% for every sex act [39]. The extent to which prevention measures are utilized by 
serodiscordant couples can also greatly influence the degree to which serodiscordant couples 
contribute to a population’s overall rate of HIV incidence. 
A number of important potential co-factors can also increase risk of transmission in 
discordant couples. High levels of HIV-1 RNA in plasma – or the viral load of an infected 
individual – are strongly associated with higher rates of transmission [152,154], as is the 
stage of infection of the HIV-infected partner (as a function of viral load). Acute infection, 
lasting approximately three months after seroconversion, and late-stage symptomatic 
infection are estimated to be 26 and 7 times more infectious than asymptomatic infection, 
respectively [155]. After acute infection and prior to the onset of AIDS, HIV-infected 
individuals often reach a set-point viral load (SPVL) at which the number of copies of HIV-1 
RNA stabilizes. SPVL ranges broadly amongst individuals, from less than 103 copies per 
millilitre of blood plasma to approximately 106 copies per millilitre [156]. As SPVL 
increases, infectiousness rises substantially and disease progression from asymptomatic 
infection to AIDS happens more quickly [157]. Hormonal contraception also increases the 
risk of HIV acquisition [158], as does pregnancy for both male-to-female and female-to-male 
transmission within serodiscordant couples [159]. Other factors – such as co-infection with 
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STIs [160,161], tropical infections that increase HIV viral load [162], anal sex (as compared 
to vaginal sex) [163], and forcible sex [164] – can additionally modify the risk of 
transmission within the couple. 
HIV transmission in serodiscordant couples is further complicated by the potential 
impact of transmission via an external partner. Self-reports of extra-couple relationships are 
often unreliable due to social desirability bias, but viral linkage to determine the transmission 
source of new infections in clinical trials found that approximately a third of infections 
among couples occurred from external partners [111]. Condom use with external partners of 
unknown serostatus is also heavily reduced [165]. In a mathematical modelling study, Bellan 
and colleagues corroborated Chemaitelly et al.’s findings of reduced within-couple 
transmission in their examination of extra-couple transmission in 18 countries in sub-Saharan 
Africa [130]. Their analysis predicted that a substantial proportion of transmission occurs 
before couple formation and through external transmission. Men, in particular, had a greater 
risk of being infected from an outside partner, with an estimated range of 18-51% of new 
infections arising from external partnerships, as compared to 13-29% of new infections 
among women. Another model by Coburn et al. attempted to quantify the extent to which 
serodiscordant couples influenced overall HIV transmission in 14 countries in sub-Saharan 
Africa [166]. Their findings demonstrated that the contribution of discordant couples to 
country-level HIV incidence is highly dependent on the specific setting and the overall 
percentage of individuals who consider themselves to be in stable relationships. 
 
1.3.4  Behavioural Factors and Serodiscordancy  
 
Understanding the contribution of serodiscordant couples to HIV incidence also 
requires in-depth knowledge about the behavioural factors that determine their beliefs about 
discordance and about their prevention options. While couples may struggle with the 
discovery of discordancy, there are a number of cultural and personal reasons to explain why 
preserving the relationship is important, aside from love. In many African societies, marriage 
is culturally expected and couples may frequently have children or desire children, which 
further reinforces the union [103]. In addition, separation could create a financial burden for 
both partners in the couple, especially for women who have fewer avenues of generating a 
liveable income and depend on their husbands for economic support. 
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Joint couples’ testing and counselling promotes better communication from both 
partners, fosters a healthy environment for disclosure, averts blame, and establishes a clear 
plan to address discordancy [131,167,168]. Couples’ counselling has been shown to 
substantially increase use of traditional HIV prevention measures like condoms [169]. 
Counselling is also essential for dispelling incorrect preconceptions about discordancy, such 
as suspicion about the accuracy of the test results or a belief that the partner is immune to 
infection [135,170]. One central question of interest in PrEP demonstration projects is to 
understand whether couples take pills to prevent HIV infection without the rigorous 
counselling and testing offered by clinical trials, though it is debatable whether the design of 
demonstration projects will be able to reveal the answer to this fully. Finally, understanding 
couples’ preferences for different biomedical interventions will continue to help inform 
expectations about their success. Both PrEP and TasP offer promise for use in serodiscordant 
couples, but only if they are well understood and demanded by the couples themselves. 
 
1.4  Adherence to Pre-Exposure Prophylaxis 
 
Adherence, or the extent to which an individual complies with a regimen of 
recommendations delivered by a health care provider, is critical to the success of any public 
health intervention that requires sustained effort to manage health [171]. Even if a biomedical 
intervention is efficacious, it may not be effective if adherence is low, and sub-optimal 
adherence can severely compromise the impact and cost-effectiveness of a program. 
Medications that require daily adherence, like the oral contraceptive pill or statins used to 
prevent cardiovascular disease, have faced poor adherence and frequent discontinuations 
despite clear prevention benefits, low cost, and ease of access [172,173]. 
One of the most consistent themes emerging from the trials of PrEP is the importance 
of adherence to the success or failure of prophylactic antiretrovirals for HIV prevention. 
While PrEP has been proven efficacious, the drugs must be taken regularly in order to have a 
substantial effect on the risk of acquiring a new infection. A range of factors may influence 
adherence to PrEP, including age, perceived risk of acquiring HIV, support within the partner 
relationship, fertility intention, and frequency of adherence counselling [174]. It is critical to 
understand the contribution of these factors to resulting adherence, as well as fully 
comprehending the relationship between patterns of adherence and sexual activity. In order 
for implementation of PrEP in communities to be both effective and cost-effective, programs 
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will need to address concerns about adherence and prioritize appropriate populations for 
interventions. 
 
 1.4.1        Historical Adherence to Global Health Interventions 
 
Adherence to medication for chronic diseases or for health prevention is notoriously 
poor globally [175]. Imperfect adherence leads to inferior health outcomes, an increased 
burden of healthcare costs for countries, and higher risks for the patients themselves. For 
many conditions, biomedical efficacy of medications are as high as is biologically possible, 
and adherence is the most modifiable factor affecting effectiveness of the drug regimen. 
One strategy to deal with poor adherence arose from the tuberculosis (TB) pandemic. 
In 1995, the WHO launched a program called Directly Observed Treatment, Short-course 
(DOTS) in order to control the spread of TB and cure infected patients [176]. Standard 
treatment for TB involves a course of chemotherapy lasting for six to eight months, but a 
substantial proportion of individuals do not complete the full treatment regimen [177]. For 
tuberculosis, the dangers of non-adherence can be severe; not only can the disease rebound in 
an individual patient, but failing to finish treatment can lead to the emergence of drug 
resistance. The DOTS strategy requires that the patient take their prescribed doses directly 
observed by a health care worker for the duration of treatment. The cure rate using DOTS 
increased from around 60% to nearly 90%, and is now the linchpin in the WHO’s global TB 
control program [178]. DOTS has been so successful that it has also been advocated for ART 
for HIV patients as well as for therapy for non-communicable diseases [179,180], and was 
successfully implemented among HIV-infected drug users in a randomized controlled trial 
during the early 2000s [181]. Furthermore, DOT was one strategy offered in the Bangkok 
Tenofovir Study of daily oral PrEP for IDUs, and resulted in 95% adherence to PrEP, as 
measured according to a study drug diary [52]. 
Maintaining high adherence to antiretroviral therapy for HIV infection poses an even 
greater challenge: treatment is life-long, and in the past, individuals have frequently suffered 
from side effects of the medication [182]. Historically, individuals have had high adherence 
to ART, with an estimated 77% of patients adhering to treatment in African countries [183]. 
In order to achieve long-term viral suppression, adherence must be consistently high [184-
186]; one study found that only half of patients had an undetectable viral load with 80-90% 
adherence, as compared to 81% of patients with 95% adherence or higher [187]. Similarly to 
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the consequences of inadequate tuberculosis treatment, failure to suppress HIV viral RNA 
can lead to faster progression to AIDS, drug-resistant mutations, and an increased risk of 
transmitting HIV to uninfected individuals. The reasons for sub-optimal adherence are 
diverse, and specific to the individual, but may include complexity of the regimen, difficulty 
of scheduling pill-taking, side effects, forgetfulness, mental health issues, and fear of 
exposure of HIV status, among others [187]. In sub-Saharan Africa, difficulties of 
transportation to and from a clinic, as well as potential ART stock-outs, can also negatively 
affect adherence [188]. 
 
1.4.2         Adherence Interventions 
 
Supporting high adherence to ART – as with any treatment or prevention regimen – 
frequently requires active methods to ensure that pills are not missed, and a number of 
interventions have been demonstrated to improve compliance. Interventions to support 
adherence to ART can be categorized as behavioural (e.g. reminder devices and DOTS), 
cognitive (e.g. education), affective (e.g. counselling), biological (e.g. nutrient supplements 
or food rations), and structural (e.g. community mobilisation) [171]. For many patients, 
counselling and education about adherence from a health service provider at initiation of 
ART can increase the ability to adhere consistently to the regimen [189]. Population-specific 
interventions, such as couples-based adherence counselling [190] or antidepressants for 
patients suffering from clinical depression [191] (as untreated depression has been associated 
with poor adherence), have also been effective. More recently, a randomised trial of mobile 
short message services (SMS) to remind patients to take their medication demonstrated 
significantly improved adherence and viral suppression [192]. Despite the host of 
interventions available, adherence to ART has still not reached desired heights, and support 
for continued adherence must be maintained over long time horizons. 
Adherence to prevention interventions can be different from adherence to treatment 
programs in many important ways, and adherence to PrEP should not be assessed using the 
same paradigm as adherence to ART. Individuals engaging in a biomedical prevention 
strategy are not treating a current problem; no event has yet occurred. In addition, there are 
often many diverse options available for prevention, which allows an individual to switch 
from one to another without necessarily sacrificing any prevention benefit. A number of 
biomedical strategies for preventing health outcomes across a wide variety of fields are 
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commonly used, and can lend insight into how adherence operates in the context of 
prevention. Statins, which are commonly taken to lower cholesterol and prevent the 
development cardiovascular disease, are widely prescribed for individuals at risk of having a 
heart attack or stroke.  Adherence to a prescribed regimen of statins is very low and there is 
high attrition over time [193-195]. Similarly, women prescribed the oral contraceptive pill to 
prevent pregnancy drop out at a rate of 32% in the first year and have a reputation as poor 
adherers [196]. Of those who continue to take the contraceptive pill, approximately half miss 
one or more pills each month, with 14-22% missing two or more pills [197,198]. Inadequate 
adherence to oral contraceptives is a significant driver of unintended pregnancies and use of 
emergency contraception, and can have public health consequences in terms of maternal 
mortality [199]. 
Taking medication for prevention poses a number of questions that do not arise for 
treatment adherence [200]. For PrEP, a public health tool that is yet to be implemented in the 
countries bearing the greatest burden of new HIV infections, it will be crucial for 
policymakers to determine how these questions should be answered. For example, to what 
degree is non-adherence due to use of other, equally valid, prevention methods? Is it 
important to monitor adherence in clinical practice, beyond the setting of a trial or 
demonstration project, when adherence to other public health interventions is not monitored? 
If adherence is monitored, what degree of adherence is necessary to prevent infections and 
justify the cost of the intervention? In response to these complexities, Haberer and colleagues 
have proposed a new “prevention-effective paradigm” to understand and measure PrEP 
adherence [200]. Using this paradigm, daily PrEP use can be successful not only with perfect 
or near-perfect adherence, but also if adherence is periodic and mapped on to times of risk 
exposure, with access to other prevention tools during periods of PrEP non-adherence. This 
new paradigm takes into account the dynamism of risk and allows for flexibility in both 
choice and timing of different HIV prevention methods. 
 
	  1.4.3        Methods of Monitoring Adherence 
 
Although adherence cannot be known perfectly unless directly observed, an 
assortment of methods are currently used to determine whether or not participants in clinical 
trials take their study pills as directed. One of the most common methods of monitoring 
adherence is self-report, a measurement by which participants recall the number of doses 
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taken and missed over a unit of time (e.g. a week or a month). The advantages of using self-
report are numerous; it is simple, inexpensive, non-invasive, and can distinguish between 
purposeful non-adherence and accidental non-adherence. However, self-reports often 
inaccurately report higher levels of adherence than detected by more reliable methods, 
possibly due to social desirability bias – i.e. reporting behaviour based on pleasing the 
conductor of the study – or recall bias – i.e. inaccuracies in reported behaviour due to an 
inability to accurately recall events that occurred in the past. For example, in the iPrEx trial, 
self-reported adherence was 94%, yet measurements of drug levels in blood and tissues 
detected tenofovir in only 51% of the subjects [49]. Unannounced home visits to count pills 
may yield a more reliable estimate, yet this technique can also suffer from manipulation, as 
patients may “pill dump” prior to the visit [201]. For patients taking ART, pharmacy refills of 
prescriptions have been demonstrated to be a better predictor of adherence than CD4 counts, 
and can predict virologic rebound in patients before it takes place [202]. Self-report, 
unannounced home visits, and pharmacy refills are all inexpensive measurement tools, but 
are likely not as accurate as other methods, and only reveal a summary measure of adherence, 
rather than distinct patterns of adherence and non-adherence. 
Electronic methods of monitoring adherence have been developed more recently. 
These include Medication Event Monitoring System (MEMS) caps, an electronic monitoring 
system installed in the caps of pill bottles, which can report every date and time a bottle is 
opened. This method is expensive but allows researchers to capture daily patterns of pill 
taking, which may be the most objective measurement of adherence over time. However, 
MEMS dosing may also be subject to biases such as the Hawthorne effect, in which 
individuals perform differently when being observed in the context of an experiment or trial 
[203]. Another option that may reveal more accurate estimates of adherence is through SMS.  
Given the proliferation of mobile phones throughout Africa in the last decade, daily 
adherence support and measurement through SMS can be used for both treatment [192] and 
prevention [204]. In addition to providing a daily reminder to take a pill, SMS provide a 
degree of anonymity that may work to reduce social desirability bias [204]. Real-time 
adherence observation is also possible through the Wisepill adherence monitor, a pill 
container that wirelessly communicates data to a server every time the device is opened.  
Wisepill has been used to monitor ART [205], and is also being used in PrEP studies [206]. 
New technologies, particularly ingestion event monitors, which can detect a swallowed pill 
through a microchip activated by fluids in the stomach or breathalysers, are also in 
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development and may be applicable to monitoring HIV treatment or prevention adherence 
[207,208]. 
Finally, adherence can be evaluated from concentrations of drug taken from bodily 
samples. Drug levels can be analysed in blood plasma, red blood cells (RBCs), serum, 
peripheral blood mononuclear cells (PBMCs), dried blood spots (DBS), cervicovaginal/rectal 
fluid and tissue, and hair. While these analyses can reveal objectively whether an individual 
is adherent or not, they cannot be performed on a large scale and provide only a broad 
measurement of adherence [209]. Blood samples typically provide a short-term assessment of 
adherence – e.g. if an individual has been consistently adherent, partially adherent, or non-
adherent over the past week [210]. Antiretroviral biomarkers from hair samples, on the other 
hand, have been shown to describe adherence trends accurately over a longer period of time, 
for both ART [211,212] and PrEP [213,214]. Given that measuring adherence by hair is 
inexpensive, easy to transport, and precise, it may be useful for measuring individual 
adherence outside of the context of a clinical trial [213]. However, adherence monitoring via 
hair may not be feasible in a real-world setting, and there may be additional costs associated 
with procuring, storing, and analysing hair on a larger scale. 
 
1.4.4  Adherence Results from the PrEP Trials and 
Demonstration Projects 
 
The wide range of efficacy estimates from clinical trials demonstrates that adherence 
has the potential to define the success or failure of a PrEP regimen. Successful trials reported 
much higher median levels of adherence than did unsuccessful trials. In an ancillary 
adherence study (AAS) as part of the Partners PrEP Study, participants achieved almost 
perfect adherence to the study drug, across multiple measures. Using MEMS data, median 
adherence was 97.2% (IQR 90.6-100.0%) and 99.1% (IQR 96.9-100.0%) by unannounced 
pill counts [215]. Only 14.6% of participants experienced a period of time during which 
adherence fell below 80%, which triggered an additional adherence intervention. The 
intervention consisted of sessions of adherence counselling, and was associated with a 
significant increase in mean adherence, from 75.7% in the month prior to the intervention to 
84.1% post-intervention (p<0.001) [216]. Importantly, the AAS found that no 
seroconversions occurred in the PrEP arm compared to 14 infections in the placebo arm, 
yielding PrEP efficacy of 100% (95% CI 83.7-100.0%, p<0.001) within the context of the 
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regular adherence monitoring and counselling. The adherence sub-study also found that lower 
adherence was associated with younger age, alcohol use, being abstinent or having sex with 
an external partner, and PrEP use beyond an initial six-month period. 
In the iPrEx Study, adherence was considerably different based on self-report versus 
drug detection [49,217]. Median self-reported adherence from interviews across all study 
locations was 100% (Interquartile Range [IQR] 94-100%) and median adherence by pill 
count was also 100% (IQR 91-103%) [101]. In contrast, approximately half of participants 
with testable blood samples had detectable tenofovir in their blood and 31% never had any 
drug detected while in the study. In addition, older age and self-reported sexual risk 
behaviour were both associated with a greater frequency of drug detection. The open-label 
extension of the study, iPrEx OLE, also confirmed that having drug in the blood was 
important for protection: HIV incidence was 0.0/100 PY for those taking more than four 
tablets per week, in comparison to 4.7/100 PY for individuals with no detectable tenofovir in 
samples [120]. 
While the results of the Partners PrEP and iPrEx are encouraging for PrEP use within 
serodiscordant couples and MSM, findings are less heartening for other populations. In the 
VOICE trial, preliminary results indicate that self-reported adherence did not correspond to 
measures of drug concentration in the blood for any of the three groups (FTC/TDF, oral TDF, 
and TDF gel) [218]. Adherence levels were consistent across all three groups, with detectable 
drug in 29% of those in the FTC/TDF group, 28% in the oral TDF group, and 23% in the 
TDF gel group, all in contrast to 90% adherence by self-report. Likewise, participants in the 
FEM-PrEP Study self-reported 95% adherence overall, yet tests of tenofovir in blood samples 
yielded adherence estimates of just 15-37% [94]. The stark difference in adherence between 
these two trials and Partners PrEP suggests that young women may not be a suitable 
population for PrEP interventions – at least in the contexts investigated in those clinical trials 
– and serodiscordant couples could be more appropriate for PrEP use. This is possibly due to 
a greater understanding of the risk of acquiring HIV within a discordant couple, or 
additionally because the support of a partnership may encourage greater adherence [103]. 
Positive adherence results from clinical trials should also be treated with some 
caution. As randomized controlled trials are designed to test the efficacy of an intervention (in 
other words, to produce a change under ideal circumstances), adherence is integral to the 
study design. For example, the adherence counselling intervention in the ancillary adherence 
sub-study of the Partners PrEP Study would not be scalable for implementation. In the trials, 
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adherence measurements are representative of pill-taking behaviour under exemplary 
conditions, which cannot be extrapolated to “real world” adherence, and therefore may lack 
external validity. On the other hand, participants in clinical trials were unaware of whether or 
not PrEP could prevent HIV acquisition, or if they were taking active drug or placebo; 
adherence in open-label studies could also be higher than observed in clinical trials for some 
populations, given that participants now know that PrEP is efficacious for HIV prevention. 
Notably, the HPTN 067 ADAPT trial of different dosing strategies with open-label oral PrEP, 
which took place among young women in South Africa, showed that the majority of women 
adhered to PrEP in the context of known efficacy [117]. 
 
  1.4.5       The Contribution of Behavioural Factors to Adherence 
 
In deciphering the divergent results of the clinical trials, it is also apparent that 
serodiscordant couples had considerably higher adherence than other populations examined 
in RCTs. Part of this discrepancy may be attributed to different risk perceptions, but 
qualitative insights from the Partners PrEP Study also suggest that commitment and support 
to the couple relationship can encourage higher adherence. Interviews with couples in the 
Partners PrEP Study revealed that the HIV-positive partner often supported high adherence 
and that PrEP can offer couples a way to deal with the tensions created by the revelation of 
discordance [103]. In addition, partners and children often provided daily reminders to take 
pills, and positive individuals taking ART might match their dosing schedule to their 
partner’s. However, for couples living with prolonged conflict in the relationship, tensions 
with the partner could negatively affect levels of adherence. If the HIV-positive partner 
remained indifferent, or even antagonistic, about the prospect of the partner taking PrEP, it 
was more difficult for the negative individual to remain determined to adhere to the daily pill 
regimen. Overall, PrEP acceptability among couples is high, with many preferring a daily pill 
to the prospect of using condoms for HIV prevention [102]. Couples who were motivated to 
stay together regardless of their serodiscordance status found PrEP to help in maintaining 
their family life as well as the economic advantages of remaining in a coupled relationship. 
Nevertheless, in a qualitative study of PrEP acceptability among MSM and female sex 
workers in Kenya, participants also reported potential barriers to adherence [219]. Most 
individuals reported a preference for intermittent as opposed to daily dosing, and cited fear of 
stigma as a reason to avoid taking pills in the presence of others. Demonstration projects 
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using PrEP in a range of locations and populations will offer a more nuanced view of how 
adherence will influence PrEP effectiveness in the context of implementation. 
 
1.4.6  Risk Perception 
 
Adherence to methods of prevention, as opposed to treatment, requires a relatively 
accurate understanding on the part of the individual of their specific risk of acquiring HIV. 
For identified serodiscordant couples, the potential risk is explicit given that both partners 
know the serostatus of the other and are committed to continuing the relationship. However, 
for other populations, the risk can be less evident, potentially leading to sub-optimal 
adherence. 
In both the Partners PrEP and VOICE Studies, age was a significant factor in 
predicting adherence to the study drug. In a population of young women under the age of 25, 
HIV acquisition may be more probable than assumed by individuals within the cohort. For 
participants in the VOICE trial, overall incidence for single women under 25 was 8.8% as 
compared to 0.8% for married women over 25 [218], yet tenofovir was detected in only 21% 
of samples from younger women, as opposed to 54% for older married women. Qualitative 
assessments in the FEM-PrEP Study showed that young women either did not perceive 
themselves to be at risk for HIV infection or assumed they had a low risk of acquiring HIV in 
the near future. At baseline, 70% of study participants agreed that they were at no risk or low 
risk and, remarkably, a greater percentage of participants (75%) agreed with the same criteria 
at the final follow-up visit [94]. Risk perception can be a problem in other populations as 
well, though possibly not to the same extent; for example, qualitative studies have shown that 
some serodiscordant couples believe the negative partner to be infected already, due to long 
periods of unprotected exposure prior to the use of PrEP [219]. 
 
1.4.7         Pharmacokinetics and Pharmacodynamics of PrEP Use 
 
As maintaining adherence to PrEP may be difficult for some individuals, knowledge 
about imperfect dosing is essential to understanding how adherence can influence the 
effectiveness of a prevention regimen. Exploring the pharmacokinetics (PK), i.e., the details 
of drug absorption, distribution, metabolism, and pharmacodynamics (PD), i.e., the response 
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generated by the body in response to the drug, can provide insight about the residual 
protection of PrEP. Multiple studies have confirmed that the efficacy of PrEP is relative to 
the level of drug concentration in the blood at the time of exposure to HIV [49,50]. In the 
Partners PrEP Study, detection of tenofovir in plasma samples strongly predicted a protective 
effect against HIV-1 infection [210]. For participants in the TDF arm with detectable 
tenofovir in plasma samples, the risk of HIV infection was reduced by 88% (95% CI 60-96%, 
p<0.001). Those in the FTC/TDF arm with a threshold TDF concentration in the blood had a 
91% (95% CI 47-98%, p=0.008) decreased risk of HIV acquisition. In addition, of the 17 
patients in the TDF arm and 12 in the FTC/TDF arm that seroconverted, only 6 and 3, 
respectively, had any detectable tenofovir in their plasma on the day of their positive test. 
Another example is the CAPRISA 004 trial, in which 36% of those who became infected had 
detectable TDF in their genital tract secretions, as opposed to 83% of HIV-negative women 
[220]. These results clearly indicate that the presence of detectable tenofovir in the blood 
strongly reduces the likelihood of an individual acquiring HIV. 
 Pharmacokinetic studies of tenofovir-based ARVs in HIV-infected and HIV-
uninfected participants reveal that intracellular tenofovir possesses a long half-life (i.e. the 
amount of time it takes for a drug to reach 50% of the initial concentration), but also that 
there is wide inter-individual variability. Tenofovir can be measured in plasma (TFV) and in 
intracellular concentrations (tenofovir diphosphate [TFV-DP], the active metabolite of 
tenofovir. In a study of HIV-infected individuals on ART, Hawkins et al. estimated the half-
life of TFV-DP from steady-state as approximately 150 hours, or 6.25 days [221], and a 
model using data from HIV-infected individuals projected the half-life to be closer to 87 
hours [222]. One study among HIV-uninfected volunteers, using steady-state dosing of 
Atripla (combined tenofovir, emtricitabine, and efavirenz), estimated the TFV-DP half-life as 
164 hours [223]. Subsequent PK studies in HIV-uninfected participants have yielded 
somewhat shorter half-lives of TFV-DP for single doses of TDF: 64 hours among both HIV-
uninfected men and women [224], and 48 hours in a study examining HIV-uninfected women 
alone [225]. For TFV in plasma, the half-life is typically shorter than in PBMCs, ranging 
from 21 to 69 hours [223-225], and concentration in the blood fluctuates throughout the day, 
from a trough of approximately 65 ng/ml prior to a new dose to a peak of 332 ng/ml one hour 
after dosing [226,227]. 
Though more work is needed on PrEP dynamics in the blood, current evidence 
suggests that tenofovir and emtricitabine retain some efficacy with intermittent dosing. 
	  
	  
55 
Evidence from the iPrEx trial suggests that oral PrEP in MSM confers some residual 
protection if doses are missed. In Anderson et al.’s analysis of adherence to daily oral 
FTC/TDF, the authors estimated necessary drug concentrations in the blood and levels of 
adherence resulting in protection from HIV-1 acquisition in a population of MSM within the 
iPrEx trial [228]. Measuring the intracellular concentrations of TFV-DP and emtricitabine 
triphosphate (FTC-TP, the active metabolite of emtricitabine) and comparing concentrations 
against HIV incidence can provide an indicator of what quantities are necessary to achieve 
different levels of protection. The authors found that a blood level of 16 fmol/106 peripheral 
blood mononuclear cells (95% CI 3-28%) was necessary for a 90% reduction in HIV 
acquisition relative to placebo in the study. Furthermore, the study indicated that blood levels 
consistent with two doses per week resulted in a 76% HIV risk reduction, while four doses 
per week conveyed a 96% reduction and seven doses a 99% reduction. These modelled 
estimates of efficacy were supported by results from the iPrEx open label extension 
demonstration project, in which the TFV-DP concentration in DBS reflected increasing 
efficacy with greater drug concentration. After adjusting for site, age, number of partners, 
unprotected anal intercourse, and syphilis, protection was estimated as 44% for a 
concentration equivalent than two doses or below per week, 84% for 2-3 doses per week, and 
100% for 4 doses or more per week [120]. 
However, these PK/PD estimates are specific to MSM, and both the pharmacokinetics 
and pharmacodynamics of PrEP may be quite different for heterosexual men and women. 
Results from the FEM-PrEP and VOICE trials suggest that adherence played an important 
role in the null results, but another contributing factor could be differences in the biological 
efficacy of PrEP in men and women. Oral dosing of FTC/TDF results in substantially lower 
drug concentrations in the vaginal tract than in rectal tissue. Concentrations of TFV-DP taken 
in genital tissues 24 hours after an oral dose of FTC/TDF are approximately 100-fold higher 
in rectal samples than in vaginal ones [229]. Topical applications of tenofovir gel also result 
in a 1,000-fold increase in concentration in vaginal tissue over oral dosing. Furthermore, 
analyses from the CAPRISA 004 trial found that 1% tenofovir gel had a half-life of 
approximately 2 days in the vaginal lumen [220], suggesting less residual protection than in 
rectal tissue. Nevertheless, there has been no statistical difference in protection between men 
and women in clinical trials that evaluated both populations, with the exception of women in 
the Partners PrEP TDF arm with low tenofovir concentrations [210]. However, there are wide 
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confidence intervals surrounding this estimate due to low sample size, and it may not be 
indicative of an actual difference. 
Despite some evidence of residual biological efficacy of PrEP, irregular dosing is 
likely to pose adherence complications. A study of intermittent dosing among MSM and 
FSW in Kenya tested daily oral FTC/TDF, as well as twice-weekly dosing with additional 
post-coital doses, against placebo regimens [230]. For participants assigned to daily dosing, 
the median adherence level, as measured by MEMS, was 83% (IQR 63-92), while individuals 
with fixed intermittent dosing had a median adherence rate of 55% (IQR 28-78). These 
results indicate that adherence to intermittent dosing may be more challenging for individuals 
than daily dosing, which allows a routine of taking a pill consistently at the same time every 
day. The ADAPT Study also observed higher adherence for participants in the daily dosing 
arm, compared to those using time-driven dosing (twice per week plus a pill after sex) and 
event-driven dosing (after sex only) [117]. However, in the IPERGAY Study, intermittent 
dosing for MSM (two pills before sex, one pill a day after sex, and one pill two days after 
sex) found 86% protection compared to placebo, suggesting that intermittent PrEP might be 
acceptable and effective for this population [53]. Further investigations into intracellular drug 
concentrations, for all target populations, will be necessary to determine if PrEP can remain 
effective with intermittent dosing. 
In particular, more work is also needed to estimate what level of tenofovir 
concentration is needed to achieve protection from an HIV challenge in heterosexual men and 
women. A preliminary dose-response curve using the median plasma TFV concentration 
from PrEP RCTs has been constructed by Hendrix to estimate the relative protection afforded 
by PrEP with different plasma concentrations of tenofovir [226]. As the dose-response curve 
takes into account results from microbicides and oral PrEP, as well as aggregating results 
from different populations, separate dose-response curves for protection based on each trial 
will be necessary to determine the accurate pharmacodynamics of PrEP for different 
circumstances. Nevertheless, the preliminary dose-response curve provides insight into the 
relationship between drug concentration and protection. For example, the estimated plasma 
TFV concentration needed to achieve 90% protection (EC90) is approximately 105-110 ng/ml 
according to Hendrix [226]. This value is much higher than what Anderson et al. estimated as 
an EC90 for MSM (10 ng/ml). The disparity between these analyses broadly suggests that the 
site of exposure is influential in determining the degree of protection an individual will 
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receive from an oral PrEP dose, and more population-specific analysis is required to 
understand what level of TFV concentration is necessary to prevent HIV acquisition. 
 
1.4.8        The Potential of Drug Resistance Due to PrEP 
 
Even though PrEP has been proven to avert HIV infections in clinical trials, sub-
optimal adherence poses population-level dilemmas as well as providing less individual 
protection from infection. Since PrEP emerged as a potential HIV prevention strategy, the 
potential for the acceleration of antiretroviral resistance has been a source of anxiety. In PrEP 
trials, several cases of resistance (both the K165R mutation and the M184V mutation for 
resistance to tenofovir and emtricitabine, respectively) did emerge, either as a result of acute 
infection during initial PrEP use or poor adherence at the time of seroconversion [49-51,94]. 
For those with an acute infection prior to taking PrEP, the resistance was either transmitted 
from the infecting partner or developed due to the presence of the ARVs. When an individual 
has some level of PrEP drugs in their blood but becomes infected, the ARVs function as only 
partly suppressive therapy – the same conditions that lead to resistant mutations with ART. 
 The possibility that improper use of PrEP could lead to an increase in the prevalence 
of resistant mutations is one of the central concerns regarding the introduction of PrEP; in 
theory, this could outweigh the benefits gained from averting new infections [123]. Because 
the medications used as PrEP are also frequently administered as treatment, it is especially 
crucial to keep resistance levels to a minimum as resistance could allow for viral rebound and 
an increasing reliance on second-line treatment regimens. As with PrEP, inconsistent 
adherence to ART presents an opportunity for resistance to occur. Currently, increasing drug 
resistance due to the rollout of ART is a serious concern, especially in resource-limited 
settings that do not have the capacity to implement ARVs beyond second-line regimens. 
Levels of antiretroviral resistance are rising in East Africa by an estimated 29% per year and 
by 14% per year in South Africa since rollout, driven primarily by resistance to first-line 
NNRTI regimens [231]. If resistance due to PrEP contributed significantly to the prevalence 
of drug resistance overall, treatment regimens would be compromised – a prospect that would 
be disastrous for the management of HIV. 
Fortunately, results from the clinical trials and mathematical modelling of PrEP 
rollout indicate that drug resistance will likely not be a major problem [232,233]. In the 
Partners PrEP Study, only 2 out of 96 persons who seroconverted during the study developed 
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resistant mutations, and both individuals had been infected prior to randomization [50]. 
Likewise, in the iPrEx and TDF2 studies, 3 and 1 participants in the active arms of the trials, 
respectively, had resistant mutations due to undetected infection at enrolment [49,51]. In 
models, any projected increase in resistance due to PrEP is dependent on several factors: the 
proportion of inadvertent use in an infected individual, efficacy of the drugs, extent of 
population coverage, and any risk compensation [234]. Models predict a range of diverse 
outcomes based on different assumptions about PrEP implementation [19], but largely 
conclude that resistance is unlikely to be a substantially detrimental factor, especially when 
seen in the context of other sources of ARV resistance (i.e. developed during ART or 
transmitted within the population) [235,236]. In a comparison of mathematical models, all 
predicted resistance to increase over the next 20 years, but attributed 50% to 63% of that rise 
to ART, 33% to 48% to transmitted resistance, and less than 4% to PrEP [236]. However, it 
should be noted that the accuracy of models is dependent on the PK/PD dynamics of PrEP, 
which, as noted, are yet to be formally validated. In addition, if PrEP use were to become 
more widespread, this could also affect the predicted amount of drug resistance arising from 
PrEP. While drug resistance is not expected to be a substantial impediment to implementing 
PrEP, it is nevertheless an important consideration for developing policies oriented towards 
improving and maintaining adherence for PrEP users. 
 
1.5  Guidelines and Policy Implications 
 
In the rapidly changing world of HIV prevention, formulating guidelines for optimal 
use of prevention measures is a continuing and urgent challenge. The principal goals of 
prophylactic interventions in Africa will be prioritizing vulnerable populations (both 
geographically [30,237] and by risk factors [238]), streamlining delivery, and conveying the 
right messages about prevention. 
 
1.5.1  Current Guidelines for ARV-Based Prevention for 
Serodiscordant Couples 
 
One of the key roles of the World Health Organization is to evaluate evidence and 
provide overarching recommendations for the implementation of health-based interventions, 
	  
	  
59 
with the intention of guiding the programs that that individual countries adopt. In the context 
of HIV, the WHO has issued guidance on a number of subjects, including the appropriate 
timing of ART initiation for different populations (e.g. adults and adolescents, children, 
pregnant women, and serodiscordant couples), testing and counselling, use of PEP, 
prevention for key populations (including ARV-based prevention), and HIV surveillance, 
among others. These recommendations are reconsidered and updated both as new evidence is 
produced and as the feasibility of scaling up interventions becomes clearer. 
Based on clinical trial results and extensive analyses surrounding the safety and 
effectiveness of TasP and PrEP, a number of recommendations for their use have been issued 
by global and local health organizations. In 2012, the CDC endorsed use of oral FTC/TDF in 
high-risk men and women and as part of a prevention package for serodiscordant couples 
trying to conceive in the United States [239]. The WHO also recommended that the HIV-
infected partner in a serodiscordant couple be offered immediate ART, regardless of their 
CD4 cell count, from April 2012 onwards [131]. Several months later, the WHO advised that 
daily oral PrEP should be considered as an additional HIV prevention option for 
serodiscordant couples, MSM, and transgender women in the context of demonstration 
projects [137]. In the United Kingdom, PrEP was recommended for MSM engaging in 
unprotected anal sex and to the HIV-uninfected partners in serodiscordant couples as of June 
2015 [240]. In 2014, both the CDC and WHO released additional guidelines regarding the 
use of PrEP in serodiscordant couples. The CDC recommends that PrEP be discussed with 
serodiscordant couples as one prevention strategy to prevent HIV infection during conception 
and pregnancy, and for sexually active adult men and women at high risk of acquiring HIV 
[241]. The WHO additionally stated that in contexts where serodiscordant couples are 
identified and in need of an additional prevention option, daily oral PrEP should be 
considered for the HIV-negative partner [242]. In addition, the WHO recommended PrEP as 
an additional HIV prevention option for use among MSM, as of July 2014 [242], and the 
CDC in the U.S. recommends PrEP for individuals at high risk of HIV acquisition – i.e. 
stable serodiscordant couples, MSM with recent condomless sex or a recent STI diagnosis, 
heterosexual men and women who do not use condoms regularly and are viewed to be at high 
risk of infection, and IDUs [243]. In September 2015, the WHO also announced an early-
release guideline regarding the use of ARVs for treatment and prevention, ahead of the 
release of the full consolidated guidelines to be released in 2016. The interim guidance 
recommends immediate ART initiation for all HIV-infected individuals and also advises that 
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PrEP should be offered as an additional prevention option for all individuals at substantial 
risk of HIV-1 acquisition (defined as annual incidence ≥3/100 PY) [24]. 
One of the most important guidelines is the determination of the CD4 cell count at 
which to start ART, which will affect the potential utility of TasP and PrEP. The 2013 WHO 
guidelines for treatment advocated ART initiation at CD4 counts <500 cells/µl [23]. The 
recent guideline change recommending ART scale-up for everyone with a positive HIV 
diagnosis will firstly require initiating treatment for additional millions of people worldwide, 
when not even all those eligible based on current guidelines are on ART regimens. In 
addition, the updated guidelines may affect the role of PrEP as a prevention strategy, given 
that a greater proportion of infected individuals should be on treatment in the future. Full 
implementation guidelines for PrEP, based on additional evidence emerging from 
demonstration projects, will be released in 2016. 
The process of deciding which recommendations to back takes into account health-
based evidence from clinical trials, demonstration projects, systematic reviews, as well as 
mathematical modelling projections of impact and cost-effectiveness [244]. Considerations 
include the strength of the evidence (e.g. RCTs provide a higher quality of evidence than do 
observational studies), limitations (e.g. study design, inconsistencies, or publication bias), and 
the magnitude of the effect. Mathematical modelling can also be a useful way to analyse 
complex questions emerging from RCTs, as policymakers often want to take into account the 
long-term costs and benefits of an intervention, which cannot be gleaned from the limited 
duration of follow-up in most clinical trials. 
 
1.6 Mathematical Modelling to Inform HIV Policy 
 
Mathematical models have been used to predict the spread of HIV-1 epidemic from 
relatively early on in the epidemic [245,246], and were first used for the purpose of 
investigating infectious disease dynamics in the 1920s. In 1927, Kermack and McKendrick 
developed the susceptible-infected-recovered (SIR) model, in which individuals are stratified 
into three compartments depending on their stage of infection, and the flow between 
compartments is determined by differential equations [247]. Deterministic compartmental 
models, such as the SIR model, are still frequently used to capture the dynamics of infection, 
and can be further stratified by age, sex, heterogeneous mixing behaviour, and any number of 
parameters relevant to the infection being modelled. The use of mathematical models for 
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infectious diseases was further developed by Anderson and May in 1991 [248]; the 
publication of Infectious Diseases of Humans provided a foundation for many critical 
concepts, including R0, the basic reproduction number that indicates the mean number of 
cases one individual generates in an entirely susceptible population for the duration of the 
infectious period. Above a threshold of R0=1, an epidemic will persist, while a value of R0 
below 1 means that an epidemic will die out. Furthermore, the text developed the use of the 
force of infection λ, or the rate at which susceptible individuals become infected in a 
population – one of the fundamental principles of modelling infectious disease transmission. 
Today, mathematical modelling is an important tool for synthesizing a diverse array 
of data and projecting the impact and cost-effectiveness of scaling up different prevention 
packages. Modelling involves making precise assumptions based on available data to create a 
comprehensive catalogue of parameters that affect disease transmission, and using these 
parameters to calibrate a particular system. Principles of good modelling include the 
incorporation of important features of the natural history and transmission of the infection in 
question, balancing complexity in model structure with available data, calibration to data, and 
the ability to explore sources of uncertainty in the model [249,250]. In addition to 
deterministic models dictated by differential equations, stochastic models, which take into 
account randomness, can also be used to simulate epidemics. This includes individual-based 
(or microsimulation) models that follow a cohort of individuals over time, or network models 
that analyse transmission through, for example, high-risk sexual networks such as FSW or 
MSM. Models can explore the paths by which individuals become infected, the number of 
infections averted by an intervention, or the cost-effectiveness boundaries between two or 
more interventions, demonstrating scenarios in which one intervention might be more 
valuable than another. 
Mathematical modelling of public health issues has become increasingly relevant to 
healthcare decision-making in recent years, though not without controversy. When models of 
infectious disease were first introduced, they were considered on the fringe of scientific 
evidence and often viewed as crude and unrealistic representations of complex biological 
systems. As data surveillance has improved and quantitative techniques have developed, 
modelling has now become a mainstream component of decisions regarding funding, 
strategy, and the large-scale development of health guidelines [244,251,252]. Nevertheless, a 
consensus has not yet emerged about the best place for modelling in the decision-making 
process. Models can lack transparency and can be seen as “black boxes” by those outside the 
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field. Furthermore, models require many simplifying assumptions (often due to insufficient 
data) and heterogeneity in behaviour can never be represented in a model as it is in the real 
world. Though their usefulness for health policy decision-making has increased over time, 
models are also not a proxy for data and models are only ever as accurate as the data that is 
fed into them. Going forward, more communication will need to be fostered between data 
collectors, modellers, and policymakers, with particular attention paid to data needed to 
inform models and the most pertinent questions for investigation in model-based analyses 
[244]. 
 
1.6.1          Modelling the Cost-Effectiveness of PrEP 
 
For serodiscordant couples, future models of prevention options are necessary to 
understand and optimise ideal cost-effective programs for African countries. After clinical 
trial results of ARV-based prevention, it will be important to examine how adherence will 
affect implementation of PrEP, and to understand what thresholds of PrEP use will be 
required to generate a substantial reduction in incidence. This will necessitate a 
comprehensive understanding of adherence to ARVs, traditional prevention methods, sexual 
transmission within couples and through external partnerships, and the context in which the 
epidemic is occurring, in order to create insightful results for policymakers. 
For policymakers, two of the most important factors in adapting guidelines for an 
intervention are its impact – i.e. how many infections are averted – and cost-effectiveness – 
i.e. if the intervention is a good use of funds or not.  Several studies have addressed these 
questions for PrEP interventions, both in developed and developing countries [124-126,253-
260]. In 2010, Pretorius et al. estimated that targeting PrEP towards high-risk women could 
avert up to 30% of new infections, at a cost ranging from $12,500-$20,000 per infection 
averted, though the cost is altered significantly by increasing ART use [256].  PrEP could 
also be cost-effective for women [258] and couples in South Africa [125], high-risk 
individuals in rural Zambia [124], and MSM in the United States [257]. The consensus of 
these studies is that PrEP can be cost-effective – and even cost-saving, under certain 
circumstances (such as high PrEP effectiveness, high-risk couples, low PrEP cost, and short 
duration of PrEP use) – but that its cost-effectiveness could be attenuated by prioritizing the 
wrong individuals, low adherence, or increasing use of treatment as prevention. 
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The cost-effectiveness of PrEP ultimately depends on a suite of changing factors: 
epidemic context, ART rollout, PrEP coverage, the cost of PrEP relative to ART, background 
incidence of the population, and individual adherence. This thesis will attempt to address 
these factors for serodiscordant couples in Africa, and provide useful and realistic estimates 
of the impact and cost-effectiveness of daily oral PrEP for this key population. 
 
1.7  Organisation of the Thesis 
 
This thesis aims to describe how serodiscordant couples in sub-Saharan Africa can 
use antiretrovirals for the purposes of preventing HIV-1 and other associated outcomes, and 
to provide recommendations for optimisation. This is accomplished through statistical 
analysis of trial and demonstration project data on adherence and behaviour of serodiscordant 
couples, and mathematical modelling of couples using an individual-based model. 
First, the potential supplementary benefit of PrEP for preventing HSV-2 infections is 
explored in Chapter 2. In Chapter 3, adherence data from the Partners PrEP Study and 
Partners Demonstration Project are analysed to shed light on the patterns of daily adherence 
to oral PrEP. In Chapter 4, I describe the development of a microsimulation model of 
serodiscordant couples to include realistic HIV-1 transmission, individual-level adherence 
patterns, PK/PD of plasma tenofovir, and empirical costs. Chapters 5 and 6 present modelling 
results regarding the impact and cost-effectiveness of a PrEP intervention for East African 
couples in the context of in-depth adherence patterns observed in the Partners PrEP Study and 
Partners Demonstration Project, respectively. Finally, Chapter 7 brings together the threads of 
the previous chapters in order to deliver recommendations for the use of antiretrovirals in 
serodiscordant couples in sub-Saharan Africa, and addresses the potential implementation of 
PrEP programs and questions in need of future analysis. 
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2  Re-evaluating the cost-effectiveness of PrEP for 
serodiscordant couples given the supplementary benefit 
of reduced HSV-2 incidence 
 
A modified version of this chapter has been published: Jewell BL, Cremin I, Pickles M, 
Celum C, Baeten JM, et al. (2015) Estimating the Cost-Effectiveness of Pre-Exposure 
Prophylaxis to Reduce HIV-1 and HSV-2 Incidence in HIV-Serodiscordant Couples in South 
Africa. PLoS One 10: e0115511.  
Abstract 
Background: Daily oral tenofovir-based pre-exposure prophylaxis (PrEP) has been shown to 
reduce the risk of acquiring HIV-1 and herpes simplex virus type 2 (HSV-2) by 75% and 
33%, respectively, among HIV-serodiscordant couples.  
Aims: The purpose of this chapter was to re-evaluate the cost-effectiveness of daily oral PrEP 
for HIV-serodiscordant couples in South Africa, in light of the supplementary benefit of 
reducing HSV-2 incidence in addition to preventing acquisition of HIV-1. 
Methods: A pre-existing microsimulation model of HIV-serodiscordant couples in South 
Africa was adapted to include HSV-2 acquisition, transmission, and interaction with HIV-1. 
The model was parameterized based on data from the Partners in Prevention HSV/HIV 
Transmission Study in which all HIV-infected partners were co-infected with HSV-2, and 
67% of HIV-uninfected partners had HSV-2 but not HIV-1. 
Results: When PrEP was assumed to have no efficacy on reducing the risk of acquiring 
HSV-2, the cost per disability-adjusted life-year (DALY) averted was $10,383 after 20 years. 
With an assumed 33% reduction in HSV-2 acquisition, the cost per DALY averted was 
$9,757 – equivalent to a 6% reduction. If all couples were dually discordant for both HIV-1 
and HSV-2, the cost per DALY averted fell to $1,445, demonstrating that the effect is limited 
by HSV-2 seroconcordance in couples. 
Conclusion: The supplementary benefit of the reduced risk of acquiring HSV-2 by means of 
PrEP means that extra health benefits are gained at no additional cost, though the benefit only 
modestly alters estimated cost-effectiveness of the intervention. 
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2.1 Background 
	  
The presence of other sexually transmitted infections has long been considered an 
important epidemiological factor that increases the risk of both HIV transmission and 
acquisition [261,262]. A number of STIs have been shown to affect the probability of 
acquiring HIV-1 [263], including herpes simplex virus type 2 (HSV-2) [108,160], bacterial 
vaginosis [264], human papilloma virus (HPV) [265], gonorrhoea [266], chlamydia [161], 
syphilis [267], and lymphogranuloma venereum (LGV) [268]. STIs can alter the risk of 
acquiring HIV through several mechanisms: for STIs that cause genital ulcers, like HSV-2 or 
syphilis, tears in the genital mucosa can function as entryways for HIV, and inflammation 
permits CD4+ cells to concentrate at the site of exposure. In addition, STIs can make an HIV-
infected person more infectious by promoting genital shedding of HIV-1, or by increasing the 
individual’s viral load. 
HSV-2, in particular, is thought to have strongly influenced the spread of the 
epidemic in southern Africa [109,110], where prevalence of the infection has reached near-
saturation in many areas [269]. The two infections work synergistically, with each promoting 
the transmission or acquisition of the other [270-272]. Individuals with HSV-2 have a 
significantly greater risk of acquiring HIV-1; a meta-analysis of longitudinal studies 
determined the relative risk (RR) as 2.7 (95% CI 1.9-3.9) for heterosexual men, 3.1 (95% CI 
1.7-5.6) for women, and 1.7 (95% CI 1.2-2.4) for MSM [108]. Susceptibility may be further 
heightened by the presence of genital ulcers, which can facilitate the entry of HIV-1 through 
breaks in the skin [153], but transmission may occur with or without the presence of 
symptomatic ulcerations. In addition, co-infection with HIV-1 and HSV-2 has been 
associated with a higher HIV-1 viral load [273-275], which in turn can lead to greater 
infectiousness of HIV-1 [108,152] and faster disease progression. Conversely, HIV-infected 
individuals are at higher risk of acquiring HSV-2 [270], and those with co-infection are also 
more likely to transmit HSV-2 to a partner [276]. 
For pregnant women, contracting HSV-2 during the third trimester can additionally 
pose a serious risk of transmission to the baby. Due to the frequency of ulcers during primary 
acute HSV-2 infection, women may pass the disease on to the neonate during birth, which 
may result in disability – primarily central nervous system disorders and encephalitis – or 
death [277]. In particular, this consequence may be concerning for populations with young 
women at high risk of acquiring HSV-2 and with high rates of fertility. For example, 
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adolescent women in South Africa have high prevalence of HIV-1, HSV-2, and pregnancy – 
6.4%, 10.7%, and 3.6%, respectively [278]. Preventing acquisition of HSV-2 among these 
women would have beneficial consequences, both in terms of reducing the risk of acquiring 
HIV-1 and by potentially averting a small number of cases of neonatal herpes infection. 
Efforts to control the spread of HSV-2 have been largely unsuccessful, as there in no 
cure and few primary prevention options are available. Condoms are only partially effective 
at preventing HSV-2 acquisition [279], though they remain the most reliable solution 
available. Despite efforts to develop a vaccine, none have been proven efficacious [280]. 
Treatment for HSV-2 infection – using the antiretroviral drugs acyclovir and valacyclovir – is 
available, and has been shown to reduce asymptomatic shedding of HSV-2 [281] and the 
recurrence of genital ulcers [111]. In addition, valacyclovir reduced the risk of acquisition of 
HSV-2 in HSV-serodiscordant couples by 48% [282], but this effect was not validated for 
HIV-1 serodiscordant couples in which the HIV-uninfected partner was also susceptible to 
HSV-2 [283]. Furthermore, a trial of HSV-2 suppressive therapy to decrease transmission of 
HIV-1 from partners co-infected with HIV-1 and HSV-2 to their HIV-1 susceptible partner 
failed to demonstrate efficacy, in spite of reducing HIV-1 viral load, the frequency of 
symptomatic HSV-2 reactivations [111], and slowing HIV-1 disease progression [284]. 
Two trials of PrEP to prevent HIV infection unexpectedly discovered that in addition 
to preventing acquisition of HIV-1, PrEP also reduced HSV-2 incidence [106,107]. 
CAPRISA 004, which tested the efficacy of a 1% topical tenofovir gel applied vaginally 
before and after sex, found that it reduced the risk of acquiring HIV-1 by 39% (95% CI 6-
60%, p=0.017) and HSV-2 by 51% (95% CI 23-70%, p=0.003) in a population of young 
South African women [48,106]. In addition, the Partners PrEP Study found that daily oral co-
formulated FTC/TDF decreased incidence of HIV-1 by 75% (95% CI 55-87%, p<0.001) and 
HSV-2 by 33% (95% CI 2-54%, p=0.038) among heterosexual HIV-serodiscordant couples 
[50,107]. Despite the positive findings from the Partners PrEP trial, there remains some 
debate concerning the efficacy of daily oral PrEP against HSV-2. One study of tenofovir 
found that administering the drug as an intravaginal gel exerted antiviral effects that 
prevented the replication of HSV-2 DNA-polymerase, but that required concentrations could 
only be achieved at the site of exposure via topical dosing [112]. In addition, patients co-
infected with HIV-1 and HSV-2 who were taking oral tenofovir-based ART showed no 
evidence of decreased shedding of HSV-1 or HSV-2 [285]. Daily oral PrEP also did not 
provide a supplementary benefit of preventing HSV-2 incidence in a population of MSM 
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enrolled in the iPrEx trial, though participants already infected with HSV-2 did exhibit fewer 
occurrences of severe ulcers [113]. These conflicting results indicate that there may be a 
difference in efficacy based on HIV status, and that the true degree of the anti-herpetic effect 
is currently unknown. The wide confidence intervals surrounding the reduction in HSV-2 
incidence in the Partners PrEP Study also imply that the effect of oral PrEP on HSV-2 could 
be lower than estimated. 
Nevertheless, HIV-serodiscordant couples are a key population for HIV prevention 
interventions and are also in need of effective ways to prevent acquisition of HSV-2, and the 
dual antiviral effects could be of substantial use to this group. Given their long-term exposure 
to the risk of acquiring HIV-1 and HSV-2 from an infected partner, low frequency of condom 
use, and demonstrated high adherence to PrEP [215], serodiscordant couples may 
additionally benefit from the reduction in HSV-2 incidence. In a previous study, Hallett et al. 
modelled the impact and cost-effectiveness of daily oral PrEP for HIV-1 prevention in a 
population of South African HIV-serodiscordant couples, without any assumed benefit of 
PrEP for preventing HSV-2 infections [125]. This analysis found that offering PrEP to this 
population could be cost-effective, and could potentially be more cost-effective than 
introducing earlier ART, depending on the characteristics of couples and the relative cost of 
PrEP to ART.  In light of the additional benefit of PrEP for preventing HSV-2 observed in 
the Partners PrEP Study, it is important to reassess the cost-effectiveness of daily oral PrEP. 
To my knowledge, no other modelling study has investigated the overall cost-effectiveness of 
daily oral PrEP inclusive of the benefit of preventing HSV-2 infections. This chapter provides 
revised estimates of the cost-effectiveness of PrEP, in terms of the cost per disability-adjusted 
life-year (DALY) averted, by incorporating HSV-2 transmission and the reduced risk of 
HSV-2 acquisition afforded by PrEP into the model. 
 
2.2  Methods 
 
2.2.1  Structure of the Mathematical Model 
 
An existing microsimulation model had previously been developed to model HIV 
transmission among HIV-serodiscordant couples in South Africa [125] and also forms the 
basis of the model described in Chapter 4. The original model by Hallett et al. included HIV-
1 transmission and disease progression, ART use, distribution of couples by age, sex, and 
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CD4 cell count, aging, background and HIV-induced mortality, pregnancies, varying 
unprotected sex acts, and hazard of infection from an external partnership. In the model, 
couples have recently undergone testing and discovered that they are serodiscordant, but the 
HIV-infected partner is ineligible for ART at national guidelines (CD4 counts <200 cells/µl 
in South Africa at the time). The model assigns sex and age to both partners, a CD4 cell count 
category (<200, 200-349, 350-499, or ≥500) to the HIV-infected partner, and monthly 
frequency of condomless sex within the couple, all according to distributions from the 
Partners in Prevention HSV/HIV Transmission Study data. A percentage of pregnancies in 
the model are preceded by a 6-month period of fertility intention, during which time the 
couple has more condomless sex acts than normal. The analysis then tracks both partners 
monthly until they die, and determines the quality-adjusted life-years (QALYs) gained from 
four strategies of PrEP use. 
I revised the model to include the HSV-2 status of the couples, transmission of HSV-
2, including multiplicative risk factors, neonatal HSV-2 infection, protected sex acts, and 
tracking of external partnerships for both partners and both infections. Briefly, the adapted 
model tracks a cohort of 100,000 heterosexual HIV-serodiscordant couples over a 20-year 
time horizon, including HIV-1 disease progression, initiation of ART, HIV-1 and HSV-2 
transmission, including to and from external partners, and vertical transmission of HSV-2 to 
neonates (Figure 2.1).  
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Figure 2.1: Model diagram of HIV-1 and HSV-2 transmission. Solid lines are potential 
events in the model; dashed lines are factors contributing to the probability of those events 
occurring. Pink lines and dark blue lines indicate pathways or factors relating to HSV-2 
transmission and HIV-1 transmission, respectively. Green diamonds indicate factors affecting 
the per sex act risk of transmission of either infection. 
	  
2.2.2 The Partners in Prevention HSV/HIV Transmission 
Study 
 
The model is parameterized for South Africa using data from the Partners in 
Prevention HSV/HIV Transmission Study [111], a randomized, placebo-controlled trial 
investigating the HSV-2 suppressive therapy acyclovir for prevention of HIV-1. From 2004-
2008, the trial enrolled 3,408 heterosexual HIV-1 serodiscordant couples from 7 countries  
(Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, and Zambia). Couples in the 
trial were ≥18 years old, reported at least three unprotected sex acts in the three months prior 
to screening, and intended to remain a couple for the foreseeable future. HIV-infected women 
who were pregnant at the time of screening were excluded, and HIV-infected women who 
became pregnant during the trial stopped taking acyclovir throughout the pregnancy. The 
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HIV-infected partner was required to have a CD4 cell count >250 cells/µl, not be taking 
ART, and be co-infected with HSV-2. 
In the trial, 69% of couples were both HSV-2 seropositive at enrolment. The age-
specific prevalence of HSV-2 in the HIV-1 uninfected partners is shown in Table 2.1. The 
model simulates only couples like those that enrolled in the trial, potentially neglecting a 
small proportion of couples in South Africa in which the HIV-1 infected partner is not co-
infected with HSV-2. These couples account for approximately 10% of all HIV-
serodiscordant couples in South Africa, according to comprehensive screening data of 
couples eligible and ineligible for the study [111]. 
 
 
Age-specific prevalence of HSV-2 (%) 
Partners in Prevention HSV/HIV Transmission Study, 2004-2008 
18-24 25-34 35-44 45+ 
HIV-1 uninfected 
men in couple 28 53 65 73 
HIV-1 uninfected 
women in couple 72 86 95 97 
Table 2.1: Prevalence of HSV-2 with respect to age, sex, and HIV-1 status from the Partners 
in Prevention HSV/HIV Transmission Study [142]. All HIV-1 infected partners in the study 
were dually infected with HIV-1 and HSV-2. 
 
 Couples were followed in the study for over two years. HIV-infected partners 
attended monthly clinic visits, and their HIV-uninfected partners attended visits every 
quarter. At these clinic visits, sexual behaviour data, including the number of protected and 
unprotected sex acts with the study partner and any external partners, were collected, and 
HIV-uninfected partners were tested for HIV-1. CD4 cell counts for HIV-infected 
participants were measured every six months, and those who became eligible for treatment 
were referred to care. Couples received an additional package of HIV prevention 
interventions, including individual and couples counselling, provision of free condoms, and 
treatment for other STIs. 
 The distribution of population characteristics and behaviours in the Partners in 
Prevention HSV/HIV Transmission Study, which were also features of the original model 
developed by Hallett et al. [125], are shown in Tables 2.2-2.10. 
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Gender of HIV-Uninfected Partner % of All Couples 
Woman 23.5 
Man 76.5 
Table 2.2: Distribution of the gender of the HIV-uninfected partner in the Partners in 
Prevention HSV/HIV Transmission Study. 
 
In partnerships in which the male partner is HIV-uninfected, 56.9% of the men were 
circumcised. In the model, circumcision reduces the risk of HIV-1 acquisition per 
unprotected sex act by 65% [286] and reduces the risk of HSV-2 acquisition by 28% per 
unprotected sex act [287]. 
 
(A) Man is HIV-uninfected Partner 
 
Woman's Age 
15-19 20-24 25-29 30-34 35-39 40-44 45-49 50+ 
Man’s 
Age 
15-19 0% 0% 0% 0% 0% 0% 0% 0% 
20-24 1% 4% 2% 1% 1% 0% 0% 0% 
25-29 1% 7% 7% 3% 1% 1% 0% 0% 
30-34 0% 4% 9% 7% 1% 1% 0% 0% 
35-39 0% 3% 5% 7% 2% 1% 1% 0% 
40-44 0% 0% 2% 4% 5% 2% 1% 0% 
45-49 0% 0% 1% 3% 1% 2% 3% 1% 
50+ 0% 0% 0% 1% 1% 1% 2% 2% 
 
(B) Woman is HIV-uninfected Partner 
 
Woman's Age 
15-19 20-24 25-29 30-34 35-39 40-44 45-49 50+ 
Man’s 
Age 
15-19 0% 0% 0% 0% 0% 0% 0% 0% 
20-24 3% 3% 0% 0% 0% 0% 0% 0% 
25-29 1% 7% 5% 0% 1% 0% 0% 0% 
30-34 0% 5% 8% 7% 8% 0% 0% 0% 
35-39 0% 1% 3% 3% 8% 5% 0% 0% 
40-44 0% 0% 3% 6% 3% 3% 1% 0% 
45-49 0% 0% 0% 0% 3% 2% 3% 3% 
≥50 0% 0% 0% 0% 2% 3% 3% 1% 
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Table 2.3: Proportional age distribution of stable partnerships in the Partners in Prevention 
HSV/HIV Transmission Study if (A) the male partner is HIV-uninfected and (B) if the female 
partner is HIV-uninfected. 
 
 Age 
Pregnancy Incidence Rate 
(/100 woman-years) 
HIV-uninfected Women 15-24 30.38 
 25-29 36.02 
 30-34 22.66 
 35-39 13.51 
 40-44 4.94 
 45+ 0.00 
HIV-infected Women 15-24 22.16 
 25-29 12.42 
 30-34 9.72 
 35-39 7.79 
 40-44 0.00 
 45+ 0.00 
Table 2.4: Age-specific incidence of pregnancy for HIV-uninfected and HIV-uninfected 
women in the Partners in Prevention HSV/HIV Transmission Study. In the model, an 
assumption is made that HIV-infected women on ART experience pregnancies at the same 
rate as women not yet on treatment. 
 
(A) HIV-infected Male Partners 
 CD4 Cell Count Category 
Man’s Age 200-349 350-499 ≥500 
15-19 27% 31% 42% 
20-24 27% 31% 42% 
25-29 27% 31% 42% 
30-34 27% 31% 42% 
35-39 27% 31% 42% 
40-44 27% 31% 42% 
45-49 27% 31% 42% 
≥50 27% 31% 42% 
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(B) HIV-infected Female Partners 
 CD4 Cell Count Category 
Man’s Age 200-349 350-499 ≥500 
15-19 0% 50% 50% 
20-24 24% 30% 46% 
25-29 22% 34% 45% 
30-34 26% 30% 45% 
35-39 30% 21% 49% 
40-44 30% 35% 35% 
45-49 33% 42% 25% 
≥50 27% 55% 18% 
Table 2.5: Age-specific distribution of individuals in each CD4 cell count category at the 
beginning of the model for (A) HIV-infected male partners and (B) HIV-infected female 
partners in the Partners in Prevention HSV/HIV Transmission Study. In the model, an 
assumption is made for men that the distribution of CD4 cell count category did not vary 
significantly with age, as sample sizes were small. 
 
Number of Condomless Sex Acts Per 
Month Percent of Couples 
0-1 64% 
1-2 14% 
2-3 9% 
3-4 4% 
4-5 3% 
5-6 2% 
6-7 1% 
7-9 1% 
9-11 1% 
>11 2% 
Table 2.6: Distribution of unprotected sex acts each month from the Partners in Prevention 
HSV/HIV Transmission Study. At the beginning of the model, each couple is assigned a 
category of unprotected sex acts. Each month, the number of unprotected sex acts is sampled 
randomly from that category, assuming a uniform distribution and a maximum number of 
unprotected sex acts equal to 30. 
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Any External Partner Over Two Years of Follow-Up 
 None Any 
HIV-Uninfected Woman 92% 8% 
HIV-Uninfected Man 79% 21% 
Table 2.7: Distribution of external partners over two years of follow-up in the Partners in 
Prevention HSV/HIV Transmission Study. In the model, there is assumed to be no interaction 
with age, and woman are assumed to under-report having an external partner due to social 
desirability bias, which is accounted for using a fit parameter (see Table 2.11). 
 
Point Prevalence of Having an External Partner 
Month 0 6 12 18 24 
Women 0% 30% 29% 67% 33% 
Men 10% 39% 56% 37% 21% 
Table 2.8: Assumed point prevalence of having an external partner, for women and men who 
ever report having an external partnership, from follow-up visits every six months in the 
Partners in Prevention HSV/HIV Transmission Study. 
	  
2.2.3  Model Assumptions and Parameters 
 
In the model, a number of parameters concerning progression of disease for HIV-
infected individuals, mortality rates on ART, dropout from ART, use of PrEP, and the 
interaction between HIV-1 and HSV-2 have been drawn from a literature review (Table 2.9). 
In addition, some simplifying assumptions regarding HSV-2 infection have been made. HSV-
2 is assumed to exhibit constant, low-level infectiousness, and episodic symptoms such as 
genital ulcers are not explicitly modelled, due to evidence of frequent asymptomatic 
reactivations [288]. Implicitly, any changes in sexual behaviour during an episode of HSV-2 
reactivation are not modelled. ART use is also assumed to have no effect on reducing the risk 
of acquiring or transmitting HSV-2, given that no observed decrease in shedding of HSV-2 
was seen in HIV-1 infected persons [285]. The use of suppressive HSV-2 therapy is also not 
modelled, given that real-world use of acyclovir and valacyclovir in South Africa is relatively 
uncommon [289]. 
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Parameter Values Source 
Infectiousness of untreated individuals 
(relative to those with CD4 counts <500 
cells/µl 
CD4 350-500: 1.00 
 Cohort of stable 
serodiscordant couples 
[46] CD4 200-350: 1.59 
CD4 <200: 4.99 
Mean time spent in CD4 cell count 
category (years)a 
Infection to CD4 <500: 
2.4 
Pooled analysis of 
African observational 
cohort studies [290] 
CD4 350-500: 2.4 
CD4 200-350: 4.6 
CD4 <200: 2.6 
Infectiousness of individuals on ART 
(relative to untreated individuals with CD4 
count <350/µl 
0.08 
Cohorts of stable 
serodiscordant couples 
[46,47] 
Mortality rates on ART (per year)  
Multiple observational 
cohort studies [291-
293] 
First year:  
ART initiation at CD4 500+ 1.3% 
ART initiation at CD4 350-500 2.5% 
ART initiation at CD4 200-350 5% 
ART initiation at CD4 <200 10% 
Subsequent years:  
ART initiation at CD4 500+ 1.3% 
ART initiation at CD4 350-500 1.3% 
ART initiation at CD4 200-350 2.5% 
ART initiation at CD4 <200 5% 
Drop-out from ART (per year) 
First year: 10% Observational data 
from programs in 
Zambia [294] Subsequent years: 5% 
PrEP efficacy against HIV-1 90% 
Consistent with the 
range of efficacy 
reported in PrEP trials 
after accounting for 
adherence 
[50,210,215] 
PrEP efficacy against HSV-2 33% Partners PrEP Study [107]  
PrEP adherence 90% 
Consistent with overall 
adherence reported in 
a sub-study of 
adherence in the 
Partners PrEP Study 
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[215] 
Multiplicative factor for increased 
susceptibility to HIV-1 if HIV-uninfected 
women is pregnant 
2.3 
Prospective studies of 
HIV transmission 
during pregnancy [159] 
Multiplicative factor for increased 
transmissibility of HIV-1 if HIV-infected 
women is pregnant 
2.2 
Prospective studies of 
HIV transmission 
during pregnancy [159] 
Multiplicative factor for increased 
susceptibility to HIV-1 if HSV-2 infection 
>1 year (prevalent HSV-2 infection) 
3.0 
Systematic review and 
meta-analysis of 
longitudinal studies 
[108] 
Multiplicative factor for increased 
susceptibility to HIV-1 if HSV-2 infection 
<1 year (incident HSV-2 infection) 
6.0 
Assumed increase in 
susceptibility due to 
frequency of ulcers 
during primary HSV-2 
infection [108,153,295-
297] 
Multiplicative factor for increased 
susceptibility to HSV-2 among those with 
HIV-1 infection 
3.7 
Cohort of adults in 
Uganda [270] 
Multiplicative factor for increased 
transmission of HIV-1 among those with 
HIV-1/HSV-2 co-infection 
3.0 
Systematic review and 
meta-analysis of 
longitudinal studies 
[108] 
Multiplicative factor for increased 
transmission of HSV-2 among those with 
HIV-1/HSV-2 co-infection 
4.0 
Cross-sectional study 
of HIV-1/HSV-2 co-
infected women [276] 
Probability of acquisition of neonatal 
HSV-2 if mother acquires HSV-2 in last 
trimester 
33% 
Cohort of pregnant 
women with HSV-2 
infection [277] 
Probability of acquisition of neonatal 
HSV-2 if mother’s HSV-2 is a reactivation 3% 
Cohort of pregnant 
women with HSV-2 
infection [277] 
Probability of child death with neonatal 
HSV-2 65% [298] 
Given child survival, probability of child 
disability with neonatal HSV-2 80% [298] 
Full cost per person-year of ART US $515 [299] 
Full cost per person-year of PrEP US $250  [125,126] 
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aMean time elapsed between entering category (CD4 cell count reaching value of upper 
bound) and exiting category (CD4 cell count drops below value of lower bound). 
Table 2.9: Key parameters and assumptions in the model. 
 
 Oral PrEP is assumed to have an intrinsic efficacy of 90% protection against HIV-1, 
consistent with the results of the Partners PrEP Study, which also took place in a population 
of HIV-serodiscordant couples [50]. PrEP is also assumed to exhibit 33% protection against 
incident HSV-2 infections [107]. Individuals using PrEP in the model are assumed to have a 
uniform overall level of adherence of 90%, which is similarly high to that of individuals in a 
serodiscordant couple in the Partners PrEP Study [215]. The degree to which PrEP is 
efficacious against HSV-2 and the proportion of unprotected sex acts protected by PrEP are 
both varied in univariate and multivariate sensitivity analyses. I also assume that couples do 
not exhibit any risk compensation due to the HIV-uninfected partner’s use of PrEP – i.e. the 
couple’s sexual behaviour remains constant whether or not PrEP is being used as a prevention 
strategy in the relationship. 
 Protected sex acts are also modelled to capture the risk of HSV-2 transmission even 
when a condom is being used during intercourse. It is assumed that couples have a mean of 4 
condom-protected sex acts per month (based on the mean number of reported protected acts 
per month in the Partners in Prevention HSV/HIV Transmission Study), except during 
periods of fertility intention, when it is assumed that no sex acts are protected. Condoms are 
assumed to provide 100% protection against HIV-1 [39] and 75% protection against HSV-2 
 [279]. 
 Either partner in the couple can form external partnerships. A proportion of couples 
never engage in any external partnerships in their lifetime; those that do have external 
partners initiate and cease the relationships to match a distribution at six-month intervals 
(Table 2.8). Each individual that acquires an external partner may only have one such partner 
at a time, and so external partnerships do not represent extensive concurrency among the 
stable couples. The probability that an external individual is infected with HIV-1 or HSV-2 is 
derived from the prevalence of the respective infection in the general population of South 
Africa (Table 2.9), multiplied by a sex-specific parameter in order to match HIV-1 and HSV-
2 incidence from external partners seen in the Partners in Prevention HSV/HIV Transmission 
Study, and is updated every six months. Regardless of the characteristics of the external 
partnership (i.e. the HIV status and HSV-2 status of the internal and external partners), the 
partnership is assumed to have six unprotected sex acts and four condom-protected sex acts. 
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The number of protected acts is equivalent to the mean of unprotected acts in stable 
partnerships during the first month, and the number of unprotected sex acts is double that of 
stable partnerships. However, the specific values of these parameters do not make a 
significant difference in the model results, as the risk of transmission from external partners 
is calibrated separately to that of stable partnerships. If any external partner from the couple 
acquires either HIV-1 or HSV-2 from their partner in the stable serodiscordant partnership, 
the external partner’s DALYs from the time of infection are tracked with the couple’s 
DALYs, and are included in final calculations of the cost per DALY averted. 
 
 HIV-1 Prevalence HSV-2 Prevalence 
Men 23.7% 17% 
Women 32.7% 53% 
Table 2.10: Assumed prevalence of HIV-1 and HSV-2 for external partners in the general 
population in South Africa. HIV-1 prevalence is drawn from a Human Sciences Research 
Council (HSRC) survey of men aged 25-49 years and women aged 20-34 years in ‘most at-
risk groups’ [300]. HSV-2 prevalence is drawn from a study by Auvert et al. of young South 
African men and women (14-24 years of age) [301]. 
	  
2.2.4 Calculating HIV-1 and HSV-2 Transmission 
Probabilities 
 
 The probability of HIV-1 transmission (𝑝!"#) within the stable partnership is 
calculated monthly, and is determined using Equation 2.1 (adapted from Hallett et al. [125]): 
 𝑝!"# = 1−    1−   𝛽!,!,!,!,!,!,! !(!!!) 1−    1−   𝜀 𝛽!,!,!,!,!,!,! !"                (2.1) 
 
where 𝛽!,!,!,!,!,!,! is the probability of HIV-1 transmission per unprotected sex act with a 
HIV-infected partner with CD4 cell count category C, ART-status A, sex S, woman’s 
pregnancy status P, man’s circumcision status Q, HIV-infected partner’s HSV-2 status V, 
HIV-uninfected partner’s HSV-2 status W, n is the number of unprotected sex acts within the 
couple (Table 2.6), θ is the percentage of unprotected sex acts protected by PrEP (i.e. taking 
into account adherence to PrEP), and ε is the intrinsic efficacy of PrEP (i.e. the reduction in 
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transmission with perfect adherence). The probability of HIV-1 transmission per condomless 
sex act is defined as follows (Equation 2.2): 
 𝛽!,!,!,!,!,!,! =   𝜋!!𝜋!!𝜋!!𝜋!!𝜋!!𝜋!!𝜋!!𝛽!                (2.2) 
 
where 𝛽!  is defined as the basic transmission probability of HIV-1 per condomless sex act 
(from a non-pregnant woman to an uncircumcised man, with a partner not on ART, of CD4 
count above 500 cells/µl, and with neither partner infected with HSV-2). 𝜋!! ,𝜋!!,𝜋!!,𝜋!! ,𝜋!! ,𝜋!! ,  and 𝜋!!  indicate the change in the probability of transmission per sex 
act depending on the HIV-infected individual’s CD4 cell count category, the ART status of 
the infected partner, the gender of the HIV-uninfected partner, the pregnancy status of the 
female partner, the circumcision status of the man if HIV-uninfected, the HIV-infected 
partner’s HSV-2 status, and the HIV-uninfected partner’s HSV-2 status, respectively (see 
Tables 2.9 and 2.11 for parameter values). 
 The probability of HIV-1 transmission from an external partner (𝑝!"#$) is determined 
using Equation 2.3 and to an external partner (𝑝!"#$%) by Equation 2.4: 
 𝑝!"#$ = 1−    1−   𝛼!,!,!,!,! !!(!!!) 1− 1− 𝜀 𝛼!,!,!,!,! !!(!!!)             (2.3) 
 𝑝!"#$% = 1−    1−   𝛼!,!,!,!,!,!,! !!(!!!) 1− 1− 𝜀 𝛼!,!,!,!,!,!,! !!(!!!)            (2.4) 
 
where 𝛼!,!,!,!,! is the probability of HSV-2 transmission (𝑝!"#) is the probability of HIV-1 
transmission per condomless sex act with an HIV-infected external partner with sex S, 
woman’s pregnancy status P if the woman is the uninfected partner, man’s circumcision 
status Q, HIV-infected partner’s HSV-2 status V, HIV-uninfected partner’s HSV-2 status W, 
and nx is the number of condomless sex acts per month in the external partnership. The model 
does not take into account the explicit CD4 cell count of the external partner and assumes no 
use of ART. The probability of HIV-1 transmission per unprotected sex act from an external 
partner (Equation 2.5) and to an external partner (Equation 2.6) are defined as follows: 
 𝛼!,!,!,!,! =   𝜅!!𝜅!!𝜅!!𝜅!!𝜅!!𝛼!𝛽!                    (2.5) 
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𝛼!,!,!,!,!,!,! =   𝜅!!𝜅!!𝜅!!𝜅!!𝜅!!𝜅!!𝜅!!𝛽!                    (2.6) 
 
where 𝛼! is the relative infectiousness of an external partner (due to prevalence of acute 
infection, increased likelihood of being in an acute stage of HIV-1 infection and having other 
co-factoring STIs in addition to HSV-2), and 𝜅!!, 𝜅!! , 𝜅!! , 𝜅!! , and 𝜅!!  represent the changes in 
probability of infection depending on sex, pregnancy status (if female), circumcision status (if 
male) of the HIV-uninfected partner, HSV-2 status of the HIV-infected external partner, and 
HSV-2 status of the HIV-uninfected partner, respectively. 𝜅!!   represents the CD4 cell count 
category and 𝜅!!  represents the ART-status of the HIV-infected individual in the stable 
partnership. 
 The probability of HSV-2 transmission (𝑝!"#) within the stable partnership is also 
calculated monthly, and is modelled using Equation 2.7: 
 𝑝!"# = 1−    1−   𝜔!,!,!,!,! !(!!!) 1−    1−   𝜏 𝜔!,!,!,!,! !"                           (2.7) 
 
where 𝜔!,!,!,!,! is the probability of HSV-2 transmission per sex act with an HSV-2 infected 
partner with sex S, man’s circumcision status Q, condom protection U, HSV-2 infected 
partner’s HIV-status Y, and HSV-2 uninfected partner’s HIV-status Z, and 𝜏  is the efficacy of 
PrEP against HSV-2. The probability of HSV-2 transmission per sex act is defined as follows 
(Equation 2.8): 
 𝜔!,!,!,! =   𝛾!!𝛾!!𝛾!!𝛾!!𝛾!!𝜔!                             (2.8) 
 
where 𝜔! is defined as the basic transmission probability of HSV-2 during an unprotected 
sex act from a woman to an uncircumcised man, in the absence of HIV-1 infection in either 
partner. 𝛾!!, 𝛾!!, 𝛾!!, 𝛾!!, and 𝛾!!  indicate the change in the probability of transmission per sex 
act depending on the sex of the HSV-2 uninfected partner, the circumcision status of the man 
(if HSV-2 uninfected), whether or not a condom was used in the sex act, the HIV-1 status of 
the HSV-2 infected partner, and the HIV-1 status of the HSV-2 uninfected partner, 
respectively. 
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The probability of HSV-2 transmission to and from an external partner (𝑝!"#$) is the 
same as that within the stable partnership, with the only substitution being the number of sex 
acts occurring in the external partnership that month (nx). 
 
2.2.5  Model Fitting and Fitted Parameters 
 
 
In addition to parameters derived from the literature, ten parameters were fit to the 
two-year sex-specific incidence of HIV-1 – from both internal and external partnerships – 
and the sex-specific incidence of HSV-2 (Table 2.11). The model was fit to overall incidence 
of HSV-2 for men and women and was not split by partnership type, as data was not collected 
on the origin of HSV-2 infections. All parameters were fit simultaneously using a weighted 
least-squares method, in which the goodness-of-fit statistic was weighted based on the 
number of person-years of observation. The parameter set with the best fit was selected from 
100,000 simulations. Confidence intervals were calculated to represent the range of incidence 
observed from 100 model simulations of approximately the same number of couples as those 
in the placebo arm of the trial (2,000). Figure 2.2 shows a visual representation of the 
incidence data and the respective model fits and confidence intervals. 
 
Parameter Fitted Value Tolerated Bounds 
Transmission probability of HIV-1 from an 
asymptomatic, non-pregnant HSV-2 uninfected 
woman to an uncircumcised, HSV-2 uninfected 
man 
0.00014 0.0001-0.00014 [302] 
Transmission probability of HSV-2 from an HIV-
uninfected woman to an HIV-uninfected, 
uncircumcised man 
0.00025 0.0001-0.01 
Relative susceptibility of women (compared to 
men) at exposures to HIV infection from stable 
partners (due to differences in condom use) 
0.25 0.25-2.0 [303-305] 
External partnership multiplier for women (due to 
underreporting) 3.0 1.0-5.0  [306] 
External partnership multiplier for increased 
infectiousness of HIV 30.0 1.0-40.0 [155,307] 
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Multiplier for increased likelihood of male external 
partners being infected with HIV 4.0 1.0-4.0 
Multiplier for increased likelihood of female 
external partners being infected with HIV 3.0 1.0-3.0 
Multiplier for increased likelihood of male external 
partners infected with HIV also being infected with 
HSV-2 
4.0 1.0-4.0 [301,308] 
Multiplier for increased likelihood of female 
external partners infected with HIV also being 
infected with HSV-2 
1.5 1.0-2.0 [301,308] 
Multiplier for male-to-female transmission of HSV-
2 1.75 1.0-6.0 [309,310] 
Table 2.11: Fitted parameters from the model, their fitted value, and the tolerated bounds 
used during the fitting procedure. 
 
 
	  
Figure 2.2: Plot of the Partners in Prevention HSV/HIV Transmission Study two-year 
incidence data (black bars) compared to the model estimates for the same time period (red 
crosses), with confidence intervals indicated by grey vertical lines and red dashed lines, 
respectively. HIV-1 transmission within stable partnerships is referred to as ‘linked’, whereas 
external transmission is referred to as ‘unlinked.’ 
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2.2.6  Modelling a PrEP Intervention 
 
 I simulated a PrEP intervention, in which the HIV-1 infected partner in the couple 
initiates ART as soon as their CD4 cell count drops below 350 cells/µl and the HIV-1 
uninfected partner takes daily oral PrEP prior to their partner’s ART initiation and for one 
year thereafter (i.e. as a “bridge” to ART). This strategy is consistent with current ART 
guidelines in South Africa, and the yearlong overlap of PrEP use by the HIV-uninfected 
partner and ART use by the HIV-1 infected partner allows sufficient time for viral 
suppression to take place in the HIV-1 infected partner [311]. 
 Health benefits and losses were measured in terms of DALYs, with each health 
condition assigned a specific disability weight to represent the burden of the condition on an 
individual’s quality of life. Disability weights reflect the severity of a health condition on a 
scale of 0 to 1, in which 0 is equivalent to perfect health and 1 is equivalent to death. In the 
model, DALYs can accrue from HIV-1 infection, respective of CD4 cell count and ART 
status, HSV-2 infection, and any life-years of disability caused by neonatal HSV-2, or the 
death of any neonates (Table 2.12). The DALY weights for HIV-1 states are from the 2010 
Global Burden of Disease Study [312]. This study did not list a specific DALY weight for 
HSV-2, and thus the value assigned is from the 2003 Iran Burden of Disease and Injury Study 
[313]. The Global Burden of Disease Study assigns weights to sexually transmitted diseases 
that are equivalent to mild or moderate abdominopelvic conditions, with a weight in the range 
of 0.012-0.123; the estimate for HSV-2 from the Iran Burden of Disease and Injury Study 
falls in the middle of this range. If an individual is co-infected with HIV-1 and HSV-2, the 
DALY weight assigned is based on the relevant HIV-1 health state, including whether or not 
the person is receiving ART and the amount of time spent on ART, summed with the DALY 
weight for HSV-2. DALYs are accrued over time, and are discounted annually at a rate of 
3%, as are costs. 
 
Health State Disability Weight Source 
Herpes simplex virus-2 0.067 Iran Burden of Disease and Injury Study 2003 [313] 
HIV: CD4 count 500+, no ART 0.051 Global Burden of Disease Study 2010 [312] 
HIV: CD4 count 350-500, no 
ART 0.051 
Global Burden of Disease 
Study 2010 [312] 
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HIV: pre-AIDS, CD4 count 
200-350, no ART 0.221 
Global Burden of Disease 
Study 2010 [312] 
AIDS: CD4 count <200, no 
ART 0.547 
Global Burden of Disease 
Study 2010 [312] 
HIV/AIDS: receiving ART, first 
year 
Assumed to be equivalent to 
disability weight at time of 
ART initiation 
--- 
HIV/AIDS: receiving ART, after 
first year 0.053 
Global Burden of Disease 
Study 2010 [312] 
HIV/HSV-2: CD4 count 500+, 
no ART 0.118 
Addition of HIV and HSV-2 
disability weights 
HIV/HSV-2: CD4 count 350-
500, no ART 0.118 
Addition of HIV and HSV-2 
disability weights 
HIV/HSV-2: pre-AIDS, CD4 
count 200-350, no ART 0.288 
Addition of HIV and HSV-2 
disability weights 
AIDS/HSV-2: CD4 count <200, 
no ART 0.610 
Addition of HIV and HSV-2 
disability weights 
HIV/AIDS/HSV-2: receiving 
ART, first year 
Assumed to be equivalent to 
HIV weight at time of 
initiation plus HSV-2 weight 
Addition of HIV and HSV-2 
disability weights 
HIV/AIDS/HSV-2: receiving 
ART, after first year 0.120 
Addition of HIV and HSV-2 
disability weights 
Neonatal death due to HSV-2 1, for a life expectancy of 60 years Statistics South Africa [314] 
Child disability due to HSV-2 0.221 
Global Burden of Disease 
Study 2010 (motor plus 
cognitive impairments due to 
encephalitis) [312] 
Table 2.12: List of DALY weights used in the model. 
 
In order to determine the cost per DALY averted, the intervention scenarios were 
compared to a baseline scenario with no PrEP and ART initiation at a CD4 cell count of 350 
cells/µl or below. One person-year of ART is assumed to cost $515 (in 2012 United States 
dollars [USD]), which includes a weighted average of first and second line ARVs, service 
delivery and monitoring costs, as well as logistical and administrative costs [299]. PrEP is 
assumed to cost $250 USD per person-year; given that PrEP has not been introduced in South 
Africa, this cost was based on values used in previous studies [125,126]. The calculation of 
the cost-effectiveness of PrEP takes the perspective of the healthcare system (unless noted 
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otherwise), in which averted HIV-1 infections benefit the system by additionally preventing 
subsequent years of ART. 
 
2.3  Results 
 
2.3.1  Cost per DALY Averted Over Time 
 
The modelled cost per DALY averted for each year of a 20-year PrEP intervention is 
shown in Figure 2.3, with the only differences in cost resulting from the 33% reduction in 
HSV-2 incidence. Assuming no protective efficacy of PrEP against HSV-2, the cost per 
DALY averted at the end of the intervention is $10,383, compared to $9,757 for PrEP with a 
33% protective effect against HSV-2 – a reduction of 6% over 20 years. In both scenarios, 
the cost per DALY averted drops dramatically over the first seven years of the intervention, 
due to the accumulation of averted HIV-1 and HSV-2 infections. If PrEP is assumed to have 
an effect on reducing HSV-2 acquisition by 33%, the intervention crosses the WHO’s cost-
effectiveness threshold of three times gross domestic product (GDP) per capita after seven 
years, and for one times GDP per capita after 17 years [315]. The number of DALYs 
generated by neonatal HSV-2 is small – less than 1% of total DALYs – and the benefit of 
reduced HSV-2 incidence accounts for an 8% reduction in neonatal HSV-2 at 20 years. 
Figure 2.4 shows the difference in averted DALYs over the 20-year intervention, as 
compared to the total DALYs averted, with a greater accumulation of averted DALYs 
towards the end of the intervention as a result of averted HSV-2 infections. At the end of the 
intervention, however, the vast majority of DALYs averted, compared to the baseline 
scenario, originate from PrEP preventing new HIV-1 infections, and the supplementary 
benefit of averting additional HSV-2 infections makes a minor contribution. 
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Figure 2.3: The discounted cost per DALY averted for a 20-year PrEP intervention with no 
assumed protection against HSV-2 acquisition and with 33% protection (both relative to a 
baseline scenario of no PrEP and ART initiation at a CD4 count of 350 cells/µl).  The dashed 
horizontal lines represent WHO thresholds for cost-effectiveness at three times GDP per 
capita ($34,320) and one times GDP per capita ($11,440) for South Africa. 
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Figure 2.4: Difference between the two scenarios in the mean number of DALYs averted per 
couple compared to total DALYs averted over the intervention period. 
	  
2.3.2  Univariate Sensitivity Analyses 
 
Figure 2.5 shows a tornado plot of univariate sensitivity analyses for potential factors 
that may contribute to the estimated cost per DALY averted. Each factor is compared to the 
baseline cost per DALY averted of PrEP with a protective effect of 33% against HSV-2 
acquisition, i.e. $9,757 per DALY averted. Raising the threshold of ART initiation from CD4 
counts of below 350 cells/µl to below 500 cells/µl, or to immediate treatment upon diagnosis, 
significantly improves the cost per DALY averted, as individuals spend less time on PrEP 
and averted HIV-1 infections result in even greater savings on ART costs. The degree to 
which PrEP prevents new HSV-2 infections is explored using the 95% confidence intervals 
from the Partners PrEP Study, but has a minimal effect on the cost per DALY averted 
compared to other factors. Varying the protection against HSV-2 yields a range of $8,853-
$10,355 per DALY averted, given 54% and 2% efficacy, respectively. A PrEP intervention in 
this population is also potentially more cost-effective if all couples are dually discordant (i.e. 
one partner has both infections and the other partner has neither), or if all couples engage in 
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more high-risk behaviours (e.g. reduced condom use and more unprotected sex or more 
external partners) than what is assumed in the baseline scenarios. If PrEP is only used during 
half of all condomless sex acts, the cost per DALY averted more than doubles, given that the 
same number of person-years of PrEP are being used, but with a reduced impact. Finally, if 
the intervention is funded separately from ART costs, the cost-effectiveness of the program is 
slightly reduced, and if PrEP costs are lower or higher than assumed, the cost per DALY 
averted changes linearly in accordance with the price of PrEP. 
 
	  
Figure 2.5: Univariate sensitivity analysis for factors affecting the cost per DALY averted at 
the end of a 20-year PrEP intervention, with a baseline assumption of a 33% protection 
against acquisition of HSV-2 (the vertical line at $9,757). The bars titled “ART Initiation 
CD4 <500” and “ART Initiation Immediately” assume increased thresholds for ART 
initiation. The bar titled “PrEP Adherence” assumes HIV-uninfected individuals are 50% 
adherent to PrEP. The bar titled “PrEP Protection Against HSV-2” explores the confidence 
intervals of the protective effect of HSV-2 from the Partners PrEP Study. The bar titled “All 
Couples HIV-1 & HSV-2 Discordant” simulates the same intervention among a set of 
couples in which one partner is dually infected with HIV-1 and HSV-2 and the other partner 
has neither infection. The bar titled “Higher-Risk Couples” assumes men are equally as likely 
to be the HIV-1 infected partner, condom use is reduced by 75%, 50% more couples have 
external partners, and the frequency of condomless sex in external partners is doubled, in 
comparison to the demographic and behavioural characteristics of the South African HIV-1 
serodiscordant couples who were enrolled in the Partners in Prevention HSV/HIV 
Transmission Study. The bar titled “Cost of PrEP Per Year” explores the cost per DALY 
averted if PrEP costs $150/PY or $350/PY, and the “PrEP Program Cost Perspective” bar 
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assumes that the cost of the PrEP intervention is separate from funding for treatment, and 
does not include savings from reduced ART need due to averted HIV infections. 
 
2.3.3  Multivariate Sensitivity Analysis 
 
In order to explore the compounded effects of parameter choice on the cost-
effectiveness of PrEP, I also conducted a multivariate sensitivity analysis. Three parameters 
that were varied in the univariate sensitivity analyses in Figure 2.5 are continuous (PrEP 
adherence, efficacy of PrEP on HSV-2, and cost of PrEP), one is ternary (ART initiation 
threshold), and three are binary (discordancy status, risk behaviour, and the program cost 
perspective). In this analysis, I chose not to vary the cost of PrEP continuously, as it only 
changes the resulting cost per DALY averted linearly. 
 The analysis was carried out using Latin Hypercube Sampling (LHS), a method which 
was first developed in 1979 by McKay et al. [316], and introduced to the field of 
epidemiology by Blower and Dowlatabadi in 1994 [317]. LHS allows the parameter space to 
be explored more efficiently than other more exhaustive methods of parameter variation; by 
forming a grid of N variables divided into M equally probably intervals, LHS samples each 
subsection of the grid only once. In this analysis, 24 separate combinations of the discrete 
binary and ternary parameters (excluding the cost of PrEP) were possible. Using LHS, I also 
selected twenty different values for both continuous variables (adherence to PrEP and the 
efficacy of PrEP on HSV-2), yielding a total of 9,600 different potential parameter sets. 
 In the analysis, the cost-effectiveness of the intervention ranged from a low of 
$486/DALY averted to a high of $5.6 million/DALY averted. In some scenarios, particularly 
those in which the ART initiation threshold is raised to CD4 counts <500 cells/µl or to 
immediate ART after a positive HIV diagnosis, the estimated cost per DALY averted ranges 
very little according to adherence and HSV-2 efficacy. This indicates that the PrEP 
intervention has less influence over the overall cost per DALY averted than does changing 
the ART initiation threshold. In these scenarios, evaluating the intervention from a program 
cost perspective can yield improved cost-effectiveness, as new HIV infections result in many 
more years of ART use. In scenarios with ART initiation at 350 cells/µl, the extremely high 
cost per DALY averted results from very low adherence (2%), during which funds are being 
spent on a PrEP intervention with the impact heavily limited by negligible adherence. 
Scenarios in which couples exhibit high-risk behaviours can lead to a lower cost per DALY 
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averted if adherence is high, as PrEP has the ability to prevent more infections, but risky 
behaviour can outweigh the benefits of PrEP if adherence is too low. The wide range of the 
cost per DALY averted, however, indicates that the true value of the cost-effectiveness of 
PrEP in this population is uncertain. 
 
ART Initiation 
Threshold 
Dually 
Discordant 
High 
Risk 
Program 
Cost 
Perspective 
Lowest 
Cost/DALY 
Averted 
Highest 
Cost/DALY 
Averted 
350  500 Immediate    $7,077 $1,794,936 
350  500 Immediate    $1,343 $1,822 
350  500 Immediate    $3,457 $5,613,708 
350  500 Immediate    $8,673 $1,814,353 
350  500 Immediate    $903 $1,560 
350  500 Immediate    $1,783 $2,145 
350  500 Immediate    $5,930 $5,685,551 
350  500 Immediate    $1,632 $2,086 
350  500 Immediate    $1,184 $1,447 
350  500 Immediate    $752 $855 
350  500 Immediate    $956 $1,288 
350  500 Immediate    $871 $942 
350  500 Immediate    $626 $782 
350  500 Immediate    $614 $644 
350  500 Immediate    $686 $769 
350  500 Immediate    $539 $584 
350  500 Immediate    $1,463 $1,768 
350  500 Immediate    $924 $1,033 
350  500 Immediate    $1,291 $1,672 
350  500 Immediate    $800 $861 
350  500 Immediate    $836 $1,005 
350  500 Immediate    $557 $589 
350  500 Immediate    $627 $699 
350  500 Immediate    $486 $524 
Table 2.13:  Ranges of the cost per DALY averted for each scenario evaluated in a 
multivariate sensitivity analysis. Green shading indicates which parameters were ‘switched 
on’ in each scenario. Yellow shading indicates that those parameters were ‘switched off’ in 
the respective scenario. 
 
2.4  Discussion 
 
In a hypothetical 20-year PrEP intervention among serodiscordant couples in South 
Africa, the ability of daily oral PrEP to prevent new HIV-1 infections dominates the total 
number of DALYs averted over time. The additional benefit of reducing HSV-2 incidence in 
the population has useful public health advantages, particularly given the paucity of primary 
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HSV-2 prevention strategies, but will not significantly affect the cost-effectiveness of a daily 
oral PrEP intervention for HIV-serodiscordant couples. This is in part due to the relatively 
mild health consequences of HSV-2 in comparison to HIV-1; preventing HSV-2 incidence 
does not avert early death or years of severe morbidity in the same way that preventing 
acquisition of HIV-1 does. In addition, HSV-2 transmission in stable couples happens 
relatively rapidly, with a median time to seroconversion of three months [318]. Given that 
oral PrEP does not provide complete protection against HSV-2, this may mean that new 
HSV-2 infections are merely postponed rather than prevented entirely. Nevertheless, HSV-2 
prevention is a potentially valuable additional benefit of PrEP, especially in populations that 
may have lower HSV-2 prevalence than serodiscordant couples in sub-Saharan Africa. 
Averting new HSV-2 infections in women – particularly during their years of fertility – could 
be especially beneficial for the health system, as the consequences of neonatal HSV-2 in 
terms of disability and death for the infant are severe. However, neonatal HSV-2 infection is 
a rare occurrence even without PrEP, and preventing new infections can only protect a small 
fraction of births in a setting where HSV-2 prevalence in women is already high. Although 
the cost of antiviral treatment for HSV-2 was not taken into account in this analysis, it is 
possible that averting HSV-2 infections could also reduce some cost to health system by 
decreasing the need for suppressive therapy. 
While preventing new HSV-2 infections may not provide a substantial economic 
incentive, it may also have less quantifiable benefits. Individuals diagnosed with HSV-2 may 
suffer from psychological distress, including social stigma, anger at the partner from whom 
the infection originated, and fear of telling future partners [319]. In addition, recurrence of 
active genital ulcers can impair the individual’s quality of sexual functioning and add stress 
to interpersonal relationships [320]. The additional antiviral benefit of PrEP may be more 
valuable on a qualitative level than economically. 
 In South Africa and throughout sub-Saharan Africa, HIV-1 and HSV-2 co-infection is 
prevalent and acquisition of HSV-2 frequently occurs early in sexual activity, regardless of 
HIV-1 status [278,321]. By the time that stable HIV-serodiscordant couples are identified by 
the health system, HSV-2 transmission has often already occurred [322]. Therefore, it stands 
to reason that PrEP could have a greater impact on reducing HSV-2 incidence and thus 
demonstrate greater cost-effectiveness in other populations with lower prevalence of HSV-2. 
Among young South African women in the CAPRISA 004 trial, for example, incidence of 
HSV-2 was 20.2 per 100 PY of observation in the placebo arm [48], indicating a population 
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that would benefit greatly by having more primary prevention options for HSV-2 available. A 
modelling study of the impact and cost-effectiveness of tenofovir gel among young women in 
Gauteng province in South Africa has also predicted that introducing coitally-dependent 
microbicide PrEP would be highly cost-effective, at less than $300 per DALY averted [323]. 
However, adherence to gel has been demonstrably low in several studies, suggesting that a 
different formulation of PrEP might be better suited for young women [95,97]. A PrEP 
intervention might provide maximal impact in a population of young women simultaneously 
susceptible to HSV-2, HIV-1, and pregnancy, given the additional risk of vertical HSV-2 
transmission. Although our analysis did not demonstrate a substantial change in the cost-
effectiveness of PrEP for serodiscordant couples based on the supplementary benefit of 
reducing HSV-2, further modelling of oral PrEP is needed to investigate the difference in 
impact and cost-effectiveness in other populations, such as young women. 
 The cost per DALY averted by means of PrEP is sharply reduced if the threshold for 
ART initiation for the HIV-1 infected partner is altered to either CD4 counts less than 500 
cells/µl or immediately upon diagnosis. In these scenarios, HIV-1 uninfected partners in the 
couples spend less time taking PrEP overall, and averting new HIV infections prevents 
further spending on costly ART. Given that the WHO-recommended threshold for ART 
initiation has recently been raised to CD4 counts below 500 cells/µl, and that early ART 
demonstrates greater cost-effectiveness than PrEP, earlier ART initiation may be preferable 
to a PrEP intervention in the population, from a cost-effectiveness point of view. However, if 
a substantial proportion of HIV-1 and HSV-2 infections originate from partnerships external 
to the couple, PrEP might be a preferable option to earlier ART. An important consideration 
for interventions for serodiscordant couples is the extent to which they can realistically be 
deemed “stable,” given that 25-30% of HIV transmission in serodiscordant couples has been 
shown to come from a source besides the stable partner [46,47]. The preferences of couples 
themselves are also relevant, and some couples might elect to have the HIV-1 uninfected 
partner take PrEP over earlier ART initiation for the HIV-1 infected partner [102], especially 
if the couple is dually discordant for both HIV-1 and HSV-2.  
 In South Africa, prioritized PrEP for serodiscordant couples could also potentially 
make a useful contribution to dual prevention of HIV-1 and HSV-2 for less overall budgetary 
impact than earlier ART initiation. In the South African sites in the Partners in Prevention 
HSV/HIV Transmission Study, 27.4% of couples tested were HIV-1 serodiscordant [148], 
which may indicate hundreds of thousands of individuals for short-term PrEP use. Unlike 
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early ART initiation, PrEP can be used as a prevention mechanism during “seasons of risk” 
only – e.g. during brief intervals of time during which the couple is trying to conceive and 
cannot use other prevention measures such as condoms – and does not necessarily require 
provision of costly medication for years. PrEP might be a useful addition to the combination 
prevention options currently available in South Africa, particularly in scenarios with earlier 
ART initiation when fewer years of PrEP use are necessary. As with all cost-effectiveness 
analyses, our analysis does not consider affordability and it is not clear whether the WHO-
recommended threshold represents the opportunity cost of displaced resources for health. 
 The model also has some important limitations. First, no other co-infecting STIs in 
addition to HSV-2 are assumed to increase the risk of transmission of either HIV-1 or HSV-
2. Secondly, the natural history of HSV-2 infection is represented simplistically in the model; 
HSV-2 is assumed to exhibit constant low-level infectiousness and no specific genital ulcer 
outbreaks are modelled. While there is still a possibility of HSV-2 transmission during 
asymptomatic periods [288], the changes in risk are more dynamic than represented in the 
model, and this could affect the rate of transmission substantially. It is also plausible that 
individuals experiencing outbreaks might reduce sexual contact around this period, but 
conversely, individuals could exhibit no change in sexual behaviour and have an increased 
risk of transmission during a brief outbreak. Thirdly, adherence to PrEP in the model is 
universal (90%), when individuals in a cohort will exhibit much greater variation than 
assumed (see Chapter 3). Metrics of adherence other than overall mean adherence can also 
indicate times of disproportionate risk depending on the intersection of non-adherence and 
sexual behaviour (see Chapter 5). Fourthly, there may be potential ethical concerns associated 
with a PrEP approach that delays the start of ART for the infected individual in the couple, 
given that early treatment could affect survival of HIV-infected individuals. Finally, the 
intrinsic efficacy of PrEP for the prevention of HSV-2 is not clear, given the wide confidence 
intervals observed in the Partners PrEP Study (2-54%) [107] and the lack of demonstrated 
protection in the iPrEx trial [113]. Further studies of this effect will help to inform the 
estimates and the degree to which PrEP can provide supplementary antiviral prevention. 
 Ultimately, the additional benefit reaped by averting a small percentage of HSV-2 
infections in HIV-1 serodiscordant couples leads to a modest decrease in the estimated cost 
per DALY averted over the course of a hypothetical 20-year PrEP intervention. The 
magnitude of this benefit does not suggest a substantial departure from our previous 
understanding of the impact and cost-effectiveness of an oral PrEP intervention in this 
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population, but may make such a program more appealing for HIV-1 serodiscordant couples, 
particularly those who are dually discordant for both HIV-1 and HSV-2, given this secondary 
beneficial effect. 
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3      Understanding patterns of adherence to oral PrEP 
among serodiscordant couples 
 
 
Abstract 
Background: The Partners PrEP Study, a randomized controlled trial (RCT) of daily oral 
pre-exposure prophylaxis (PrEP) among serodiscordant couples in Kenya and Uganda, found 
that tenofovir-based PrEP reduced risk of HIV-1 acquisition by up to 75% overall, with 
protection rising to 91% for participants with detectable tenofovir in blood samples. In light 
of the successful results from the trial, the Partners Demonstration Project enrolled new 
serodiscordant couples in East Africa and investigated the use of PrEP for the HIV-
uninfected partner as a “bridge” to ART initiation for the HIV-infected partner. 
Aims: The objective of this chapter was to analyse and understand individual-level and 
overall patterns of adherence to PrEP for serodiscordant couples, both in a rigorous clinical 
trial setting and in the context of open-label use with less clinical oversight.  
Methods: One metric of adherence in the Partners PrEP Study and Partners Demonstration 
Project was through electronic pill bottle monitoring via the Medication Event Monitoring 
System (MEMS). A total of 1,144 participants and 899 participants were analysed from the 
trial and demonstration project data, respectively. Statistical analyses were performed to 
summarize overall adherence, factors associated with lower adherence, changes in adherence 
over time, and to compare adherence between the two populations. 
Results: Median overall adherence in the Partners PrEP Study was 92.4% (95% confidence 
interval [CI] 81.7-97.2%) and 84.5% (95% CI 63.9-94.7%) in the Partners Demonstration 
Project. Younger age was significantly associated with lower adherence in both settings, and 
male gender was associated with lower adherence in the trial but not the demonstration 
project. Adherence declined significantly over a year’s time by 6.6% in the Partners PrEP 
Study but increased by 1.2% over a year in the Partners Demonstration Project. 
Conclusion: Adherence to PrEP was high in both the Partners PrEP Study and the Partners 
Demonstration Project, but moderately lower in a population of younger couples with open-
label PrEP use and less clinical monitoring. 
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3.1  Background 
 
In Chapter 2, one of the key limitations of the model was the lack of resolution for 
PrEP adherence. As adherence to daily oral PrEP has been shown to vary widely both 
between [96] and within populations [210], and differences have had critical implications for 
the degree of protection against HIV [50,94], understanding realistic patterns of adherence 
will be essential for modelling exercises and future PrEP implementation. 
The importance of adherence for prevention is substantially more complex than for 
treatment. While sustaining lifelong high adherence to ART is necessary to prevent viral 
rebound, drug resistance [324,325], and disease progression, adherence to PrEP only needs to 
be “prevention-effective” [200] – i.e., good enough to prevent seroconversion during 
exposures to HIV. Risk may not be constant over time for many individuals, and low 
adherence does not necessarily constitute a PrEP failure, as it may correspond to periods of 
abstinence [326] or consistent use of other HIV prevention measures. In the prevention-
effective adherence paradigm described by Haberer and colleagues [200], successful PrEP 
adherence should be viewed not as near-perfect adherence, but through a more realistic lens 
that takes into account multiple strategies for HIV prevention, the timing of risk behaviour in 
conjunction with adherence, and the dynamism of risk. 
As most of PrEP adherence data exists within the context of clinical trials, a number 
of questions surrounding adherence have yet to be answered. Firstly, it will be important to 
understand individual distributions of PrEP adherence and non-adherence, rather than simply 
using broad summary statistics (e.g. mean adherence across the cohort). Secondly, knowing 
how adherence differs from a trial setting to open-label use, with known efficacy of PrEP, 
will inform what types of adherence are likely to be observed in a real-world PrEP 
intervention. Thirdly, determining which metrics of adherence would be most useful for 
measuring the effectiveness of a prevention program would be helpful for future 
implementation of PrEP programs. Finally, realistically assessing what degree of population-
level adherence is sufficient to avert a substantial proportion of infections – and whether or 
not such adherence is likely to be achievable – will be crucial for programmatic success. 
In the following work, I analyse trends and patterns from two separate cohorts of 
serodiscordant couples in East Africa, one in the context of a rigorous clinical trial (the 
Partners PrEP Study) and one with open-label PrEP use and less oversight (the Partners 
Demonstration Project). The results of this analysis shed light on the multiple ways in which 
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adherence to PrEP can be measured, and additionally form the basis of the adherence 
adaptations of the model described in Chapter 4. 
  
3.2  Methods 
 
In this chapter, I perform descriptive statistical analyses on individual-level adherence 
data for PrEP among serodiscordant couples. In order to understand realistic adherence 
patterns I analyzed and compared data from two sources: the Partners PrEP Study, a 
randomized, placebo-controlled trial of daily oral PrEP [50], and the Partners Demonstration 
Project, an open-label study of the implementation of ART and PrEP [327].  
 
3.2.1  Introduction to the Partners PrEP Study 
 
The Partners PrEP Study was a phase III, randomized, placebo-controlled trial that 
was conducted among 4,747 heterosexual HIV-1 serodiscordant couples at nine sites in 
Kenya and Uganda [50]. The trial enrolled couples from July 2008 until November 2010, and 
follow-up continued through 2012. Criteria for enrollment of HIV-uninfected partners in the 
couples included age between 18 and 65 years old, recent sexual intercourse with their study 
partner, and the intention to remain in a relationship with the study partner. In addition, 
participants were required to have normal renal function, no hepatitis B infection, and women 
could not be pregnant or breastfeeding. HIV-infected partners were required to be ineligible 
for ART according to national guidelines at the time. HIV-uninfected partners were 
randomized to one of three available arms: daily oral TDF PrEP, FTC/TDF PrEP, or placebo. 
In addition to receiving study pills, couples were provided with access to extensive HIV-1 
prevention services, including counseling to encourage risk reduction, HIV-1 testing and 
post-testing counseling, provision of free condoms, STI testing and treatment, and referral to 
other HIV-1 prevention services such as VMMC and PEP.  
During the study, both partners attended regular clinic visits. HIV-uninfected partners 
had monthly visits; at each visit, the individual was tested for HIV-1, returned any unused 
pills from the previous month, and given 30 days’ worth of medication for the upcoming 
month. In addition, they received individual adherence counseling and were assessed for any 
side effects from the medication. If an HIV-uninfected woman became pregnant at any point 
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during the study, her medication was withheld for safety reasons during pregnancy and 
throughout periods of breastfeeding. HIV-infected partners attended quarterly clinic visits at 
which they received HIV-1 care services and viral load monitoring. CD4 counts were 
measured every six months, and individuals who became eligible for ART according to 
national guidelines were counseled and referred to an external clinic for treatment. 
 In July 2011, the independent data and safety monitoring board for the trial 
recommended that the results of the study become publicly available and the placebo arm be 
discontinued due to demonstration of efficacy in both active arms. By this date, 67% fewer 
HIV-1 infections (95% CI 44-81%, p<0.0001) had occurred in the TDF arm and 75% fewer 
infections (95% CI 55-87%, p<0.0001) had occurred in the FTC/TDF arm [50]. Both TDF 
alone and FTC/TDF demonstrated protection among men and women, and both medications 
were found to be very safe. In addition, retention and adherence were high throughout the 
trial – more than 96% of participants remained in the study throughout follow-up, and median 
adherence was higher than 97% by self-report, unannounced pill counts (UPC) and electronic 
monitoring [215]. For participants with detectable tenofovir concentrations in blood plasma, 
protection was estimated to be approximately 90% [210]. 
The Partners PrEP ancillary adherence study (AAS) – a sub-study of adherence to 
PrEP – was simultaneously conducted among a sample of 1,147 participants enrolled at three 
sites in Uganda (Kabwohe, Kampala, and Tororo) [215]. For individuals enrolled in the AAS, 
adherence was measured using UPC and MEMS, which recorded the time and date of every 
opening of the pill bottle. Participants in the AAS received initial adherence counseling 
standard to all PrEP users in the trial. Additionally, if an individual’s adherence fell below 
80% according to UPC, the individual received an intensive adherence counseling 
intervention. This intervention had a significant effect on improving adherence; mean 
adherence rose from 75.7% in the month prior to the intervention to 84.1% in the month 
following the intervention (p<0.001) [216]. In this chapter, I use participant MEMS 
adherence data from the AAS to evaluate overall adherence and individual-level patterns of 
adherence within the Partners PrEP Study. Data used in this analysis were collected from 
November 2009 – October 2012, with variable lengths of follow-up for each couple. 
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3.2.2  Introduction to the Partners Demonstration Project 
 
The Partners Demonstration Project is an on-going open-label study seeking to assess 
the implementation of antiretrovirals for HIV-1 prevention, including ART for HIV-infected 
individuals and PrEP for HIV-uninfected individuals, in a more realistic setting than that of a 
clinical trial [327]. The study enrolled 1,013 heterosexual HIV-1 serodiscordant couples at 
four sites in Kenya (Kisumu and Thika) and Uganda (Kabwohe and Kampala) from 
November 2012 until August 2014, none of whom had been enrolled in the Partners PrEP 
Study. Couples were recruited based on an empiric risk score composed of factors indicating 
a higher risk of HIV-1 transmission, including younger age, recent unprotected sex, and a 
HIV-infected partner with a high viral load [145]. Of all couples screened for enrolment, 77% 
of couples met the necessary criteria of having a risk score ≥5. In the demonstration project, 
HIV-uninfected individuals take PrEP up until the time that their HIV-infected partner 
initiates ART and for six months thereafter – otherwise known as using PrEP as a “bridge” to 
treatment. Over 848 PY of follow-up time to date (through 5 January 2015), HIV-uninfected 
partners used PrEP prior to ART initiation for the HIV-infected partner for 48% of the time, 
PrEP and ART use overlapped for 27% of the time, ART alone was used 16% of the time, 
and neither for 9% of the time, according to pharmacy refill data [328]. Uptake of PrEP was 
high, with 95% of individuals initiating PrEP at enrolment; 91% of those individuals 
continued using PrEP at 6 months after enrolment, and 84% were still using PrEP one year 
after enrolment [328]. Reasons for not using PrEP one year after enrolment included partner 
ART use, loss to follow-up, pregnancy or breastfeeding, individual preference, or partnership 
dissolution [328]. 
As opposed to the trial, no placebo-controlled group is included in the demonstration 
project for ethical reasons, and so a counterfactual model was constructed by the Partners 
Demonstration Project team to estimate expected incidence in the absence of the intervention. 
The model was based on bootstrapped simulations of a subset of data from the placebo arm of 
the Partners PrEP Study, using couples whose risk scores and duration of follow-up time 
matched recruitment for the demonstration project. The model predicted that incidence in the 
absence of the demonstration project would be 5.2/100 PY (95% CI 3.7-6.9/100 PY), with an 
expected 39.7 infections over the follow-up time accrued [121]. As of January 2015, two 
infections had occurred, and both individuals who became infected had no detectable 
tenofovir in their blood at the time of seroconversion; this equated to a 96% lower incidence 
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(p<0.0001) than predicted. In addition, adherence was also high according to pharmacy refills 
and a subset of blood tests, with 86% of randomly selected participants taking PrEP having 
detectable tenofovir in plasma at clinic visits [328].  
In addition to evaluating adherence within the Partners PrEP trial, I used data 
collected within the Demonstration Project to evaluate patterns of adherence in a setting with 
less clinical involvement. This includes individual-level MEMS adherence data, which were 
collected from November 2012 to January 2015, which accounts for 42% of planned follow-
up time [121]. The demonstration project will report complete results in 2016. Importantly, 
results presented here use data available to date, but may change when the full dataset is 
available. Within the demonstration project, an additional adherence study (the Partners 
Mobile Adherence to PrEP Study [PMAPS]) is also being conducted among 368 participants 
in Thika and Kampala to assess the interaction between adherence and sexual behavior. 
Participants in the study received daily SMS surveys regarding adherence and sexual 
behavior over 14 days prior to a scheduled clinic visit. 
By comparing adherence across two separate sets of couples, time periods, and levels 
of clinical involvement, we can assess the types of adherence behavior that are likely to be 
observed in implementation settings. Adherence data from the demonstration project is 
different from the trial in three major ways: one, the efficacy of PrEP is now known and 
individuals are aware that they are receiving active drug; two, participants attend fewer clinic 
visits and received less rigorous adherence counselling (i.e. poor adherence did not trigger an 
additional counselling intervention), and three, the study is incomplete and patients have had 
less follow-up time. However, it is also important to keep in mind that demonstration projects 
are still highly monitored and that they are only a step towards realistic conditions, rather 
than a genuine proxy for the real world. 
 
3.2.3  Data Analysis and Assumptions 
 
In conducting the data analysis, I made several decisions regarding the metrics by 
which “adherence” was determined. For each individual, mean adherence by MEMS was 
estimated by dividing the number of days on which a pill was taken by the number of days on 
which a pill was expected to be taken in the study. In analyses examining changes in 
adherence over time, monthly adherence for each individual was calculated using the same 
method for each 30-day period the participant was enrolled in the study, with months of less 
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than 20 days of observation (i.e. during the final period of follow-up time) removed from the 
analysis. Breaks in adherence were estimated by calculating the longest consecutive sequence 
of non-adherent days while a participant was expected to be taking PrEP, excluding 
cessation. 
For the purposes of this analysis, I made several assumptions regarding the adherence 
data from both the Partners PrEP Study and the Partners Demonstration Project. Firstly, I 
assumed that an individual reporting more than one pill bottle opening per day only took one 
pill on that day. Therefore, overall adherence was adjusted and limited to a maximum of 
100% per individual. Secondly, I removed instances of pill bottle openings by study staff 
during clinic visits, as well as data from days on which there was a protocol-defined drug 
hold or hiatus. In the trial, reasons for study drug interruptions included pregnancy and 
breast-feeding (5.3% of follow-up time for all women) and adverse events (0.6% of follow-
up time) [50]. In the demonstration project, 84% of HIV-uninfected partners whose partners 
had not yet initiated ART were still taking PrEP 12 months after enrolment. For those 
participants who discontinued PrEP use, reasons included ART use for the HIV-infected 
partner (41%), loss to follow-up (30%), pregnancy or breastfeeding (9%), unwillingness to 
continue taking PrEP (8%), and dissolution of the partnership (6%) [328]. Thirdly, in the 
Partners PrEP Study only, adherence was briefly misrepresented for all participants during a 
short period of time after efficacy in the trial was revealed by the DSMB in July 2011. During 
that month, placebo arm participants were re-randomized to receive either TDF alone or 
combination FTC/TDF [329]. Due to the re-randomization, study drugs were not available to 
some participants for a brief period of time, and so data from the full month of July were 
removed from the analyses. No such cut was necessary for the Demonstration Project dataset. 
Several methods of analysis were used in order to describe the adherence data fully. 
In these analyses, summary measures of adherence are calculated for each individual, and 
then for the whole cohort (i.e. “overall” adherence). First, descriptive statistical analyses were 
done to visualize and summarize both sets of data, including the following: mean and median 
adherence overall and by age and sex categories; distribution of adherence according to ten 
percent adherence categories (e.g. mean adherence of 0-10%, 10-20%, etc.); mean monthly 
adherence overall and by age and sex categories; the longest breaks in adherence; and 
visualization of individual patterns of adherence. Second, t-tests and analysis of variance 
(ANOVA) were carried out to assess differences in adherence between the trial and the 
demonstration project, and between groups (by sex and age). A t-test is a statistical 
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parametric test designed to examine the difference between two means, and either validate or 
reject the null hypothesis that there is no significant difference between the tested groups. P 
values <0.05 were considered significant. ANOVA is another statistical tool used to test the 
degree of variance between groups to determine if the observed degree of variance is 
significant or due to chance. Third, multiple linear regressions were performed to quantify 
changes in adherence based on covariates. A multiple linear regression models the 
relationship between multiple covariates and a response variable by fitting a linear equation 
to the data, in order to determine if there is any significant change in the response variable 
according to the covariates. Fourth, cross-sectional panel data analyses were conducted in 
order to assess any changes in adherence over time. Panel data analysis deals with 
longitudinal time-series data; i.e. cases in which multiple observations are recorded for each 
individual over time. Specifically, I used generalized estimating equations (GEE), which are 
semi-parametric regression models used to analyze population-averaged effects in 
longitudinal data. All analyses were carried out using Stata version 12.1. These analyses 
effectively summarize and quantify important trends in adherence data within and between 
the two populations studied here.  
 
3.3  Results 
 
3.3.1   Adherence in the Partners PrEP Study 
 
A total of 1,144 HIV-uninfected individuals from the Partners PrEP Study AAS were 
analysed. 53% of participants in the sub-study were male and the median age was 34 years 
(IQR 30-40). The median length of follow-up time in the study was 1.3 years (IQR 0.75-1.75 
years), with 14% of participants contributing data for 0-6 months of PrEP use, 22% for 6-12 
months, 29% for 12-18 months, 19% for 18-24 months, and 16% for more than 24 months. 
 
3.3.1.1 Overall Adherence 
  
In the AAS, adherence was high overall according to MEMS. Adherence across the 
total population in the AAS had a mean of 85.3% (standard deviation [SD] 18.3) and a 
median of 92.4% (IQR 81.7-97.2%) (Table 3.1). Using an unpaired t-test and ANOVA, 
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respectively, adherence was significantly different between men and women (p<0.0001) and 
between age categories (p<0.0001). 
 
Category Mean (SD) Median (IQR) N 
Overall 85.3% (18.3) 92.4% (81.7-97.2%) 1,144 
By Gender 
Men 82.4% (20.4) 89.7% (76.3-95.7%) 605 
Women 88.6% (14.5) 94.3% (85.5-98.0%) 539 
By Age 
<25 83.7% (12.6) 88.1% (88.0-90.7%) 88 
25-34 83.3% (19.4) 91.1% (78.1-96.8%) 500 
35-44 88.3% (16.1) 93.8% (86.6-97.7%) 407 
≥45 90.1% (13.0) 93.4% (87.6-97.8%) 149 
Table 3.1: Summary of overall adherence to PrEP in the Partners PrEP Study AAS. SD = 
standard deviation. IQR = interquartile range. 
 
The distribution of mean adherence, according to ten percent categories, is given in 
Figure 3.1. The majority of participants (58%) had overall mean adherence greater than 90%, 
and 6% of PrEP users had mean adherence lower than 50%. 
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Figure 3.1: Distribution of mean overall adherence in the Partners PrEP Study AAS 
according to MEMS. 
3.3.1.2 Adherence by Age and Gender 
 
Overall mean and median adherence are presented in Table 3.2, both by age 
categories and by gender. The highest mean adherence was observed among women aged 45 
years and older, with the lowest mean adherence among men below 25. The highest 
adherence by age and sex was among women aged 45 and older, though adherence was 
similarly high for women aged 35-44. 
 
Category Mean (SD) Median (IQR) N 
Men 
Ages <25 72.5% (24.6) 80.5% (62.9-90.7%) 50 
Ages 25-34 79.7% (21.1) 86.6% (72.2-95.0%) 259 
Ages 35-44 85.0% (19.0) 92.2% (81.9-97.0%) 194 
Ages ≥45 89.4% (12.2) 92.7% (86.7-97.6%) 102 
Women 
Ages <25 79.2% (22.3) 86.4% (69.7-94.5%) 38 
Ages 25-34 87.2% (16.5) 94.2% (82.3-97.9%) 241 
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Ages 35-44 91.3% (12.2) 95.0% (89.4-98.1%) 213 
Ages ≥45 91.6% (14.5) 95.0% (90.4-98.8%) 47 
Table 3.2: Mean and median adherence overall, by age and gender categories, in the Partners 
PrEP Study AAS. SD = standard deviation. IQR = interquartile range. 
 
I also quantified the difference in adherence based on age and sex using a multiple 
linear regression, which shows that both age and sex are significant independent predictors of 
overall adherence (Table 3.3). On average, men had 6.4% lower adherence than women, and 
older age was equated with a 12-15% increase in overall adherence. However, the R2 of the 
model was low, signifying that age and sex do not account for most of the variance observed 
in the data. 
 
Category Change in Mean Adherence 95% CI p 
By Gender 
Women Reference — — 
Men -6.4% -4.3 — -8.5% <0.0001* 
By Age 
<25 Reference — — 
25-34 7.6% 3.6-11.6% <0.0001* 
35-44 12.3% 8.3-16.4% <0.0001* 
≥45 15.5% 10.8-20.1% <0.0001* 
Table 3.3: Multivariable regression (joint model) of changes in mean adherence per year 
depending on age and sex in the Partners PrEP Study AAS. Adjusted R2 = 0.0726. * = 
statistically significant at 0.05 level. 
 
3.3.1.3 Changes in Adherence over Time 
 
 Adherence to ART has a tendency to decline over time [330], and likewise, higher 
adherence has been associated with the first six months of PrEP use [215]. In order to 
investigate any changes in adherence to PrEP over time in the Partners PrEP AAS, I 
examined mean adherence on a month-by-month basis overall (Figure 3.2) and for each age 
and sex category (Figures 3.3-3.10). As the number of individuals reporting adherence in the 
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study decreases over time, red shading is used to highlight when the sample size has fallen 
below 30 and there should be less confidence in the displayed results. 
 
	  
Figure 3.2: Change in mean overall adherence over two years of follow-up for all 
participants in the Partners PrEP Study AAS. Grey bars indicate 95% confidence intervals. 
	  
Figure 3.3: Change in mean overall adherence over two years of follow-up for women aged 
<25 at enrolment in the Partners PrEP Study AAS. Grey bars indicate 95% confidence 
intervals; red shading indicates the period of time in which sample size <30 and results 
should be treated with caution. 
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Figure 3.4: Change in mean overall adherence over two years of follow-up for women aged 
25-34 at enrolment in the Partners PrEP Study AAS. Grey bars indicate 95% confidence 
intervals. 
	  
Figure 3.5: Change in mean overall adherence over two years of follow-up for women aged 
35-44 at enrolment in the Partners PrEP Study AAS. Grey bars indicate 95% confidence 
intervals. 
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Figure 3.6: Change in mean overall adherence over two years of follow-up for women aged 
45 and older at enrolment in the Partners PrEP Study AAS. Grey bars indicate 95% 
confidence intervals; red shading indicates the period of time in which sample size <30 and 
results should be treated with caution. 
 
	  
Figure 3.7: Change in mean overall adherence over two years of follow-up for men aged <25 
at enrolment in the Partners PrEP Study AAS. Grey bars indicate 95% confidence intervals; 
red shading indicates the period of time in which sample size <30 and results should be 
treated with caution. 
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Figure 3.8: Change in mean overall adherence over two years of follow-up for men aged 25-
34 at enrolment in the Partners PrEP Study AAS. Grey bars indicate 95% confidence 
intervals. 
 
Figure 3.9: Change in mean overall adherence over two years of follow-up for men aged 35-
44 at enrolment in the Partners PrEP Study AAS. Grey bars indicate 95% confidence 
intervals. 
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Figure 3.10: Change in mean overall adherence over two years of follow-up for men aged 45 
and older at enrolment in the Partners PrEP Study AAS. Grey bars indicate 95% confidence 
intervals; red shading indicates the period of time in which sample size <30 and results 
should be treated with caution. 
	  
 
Mean adherence was most volatile over time for women aged under 25 because the 
sample size for this cohort (38 individuals at enrolment) was smaller than any other observed 
group. From these descriptive analyses, a downward trend is evident for all age and sex 
categories, although the effect appears to be less pronounced for older age groups. In order to 
quantify the observed trends, longitudinal panel analyses in the form of generalized 
estimating equations were used to evaluate the degree and significance of any decline over 
time (Table 3.4). 
 
Category 
Change in Mean 
Adherence per Year 
of PrEP Use 
95% CI p 
Overall -6.6% -7.7 – -5.4% <0.0001* 
By Gender 
Men -7.0% -8.7 – -5.3% <0.0001* 
Women -5.9% -7.4 – -4.4% <0.0001* 
By Age 
<25 -9.0% -13.3 – -4.6% <0.0001* 
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25-34 -7.2% -9.2 – -5.3% <0.0001* 
35-44 -6.1% -8.0– -4.3% <0.0001* 
≥45 -4.0% -6.5 – -1.4% 0.002* 
Table 3.4: Change in mean adherence over two years of follow-up in the Partners PrEP 
Study AAS, according to gender and age. CI = confidence interval. * = statistically 
significant at 0.05 level. 
 
A statistically significant decline in adherence was observed over time for all cohorts, and the 
decline over time was slightly more pronounced for male participants. Mean adherence 
declines are most evident for those with younger ages, and increasing age led to more 
stability in adherence over time. The interaction between gender and age was also 
investigated, but gender did not significantly modify the effect of age on the decline over 
time (p=0.139). 
 
3.3.1.4 Breaks in Adherence 
 
 Other metrics of adherence may be useful for assessing risk of HIV-1 seroconversion. 
In particular, long periods of non-adherence may be a greater indication of risk than mean 
adherence, as short breaks (<2-3 days) may still provide some degree of protection due to the 
pharmacological “forgiveness” of PrEP [53,228]. The distribution of the longest break in 
adherence for individuals in the trial and the corresponding cumulative distribution function 
(CDF) are shown in Figure 3.11. A given point on the CDF shows the probability (on the y-
axis) that an individual will have a break equivalent to or lower than the value on the x-axis. 
In this instance, the length of the “break” in adherence is defined as the number of 
consecutive days that an individual does not open the MEMS pill bottle, excluding non-
adherence during PrEP cessation (i.e. non-adherence with no future re-initiation). Breaks in 
adherence including periods of cessation were also investigated (see Appendix B). 
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Figure 3.11: Distribution of longest period of non-adherence per individual (not including 
cessation) in the Partners PrEP Study AAS. The light blue shaded area represents the 
cumulative distribution function (CDF). 
 
 The distribution is right-skewed, with a mean of a maximum of 11 consecutive days 
of PrEP missed and a median of 4 days. The CDF shows that 94% of individuals never took a 
break longer than a month, 84% never took a break longer than two weeks, and 74% never 
took a break longer than one week. A small percentage of PrEP users (3%) were perfectly 
adherent throughout the sub-study, but the greatest proportion of users only missed one 
consecutive day of dosing. This suggests that PrEP would provide a relatively continuous 
level of protection for many individuals. In addition, breaks in adherence have been 
significantly associated with periods of abstinence [326], and so long periods of non-
adherence may not necessarily correspond to an increased risk of HIV acquisition. 
 
3.3.1.5 Individual Adherence Patterns 
 
 Adherence has thus far been described in terms of broad cohort characteristics. 
However, while overall adherence can describe trends in a population, adherence varies 
substantially between individuals and these variations may be important for determining the 
risk of HIV-1 infection. Daily adherence and non-adherence for each individual in the AAS 
are represented in Figure 3.12. 
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Figure 3.12: Visual representation of all individual adherence patterns (N=1,144), in order of 
decreasing mean adherence. Each horizontal line represents an individual in the study. Green 
points represent a day on which a PrEP dose was taken, and red points indicate a day on 
which a PrEP dose was not taken. 
	  
 Individual-level mean adherence is highly concentrated at the upper end of the 
adherence spectrum. In addition, several patterns of non-adherence can be detected in the 
distribution. Some individuals appear to have high adherence during the first few months of 
PrEP use before ceasing use completely, while others may go through cycles of having 
“streaks” of good adherence followed by longer breaks in PrEP use. Others appear to have 
low adherence overall but continue use PrEP occasionally, even over long periods of time. 
 
 
 3.3.2    Adherence in the Partners Demonstration Project 
 
A total of 899 individuals from the Partners Demonstration Project took PrEP and 
reported adherence data via MEMS. Participants in the study were 65% male and had a 
median age of 30 years (IQR 26-36). The mean length of follow-up time in the study was 7 
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months, with 50% of participants contributing data for 0-6 months of PrEP use, 34% for 6-12 
months, 14% for 12-18 months, and 2% for more than 18 months. 
 
3.3.2.1 Overall Adherence 
 
In the Partners Demonstration Project, adherence was high overall according to 
MEMS (Table 3.5). Mean adherence was 75.4% (SD 25.1) and the median was 84.5% (IQR 
63.9-94.7%). Compared to overall adherence in the trial, mean and median adherence in the 
demonstration project were lower (by approximately 10% and 8%, respectively). Using an 
unpaired t-test and ANOVA, respectively, adherence was not significantly different between 
men and women (p=0.2420), but was significantly different between age categories 
(p=0.0188). 
 
Category Mean (SD) Median (IQR) N 
Overall 75.4% (25.1) 84.5% (63.9-94.7%) 899 
By Gender 
Men 74.7% (24.0) 82.7% (63.4-93.3%) 582 
Women 76.7% (26.9) 89.7% (65.5-96.4%) 317 
By Age 
<25 71.5% (26.3) 80.4% (50.9-92.1%) 181 
25-34 74.8% (25.2) 83.3% (63.4-94.1%) 445 
35-44 79.1% (23.1) 89.4% (68.3-96.4%) 193 
≥45 78.2% (25.1) 88.9% (71.1-96.0%) 80 
Table 3.5: Summary of overall adherence to PrEP in the Partners Demonstration Project. SD 
= standard deviation. IQR = interquartile range. 
 
The distribution of mean adherence, according to ten percent categories, is given in 
Figure 3.13. Across all participants, 38% of users had mean adherence greater than 90%, 58% 
had mean adherence greater than 80%, and 16% had mean adherence below 50%. The 
distribution of adherence is right-skewed, meaning that PrEP users were more frequent in 
high-adherence categories than low-adherence categories, similar to the trial. However, fewer 
individuals had mean adherence greater than 90% in the demonstration project relative to the 
trial (38% versus 58% of all participants, respectively), and there was a greater proportion of 
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individuals with mean adherence below 50% in the demonstration project (16% compared to 
6% in the trial). 
 
	  
Figure 3.13: Distribution of mean overall adherence in the Partners Demonstration Project, 
according to MEMS data. 
	  
3.3.2.2 Adherence by Age and Gender 
 
 A summary of adherence by age and gender categories is shown in Table 3.6. Mean 
adherence was highest among older men and women, similar to what was observed in the 
trial. Adherence was also lowest among PrEP users aged 24 and younger and improved with 
older age, consistent with patterns observed in the trial data. 
 
Category Mean (SD) Median (IQR) N 
Men 
Ages <25 72.2% (23.9) 79.8% (54.5-90.3%) 98 
Ages 25-34 73.1% (25.2) 80.4% (62.0-92.8%) 292 
Ages 35-44 78.5% (20.3) 85.8% (67.4-93.8%) 128 
Ages ≥45	  78.2% (24.7) 88.5% (72.4-95.6%) 64 
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Women 
Ages <25 70.7% (28.9) 81.6% (47.8-95.2%) 83 
Ages 25-34 78.2% (24.9) 89.7% (67.1-95.3%) 153 
Ages 35-44 80.5% (28.0) 93.7% (77.1-97.6%) 65 
Ages ≥45 78.5% (27.3) 89.8% (68.9-97.3%) 16 
Table 3.6: Mean and median adherence overall, by age and gender categories, in the Partners 
Demonstration Project. SD = standard deviation. IQR = interquartile range. 
 
Using a multiple linear regression, I explored the differences in adherence based on 
age and gender (Table 3.7). On average, men had 2.0% lower adherence than women, though 
this difference was not significant. In addition, adherence did not vary significantly between 
the two younger age categories, but was significantly higher among PrEP users aged 35 and 
older, by approximately 7% on average. In the trial, women had significantly higher 
adherence than men, but this pattern was not observed in the demonstration project data. 
 
Category Change in Mean Adherence 95% CI p 
By Gender 
Women Reference — — 
Men -2.0% -5.5 — 1.4% 0.242 
By Age 
<25 Reference — — 
25-34 3.3% -1.0 – 7.0% 0.134 
35-44 7.6% 2.6-12.7% 0.003* 
≥45 6.7% 0.1-13.3% 0.045* 
Table 3.7:  Multivariable regression of changes in mean adherence depending on age and sex 
in the Partners Demonstration Project. Adjusted R2 = 0.0078. * = statistically significant at 
0.05 level. 
 3.3.2.3	   Changes	  in	  Adherence	  over	  Time	  
 
I examined mean adherence on a month-by-month basis across all PrEP users in the 
demonstration project (Figure 3.14) and for each age and sex category (Figures 3.15-3.22) in 
order to visualize any changes over time. As less follow-up time was available to analyse in 
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the demonstration project, results are displayed for the first 12 months of PrEP use. Because 
the number of individuals reporting adherence in the study decreases over time, red shading 
is used to highlight when the sample size has fallen below 30 and there should be less 
confidence in the displayed results. 
 
	  
Figure 3.14: Change in mean overall adherence over 18 months of follow-up in the Partners 
Demonstration Project. Grey bars indicate 95% confidence intervals. 
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Figure 3.15: Change in mean overall adherence over one year of follow-up for women aged 
24 and younger at enrolment in the Partners Demonstration Project. Grey bars indicate 95% 
confidence intervals; red shading indicates the period of time in which sample size <30 and 
results should be treated with caution. 
 
 
	  
Figure 3.16: Change in mean overall adherence over one year of follow-up for women aged 
25-34 at enrolment in the Partners Demonstration Project. Grey bars indicate 95% confidence 
intervals; red shading indicates the period of time in which sample size <30 and results 
should be treated with caution. 
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Figure 3.17: Change in mean overall adherence over one year of follow-up for women aged 
35-44 at enrolment in the Partners Demonstration Project. Grey bars indicate 95% confidence 
intervals; red shading indicates the period of time in which sample size <30 and results 
should be treated with caution. 
 
	  
Figure 3.18: Change in mean overall adherence over 8 months of follow-up for women aged 
45 and older at enrolment in the Partners Demonstration Project. Grey bars indicate 95% 
confidence intervals; red shading indicates the period of time in which sample size <30 and 
results should be treated with caution. 
	  
	  
120 
	  
Figure 3.19: Change in mean overall adherence over one year of follow-up for men aged 24 
and younger at enrolment in the Partners Demonstration Project. Grey bars indicate 95% 
confidence intervals; red shading indicates the period of time in which sample size <30 and 
results should be treated with caution. 
 
	  
Figure 3.20: Change in mean overall adherence over one year of follow-up for men aged 25-
34 at enrolment in the Partners Demonstration Project. Grey bars indicate 95% confidence 
intervals. 
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Figure 3.21: Change in mean overall adherence over one year of follow-up for men aged 35-
44 at enrolment in the Partners Demonstration Project. Grey bars indicate 95% confidence 
intervals; red shading indicates the period of time in which sample size <30 and results 
should be treated with caution. 
 
	  
Figure 3.22: Change in mean overall adherence over one year of follow-up for men aged 45 
and older at enrolment in the Partners Demonstration Project. Grey bars indicate 95% 
confidence intervals; red shading indicates the period of time in which sample size <30 and 
results should be treated with caution. 
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From these descriptive analyses, a slight increase in adherence over time is visible, in 
contrast to the decline over time that occurred in the trial. In order to quantify the observed 
trends, generalized estimating equations were used to evaluate the degree and significance of 
any change in adherence over time (Table 3.8). Adherence increased significantly over time, 
but by a small margin (1.2%). For women and older age groups, no significant change in 
adherence over time was observed. The relationship between age and gender was also 
investigated, but the interaction between the two did not significantly modify the change in 
adherence over time (p=0.127). Changes in adherence over time were also analysed for 
individuals with less than 6 months of follow-up data, as compared to individuals with 6 
months or more of follow-up time. For individuals with a shorter duration of follow-up, there 
was no significant change in adherence over time (p=0.052), while individuals with more 
than 6 months of follow-up demonstrated a small overall increase in adherence of 0.83% per 
year (95% CI 0.04-1.62%, p=0.039). Compared to the trial, mean adherence remained stable 
over one year as opposed to declining over time, though the average duration of follow-up in 
the demonstration project dataset was shorter than in the trial data, and so any change over 
time may be less apparent. 
 
Category 
Change in Mean 
Adherence per Year 
of PrEP Use 
95% CI p 
Overall 1.2% 0.5 – 1.9% <0.0001* 
By Gender 
Men 1.3% 0.5 – 2.2% 0.003* 
Women 1.0% -0.1 – 2.0% 0.067 
By Age 
<25 1.8% 0.03 – 3.5% 0.046* 
25-34 1.2% 0.3 – 2.1% 0.010* 
35-44 0.8% -0.7 – 2.3% 0.287 
≥45 1.8% -0.8 – 4.3% 0.169 
Table 3.8: Decline in mean adherence over two years of follow-up in the Partners 
Demonstration Project. CI = confidence interval. * = statistically significant at 0.05 level. 
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3.3.2.4 Breaks in Adherence  
 
 The distribution of the longest break in adherence and the CDF for participants in the 
Partners Demonstration Project are shown in Figure 3.23. As with the trial data, the breaks 
are defined as the number of consecutive days that an individual does not open the MEMS 
pill bottle, excluding non-adherence during PrEP cessation. Breaks in adherence including 
PrEP cessation were also investigated (see Appendix B). 
The CDF shows that 64% of PrEP users never missed more than one consecutive 
week of dosing, while 76% never took a break longer than two weeks, and 88% never took a 
break longer than a month. The distribution is right-skewed, with a mean of a maximum of 13 
consecutive days of PrEP missed and a median of 5 days. Similarly to the trial, a small 
percentage of PrEP users (5%) were perfectly adherent and the greatest proportion of users 
only missed one consecutive day of dosing. However, twice as many PrEP users missed more 
than 30 consecutive days in the demonstration project compared to the trial (12% vs. 6%), 
and those missing more than a month of PrEP make up the fourth largest proportion of users. 
 
	  
Figure 3.23: Distribution of longest period of non-adherence per individual (not including 
cessation) in the Partners Demonstration Project. The light blue shaded area represents the 
cumulative distribution function (CDF). 
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3.3.2.5 Individual Adherence Patterns 
 
Daily patterns of adherence for each individual in the Demonstration Project can be 
seen in Figure 3.24. Compared to the trial, individual mean adherence is more distributed and 
less concentrated at the upper end of the spectrum. Similar patterns of PrEP use and non-use 
can be seen for individuals at all levels of adherence. 
	  
Figure 3.24: Visual representation of all individual adherence patterns (N=899), in order of 
decreasing mean adherence. Each horizontal line represents an individual in the study. Green 
points represent a day on which a PrEP dose was taken, and red points indicate a day on 
which a PrEP dose was not taken. 
	  
3.3.2.6 Intersection of Sex Acts and Adherence 
 
  In the PMAPS data set, 146 participants responded on at least one day about both 
their sexual behaviour and PrEP use on the previous day, for a total of 988 person-days of 
observation. Of those 146 individuals, 73% were male and the median age was 29 years (IQR 
26-35). Participants in the study reported behaviour for a median of 7 days (IQR 5-8), with 
39% reporting data for <7 days and 61% reporting data for 7 days or more. Figure 3.25 shows 
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the proportional frequency of PrEP adherence, sex, and condom use across all participants 
and days of observation in the PMAPS data. The small areas in which the purple and orange 
circles do not overlap the blue circle represent the proportion of days on which a sex act 
occurred simultaneously with a missed PrEP dose. 
 
	  
Figure 3.25: Proportional Venn diagram of frequency of PrEP adherence, sex (both with and 
without a condom), and condom-protected sex. Percentages indicate the percentage of all 
days across all individuals that the corresponding event was observed.  
 
For all days on which an SMS report was recorded, sex occurred on 35% (SD 48) of the days. 
Of all the days on which sex occurred, 30% were days on which a condom was not used 
during the sex act. For all days reported in the study, PrEP doses were not taken on 12% of 
the days. For days on which a dose was missed, condomless sex occurred on a mean of 2% of 
those days (SD 5), with a median of 0 days (IQR 0-0) for the cohort. Across all instances of 
condomless sex, participants also missed PrEP on 7% of those days. Overall mean adherence 
per individual (throughout the duration of follow-up in the Demonstration Project) was not 
significantly associated with the frequency of condomless sex acts occurring on days of 
missed doses in the PMAPS study (p=0.68). 
 
PrEP dose taken
88%
Sex
35%
25%
Condom used during sex
All days in the study
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3.3.3  Comparing Trial and Demonstration Project Adherence 
 
 Overall, mean adherence to PrEP was significantly lower in the demonstration project 
than in the trial using MEMS using a t-test (75.4% versus 85.3%, p<0.00001). In the 
Demonstration Project, adherence varied less by age and gender than in the trial, possibly as a 
result of recruiting a higher percentage of younger couples via the risk score. In addition, 
fewer participants in the Demonstration Project were above each threshold of mean 
adherence (e.g. 58% of users were above 80% mean adherence in the Demonstration Project 
compared to 78% in the trial), as can be seen in Figure 3.26. 
 
	  
Figure 3.26: Comparison of the proportion of PrEP users above adherence thresholds in the 
Partners PrEP Study AAS and the Partners Demonstration Project. 
 
 In addition, several patterns observed in the adherence data from the trial were not 
replicated in the Demonstration Project. First, adherence in the trial was significantly 
different between men and women, with men having, on average, 6.4% lower mean 
adherence. In the Demonstration Project, men had on average 2.0% lower adherence, but this 
difference was not significant. Second, a significant decline in adherence over time (6.6% 
over a year) was detected in the trial, for every age and sex category. This decline was not 
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evident in the Demonstration Project data; instead, adherence was more stable over time with 
a slight (1.2%) increase over a year. Third, breaks in adherence lasting more than 1-2 days 
were more frequent in the Demonstration Project, with a greater percentage of the cohort not 
using PrEP for more than a month at a time (Figure 3.27), some of which is attributable to the 
participant ceasing to use PrEP. In both the trial and the demonstration project, at least one 
long break in adherence (i.e. lasting 7 days or longer) was common; in the demonstration 
project, 40% of PrEP users took a long break (including cessation), as compared to 25% of 
individuals in the trial (not including cessation). These breaks may be important for PrEP use, 
as protection will drop substantially. However, such breaks are only critical if risk exposure 
corresponds to the same periods of time. 
 
	  
Figure 3.27: Comparison of the cumulative distribution functions (CDFs) of the maximum 
consecutive of non-adherence between the Partners PrEP Study (including and not including 
cessation of PrEP) and the Partners Demonstration Project (including and not including 
cessation of PrEP). 
 
3.4  Discussion 
 
 In this chapter, I analysed overall adherence and individual patterns of adherence to 
PrEP among HIV-serodiscordant couples in Kenya and Uganda based on daily electronic 
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monitoring data from both a clinical trial with intensive adherence counselling and a 
demonstration project without a specific adherence intervention. Recruitment for the 
demonstration project differed to that for the trial by focusing on couples with “risk scores” 
≥5 [145] – e.g. younger couples, those in which the HIV-infected partner had a high SPVL, 
and who had engaged in recent condomless sex. According to MEMS data, adherence in the 
Partners PrEP Study was high when averaged across the study cohort, with a mean of 85.3% 
and a median of 92.4%, while adherence in the demonstration project was somewhat lower 
overall, with a mean of 75.4% and a median of 79.8% - a statistically significant difference. 
Adherence in the trial also declined over time (by 6.6% per year, on average), whereas 
adherence rose by 1.2% per year in the Demonstration Project. Three important conclusions 
can be gained from this analysis: firstly, adherence in the context of known efficacy is 
moderately lower than adherence in the context of a clinical trial, but still remains high. 
Secondly, age in particular is significantly associated with adherence, both in terms of the 
overall mean adherence and the degree of change in adherence over time. Thirdly, in the 
limited data available regarding the intersection of adherence and sex, days of non-adherence 
occur on days of condomless sex rarely, and non-adherence is associated with periods of 
abstinence. 
 By analysing two cohorts of serodiscordant couples, we can compare and contrast 
adherence between the two populations. Similarities between the trial and the demonstration 
project include high overall adherence in the cohorts, with a large proportion of users with 
mean adherence greater than 90%, and significant increases in adherence with older age. The 
association between higher adherence and older age has also been observed in other PrEP 
studies across multiple populations [120,331]. Importantly, a substantial proportion of PrEP 
users in both cohorts also took at least one break lasting longer than a week. Such breaks in 
adherence may be indicative of periods of greater susceptibility to HIV, but also may be 
purposeful in many cases (e.g. due to abstinence or use of other prevention methods). 
Several important differences between trial and demonstration project adherence were 
also apparent. Mean adherence was lower by about 10% in the context of open-label PrEP, a 
result that contrasts with the changes in adherence between the iPrEx clinical trial and its 
open-label extension (OLE). In the OLE, 71% of enrolled participants who supplied 
b[49]lood plasma samples had detectable TFV, though this varied substantially by geographic 
region [120], as compared to 50% of samples with detectable TFV in the trial . Several 
reasons could explain this difference: first, overall adherence observed in the Partners PrEP 
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Study was much higher than any other population, and therefore would be difficult to match, 
even in the context of proven PrEP efficacy. Estimated adherence in the Demonstration 
Project is comparable to that observed in the iPrEx OLE, despite the differing direction of the 
change in adherence. Second, individuals in the trial received an intensive adherence 
counselling intervention if at any point adherence fell below 80% [216]. In the trial AAS, 
15% of individuals received the intervention, and adherence subsequently improved 
significantly in the subsequent month. As this intervention was not part of the Demonstration 
Project adherence study, some participants’ adherence at the lower end of the spectrum may 
have suffered without such intensive support. Third, as PrEP was known to be effective at the 
time of enrolment in the demonstration project, some participants may have altered their 
dosing behaviour based on perceived risk (i.e., choosing to take pills only during periods of 
increased sexual activity or when having sex with an external partner). 
In addition, changes in overall adherence over time differed between trial and 
Demonstration Project. In the trial, adherence declined significantly as time on PrEP 
increased (falling by 4-9% per year, depending on age), for both men and women and 
participants in all age cohorts. This decline over time observed in the trial was consistent with 
changes observed in the iPrEx trial [217]. However, in the demonstration project, adherence 
did not decline over time, but actually increased slightly overall (by 1.2% per year of 
observation). The stability of adherence over time in the Demonstration Project could be a 
result of several factors. Follow-up time in the Demonstration Project dataset analysed here 
was, on average, less than half the time available for the trial. This could mean that adherence 
would decline with further PrEP use, a trend that would not be seen with limited follow-up 
time. Alternatively, the decline over time could be related to the fact that PrEP efficacy was 
unknown for the majority of person-years observed in the trial. The observed stability of 
adherence over time is surprising, but also promising for individuals who may use PrEP for 
longer periods of time. 
Strengths of this data analysis include the large sample size in both the trial and the 
Demonstration Project, including across almost all age and sex categories. In addition, for the 
Partners PrEP Study dataset, adherence according to MEMS is consistent with other reported 
measures of adherence, including unannounced pill counts [215], self-report [50], and 
pharmacokinetic drug levels [210]. In the Demonstration Project, HIV-1 incidence has also 
been reduced by an estimated 96% according to an interim analysis [121], corroborating the 
high adherence estimates from this analysis. MEMS data also produces individual patterns of 
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adherence to PrEP, which both yields continuous estimates of adherence over time and 
permits examination of the realistic intersection between non-adherence and risk behaviour. 
In addition, a short-term SMS study of sexual behaviour among a subset of participants also 
supplying MEMS data was linked to overall adherence behaviour, providing data on the 
frequency of condomless sex and non-adherence for the first time in any population. 
However, there are a number of substantial uncertainties and weaknesses inherent in 
the data analysed here. Adherence in both the trial and the demonstration project may be 
artificially high as a result of participation in a study. By using MEMS to monitor adherence, 
participants may have been subject to the Hawthorne effect, in which behaviour changes as a 
result of being observed [203]. Social desirability could also potentially have played a role in 
maintaining high adherence. Participants in the Demonstration Project may have experienced 
less influence of these biases as contact with study staff was minimized, but were still subject 
to using a device that recorded behaviour daily. In addition, as follow-up has not yet been 
completed on the Demonstration Project, estimates of changes in adherence over time should 
be treated with caution and may change with longer duration of time on PrEP and larger 
sample sizes for adherence after an initial six months. Finally, the PMAPS sub-study of 
adherence and the frequency of sex and condom use was conducted among a small sample of 
PrEP users and for a short amount of time, with a maximum of 14 days of observation. 
Sample size for determining the intersection of non-adherence and sex was further reduced 
by the relatively infrequent occurrence of condomless sex. Furthermore, estimates of the 
frequency of condomless sex and non-adherence may be biased by the short period of 
observation time. The rate of both condomless sex and non-adherence over a longer period of 
time might be different to what was observed in the study if, for example, the SMS 
questionnaires coincided with a temporary period of abstinence, or if adherence during the 
time of observation happened to be higher or lower than average. Further work is needed 
concerning the interaction of risk and adherence, as is data on corresponding drug 
concentrations during exposures to risk. 
 Many additional analyses of this data are possible. To better understand motivators 
behind adherence, analyses could be conducted using covariates other than age and gender 
(e.g. sexual behaviour and alcohol use), which have been shown to influence adherence in a 
separate analysis of the Partners PrEP Study AAS [215]. In addition, in order to determine 
specifically when the greatest change in overall adherence to PrEP occurs, a change-point 
analysis could be conducted to detect points of inflection [332]. This could potentially 
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highlight times in the trajectory of PrEP use at which changes in adherence are likely to 
occur. Furthermore, modelling work using both the trial and Demonstration Project data 
could help to answer some of the questions surrounding adherence, including which metrics 
of adherence best predict risk of seroconversion and what distribution of adherence is 
sufficient to generate impact. In order to understand how the patterns of adherence described 
in this chapter would affect the resulting effect of PrEP in a “real-world” setting, I adapted a 
microsimulation model to incorporate daily individual patterns of adherence to PrEP, as well 
as the PK/PD of tenofovir-based PrEP (Chapter 4), and produced estimates of impact and 
cost-effectiveness for serodiscordant couples in East Africa according to trial adherence 
(Chapter 5) and Demonstration Project adherence (Chapter 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
132 
4      Adaptation of a microsimulation model to include 
realistic adherence to PrEP 
 
Abstract 
Background: A microsimulation model was previously developed to investigate the optimal 
uses of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) for serodiscordant 
couples in South Africa. 
Aims: The goal of this chapter was to describe the adaptations made to the microsimulation 
model, for the purposes of (1) incorporating realistic patterns of adherence to PrEP, including 
individual-level daily adherence and an hourly pharmacokinetics/pharmacodynamics 
(PK/PD) sub-model, (2) adapting HIV-1 transmission and disease progression to vary based 
on infected individuals’ set-point viral load (SPVL), and (3) parameterizing two versions of 
the model, based on data from the Partners PrEP Study and the Partners Demonstration 
Project. 
Methods: Using electronic monitoring data on daily adherence to PrEP, adherence is 
predicted using a set of hidden Markov models (HMMs). In order to predict the 
corresponding concentration of tenofovir (TFV) in plasma on days of condomless sex, a two-
compartment open model of TFV was implemented. Data on demographic characteristics, 
sexual behaviour, and HIV-1 incidence from the Partners PrEP Study were used to 
parameterize and calibrate the model for the trial setting. The model was re-parameterized 
with demographic and sexual behaviour data from the Partners Demonstration Project, but 
was not re-calibrated.  
Conclusion: A detailed microsimulation model was adapted to provide a framework with 
which to analyse the importance of adherence to PrEP and the realistic cost-effectiveness of 
antiretroviral-based prevention for serodiscordant couples in East Africa. 
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4.1 Background 
 
Mathematical modelling is a key resource for decision-making in public health 
[249,250]. For epidemiological purposes, models typically synthesize data about the natural 
history of a disease and the population characteristics of those infected and at risk of infection 
in order to estimate where future infections come from, the effectiveness of interventions to 
prevent transmission, or the costs and benefits of introducing a new program [249]. 
Mathematical models primarily seek to represent a system faithfully, whilst still retaining 
parsimony, and contribute to scientific knowledge or the development of public policy. 
In order to model transmission of infectious diseases, both deterministic 
compartmental models and stochastic individual-based models can be used to evaluate and 
project health outcomes. Deterministic models group individuals into distinct compartments, 
and individuals may transfer from compartment to compartment (i.e. from susceptible to 
infected) over time. These models can be developed with added complexity to include 
heterogeneous mixing, age-structure, or variable infectivity, but each individual in a given 
compartment is equivalent in every way to another individual within the same compartment. 
Stochastic individual-based models, otherwise known as agent-based or microsimulation 
models, are increasingly being used for the purposes of examining public health questions, 
particularly disease transmission. As they are comprised of a number of individual “agents” 
within an environment, individual-based models are able to capture detailed behaviours of 
members of a population and natural stochastic effects. As opposed to classifying all 
individuals into compartments, in which behaviour is completely homogenized by category, 
individual-based models allow each individual to retain distinct characteristics and 
behaviours, such as age, sex, circumcision status, and CD4 cell count category (if HIV-
infected). Life events – e.g. pregnancy, ART initiation, and mortality – occur over time and 
individuals can be followed until they die. 
Using individual-based models to simulate ecological processes such as disease 
transmission has several distinct advantages. Individual-based models are able to include 
more complexity more easily than deterministic models, which grants the model a higher 
degree of realism and therefore a greater likelihood of faithfully capturing the true behaviour 
within a population. Additionally, individual-based models are very flexible, as they allow a 
wide range of parameters and variables to be specified and varied in accordance with 
analytical needs. However, individual-based models have some limitations that make them 
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suitable only under certain conditions. Because of their added complexity, individual-based 
models require a high volume of data, as they have many input parameters. In addition, 
tracking individuals over time requires extensive computational resources, and running the 
model can take much more time to deliver results than would a deterministic model. 
For a potential daily oral PrEP intervention among couples, understanding and 
optimising adherence to PrEP will be critical to the effectiveness of the intervention. Based 
on the collective efficacy results for oral PrEP in randomized controlled trials [49-54,94,95], 
adherence is the “Achilles heel” of PrEP, and it is not yet known to what extent adherence 
would affect the success of an intervention [333]. For example, it will be necessary to know if 
an intervention has the potential to be cost-effective, which factors primarily drive the cost-
effectiveness (or lack thereof), and what type of adherence across the target population is 
sufficient to generate a given reduction in infections. While descriptive analyses of adherence 
data from the Partners PrEP Study and Partners Demonstration Project (see Chapter 3) are 
useful for assessing likely patterns of adherence to PrEP for individuals in HIV-1 
serodiscordant partnerships, it is unknown how these patterns would interact with other 
relevant co-factors and to what extent adherence determines the effectiveness and utility of an 
intervention. In response to these questions, I adapted and parameterized a pre-existing 
microsimulation model [125] to explore the role of adherence in determining the long-term 
impact and cost-effectiveness of antiretroviral-based HIV prevention for serodiscordant 
couples in Kenya and Uganda. 
The microsimulation model of serodiscordant couples in East Africa described in this 
chapter provides a useful and realistic framework for analysing the outcomes of a potential 
PrEP intervention for this population. The model is also flexible to varying the parameters so 
as to compare adherence to PrEP in a rigorous trial setting (Partners PrEP Study, Chapter 5) 
to adherence to PrEP in a more realistic environment with less monitoring (Partners 
Demonstration Project, Chapter 6). To my knowledge, no other microsimulation model has 
included daily adherence patterns and the corresponding pharmacokinetics and 
pharmacodynamics of oral tenofovir-based PrEP to investigate the long-term impact and 
cost-effectiveness of PrEP. In summary, I adapted an individual-based model of HIV 
transmission among serodiscordant couples for the purpose of examining the degree to which 
patterns of adherence affect the overall impact and cost-effectiveness of antiretroviral-based 
prophylactic HIV prevention for this population in East Africa. 
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4.2 Methods 
 
4.2.1 Structure of the Mathematical Model 
 
 The individual-based model follows a cohort of heterosexual HIV-serodiscordant 
couples in East Africa over time. The model structure is loosely based on a pre-existing 
model developed by Hallett and colleagues, which was constructed to analyse the optimal 
uses of ARVs for HIV prevention among serodiscordant couples in South Africa [125]. The 
original model followed a cohort of serodiscordant couples over time and included HIV-1 
disease progression, transmission, treatment, and basic PrEP use. The model also included 
pregnancies for female partners (both HIV-uninfected and HIV-infected), monthly 
unprotected sex acts, and HIV transmission from external partners to the HIV-uninfected 
partner. The model was parameterized based on data from the Partners in Prevention 
HSV/HIV Study [111,142]. As no data from any of the oral PrEP trials had been released at 
the time of the development of the original model, PrEP was assumed to be used during 90% 
of sex acts and was assumed to have an intrinsic efficacy of 90%, leading to a functional 
effectiveness of 81% for every individual on PrEP. 
 In order to examine questions regarding PrEP use and adherence, I revised the model 
to include daily adherence profiles and the corresponding hourly 
pharmacokinetics/pharmacodynamics (PK/PD) of oral FTC/TDF PrEP. In addition, I added 
variable risk of transmission and speed of disease progression according to the HIV-1 RNA 
set-point viral load of any HIV-infected individuals in the model [152]. Both HIV-uninfected 
and HIV-infected partners in the couple can also now acquire external partners, and external 
partners can become infected via either partner in the couple with their infection tracked in 
detail. Finally, I included detailed empirical cost estimates for both PrEP and ART. The 
model was coded in Matlab R2102b.	  
 A simple diagram of the individual-based model can be seen in Figure 4.1. The model 
begins with the assumption that each couple has recently taken HIV-1 tests together and 
discovered that one partner is HIV-infected and the other is not. From there, the age and sex 
of both partners are assigned, and the CD4 cell count category (200-349, 350-499, or ≥500 
cells/µl) and HIV-1 RNA set-point viral load category (<400, 400-3,499, 3,500-9,999, 
10,000-49,999, or ≥50,000 copies/ml) are assigned to the HIV-infected partner; each 
characteristic is drawn randomly from the relevant distribution from the Partners PrEP Study 
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data (see section 3.2.2.1) or the Partners Demonstration Project data (see section 3.2.2.2), 
depending on the relevant analysis. A number of events can occur to the couple throughout 
their lifetimes: either partner can die from background (non-HIV related) mortality, progress 
through CD4 count categories, become pregnant, and begin or terminate external 
partnerships. Some pregnancies are prefaced by a six-month period of pregnancy intention, 
during which the couple has an additional number of condomless sex acts, and some are 
unintentional (i.e. no period of fertility intention precedes the pregnancy). The HIV-infected 
partner can also initiate ART, stop taking ART, or die of HIV-related causes, and infect an 
external partner if the external partner was uninfected at the time of the relationship. The 
HIV-uninfected partner can become infected from either the stable partner or an external 
partner (and can subsequently infect external partners if seroconversion has occurred), and 
begin or cease using PrEP (Figure 4.2). If the HIV-uninfected partner begins taking PrEP, he 
or she is assigned a 10% “adherence category” according to the distribution of mean 
adherence from the Partners PrEP trial ancillary adherence study (AAS). Individuals are 
assumed to follow similar patterns of PrEP adherence throughout the duration of time that 
they are taking PrEP. 
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Figure 4.1: Schematic of characteristics, simulated events, and outcomes within the model. 
Incoming arrows indicate factors that affect the respective event or outcome. 
 
Applies to HIV-infected
individuals
Applies to HIV-uninfected
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Figure 4.2: Model flowchart for PrEP use in intervention scenarios. 
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 HIV-infected individuals in the model can initiate ART at CD4 thresholds of <200 
cells/µl, <350 cells/µl, <500 cells/µl, or immediately. Once an individual initiates ART, his 
or her probability of transmitting HIV decays exponentially over the course of the first six 
months to reach a value of 8% of that for an individual with the same CD4 cell count 
category but no ART [125]. Mortality rates for individuals on ART depend on the CD4 count 
at ART initiation and the length of time on ART. If the HIV-infected partner initiates ART 
and the HIV-uninfected partner is taking PrEP, the HIV-uninfected individual continues 
taking PrEP for six months in order to allow time for viral suppression to occur for the HIV-
infected partner, in keeping with the strategy of PrEP and ART use in the Partners 
Demonstration Project. In default analyses, individuals on ART are assumed to experience no 
dropout from ART programs once treatment has been initiated. In sensitivity analyses, in 
which the dropout rate is explored, individuals that have dropped off ART face an increased 
risk of mortality and cannot reinitiate ART once they are no longer in the healthcare system. 
HIV-1 transmission from and to external partners can also occur in the model. Both 
HIV-infected and HIV-uninfected partners in the couple can acquire an external partner or 
end an external partnership in such a way as to match a distribution of those engaging in 
outside relationships at any given point in time (see Tables 4.6 and 4.14). Women are 
assumed to under-report having an external partner, and so more female partners of both HIV 
statuses have an external partner at some point in time than is reported in the data (see section 
4.25). 
 
4.2.2  Calculating HIV-1 Transmission Probabilities 
 
While the HIV-uninfected partner in the couple is taking PrEP, the probability of 
HIV-1 transmission (𝑝) within the stable partnership or an external partnership is calculated 
on each day the couple has condomless sex, and is determined using Equation 4.1:  
 𝑝 =   𝛽!,!,!,!,!,! 1−   𝜀!                             (4.1) 
 
where 𝛽!,!,!,!,!,! is the probability of HIV-1 transmission per condomless sex act with a 
HIV-infected partner with set-point viral load V, CD4 cell count category C, ART-status A, 
gender S, woman’s pregnancy status P, man’s circumcision status Q, and 𝜀!   is the efficacy of 
PrEP, depending on the protection K provided by the plasma TFV concentration that day. It is 
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assumed that no female external partners are pregnant. The probability of transmission per 
condomless sex act is modelled using Equation 4.2: 
 𝛽!,!,!,!,!,! =   𝜋!!𝜋!!𝜋!!𝜋!!𝜋!!𝜋!!𝛽!                 (4.2) 
 
where 𝛽!  is defined as the basic transmission probability of HIV-1 per condomless sex act 
(from a non-pregnant woman to an uncircumcised man, with the woman’s SPVL category of 
≥50,000 copies/ml and no ART use). 𝜋!! ,𝜋!! ,𝜋!!,𝜋!!,𝜋!!  and  𝜋!!   indicate the relative 
probability of transmission per sex act depending on the HIV-infected individual’s set-point 
viral load, CD4 cell count category, ART status, and the gender of the HIV-uninfected 
partner, the pregnancy status of the female partner, and the circumcision status of the man if 
HIV-uninfected, respectively (see sections 4.2.3.1 and 4.2.3.2 for Partners PrEP Study and 
Partners Demonstration Project distributions, respectively). 
 When the HIV-uninfected partner is not taking PrEP, the probability of HIV-1 
transmission (𝑝!) is calculated monthly using Equation 4.3: 
 𝑝! = 1−    1−   𝛽!,!,!,!,!,! !                             (4.3) 
 
where n is the number of condomless sex acts the couple has that month. The transmission 
probability is calculated monthly when PrEP is not being used within the couple, as the 
probability of transmission remains constant for any days of condomless sex. 
 
4.2.3   Model Parameterization 
 
  The first version of the model (used to produce the results in Chapter 5) was 
parameterized using population data from the Partners PrEP Study, adherence data from the 
Partners PrEP Study AAS, population pharmacokinetics from a tenofovir study using 
Partners PrEP dosing data [334], and pharmacodynamics from a synthesized model of PrEP 
trials [226]. Descriptive analyses of adherence are described fully in Chapter 3 (see section 
3.3.1); briefly, overall adherence to PrEP was high, with a mean of 85% and median of 92% 
across all participants in the AAS. 
 A second version of the model was parameterized using population data and 
adherence data from the Partners Demonstration Project (see Chapter 3, section 3.3.2). 
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Adherence was moderately lower than in the trial, with a mean of 75% and a median of 85%. 
As the Demonstration Project does not include a placebo arm, the model was only fit to data 
from the Partners PrEP Study (see section 4.2.5). Analyses using the Partners Demonstration 
Project data are parameterized using the population characteristics and adherence patterns 
from the Demonstration Project (see Chapter 3, section 3.2.2.1), but retain the model fit 
without PrEP from the control arm of the trial population (see Chapter 3, section 3.2.2.1). 
 
4.2.3.1   Population Characteristics of the Partners PrEP Study Couples 
 
 The population characteristics of the couples in the model are drawn randomly from 
distributions of data from the Partners PrEP Study. All characteristics are those used in the 
default model scenario. Population characteristics from the Partners PrEP Study included in 
the model are described in Tables 4.1-4.8 below. 
 
Gender of HIV-Uninfected Partner Percentage 
Man 62.4 
Woman 37.6 
Table 4.1: Assumed gender distribution of HIV-1 infection among the stable serodiscordant 
couples in the model, from data in the Partners PrEP Study. In partnerships where the man is 
the HIV-uninfected partner, 53% of the men were circumcised. In the model, circumcision 
reduces HIV transmission by 65% [40]. 
 
(A) If Male Partner is HIV-Uninfected 
 
Woman’s Age 
≤24 25-34 35-44 45-54 ≥55 
Man’s Age 
≤24 8.0% 2.0% 0.1% 0.0% 0.0% 
25-34 15.0% 24.8% 3.3% 0.2% 0.0% 
35-44 2.9% 16.0% 10.6% 0.8% 0.3% 
45-54 0.7% 4.5% 5.3% 1.9% 0.1% 
≥55 0.2% 0.8% 1.6% 1.0% 0.2% 
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(B) If Female Partner is HIV-Uninfected 
 
Woman’s Age 
≤24 25-34 35-44 45-54 ≥55 
Man’s Age 
≤24 1.6% 0.3% 0.0% 0.0% 0.0% 
25-34 8.5% 1.7% 2.4% 0.1 0.0% 
35-44 2.4% 23.9% 18.3% 1.3% 0.1% 
45-54 0.6% 4.4% 1.1% 3.8% 0.0% 
≥55 0.0% 0.2% 1.3% 2.4% 0.5% 
Table 4.2: Assumed proportional age distribution of stable partnerships in the model if (A) 
the male partner is HIV-uninfected and (B) if the female partner is HIV-uninfected, from data 
in the Partners PrEP Study. 
 Woman’s Age 
Pregnancy Incidence Rate 
(/100 woman-years) 
HIV-Uninfected Women 
≤24 25.28 
25-34 14.53 
35-44 4.09 
≥45 0.00 
Uninfected Total  10.55 
HIV-Infected Women 
≤24 23.70 
25-34 15.17 
35-44 5.02 
≥45 0.00 
Infected Total  13.97 
Table 4.3: Age-specific incidence of pregnancy for HIV-uninfected and HIV-uninfected 
women, from data in the Partners PrEP Study. An assumption is made that HIV-infected 
women on ART experience pregnancies at the same rate as women not yet on treatment. 
(A)  HIV-Infected Men Aged ≤24 
 CD4 Cell Count Category 
Viral Load Category 
(copies/ml) 200-349 350-499 ≥500 
<400 0.0% 0.0% 0.0% 
400-3,499 9.1% 3.0% 0.0% 
3,500-9,999 9.1% 3.0% 0.0% 
10,000-49,999 24.2% 9.1% 6.1% 
≥50,000 24.2% 6.1% 6.1% 
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(B) HIV-Infected Men Aged 25-34 
 CD4 Cell Count Category 
Viral Load Category 
(copies/ml) 200-349 350-499 ≥500 
<400 1.5% 1.3% 0.0% 
400-3,499 10.2% 2.8% 0.7% 
3,500-9,999 9.3% 5.4% 2.2% 
10,000-49,999 16.1% 12.8% 7.6% 
≥50,000 8.9% 12.4% 8.9% 
 
(C) HIV-Infected Men Aged 35-44 
 CD4 Cell Count Category 
Viral Load Category 
(copies/ml) 200-349 350-499 ≥500 
<400 1.8% 0.9% 0.1% 
400-3,499 8.8% 3.9% 2.0% 
3,500-9,999 7.0% 4.4% 3.2% 
10,000-49,999 14.4% 13.6% 6.5% 
≥50,000 8.5% 13.9% 10.9% 
 
(D) HIV-Infected Men Aged ≥45 
 CD4 Cell Count Category 
Viral Load Category 
(copies/ml) 200-349 350-499 ≥500 
<400 1.3% 0.5% 1.0% 
400-3,499 8.6% 4.1% 4.3% 
3,500-9,999 5.6% 4.8% 2.0% 
10,000-49,999 12.2% 11.7% 9.6% 
≥50,000 7.9% 14.7% 11.7% 
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(E) HIV-Infected Women Aged ≤24 
 CD4 Cell Count Category 
Viral Load Category 
(copies/ml) 200-349 350-499 ≥500 
<400 4.1% 0.0% 0.3% 
400-3,499 15.9% 2.4% 0.5% 
3,500-9,999 15.2% 5.5% 2.5% 
10,000-49,999 20.7% 10.1% 3.7% 
≥50,000 8.5% 6.7% 3.7% 
 
(F) HIV-Infected Women Aged 25-34 
 CD4 Cell Count Category 
Viral Load Category 
(copies/ml) 200-349 350-499 ≥500 
<400 3.8% 0.7% 0.2% 
400-3,499 15.4% 4.9% 2.2% 
3,500-9,999 12.6% 6.3% 2.6% 
10,000-49,999 15.2% 12.2% 6.1% 
≥50,000 5.2% 6.7% 5.7% 
 
(G) HIV-Infected Women Aged 35-44 
 CD4 Cell Count Category 
Viral Load Category 
(copies/ml) 200-349 350-499 ≥500 
<400 5.0% 1.3% 1.3% 
400-3,499 16.0% 5.7% 2.9% 
3,500-9,999 11.2% 7.8% 4.2% 
10,000-49,999 13.1% 9.1% 6.5% 
≥50,000 3.8% 5.9% 6.1% 
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(H) HIV-Infected Women Aged ≥45 
 CD4 Cell Count Category 
Viral Load Category 
(copies/ml) 200-349 350-499 ≥500 
<400 3.0% 2.0% 0.0% 
400-3,499 11.0% 7.0% 4.0% 
3,500-9,999 13.0% 8.0% 6.0% 
10,000-49,999 5.0% 8.0% 8.0% 
≥50,000 8.0% 6.0% 11.0% 
Table 4.4: Assumed age-specific joint distribution of individuals in each CD4 cell count and 
set-point viral load category from data in the Partners PrEP Study for (A) HIV-infected men 
aged ≤24, (B) HIV-infected men aged 25-34, (C) HIV-infected men aged 35-44, (D) HIV-
infected men aged ≥45, (E) HIV-infected women aged ≤24, (F) HIV-infected women aged 
25-34, (G) HIV-infected women aged 35-44, and (H) HIV-infected women aged ≥45. An 
assumption is made that HIV-infected partners in the study have reached their SPVL (i.e. that 
they are not in the acute infection phase). 
 
(A) HIV-Uninfected Partners 
Any External Partners at Enrolment and/or During Two Years of Follow-Up 
 None Any 
Man 56.8% 43.2% 
Woman 89.9% 10.1% 
 
(B) HIV-Infected Partners 
Any External Partners at Enrolment and/or During Two Years of Follow-Up 
 None Any 
Man 66.3% 33.7% 
Woman 90.2% 9.8% 
Table 4.5: Proportion of (A) HIV-uninfected partners and (B) HIV-infected partners ever 
reporting having an external partner at enrolment or at any point during two years of follow-
up in the Partners PrEP Study. 
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Time (months) 
0 (enrolment) 6 12 18 24 
HIV-Uninfected Man 31% 33% 40% 36% 35% 
HIV-Uninfected 
Woman 4% 11% 15% 17% 24% 
HIV-Infected Man 44% 42% 46% 36% 39% 
HIV-Uninfected 
Woman 10% 9% 22% 30% 32% 
Table 4.6: Assumed point prevalence of having an external partner every six months from 
time of enrolment (time=0), for individuals who ever report having an external partner in the 
Partners PrEP Study. 
 
 
Mean Number of Monthly Condomless Sex Acts 
with External Partner 
HIV-Uninfected Man 4.07 
HIV-Uninfected Woman 2.32 
HIV-Infected Man 1.54 
HIV-Infected Woman 1.84 
Table 4.7: Mean number of condomless sex acts per month with an external partner for HIV-
uninfected and HIV-infected men and women in the Partners PrEP Study. 
 
 Age of HIV-Uninfected Partner 
Mean # of Monthly 
Condomless Sex Acts ≤24 25-34 35-44 45-54 ≥55 
Man 1.11 0.90 0.66 0.45 0.35 
Woman 0.97 0.83 0.64 0.51 0.08 
Table 4.8: Mean number of condomless sex acts per month within the stable partnership, 
according to the sex of the HIV-uninfected partner in the couple, from data in the Partners 
PrEP Study.  
 
4.2.3.1.1   Assumptions about Sex Behaviour Data 
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In the Partners PrEP Study, sexual behaviour was reported via monthly questionnaires 
in which participants were asked to state the total number of sex acts with their stable partner 
(specifying what proportion took place with and without a condom) and any external partner 
each month. However, sexual behaviour reporting can be biased in a number of ways, based 
on the method of reporting (e.g. anonymous self-reports or face-to-face interviews) or social 
desirability and recall biases [335]. A small sub-study of daily SMS surveys took place 
among 96 participants over 60 days to investigate the frequency of risk behaviours 
(condomless sex and missed PrEP doses) in the context of daily reporting [204]. In the study, 
unprotected sex was reported in 35.2% of months (versus 15.9% of months in monthly 
questionnaires) and missing at least one PrEP dose in a month was reported in 54.5% of 
months compared to 13.1% of months in the monthly clinic questionnaires, both of which 
were significant differences (p<0.01) [336]. 
In order to correct for underreporting of sexual risk behaviour in the model, several 
additional assumptions were made about the reported data in the Partners PrEP Study. In the 
model, the number of condomless sex acts in a given month is drawn from a Poisson 
distribution using the relevant mean number of condomless sex acts for the stable partnership 
and any external partnership. When drawing from the distribution, the mean is multiplied by 
a factor of 1.2, consistent with the difference in underreporting of unprotected sex resulting 
from the SMS sub-study [204]. Though the degree of this difference was not significant 
(p=0.4), HIV-1 incidence in the placebo arm and rates of pregnancy in both arms of the trial 
suggest that the reported number of unprotected sex acts may be lower than specified in 
monthly questionnaires. A second assumption is made that women in the study under-
reported ever having an external partner, due to gender norms about socially acceptable 
sexual behaviour. For women in sub-Saharan Africa, sexual partnerships outside of marriage 
can be met with disapproval, and there may be social costs associated with reporting external 
partners [306,337]. In order to adjust for this assumed under-reporting, a parameter was 
calibrated to adjust the proportion of women ever having an external partnership (see section 
4.2.5). 
The model also contains several simplifying assumptions about changes in sexual 
behaviour over time. When an individual ages in the model, the mean number of condomless 
sex acts changes to match the mean for the respective adherence category. It is also assumed 
that once both partners in the couple are over the age of 65 that no more condomless sex acts 
occur, due to insufficient data about this age category. Lastly, if the initially HIV-uninfected 
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partner seroconverts, any future condomless sex acts with external partners are drawn from 
the same distribution as that for HIV-infected individuals. 
4.2.3.2   Population Characteristics of the Partners Demonstration Project 
Couples 
 
 The second version of the model (used to produce results in Chapter 6) was re-
parameterized with data from the Partners Demonstration Project, in order to compare 
adherence in the trial to adherence in the context of a demonstration project. Recruitment for 
the Partners Demonstration Project differed from the Partners PrEP Study in that only “high-
risk couples” (i.e. couples that had scores ≥5 according to a risk score) were enrolled. HIV-
uninfected partners in the demonstration project were younger overall (median of 29 years 
[IQR 26-36]) and more HIV-infected partners had a high set-point viral load (≥10,000 
copies/ml). In addition, the Partners Demonstration Project enrolled some couples in which 
the HIV-infected partner was eligible for ART at enrolment, and thus the average CD4 cell 
count was somewhat lower in the Demonstration Project population (median 429 [IQR 261-
616]) than in the trial (median 497 [IQR 375-662]). Population characteristics of the couples 
from the Demonstration Project are presented in Tables 4.9-4.16. 
 
Sex of HIV-Uninfected Partner Percentage 
Man 67.0 
Woman 33.0 
Table 4.9: Assumed sex distribution of HIV-1 infection among the stable serodiscordant 
couples in the model, from data in the Partners Demonstration Project. In partnerships where 
the man is the HIV-uninfected partner, 67% of the men were circumcised. In the model, 
circumcision reduces HIV transmission by 65% [40]. 
 
(A) If Male Partner is HIV-Uninfected 
 
Woman’s Age 
≤24 25-34 35-44 45-54 ≥55 
Man’s Age 
≤24 14.9% 2.2% 0.0% 0.0% 0.0% 
25-34 24.3% 25.3% 1.2% 0.0% 0.0% 
35-44 3.4% 12.1% 6.2% 0.0% 0.0% 
45-54 0.4% 2.2% 3.8% 0.7% 0.0% 
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≥55 0.0% 0.7% 1.3% 0.9% 0.0% 
 
(B) If Female Partner is HIV-Uninfected 
 
Woman’s Age 
≤24 25-34 35-44 45-54 ≥55 
Man’s Age 
≤24 6.6% 0.9% 0.0% 0.0% 0.0% 
25-34 15.3% 20.1% 2.7% 0.0% 0.0% 
35-44 4.8% 21.0% 9.0% 0.6% 0.0% 
45-54 0.6% 5.1% 7.2% 2.7% 0.0% 
≥55 0.0% 0.3% 1.2% 2.1% 0.0% 
Table 4.10: Assumed proportional age distribution of stable partnerships in the model if (A) 
the male partner is HIV-uninfected and (B) if the female partner is HIV-uninfected, from data 
in the Partners Demonstration Project. 
 
 Woman’s Age 
Pregnancy Incidence Rate 
(/100 woman-years) 
HIV-Uninfected Women 
≤24 52.60 
25-34 24.20 
35-44 0.07 
≥45 0.00 
Uninfected Total  24.90 
HIV-Infected Women 
≤24 25.10 
25-34 15.90 
35-44 11.70 
≥45 0.00 
Infected Total  18.50 
Table 4.11: Age-specific incidence of pregnancy for HIV-uninfected and HIV-uninfected 
women, from data in the Partners Demonstration Project. An assumption is made that HIV-
infected women on ART experience pregnancies at the same rate as women not yet on 
treatment. 
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(A) HIV-Infected Men Aged ≤24 
 CD4 Cell Count Category 
Viral Load 
Category 
(copies/ml) 
 
<200 200-349 350-499 ≥500 
<400 3.7% 1.0% 1.0% 0.3% 
400-3,499 14.2% 1.7% 0.7% 0.3% 
3,500-9,999 5.4% 4.1% 0.7% 0.0% 
10,000-49,999 17.9% 6.8% 8.4% 3.7% 
≥50,000 10.5% 6.4% 6.8% 6.4% 
 
(B) HIV-Infected Men Aged 25-34 
 CD4 Cell Count Category 
Viral Load 
Category 
(copies/ml) 
 
<200 200-349 350-499 ≥500 
<400 3.3% 10.3% 0.8% 0.3% 
400-3,499 6.1% 2.8% 1.5% 0.0% 
3,500-9,999 6.4% 1.5% 1.5% 0.8% 
10,000-49,999 12.8% 6.6% 9.4% 2.3% 
≥50,000 8.2% 12.0% 10.2% 12.5% 
 
(C) HIV-Infected Men Aged ≥35 
 CD4 Cell Count Category 
Viral Load 
Category 
(copies/ml) 
 
<200 200-349 350-499 ≥500 
<400 0.8% 0.4% 0.0% 0.8% 
400-3,499 3.0% 1.5% 0.4% 0.8% 
3,500-9,999 1.1% 1.1% 1.1% 0.4% 
10,000-49,999 13.7% 4.6% 7.2% 1.5% 
≥50,000 12.5% 9.1% 18.6% 21.3% 
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(D) HIV-Infected Women Aged ≤24 
 CD4 Cell Count Category 
Viral Load 
Category 
(copies/ml) 
 
<200 200-349 350-499 ≥500 
<400 3.7% 1.1% 1.1% 0.4% 
400-3,499 14.7% 1.8% 0.7% 0.4% 
3,500-9,999 5.1% 4.4% 0.7% 0.0% 
10,000-49,999 17.6% 6.6% 8.1% 3.7% 
≥50,000 10.6% 6.2% 7.3% 5.9% 
 
(E) HIV-Infected Women Aged 25-34 
 CD4 Cell Count Category 
Viral Load 
Category 
(copies/ml) 
 
<200 200-349 350-499 ≥500 
<400 3.3% 1.1% 0.7% 0.4% 
400-3,499 7.0% 2.6% 1.5% 0.0% 
3,500-9,999 6.7% 1.1% 2.2% 1.1% 
10,000-49,999 13.0% 7.4% 10.7% 3.0% 
≥50,000 5.6% 11.5% 8.9% 12.2% 
 
(F) HIV-Infected Women Aged ≥35 
 CD4 Cell Count Category 
Viral Load 
Category 
(copies/ml) 
 
<200 200-349 350-499 ≥500 
<400 0.0% 1.1% 0.0% 0.0% 
400-3,499 2.3% 3.4% 0.0% 2.3% 
3,500-9,999 1.1% 3.4% 1.1% 1.1% 
10,000-49,999 17.0% 4.5% 13.6% 2.3% 
≥50,000 6.8% 6.8% 15.9% 17.0% 
Table 4.12: Assumed age-specific joint distribution of individuals in each CD4 cell count 
and set-point viral load category, from data in the Partners Demonstration Project, for (A) 
HIV-infected men aged ≤24, (B) HIV-infected men aged 25-34, (C) HIV-infected men aged 
≥35, (D) HIV-infected women aged ≤24, (E) HIV-infected women aged 25-34, and (F) HIV-
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infected women aged ≥35. An assumption is made that HIV-infected partners in the study 
have reached their SPVL (i.e. that they are not in the acute infection phase). 
 
(A) HIV-Uninfected Partners 
Any External Partners at Enrolment and/or During Follow-Up 
 None Any 
Man 73.4% 26.6% 
Woman 91.0% 9.0% 
 
(B) HIV-Infected Partners 
Any External Partners at Enrolment and/or During Follow-Up 
 None Any 
Man 77.0% 23.0% 
Woman 93.4% 6.6% 
Table 4.13: Proportion of (A) HIV-uninfected partners and (B) HIV-infected partners ever 
reporting having an external partner at enrolment or at any point during follow-up in the 
Partners Demonstration Project. 
 
 
Time (months) 
0 (enrolment) 6 12 18 
HIV-uninfected man 44.6% 37.3% 29.9% 10.2% 
HIV-uninfected 
woman 16.7% 36.7% 40.0% 16.7% 
HIV-infected man 41.6% 29.9% 28.6% 10.4% 
HIV-infected woman 15.6% 33.3% 26.7% 22.2% 
Table 4.14: Point prevalence of having an external partner every six months from time of 
enrolment (time=0), for individuals who ever report having an external partner in the Partners 
Demonstration Project. 
 
 
Mean Number of Monthly Condomless Sex Acts 
with External Partner 
HIV-Uninfected Man 4.25 
HIV-Uninfected Woman 3.52 
HIV-Infected Man 1.27 
HIV-Infected Woman 1.86 
	  
	  
153 
Table 4.15: Mean number of condomless sex acts per month with an external partner for 
HIV-uninfected and HIV-infected men and women, from data in the Partners Demonstration 
Project. 
 
 Age of HIV-Uninfected Partner 
Mean # of Monthly 
Condomless Sex Acts ≤24 25-34 35-44 ≥45 
Man 2.90 2.15 2.21 1.65 
Woman 2.46 2.18 1.81 2.03 
Table 4.16: Mean number of condomless sex acts per month within the stable partnership, 
according to the sex of the HIV-uninfected partner in the couple, from data in the Partners 
Demonstration Project. 
 
4.2.3.3   HIV-1 Infections among External Partners 
 
If either partner in the stable couple forms an external partnership, the external 
partner’s HIV status is determined by drawing from the sex-specific HIV prevalence, 
averaged across Kenya and Uganda (Table 4.17). If the external partner is initially HIV-
uninfected, their HIV status is updated every six months. 
 
 HIV Prevalence in the General Population 
Men (Kenya, ages 15-64, 2012) 4.4% [338] 
Men (Uganda, ages 15-49, 2011) 6.1% [339] 
Men (average) 5.3% 
Women (Kenya, ages 15-64, 2012) 6.9% [338] 
Women (Uganda, ages 15-49, 2011) 8.3% [339] 
Women (average) 7.6% 
Table 4.17: Sex-specific prevalence of HIV-1 among the general population in Kenya and 
Uganda. 
 
If an external partner seroconverts (either from an individual external to the stable 
couple or from a partner in the stable couple), the individual’s set-point viral load and CD4 
cell count category are drawn from the gender-specific joint SPVL/CD4 distribution of the 
stable couples, averaged across all ages. If an external partner does acquire HIV from either 
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partner in the stable couple, the external partner’s infection and resulting health outcomes are 
tracked in the same way as that of the stable partners. External partners are also assumed to 
be eligible for ART at the same CD4 cell count threshold as couples in the model, with the 
assumption that 90% of external partners are tested and diagnosed with HIV-1, 90% of those 
tested are connected to care, and 90% of those connected to care are on ART. ART use is not 
tracked for any external partner unless that external partner has become infected from a 
partner in the stable couple. 
 
4.2.3.4   Pregnancy 
 
 Both HIV-uninfected and HIV-infected women in the model may experience 
pregnancies throughout their lifetimes. Prior to pregnancy, a proportion of couples go through 
a period of “fertility intention,” in which the couple plans to have a child and actively 
changes their behaviour in order to do so. In addition, pregnant women have been shown to 
be both more susceptible to acquiring HIV-1 if HIV-uninfected and more likely to transmit 
HIV-1 if already infected [159,340]. Parameters relating to pregnancy in the model are shown 
in Table 4.18: 
 
Parameter Value 
Multiplicative factor for increased risk of HIV-
1 acquisition when an HIV-uninfected woman 
is pregnant 
2.3 [159] 
Multiplicative factor for increased risk of HIV-
1 transmission when a HIV-infected woman is 
pregnant 
2.2 [159] 
Percentage of all pregnancies that are 
planned by the couple 80% [125] 
Duration of fertility intention, for couples 
planning a pregnancy 6 months [125] 
Increase in condomless sex acts during 
periods of fertility intention 
4 additional condomless sex acts per month 
of fertility intention [125] 
Table 4.18: Assumed parameters relating to pregnancy in the model. Fertility intention 
parameters are not varied based on the HIV-1 status of the woman in the couple.  
	  
	  
	  
155 
	  
4.2.3.5   HIV-1 Transmission and CD4 Cell Count Progression by Set-
Point Viral Load 
 
In the model, HIV transmission is dependent on the set-point viral load (SPVL) of the 
HIV-infected partner. SPVL varies from individual to individual, and is those with higher 
SPVLs are associated with being more infectious [152] and experiencing faster CD4 cell 
count decline [341]. Table 4.19 presents the relative risk of HIV transmission and the mean 
duration of time in each CD4 cell count category, with respect to the SPVL category. In the 
default model scenario, the SPVL for each individual remains stable over time, with changes 
in infectiousness due to CD4 cell count decline. The relative risk of transmission and duration 
of time spent in each CD4 cell count category are also equivalent for individuals with SPVLs 
<400 copies/ml and those with viral loads between 400-3,499 copies/ml because data was 
insufficient to detect any differences. This distinction also allows sensitivity analyses to 
reduce the relative risk of transmission for those with a viral load below 400 copies/ml to 0 
(i.e., equivalent to being on ART). 
 
HIV-1 SPVL 
(copies/ml) 
Relative Risk 
of 
Transmission 
[152]  
Duration of 
Time in CD4 
≥500 
(Years)* 
[341] 
Duration of 
Time in CD4 
350-499 
(Years)* 
[341]  
Duration of 
Time in CD4 
200-349 
(Years)*  
[341] 
Duration of 
Time in 
CD4  <200 
(Years)* [341] 
<400 0.08 5.65 2.76 4.86 0.98 
400-3,499 0.08 5.65 2.76 4.86 0.98 
3,500-9,999 0.49 4.15 3.48 2.38 2.58 
10,000-49,999 0.58 2.86 2.61 4.23 1.03 
≥50,000 1.00 1.75 1.72 3.65 0.67 
Table 4.19: Relative risk of transmission of HIV-1 with respect to HIV-1 RNA viral load 
(measured in copies/ml) and duration of time in each CD4 category (years). *net of mortality. 
 
 The probability of an HIV-infected individual not on ART transitioning from one 
CD4 cell count category to another per month (𝑝!) is given by Equation 4.4: 
 𝑝! = 1−   𝑒!!.!"#!!,!                               (4.4) 
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where 𝜑!,!  is the duration of time spent in the current CD4 cell count category for an HIV-
infected partner with set-point viral load V and CD4 cell count category C. When HIV-
infected individuals are on ART, their CD4 cell count category remains the same as the CD4 
cell count category at which they initiated ART and their viral load drops to 92% of their 
baseline transmission probability. 
 
4.2.3.6   Mortality 
 
 In the model, all individuals experience a risk of background mortality (i.e. not related 
to HIV status) and HIV-infected individuals also experience an elevated risk of mortality 
from HIV-related causes. Background mortality rates are calculated based on both age and 
gender. Because the model is parameterized for cohorts in both Kenya and Uganda, the age-
specific mortality rates are an average of the respective mortality rates in both Kenya and 
Uganda. Background mortality rates were derived by fitting the function 𝑦 = 𝛼𝑒!" to age-
specific, non HIV-related mortality projections for 2014 in Spectrum, where 𝑦 is the 
mortality rate and 𝑥 represents the exact age of the individual. The calibrated parameters for 
men are 𝛼 = 0.0003 and 𝛽 = 0.2081 for men, and 𝛼 = 0.0001  and 𝛽 = 0.2215 for women 
(Figure 4.3). 
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Figure 4.3: Modelled age-specific mortality rates for men (green line) and women (purple 
line) in Kenya and Uganda, East Africa. 
 
HIV-infected individuals also experience an additional risk of mortality caused by 
HIV-1. HIV-related mortality rates are determined by CD4 cell count and time on ART 
(Table 4.20). 
 
 
Mortality in First Year 
(%/Year) 
Mortality in Subsequent 
Years (%/Year) 
CD4 Cell Count at ART 
Initiation   
≥500 1.3 1.3 
350-500 2.5 1.3 
200-350 5.0 2.5 
<200 10.0 5.0 
Table 4.20: HIV-related mortality rates for HIV-infected individuals in the first year of ART 
use and for subsequent years, depending on the CD4 cell count category at the time of ART 
initiation [291-293]. 
 
 The probability of an HIV-infected individual dying from HIV-related causes (𝑝!) per 
month is determined using Equation 4.5: 
 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
15 25 35 45 55 65 75 85 
M
or
ta
lit
y 
Ra
te
 (/
Ye
ar
) 
Age (Years) 
Men in East Africa Women in East Africa
	  
	  
158 
𝑝! = 1−   𝑒!!.!"#!!,!                   (4.5) 
 
where 𝜇!,!   is the HIV-related mortality rate for an HIV-infected partner with time since ART 
initiation T and CD4 cell count category C. 
 
4.2.3.7 Hidden Markov Models to Describe Adherence to PrEP 
 
Patterns of adherence to PrEP in the Partners PrEP Study and Partners PrEP 
Demonstration Project have been described in detail in Chapter 3. Briefly, adherence was 
high overall across both cohorts (mean of 85% in the trial and 75% in the demonstration 
project), but with high inter-individual variability and younger age was significantly 
associated with lower adherence within both cohorts. In the model, I needed to represent the 
variety of realistic adherence patterns in the model, informed by the MEMS data. As the 
MEMS data is also restricted by the observation time for each individual, adherence needed 
to be extrapolated into the future in such a way as to capture both patterns and changes over 
time. 
In order to form appropriate assumptions for propagating adherence patterns forward 
in time, I developed a set of hidden Markov models (HMMs). A hidden Markov model is a 
stochastic probabilistic model used to describe a Markov process of a sequence of discrete 
observations generated from a set of unobserved (or ‘hidden’) states. The Markov system 
consists of a set of N states Sj = {s1, s2, …, sN} and a sequence of M observations vk = {o1, o2, 
…, oM}, with discrete time intervals t = {t1, t2, …, T}. At a given time-step t, the model is in a 
single state, denoted as qt. The system is characterized by a first-order Markov chain in which 
only the current state at any given time-step determines the transition probability to any other 
state, i.e., P(qt = sj | qt-1 = si, qt-2 = sk, …) = P(qt = sj | qt-1 = si). The model (λ) is defined by the 
parameters A (the transition matrix), B (the emission matrix), and π (the initial state 
probability distribution), such that λ = (A, B, π).  The parameters are more formally described 
as: 
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• A, the transition matrix determining the probability of switching to state j from state i 
at each time-step t. 
A = {aij}   = a11 a12 … a1N  =  P(qt+1=sj | qt = si), 
  a21  a22 …  a2N        1 ≤ i, j ≤ N  
      :   :    : 
    aN1 aN2 … aNN 
 
• B, the emission matrix determining the probability of producing observation k from 
state j at each time-step t. 
B = {bik} = b11 b12 … b1M  =  P(ot = vk | qt = si), 
  b21 b22 … b2M   1 ≤ i  ≤ N  
    :   :    :  1 ≤ k ≤ M 
    bN1 bN2 … bNM    
 
• π, the probability vector of initial starting states. 
π = {πi} =  { π1, π2, … πN}         =  P(q1 = Si),  
          1 ≤ i  ≤ N 
 
All three parameter coefficients must also have the following property, where 𝑚 is the 
specific probability vector: 
𝑚!" = 1!!!!  
The structure of the HMM was motivated by a visual inspection of individual patterns 
of adherence (see Chapter 3, section 3.3.2.5 and Figures 4.5-4.11) showing “blocks” of high 
and low adherence with switching in between. Each HMM is therefore composed of two 
states (S1, S2), which represent being in either a “high-frequency” or a “low-frequency” state 
of adherence, and two possible observations (O1, O2), which represent a PrEP dose being 
taken or missed. Within each category, being in the high-frequency state indicates a higher 
probability (within the emission matrix) that the individual will take their dose on a given 
day, but it is possible for the individual to take or miss a dose in both high-frequency and 
low-frequency states. Figure 4.4 is a diagram of the format for the structure of the HMMs: 
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Figure 4.4: Discrete two-state HMM (S1 and S2) with two observable outputs (O1 and O2). a11 
is the probability of the individual remaining in S1; a12 is the probability of the individual 
transitioning from S1 to S2; a21 is the probability of the individual transitioning from S2 to S1; 
a22 is the probability of the individual remaining in S2. b11 is the probability of an individual in 
S1 producing output O1; b11 is the probability of an individual in S1 producing output O2; b21 is 
the probability of an individual in S2 producing output O1; b22 is the probability of an 
individual in S2 producing output O2. 
For the purposes of characterizing and extending patterns of adherence beyond the 
trial data, I had two aims: (1) to represent the patterns observed in the data faithfully, and (2) 
to do so with as parsimonious a model as possible. I represented adherence on a day-by-day 
basis for 1,144 participants from the Partners PrEP Study AAS. I classified individuals first 
according to eight age- and gender-specific categories: women aged ≤24, 25-34, 34-44, and 
≥45, and males ≤24, 25-34, 34-44, and ≥45. I then further categorized participants from the 
trial data according to each individual’s mean adherence to PrEP (i.e. the number of doses 
taken divided by the number of doses expected, with maximum adherence of 100%) over the 
course of the study period, the length of which varied by participant. I separated the data by 
10% brackets of mean adherence (e.g. 90-100%, 80-90%, etc.) in order to describe the 
adherence data for each age- and sex-specific category. Every 10% adherence bracket was 
described by a separate HMM, which was trained using only sequences of participants that 
fell within the respective adherence bracket. 
One of the benefits of using a hidden Markov model is that the model can learn from 
sequences of data in order to adjust the parameters of the model to best fit the observations – 
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i.e., by choosing λ = (A, B, π) that maximizes P(O|λ). In this case, this is the model (λ) that 
best describes the probability of observing the data given the model, consisting of a transition 
matrix describing the frequency of switching between high-frequency and low-frequency 
adherence states (A), an emission matrix describing the frequency of observing a taken or 
missed PrEP dose while in a high-frequency or low-frequency state, and the initial 
distribution of individuals in a high-frequency or low-frequency state (π). The Baum-Welch 
algorithm, which starts with random initial guesses of all parameters, uses the expectation-
maximization) algorithm and “training” sequences of observations to locally maximize 
P(O|λ). The algorithm then iteratively adjusts the parameter set to find the maximum 
likelihood estimate of the HMM parameters. 
To evaluate age and gender categories from the ten constructed HMMs, I used the 
distribution of participants in each adherence category from the data to create a new 
population of individuals with similar adherence patterns. In order to determine goodness-of-
fit, I examined a number of markers to evaluate the model’s fit as compared to the data.  
First, I compared the distribution of adherence patterns per age- and gender-specific category 
visually. Figures 4.5-4.11 show the comparison of day-by-day patterns of adherence and non-
adherence from data to model, with data patterns displayed at the top and model patterns 
displayed on the bottom. The number of days per participant varied widely in the MEMS 
data; in the models, each participant’s adherence was recorded for 1,000 days. 
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Figure 4.5: Visual comparison of daily adherence and non-adherence for women aged ≤24 
years old from data in the Partners PrEP Study AAS (A) and the hidden Markov models (B). 
Each line represents an individual, with green points representing days on which a PrEP dose 
was taken and red points representing days on which a PrEP dose was not taken. 
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Figure 4.6: Visual comparison of daily adherence and non-adherence for women aged 25-34 
years old from the data in the Partners PrEP Study AAS (A) and the hidden Markov models 
(B). Each line represents an individual, with green points representing days on which a PrEP 
dose was taken and red points representing days on which a PrEP dose was not taken. 
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Figure 4.7: Visual comparison of daily adherence and non-adherence for women aged 35-44 
years old from the data (A) and the hidden Markov models (B). Each line represents an 
individual in the Partners PrEP Study, with green points represent days on which a PrEP dose 
was taken and red points represent days on which a PrEP dose was not taken. 
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Figure 4.8: Visual comparison of daily adherence and non-adherence for women aged 45 and 
older from the data (A) and the hidden Markov models (B). Each line represents an individual 
in the Partners PrEP Study, with green points represent days on which a PrEP dose was taken 
and red points represent days on which a PrEP dose was not taken. 
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Figure 4.9: Visual comparison of daily adherence and non-adherence for men aged ≤24 years 
old from the data in the Partners PrEP Study AAS (A) and the hidden Markov models (B). 
Each line represents an individual, with green points representing days on which a PrEP dose 
was taken and red points representing days on which a PrEP dose was not taken. 
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Figure 4.10: Visual comparison of daily adherence and non-adherence for men aged 35-44 
years old from the data in the Partners PrEP Study AAS (A) and the hidden Markov models 
(B). Each line represents an individual, with green points representing days on which a PrEP 
dose was taken and red points representing days on which a PrEP dose was not taken. 
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Figure 4.11: Visual comparison of daily adherence and non-adherence for men aged 45 years 
and older from data in the Partners PrEP Study AAS (A) and the hidden Markov models (B). 
Each line represents an individual, with green points representing days on which a PrEP dose 
was taken and red points representing days on which a PrEP dose was not taken. 
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In these plots, several trends can be distinguished. Firstly, many PrEP users were 
clustered in “blocks” of adherence, particularly with higher mean adherence. Blank spaces 
(i.e. areas with no applicable individuals in the study) in the plots also show that adherers 
tend to group together as either “good” or “bad” adherers. However, there were some 
individuals in every 10% band of mean adherence, showing that not all PrEP users would be 
accounted for by a dichotomous “good”/”bad” approach to representing adherence. 
In order to further evaluate the HMM models in relation to the data, I compared the 
overall mean adherence (Figure 4.12), and the maximum “breaks” of non-adherence (Figure 
4.13) between the HMMs and the data. Additional data-model comparison figures can be 
seen in Appendix C. Overall, I was content that the model for adherence achieved its purpose 
of representing daily adherence patterns accurately. 
 
	  
Figure 4.12: Comparison of mean overall adherence by age and sex category between data 
from the Partners PrEP Study AAS (orange bars) and HMMs (red bars). 
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Figure 4.13: Comparison of mean maximum consecutive days of non-adherence by age and 
sex category between data from the Partners PrEP Study AAS (orange bars) and HMMs (red 
bars). 
 
4.2.3.8   Pharmacokinetics and Pharmacodynamics of Oral Tenofovir 
 
  Once daily adherence has been determined, it is important to relate pill-taking 
behaviour to the protective efficacy of PrEP. This is first accomplished by including a 
pharmacokinetic (PK) model of tenofovir to simulate drug concentrations over time.  
Population pharmacokinetic models estimate the average concentration of a drug over time 
by pooling a number of individual pharmacokinetic profiles with different characteristics, 
often with the purpose of estimating an effective dose [222,342,343]. 
 I implemented a simple, two-compartment open “PK model” of tenofovir (TFV) in 
plasma (Figure 4.14), nested within the overall model. Emtricitabine concentrations are not 
modelled because the protective effect of TDF versus combination FTC/TDF does not differ 
significantly for heterosexual serodiscordant couples [344]. The two compartments, central 
and peripheral, broadly represent the first areas to absorb the drug (typically blood plasma, 
heart, lungs, liver, and kidneys) and the areas of the body that the drug takes longer to reach 
(such as muscle tissue and fatty tissues), respectively; these compartments are not intended to 
be explicitly biologically representative, but do give the correct profile of TFV concentrations 
in plasma over time [345]. In the model, a 300mg dose of TDF is assumed for every dose 
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[346], with the concentration absorbed by the first compartment before diffusing to the 
secondary compartment. Once a dose has been taken, TFV can move between the two 
compartments and is eliminated from the second compartment alone. TFV concentrations in 
plasma are measured in the PK model as the amount of drug in the second compartment alone 
at any given point in time. 
    
	  
Figure 4.14: Two-compartment open model of tenofovir absorption, distribution, and 
elimination. Compartment 1 (central compartment) represents the concentration of blood in 
plasma; compartment 2 (peripheral compartment) represents the concentration of blood in 
tissue. ka represents the rate of absorption into compartment 1, and ke represents the rate of 
elimination from compartment 1. k12 represents the rate of flow between compartment 1 and 
compartment 2, and k21 represents the rate of flow between compartment 2 and compartment 
1. VC and VP represent the apparent volumes of distribution for compartment 1 and 
compartment 2, respectively. 
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In the model, sequential daily dosing results in a new dose being taken exactly 24 
hours after the previous dose. TFV concentrations are modelled hourly, and the midpoint of 
drug concentrations throughout the day is used to approximate the overall protection during 
any condomless sex occurring on that day. An assumption is made that the time of pill-taking 
on a given day does not interact significantly with the timing of a condomless sex act. Based 
on a SMS sub-study in the Partners PrEP Study, the occurrence of condomless sex was not 
correlated with daily PrEP use [204]. If an individual misses a subsequent dose of PrEP but 
still has residual drug concentration from previous doses, the plasma TFV concentration 
continues to decay until another dose is taken or the concentration reaches 0 ng/ml. 
 Pharmacokinetic parameters were derived from a population PK model of tenofovir 
dosing in plasma from the Partners PrEP Study by Lu et al. [334] (Table 4.21). Two 
population PK models – one using patient-reported dosing information (PRDI) alone, and the 
other using MEMS recorded dosing in combination with PRDI – were fit by Lu and 
colleagues using NONMEM (a non-linear mixed effects modelling package for population 
PK models). Both sets of data fit a two-compartment open model with first-order absorption 
and elimination. The absorption rate constant, ka, signifies the rate at which the oral dose is 
absorbed from the stomach and intestines into blood plasma, and is measured in units of 
inverse time. 
 
Parameter (Units) Median (95% CI) 
CL(L/h) 62 (57-66) 
V1(L) 345 (211-692) 
ka(/h) 1.5 (fixed) 
V2(L) 830 (612-1102) 
Table 4.21: Pharmacokinetic parameters assumed in the model, adapted from Lu et al. [334]. 
CL = clearance (litres/hour). V1 = apparent volume of the first compartment (litres). ka = 
elimination constant (/hour). V2 = apparent volume of the second compartment (litres). 
 
For our purposes, an adapted version of the PRDI/MEMS model was used. The 
simplified model does not include inter-individual variability of creatinine clearance, central 
compartment volume, or the absorption rate constant, all of which were included in Lu et al.’s 
PRDI/MEMS model. Age, weight, and sex have all been shown to have significant effects on 
the pharmacokinetic parameters of oral drug absorption [347,348]. Nevertheless, I assumed 
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that including these parameters would not substantially alter the population-level results, 
while they would significantly decrease the efficiency of the model’s computational run-time. 
The PK model simulates the hourly absorption and elimination of each PrEP dose 
over time. The system is modelled by simulating the rate of change in drug concentration in 
each compartment through differential equations. The equations governing the system are 
given as follows (Equations 4.6-4.9): 
 𝑘! =    !"!!                              (4.6) 𝐶! =   !"#$!!                         (4.7) !!!!" =   !!!∙  !!∙  !!(!)!!                                    (4.8) !!!!" =    !!∙  !!∙  !! ! !  !!∙  !!  ∙  !!(!)!!                                  (4.9) 
 
where ke is the rate of elimination of the drug per hour, C0 is the initial drug concentration, 
Dose is the dose amount (in mg), V1 is the volume of compartment 1, ka is the rate of 
absorption, C1 is the concentration in compartment 1 at time t, C2 is the concentration in 
compartment 2 at time t, and V2 is the volume of compartment 2. An example pattern of 
tenofovir concentrations with daily dosing over a week’s time and subsequent decay is given 
in Figure 4.15. Simulated peak and trough concentrations match pharmacokinetic studies of 
TFV in plasma well [223,225,227,349]. 
 
	  
Figure 4.15: Modelled hourly TFV concentrations for 7 days of daily dosing, and decay after 
day 7. The solid black line represents the default pharmacokinetic model and blue shading 
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indicates credible alternative curves using 95% CIs of parameters from the PRDI/MEMS 
model by Lu et al. 
 
 The next step is translating the pharmacokinetics of tenofovir to its 
pharmacodynamics, i.e. the protection afforded by PrEP at varying drug concentrations. Thus 
far, a complete pharmacodynamics model tenofovir-based PrEP has not been determined for 
heterosexual couples. A crude dose-response curve for TFV in plasma has been constructed 
by Dr. Craig Hendrix, which takes into account PrEP RCT results from iPrEx, TDF2, 
Partners PrEP, VOICE, and FEM-PrEP [226], an adapted version of which is presented in 
Figure 4.16. 
 
	  
Figure 4.16: Dose-response curve for tenofovir in plasma among PrEP trials, adapted from 
[226]. The solid black line gives the dose-response using median plasma TFV concentrations 
in the trials. Circles are indicative of the route of transmission (black = heterosexual, red = 
IDU, blue = MSM, pink = vaginal). Dotted lines represent estimates from the iPrEx trial and 
VOICE TDF gel arm that were adjusted due to higher infection risk requiring a greater drug 
concentration for MSM and low plasma TFV concentrations from gel dosing, respectively. 
 
I then fit the sigmoidal dose-response curve using the Hill equation, which is given by 
Equation 4.10: 
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 𝒀 =   𝑬𝒎𝒊𝒏 +    𝑬𝒎𝒂𝒙!𝑬𝒎𝒊𝒏𝟏! 𝑬𝑪𝟓𝟎𝒙 𝑯𝒊𝒍𝒍𝑺𝒍𝒐𝒑𝒆                                  (4.10) 
 
where 𝑌 is the expected response to dose 𝑥, 𝐸!"# is the minimum expected response from a 
dose 𝑥 > 0, 𝐸!"# is the maximum expected response from an infinite dose, 𝐸𝐶!" is the 
estimated concentration to achieve 50% efficacy, and 𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒 is the slope at the steepest 
point in the curve. The fit parameters for Figure 4.16 are presented in Table 4.22. 
 
Parameter Name Parameter Value 𝐸!"# 0% 𝐸!"# 100% 𝐸𝐶!" 42.95 ng/ml 𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒 2.289 
Table 4.22: Parameters derived from fitting the Hill equation to plasma TFV concentrations 
from Figure 4.16. 
 
Although no PrEP RCT among heterosexual couples has demonstrated overall 
efficacy above 75%, sub-studies of adherence relative to seroconversion have predicted that 
the intrinsic efficacy of oral PrEP lies somewhere between 90-100% [210,228]. In order to 
explore the full range of PK/PD profiles, I also modelled a range of dose-response curves in 
which peak efficacy (𝐸!"#) falls between 80% and 100% (Figure 4.17). This accounts for a 
slower rise in efficacy and lower maximum efficacy even with regular dosing and a high TFV 
concentration in plasma. 
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Figure 4.17: Modelled dose-response curve of TFV concentrations in plasma versus efficacy.  
The dark blue line represents the expected efficacy curve and the light blue shading 
represents a range of credible alternative dose-response curves, with Emax adjusted between 
80-100%. 
	  
4.2.4   Improving Model Efficiency 
  
On the most granular level, the PK model runs on a scale of hours. As it is 
computationally burdensome to run an hourly model on the scale of years of PrEP use for 
thousands of couples, I developed several methods of reducing the run-time of the PK model. 
First, condomless sex acts are determined for each month in the upcoming year, and the risk 
of HIV-1 transmission is only ever calculated if condomless sex is occurring in a given 
month. In addition, daily adherence is projected for the adherence model over the same 
period of time. Once a condomless sex act is known to occur in a month, that sex act is 
randomly distributed to one day of the month. Secondly, to prevent the PK model from 
running hourly throughout the month, the PK model only begins running seven days before 
the condomless sex act occurs (in order to capture recent dosing behaviour and avoid using 
that part of the model if no condomless sex occurs). Thirdly, if the individual was fully 
adherent throughout the week prior to the condomless sex act (i.e. no doses were missed), the 
individual’s TFV concentrations are assumed to be at steady-state, and the daily midpoint 
value of an individual at steady-state is used in place of running the PK model. These 
adjustments to the code improved the efficiency of the model in default scenarios by more 
than threefold. 
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4.2.5  Model Calibration 
 
 The model was calibrated to the gender-specific incidence of HIV-1 in the placebo 
arm of the Partners PrEP Study per 100PY of observation, and separated by the source of the 
infection (Table 4.23). Infections that originated within the couple are classified as “internal,” 
while infections that occurred via an outside partnership are deemed “external.” The origin of 
one infection acquired by a woman was not able to be established conclusively and is 
categorized as “unknown.” I chose to omit the single unknown infection and fit the model to 
internal and external infections only. 
 
 
Source of Infection 
Internal (95% CI) External (95% CI) Unknown (95% CI) 
Men 1.63 (1.04-2.43) 0.27 (0.07-0.69) 0.00 (0.00-0.00) 
Women 2.71 (1.75-4.00) 0.33 (0.07-0.96) 0.11 (0.00-0.61) 
Total 2.05 (1.52-2.71) 0.29 (0.12-0.60) 0.04 (0.00-0.22) 
Table 4.23: HIV-1 incidence (/100 PY) over two years of follow-up in the placebo arm of the 
Partners PrEP Study according to gender and the source of the infection. Internal infections 
are those that originate from within the stable partnership, while external infections are those 
that originate from an external partnership. Unknown infections were those whose source 
could not be formally identified. 
 
 In order to determine the amount of couples needed to reduce stochastic noise and 
produce consistent results, I ran variable numbers of couples (ranging from 1,000 to 1 
million) and calculated the mean DALYs per couple for each simulation (see Appendix C, 
Figure 3). Stochasticity was apparent until 100,000 couples (i.e. 200,000 individuals) were 
simulated. Model calibration and results were therefore conducted across cohorts of 100,000 
couples. 
Four parameters were fit to match the two-year HIV-1 incidence for both men and 
women – the basic rate of transmission of HIV-1 (β0), a multiplicative factor for the increased 
infectiousness of external partners (𝛿), the relative susceptibility of women to HIV infection 
(𝜋!), and a multiplicative factor for the number of women that ever have an external partner 
(𝑏) (Table 4.24). The parameters were fit simultaneously using a grid search technique over a 
specified range for each of the four parameters, and each parameter value was selected based 
on the combined sum-of-squares error resulting in the smallest difference across all 
parameters.  
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Parameter Parameter Meaning Fitted Value 
Range of 
Tolerable 
Values 
𝜷𝟎 Basic HIV-1 transmission rate from an asymptomatic, non-pregnant woman with a HIV-1 SPVL of >50,000 copies/ml to an 
uncircumcised man 
0.0051 0.001-0.010 
[79,152,302] 
	  
	  𝜹 Relative HIV-1 infectiousness of external partners compared to stable partner with asymptomatic infection (due to differences 
in STI co-factors and prevalence of acute 
infection) 
10 1-40 [155,307] 
	  𝝅𝑲 Relative susceptibility of women to HIV-1 infection compared to men (due to 
differences in condom use) 
1.0 0.5-2.0 [303,305] 
	  𝒃 Ratio of the assumed proportion of women that ever have an external partner to the 
proportion of women reporting an external 
partner in the first two years of the study 
4.0 1.0-4.0 [306] 
Table 4.24: Parameter definitions and fitted values for the baseline scenario. 
 
The model fit and confidence intervals for the parameters are presented in Figure 4.18. Model 
confidence intervals were simulated by running 100 sets of 2,000 couples (approximately the 
same sample size as observed in the placebo arm of the trial); the bounds represent the lowest 
and highest estimates observed among these sets of couples due to stochasticity. Confidence 
intervals were also checked for convergence. 
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Figure 4.18: Model fit and confidence intervals. Black boxes represent incidence observed in 
the data and black lines represent the 95% confidence intervals. Red cross represent incidence 
predicted by the model and red dashed lines represent confidence intervals. 
 
The frequency of condomless sex coinciding with non-adherence was modelled using 
weighted sampling of condomless sex acts, without replacement. Days of the month were 
assigned a weight (𝛼), with negative values of 𝛼 leading to a higher probability of 
condomless sex acts occurring on days of PrEP non-adherence, while positive values of 𝛼 
indicate a higher probability of condomless sex acts occurring on days of PrEP adherence. 
For results produced using the Partners PrEP Study parameterization (see Chapter 5), 𝛼 was 
assigned a weight of 0 (i.e. the relationship between PrEP dosing and condomless sex was 
assumed to be independent), as no data on the timing of sex acts in relation to adherence was 
available. For model results produced using the Partners Demonstration Project 
parameterization (see Chapter 6), 𝛼 was calibrated using a least squares technique comparing 
the percentage of condomless sex acts occurring on days of non-adherence in the data (7%, 
see Chapter 3, section 3.3.2.6) to that observed in model simulations. The calibrated value (𝛼 
=20) is used in the default Demonstration Project simulations. Alternative values of 𝛼 are 
also explored in sensitivity analyses in Chapters 5 and 6. 
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4.2.6   Cost-Effectiveness Calculations 
 
 The calculation of cost-effectiveness in the model takes into account marginal gains 
of using PrEP by comparing scenarios in which PrEP is available to HIV-uninfected partners 
in serodiscordant couples to counterfactual scenarios in which PrEP is not introduced. For 
example, in a scenario in which the HIV-infected partner initiates ART at a CD4 count of 350 
cells/µl or below, the only difference in the comparable PrEP intervention scenario would be 
PrEP use for the HIV-uninfected partner prior to the HIV-infected partner’s ART initiation 
and for six months thereafter (i.e. until the partner reaches viral suppression). 
The cost-effectiveness calculation compares the DALYs accumulated in the PrEP 
intervention scenario to those accumulated in the baseline scenario. All health states included 
in the model, and their respective accompanying disability weights from the Global Burden 
of Disease Study 2010 [312], are listed in Table 4.24 (see Chapter 2, section 2.2.5 for further 
discussion of DALY weighting). Asymptomatic HIV states are defined as primary infection 
with no noticeable symptoms and CD4 cell counts ≥350 cells/µl; pre-AIDS states are defined 
as the beginnings of symptomatic HIV infection (e.g. moderate weight loss, occurrence of 
opportunistic infections) with CD4 cell counts 200-350 cells/µl; AIDS states are defined as 
severe symptomatic infection as a result of immune system damage (e.g. Kaposi’s sarcoma, 
candidiasis, or chronic HSV-2 infection) [350]. For individuals receiving treatment, the 
disability weight assigned to the first year of use is equivalent to that of the individual’s CD4 
cell count category at the point of ART initiation. DALYs and costs (person-years of PrEP 
and ART use) are discounted at a rate of 3% annually, which is consistent with WHO 
guidelines for discounting health costs [315]. 
 
Health State Disability Weight 
HIV: asymptomatic, CD4 count 500+ 0.051 
HIV: asymptomatic, CD4 count 350-500 0.051 
HIV: pre-AIDS, symptomatic, CD4 count 200-
350 
0.221 
AIDS: not receiving ART, CD4 count below 
200 
0.547 
HIV: receiving ART, first year, at CD4 count 
500+ 
0.051 
HIV: receiving ART, first year, at CD4 count 
350-500 
0.051 
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HIV: receiving ART, first year, at CD4 count 
200-350 
0.221 
AIDS: receiving ART, first year, at CD4 count 
below 200 
0.547 
HIV/AIDS: receiving ART, second year and 
beyond, all CD4 counts 
0.053 
Table 4.25: Assumed disability weights for health states included in the model [312]. 
 
 Cost-effectiveness calculations were also performed using the most up-to-date 
estimates available for providing PrEP to HIV-uninfected individuals and ART to HIV-
infected individuals.  The costs were estimated by Roger Ying at the University of 
Washington from a time and motion study conducted in Uganda in February 2014 (Table 
4.25) [351]. Cost estimates take into account both the annual cost of the antiretroviral 
medication itself, as well as service delivery costs (e.g. staff salaries, monitoring tests, and 
transportation). In order to reduce costs from the “as studied” scenario to the “ideal” scenario, 
staff salaries are estimated based on local salaries and task shifting, ARV prices are based on 
local prices rather than ceiling costs, and monitoring costs are based on point-of-care (POC) 
tests rather than lab tests. DALYs and costs are discounted annually by 3%. In the model, 
baseline costs are taken from the “as studied” scenario, and sensitivity analyses examine how 
cost-effectiveness may vary if the costs of PrEP and ART change in accordance with the 
“ideal” scenario. However, the key relationship is the ratio of the cost of PrEP to the cost of 
ART, which remains similar in both scenarios (45% for the “as studied” scenario and 41% for 
the “ideal scenario”). 
 
(A) 
 
PrEP (for HIV-Uninfected 
Individuals) 
ART (for HIV-Infected 
Individuals) 
Category $/person (USD) % $/person (USD) % 
Start-up 9.46 2.82 9.08 1.12 
Personnel 44.07 13.15 46.88 6.34 
Transport 2.09 0.62 2.09 0.28 
Monitoring 60.97 18.19 222.81 30.11 
ARV medication 152.99 45.64 305.98 41.35 
Other 
medications 
55.33 16.50 60.33 8.15 
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Office supplies 10.31 3.08 92.83 12.55 
Total (USD) $335.22 100 $740.00 100 
 
(B) 
 
PrEP (for HIV-Uninfected 
Individuals) 
ART (for HIV-Infected 
Individuals) 
Category $/person (USD) % $/person (USD) % 
Start-up 6.55 4.75 5.07 1.51 
Personnel 5.06 3.67 7.53 2.24 
Transport 1.45 1.05 1.45 0.43 
Monitoring 34.42 24.96 51.31 15.25 
ARV medication 37.50 27.20 156.00 46.38 
Other 
medications 
45.77 33.19 50.76 15.09 
Office supplies 7.14 5.18 64.23 19.10 
Total (USD) $137.89 100 $336.35 100 
Table 4.26: Breakdown of costs for one person-year of PrEP and one person-year of ART in 
Uganda in (A) the as-studied scenario and (B) the ideal scenario, using 2012 USD [351]. 
 
 One potential limitation to these costs is that there are no “fixed” and “variable” costs, 
as some individual components of the total estimated cost may change at a faster rate than 
others. For example, viral load monitoring for patients on ART could soon be much less 
expensive, due to the development of rapid and affordable POC tests, as opposed to clinical 
or CD4 count monitoring [352]. In addition, these costs do not take into account potential 
additional costs for PrEP, such as the costs of finding and recruiting serodiscordant couples, 
the opportunity cost for clients, lab monitoring of PrEP users for HIV and pregnancy, 
including re-tests, or the management of any adverse events as a result of PrEP use. 
 
4.3 Discussion 
 
 This chapter has described in detail the development of an individual-based model of 
HIV-serodiscordant couples in East Africa, with the purpose of analysing the contribution of 
adherence to PrEP to the long-term impact and cost-effectiveness of a potential intervention. 
The model follows a cohort of serodiscordant couples in Kenya and Uganda, and monitors 
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their mortality from background and HIV-related causes, progression of CD4 cell count and 
ART initiation for HIV-infected individuals, pregnancies, PrEP use for HIV-uninfected 
individuals, and external partnerships. It provides a quantitative framework to analyse the 
effect of HIV prevention interventions and to explore uncertainty regarding daily adherence 
patterns, pharmacokinetic and pharmacodynamics efficacy of PrEP, and other factors 
influencing the potential impact and cost-effectiveness of a PrEP intervention for 
serodiscordant couples. 
 Although the model is a very detailed representation of HIV-1 transmission among 
serodiscordant couples, it does have some limitations. As with all models, assumptions are 
required, and any assumption requires a simplification of reality. These assumptions broadly 
fall into two categories: those made to maintain parsimony within the model, and those made 
due to limitations within the data. As new data becomes available, the model can be updated 
to reflect increasingly realistic inputs and therefore produce even more reliable results.  
 Firstly, the model does not include any effect of other STIs on HIV transmission 
[107,263]. In sub-Saharan Africa, HSV-2 in particular plays a significant role in driving HIV 
transmission [110,160]. HIV-1 serodiscordant couples in East Africa are likely to face a high 
burden of HSV-2, and concurrent prevalence of HSV-2 and HIV-1 raises the risk of 
transmissibility of HIV-1 by approximately threefold [108]. For couples, PrEP has also been 
shown to have an antiviral effect on HSV-2, reducing transmission by 33% [107]. This effect 
was not included in the model, but HIV-1/HSV-2 co-infection and the supplementary benefit 
of PrEP in reducing HSV-2 incidence are discussed in Chapter 2 and was not found to affect 
the cost-effectiveness of PrEP substantially. Other STIs, such as gonorrhoea [161,266]a, 
bacterial vaginosis [264], and HPV [265] have also been shown to contribute to the 
susceptibility of individuals to acquiring HIV-1; none of these effects are explicitly modelled 
as STIs are not tracked in the model and the calibrated parameters implicitly account for 
increased risk of transmission acquisition due to STIs. 
 Secondly, data regarding sexual behaviour can be unreliable [353,354]. In the Partners 
PrEP trial, a sub-study using daily SMS found that both men and women reported more 
unprotected sex acts than at monthly clinic visits; 24% of observation-months included 
reported unprotected sex from the SMS study and not at clinic visits [204]. Although the 
incidence rate ratio of the frequency of unprotected sex found in the study (1.2) was not 
significant, it did indicate a degree of underreporting, and other analyses from the study 
showed significant increases in the reports of risk behaviour in the SMS study compared to 
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monthly clinic questionnaires [204,336]. As the sub-study included a small sample size of 96 
individuals, the actual degree to which condomless sex is unreported is uncertain, or if it is 
indeed truly underreported. 
 Misreporting of behaviour is also related to several biases inherent to personal data 
collection. Firstly, the HIV-uninfected participants in the Partners PrEP Study and the 
Partners Demonstration Project reported behaviours (including the total number of sex acts 
with their stable partner that month, how many of those sex acts were unprotected, any sex 
with external partners, and adherence to PrEP) only at monthly clinic visits. Because 
participants were asked to report the frequency of these behaviours over a month-long time 
period, they may have suffered from recall bias [355], or an inaccurate memory of the past. 
Recall bias in epidemiology is a systematic error (as opposed to random error) in which 
individuals experience difficulty remembering past events accurately. Studies of adherence 
reporting behaviour among HIV patients taking ART have revealed that individuals tend to 
remember specific events from a recent period of time (e.g. several days), and beyond that 
remember broad patterns [356]. This often leads to underreporting of events over time, like 
the total number of sex acts or missed doses in the past month. Secondly, participants may 
have exhibited social desirability bias, or a desire to please the clinicians and researchers 
conducting the study [357,358]. Thirdly, participants may have unknowingly changed or 
improved their behaviour while in the study as a consequence of being observed, known as 
the “Hawthorne effect” [203]. If this effect had significant influence over the participants in 
the study, the true frequency of unprotected sex in this population, outside of the context of a 
highly monitored clinical trial, might be greater than reported, and true adherence could also 
be lower. 
There are other factors that might be predictive of adherence that are not included in 
the model. These include heavy alcohol use and abstinence, both of which have been shown 
to be significantly associated with lower adherence [215,326]. In addition, while sexual 
partnerships outside of the primary couple are modelled, adherence behaviour in the model is 
assumed to operate independently from these external partnerships, which may be 
misrepresentative [326]. Many other individual characteristics that could influence adherence 
– such as polygamous marriage, depression, travel time to clinic, and the extent of side 
effects – are not modelled explicitly but are not anticipated to have a substantial effect on the 
results. 
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 In addition, MEMS dosing could be potentially misrepresentative of adherence 
patterns in several ways. As the pill bottles only record the time of each bottle opening, there 
is a broad assumption that each bottle opening equates to a dose being taken at that moment. 
This does not account for instances in which the pill bottle might be opened without 
removing a pill (“curiosity openings”) [230,359], or when the participant removes a pill 
without taking it (“pill dumps”), or removing multiple pills in one opening (“pocket doses”). 
Any of these occurrences could bias the MEMS data by either underreporting or over-
reporting adherence. It is reassuring, however, that multiple metrics of adherence in the trial 
were consistently high (median 99.1% by UPC, 97.2% by MEMS, and 97% by doses taken 
from returned pill bottles) [50,215]. Lastly, individuals in the Partners PrEP Study received 
an intensive adherence intervention if monthly adherence fell below 80% and the intervention 
significantly increased adherence in the following month [216]. However, such intensive 
adherence counselling is unlikely to be feasible for implementation in real-world settings, and 
so the MEMS data from the trial is representative of couples subject to greater adherence 
counselling than is likely to be realistic for an intervention. 
 Furthermore, the external validity (or the generalizability of results) of the adherence 
patterns from both the trial and the demonstration project is unclear [360]. As RCTs for 
biomedical interventions are designed to evaluate efficacy and demonstrate internal validity, 
they are conducted with a high degree of control over participants’ behaviour (e.g. frequent 
monitoring, clinic visits, and adherence interventions) [361]. Demonstration projects, which 
serve to investigate whether a promising intervention is feasible, scalable, and effective under 
more realistic conditions, attempt to provide more external validity for the intervention [362]. 
Though PrEP demonstration projects are a step closer toward the “real-world,” they also 
require relatively intensive clinical monitoring of participants (as exemplified by the MEMS 
pill bottles used in the Partners Demonstration Project) that would not be feasible in 
implementation settings. While the adherence results from both the Partners PrEP Study and 
the Partners Demonstration Project are encouraging, they should also be treated with caution 
as serodiscordant couples may behave differently with less clinical oversight. 
 Participants in both the Partners PrEP Study and the Partners Demonstration Project 
also had different durations of follow-up time. In the trial, participants in the AAS had a 
median duration of adherence follow-up time of 1.3 years (see Chapter 3). Adherence data 
from the demonstration project is potentially not fully representative of total adherence, as 
follow-up has not yet been completed, and the median length of follow-up for PrEP users as 
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of January 2015 was seven months. In addition, some change in adherence over time was 
observed in the trial and Demonstration Project, but was most pronounced for younger men 
and women. Any change over time is not explicitly assumed in the default model analyses. It 
is also not known if adherence patterns might change substantially over longer time horizons, 
or if any decline in adherence over the initial one to two years would stabilize or continue to 
decline further. 
 In terms of data gaps, one of the most important is the lack of information on the 
timing of unprotected sex acts in relation to PrEP non-adherence. While adherence to PrEP 
was measured by MEMS on a sub-daily basis in the Partners PrEP Study, sex acts were only 
reported monthly. In the Partners Demonstration Project, a small SMS sub-study reported the 
daily frequency of sex (with and without a condom) as well as PrEP adherence over a short 
period of time. The study found that on days when a PrEP dose was missed, sex acts not 
protected by a condom also occurred on 2% of those days, but the study was small and time-
limited (see Chapter 3, section 3.3.2.6). The exact intersection between adherence and 
condomless sex is crucial for determining the risk of acquisition at each unprotected sex act 
and more data will need to be collected to ascertain the relative frequency of this behaviour. I 
also chose to model daily adherence rather than sub-daily adherence, though it is plausible 
that the number of hours between a dose and an unprotected sex act could affect the risk of 
HIV-1 acquisition, particularly if dosing is inconsistent and steady-state concentrations have 
not yet been achieved. 
 Finally, the model includes a simplified representation of the PK/PD of oral tenofovir. 
The degree to which an individual is protected may depend on a number of factors, including 
the site of exposure to infection [226,363]. Firstly, the model does not include any differences 
in the drug concentration or HIV protection according to the sex of the HIV-uninfected 
individual taking PrEP, given that the Partners PrEP Study did not show any difference in 
protection between men and women with oral PrEP [364]. However, there is potential for a 
differential in drug concentrations – and therefore protection – according to the anatomical 
site of exposure. When taken orally, tenofovir is detected in 33 times higher concentrations in 
rectal tissue as opposed to blood plasma [365], and significantly higher in rectal tissue 
compared to vaginal tissue [343]. Therefore, MSM may experience greater protection from 
PrEP than do heterosexual men or women. Vaginal concentrations of tenofovir are also 
significantly lower than microbicide dosing, by approximately 100-fold [226,343,365]. In 
addition, the only two studies that have demonstrated efficacy greater than 75% – IPERGAY 
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[53] and the PROUD Study [54] – took place among MSM in high-income countries. While 
we can be confident that PrEP can be effective at preventing acquisition of HIV-1 to some 
degree, similarly high levels of protection have not been demonstrated for heterosexual 
couples in a clinical trial setting in sub-Saharan Africa.  
Other sources of inter-individual variability in the pharmacokinetics of oral PrEP – 
such as age, sex, body weight, and creatinine clearance – were also not included in the model 
[222]. On an individual level, inter- and intra-individual variability can significantly affect 
the pharmacokinetics of tenofovir. Studies of oral tenofovir dosing among HIV-infected 
patients have demonstrated variability in plasma drug concentrations between individuals 
ranging from approximately 25-50% [223] . The coefficient of variation is similar for PrEP 
studies. In the HPTN 066 study of directly observed FTC/TDF dosing among healthy HIV-
uninfected men and women, the coefficient of variation for steady-state concentrations with 
daily dosing varied between 33-63% from individual to individual [227]. In addition, even 
intra-individual concentrations from day to day varied by 14% to 34%. Such variability could 
considerably affect an individual’s risk of acquisition. In a Partners PrEP Study analysis 
relating TDF concentrations to protection, 5 out of 29 individuals who seroconverted 
appeared to have consistent adherence to PrEP [210], an observation that could have been 
due to inter- or intra-individual variability. 
 Tenofovir may also exhibit greater pharmacological “forgiveness” in the event of 
missed doses than assumed in the model. Studies of TFV in plasma have estimated a half-life 
ranging from 12-69 hours [221,223,225]; however, the long-acting form of the drug, 
tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMC) has an 
extended half-life of approximately 116 hours [366]. In a study of directly observed dosing of 
TDF in healthy adults, steady-state concentrations were achieved with plasma TFV after two 
doses, and within seven doses for PBMC TFV-DP [343]. In addition, TFV-DP was detected 
two weeks after the final dose, unlike plasma TFV. It is plausible that residual TFV-DP in 
PBMCs could allow for some limited protection even during longer breaks from dosing, an 
effect that would not be captured in the model. 
In summary, a detailed microsimulation model was adapted to analyse the 
contribution of realistic adherence patterns and the pharmacokinetics/pharmacodynamics of 
oral FTC/TDF PrEP. The model includes daily adherence to PrEP, hourly pharmacokinetics 
and daily pharmacodynamics of tenofovir, HIV-1 transmission to and from external partners 
for both partners, and HIV-1 set-point viral load for HIV-1 infected individuals, including 
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variable risks of transmission and disease progression. Model limitations include observation 
of adherence behaviour, simplifications of the PK model and inter-individual variability, the 
accuracy of the pharmacodynamics model, and data uncertainties, particularly regarding the 
intersection of unprotected sex and PrEP non-adherence. Further data will continue to 
improve the reliability of the model’s outputs. 
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5      The importance of adherence to PrEP: insights 
from a mathematical model 
 
Abstract 
Background: HIV-1 serodiscordant couples are a target population for a daily oral tenofovir-
based pre-exposure prophylaxis (PrEP) intervention in sub-Saharan Africa. PrEP 
effectiveness is highly dependent on adherence. 
 
Aims: There are two objectives in this chapter: (1) to evaluate the effect of realistic 
adherence to PrEP on the projected impact and cost-effectiveness of an intervention, and (2) 
to determine which indicators of adherence are most important for determining the outcomes 
of an intervention. 
 
Methods: Using a microsimulation model of serodiscordant couples in East Africa, a PrEP 
intervention was simulated using three different scenarios of antireteroviral therapy (ART) 
initiation (at CD4 counts <350 cells/µl, <500 cells/µl, or universal ART) and two scenarios of 
intrinsic PrEP efficacy (100% or 80%). The cost per infection averted and cost per disability-
adjusted life-year (DALY) averted were calculated over the lifespan of the couples and 
results were statistically analysed to determine covariates predicting seroconversion during 
PrEP use. 
 
Results: A PrEP intervention would only be cost-effective for this population if PrEP is less 
expensive than current costs and is introduced with universal ART ($163/DALY averted), 
and could be cost-saving if couples have high-risk characteristics. Missing PrEP doses on 
days of sex acts is highly predictive of HIV-1 infection. 
 
Conclusions: A PrEP intervention for serodiscordant couples has the potential to be cost-
effective or cost-saving in East Africa, but couples must be identified early in the relationship 
and PrEP must be used for short periods of time during periods of high risk. Individuals must 
also have high adherence during the period of PrEP use, particularly surrounding times of 
sexual activity. 
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5.1 Background 
 
 Targeting PrEP to individuals in sub-Saharan Africa must be resource-efficient by 
prioritizing those who are at greatest risk of HIV acquisition, most likely to be adherent to 
PrEP, and for whom less expensive interventions would not bring as great a benefit. 
Providing PrEP for the HIV-uninfected partner in a serodiscordant couple, prior to ART 
initiation for the HIV-infected partner and until the partner achieves viral suppression – i.e. as 
a “bridge” to ART – is one potential window of opportunity for PrEP use [121]. Given 
limited resources for HIV prevention in sub-Saharan Africa, it is also important to assess the 
likely ‘value for money’ of a promising intervention. Previous modelling studies attempting 
to evaluate the cost-effectiveness of oral PrEP for various populations have provided 
estimates either prior to efficacy data becoming available [125,255,256,258] or without 
taking into account individual-level data concerning adherence [124,257,259,260]. To my 
knowledge, all previous studies of the impact and cost-effectiveness of PrEP have only used 
shorthand metrics to approximate adherence (e.g. 90% of sex acts are protected by PrEP 
[125,127] or 80% of PrEP users are ‘good’ adherers and 20% are ‘bad’ adherers [260]). This 
approach to adherence glosses over individual patterns of PrEP use and is a broad 
approximation of true variations in behaviour within in the population. 
Analysis in Chapter 3 of adherence patterns in the Partners PrEP Study showed that 
adherence to PrEP was high (with a mean of 85% and median of 92%) in the context of a 
randomized controlled trial with a successful intervention designed to improve adherence for 
participants with monthly adherence below 80% [216]. Nevertheless, PrEP adherence was 
not perfect; 42% of individuals in the study had mean adherence below 80% and a quarter 
took at least one break lasting a week or longer. Long breaks in adherence are important for 
PrEP effectiveness as the half-life of tenofovir in plasma is relatively short [223,225], and 
protection against HIV-1 is likely to drop substantially over the course of several days. 
While analysis of data on adherence observed in the study provides valuable 
information about the potential acceptability of PrEP, it is unknown how these varied patterns 
could affect the proportion of HIV infections averted or the potential cost-effectiveness of the 
intervention. A 2011 modelling study of the optimal uses of ARVs for prevention in 
serodiscordant couples in South Africa found that strategic use of PrEP could be cost-
effective, and potentially more cost-effective than earlier ART if PrEP effectiveness was high 
and the relative cost of PrEP to ART was low [125]. However, this study was not informed 
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by results from oral PrEP trials; we are now able to incorporate new data to evaluate the 
degree to which realistic adherence to PrEP will affect the resulting health economics of a 
potential intervention in a priority risk group. Using the model developed in Chapter 4, I 
examine the long-term effect of daily patterns of adherence to PrEP for the impact of a 
potential PrEP intervention and estimate cost-effectiveness for serodiscordant couples in East 
Africa. In addition, the individual risk of HIV-1 acquisition associated with different 
indicators of adherence is investigated. 
   
5.2 Methods 
 
A full description of the model structure and parameters can be found in Chapter 4. 
Briefly, the model follows a cohort of HIV-1 serodiscordant couples from the moment the 
couples are identified (which is assumed to be shortly after seroconversion) and engage with 
the healthcare system. The model tracks HIV-1 transmission, disease progression, PrEP use 
and individual-level daily adherence behaviour (including a PK/PD model of tenofovir), ART 
initiation, mortality, pregnancy, and external partnerships over time until both partners die. 
The model is parameterized using demographic data from the Partners PrEP Study [50] (see 
Chapter 4, 4.2.2.1) and adherence data from an ancillary adherence sub-study [215] that took 
place within the trial (see Chapter 3, 3.3.1 for further analysis of adherence patterns). 
Importantly, no data was available regarding the intersection between unprotected sex acts 
and adherence behaviour, and therefore monthly condomless sex acts are modelled to occur 
independently of daily adherence behaviour. 
Three ART initiation thresholds are modelled: ART for CD4 counts <350 cells/µl, 
<500 cells/µl, or universal ART (i.e. immediate ART initiation for all HIV-infected 
individuals). In each scenario, the HIV-uninfected partner initiates PrEP as a “bridge” to 
ART use for the HIV-infected partner; i.e. PrEP is used by the HIV-uninfected partner up to 
and for six months after the HIV-infected partner initiates ART, in order to allow for viral 
suppression to occur. This strategy has been successfully implemented in the Partners 
Demonstration Project [121] and has been specified to be a cost-effective way to use PrEP for 
serodiscordant couples [125]. PrEP intervention scenarios are compared to baseline scenarios 
with no PrEP use and a respective ART initiation threshold. 
Cost-effectiveness is calculated from a health system perspective, in which averted 
HIV-1 infections save on future years of ART use, and costs are discounted by 3% annually. 
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In the following analyses, I use a cost-effectiveness threshold of $500/DALY averted, which 
captures the realistic opportunity cost of resources displaced for the intervention for sub-
Saharan African countries [367]. The WHO-recommended thresholds of one times the gross 
domestic product (GDP) per capita or three times GDP per capita (the equivalent of $657-
1,971 or $1,246-3,378 in Uganda and Kenya, respectively [368]) probably overestimate the 
true budgetary scope of initiating an intervention in resource-limited countries. 
A multivariate sensitivity analysis was conducted to analyse the effect of six 
parameters on the resulting cost per DALY averted. In the sensitivity analysis, high-risk 
couples have an increased frequency of condomless sex three times that reported in the trial, 
and HIV-uninfected individuals have 1.5 times as many external partners. Additional 
scenarios explored in the sensitivity analysis include PrEP prioritized for younger individuals 
(<35 years old when first prescribed PrEP), lower adherence to ART (resulting in an overall 
reduction in transmission of 75%), a decline in PrEP adherence over time (in which 
individuals drop to the next lowest adherence category with each year of PrEP use), a 
correlation between PrEP non-adherence and sexual activity (i.e. any missed doses occur on 
days of condomless sex), and delayed PrEP initiation until the couple’s first pregnancy to 
account for time needed to identify couples for the intervention. All possible permutations of 
the six discrete parameters are explored in order to evaluate the effect of the each parameter 
on the resulting cost-effectiveness, and the median value across the additional five parameters 
is reported. 
A logistic regression analysis was conducted on model results in order to determine 
the metrics of adherence that best predict seroconversion among the modelled couples. The 
regression models included mean adherence during the first year of PrEP use, the longest 
consecutive sequence of non-adherence to PrEP (i.e. the single longest break in adherence per 
individual), ever missing a dose on a day of condomless sex while taking PrEP, and the mean 
number of missed doses occurring on days of condomless sex per month of PrEP use. The 
model controls for the sex of the HIV-uninfected partner, age at the start of the simulation, 
and the SPVL category of the HIV-infected partner. A multiple regression was performed to 
investigate which indicator of adherence was most strongly associated with risk of HIV-1 
seroconversion while the individual was taking PrEP. The likely cost per DALY averted, if 
the entire population had adherence according to a category within a given adherence metric, 
was also calculated. This was accomplished by performing a linear regression on the 
modelled results for each category of a given adherence metric, which showed the relative 
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change in DALYs, person-years of PrEP, and person-years of ART for each category. All 
analyses for the logistic and linear regressions were performed using Stata version 12.1. 
 
5.2.1  Objectives 
 
The results presented in this chapter attempt to answer four main questions: 
 
1) What is the realistic impact and cost-effectiveness of a PrEP intervention among 
serodiscordant couples in East Africa, given true adherence patterns? 
2) Which factors are most strongly associated with the overall cost-effectiveness of 
PrEP for serodiscordant couples? 
3) What metrics of adherence are most predictive of an increased risk of 
seroconversion while an individual is using PrEP? 
4) What are the policy implications for a potential PrEP intervention among 
serodiscordant couples? 
 
5.3 Results 
 
5.3.1  Impact and Cost-Effectiveness of a PrEP Intervention 
 
Infections and DALYs averted are presented over 10 years for a PrEP intervention for 
three different ART initiation scenarios – at CD4 counts <350 cells/µl, <500 cells/µl, and 
universal ART for all HIV-infected individuals (Figure 5.1). Two different assumptions about 
the PK/PD of oral tenofovir PrEP, one in which PrEP has peak efficacy and one in which 
PrEP efficacy peaks at 80% regardless of adherence (see Chapter 4, section 4.2.2.7), are 
modelled to give a range of estimated infections and DALYs averted. 
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Figure 5.1: Cumulative infections averted (A) and DALYs averted (B) by a PrEP 
intervention over 10 years for three different ART initiation scenarios (ART for individuals 
with CD4 counts ≤350 cells/µl, ≤500 cells/µl, or universal ART) and two different 
assumptions about maximum PrEP efficacy. Solid lines represent PrEP PK/PD with 
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maximum PrEP intrinsic efficacy of 100%; dotted lines represent PrEP PK/PD with reduced 
intrinsic efficacy (80%). 
 
With ART initiation at CD4 counts <350 cells/µl, as in the trial, nearly 2% of 
infections are averted within the first year of the intervention, meaning that almost all new 
infections are averted by PrEP, given expected incidence of 2.0/100 PY. The cumulative 
number of infections continues to increase beyond the first year, but the slope of the line 
becomes shallower, as fewer infections take place in later years regardless of PrEP use. This 
is partly due to a reduced number of susceptible individuals (as a result to prior 
seroconversions) and partly due to the modifying effect of viral load on the risk of 
transmission per sex act. HIV-infected partners with high viral loads (≥10,000 copies/ml) are 
more likely to infect their stable partner more quickly than individuals with lower viral loads, 
and as time progresses, remaining serodiscordant couples are more likely to be at a lower risk 
of transmitting HIV. 
The sources of infections averted in each ART scenario are presented in Figure 5.2. 
As the CD4 cell count threshold for ART initiation increases, a greater percentage of averted 
infections come from the stable partner rather than external partnerships. With the lowest 
ART threshold, individuals spend more time on PrEP (approximately 3 years, on average), 
allowing more time for external partnerships to be formed and therefore for infections to be 
averted from a source outside the stable couple. 
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Figure 5.2: Proportion of infections averted by PrEP over the lifetime of the cohort, for ART 
initiation thresholds at CD4 counts of (A) <350 cells/µl, (B) <500 cells/µl, and (C) universal 
ART. “Stable partner” infections are linked to transmission from the HIV-infected partner in 
the serodiscordant couple; “external partner” infections originate from an HIV-infected 
external partner outside the stable couple; and “stable partner to external partner” infections 
result from the originally HIV-uninfected partner in the stable partner seroconverting and 
subsequently infected an HIV-uninfected external partner. 
 
I also estimated incremental cost-effectiveness ratios (ICERs) over the lifetime of the 
cohort for a PrEP intervention at three different thresholds of ART initiation and with two 
different estimates of the intrinsic efficacy of PrEP (Table 5.1). “Maximum PrEP efficacy” 
(i.e. with perfect adherence) is assumed to be 100%, whereas “reduced PrEP efficacy” is 
assumed to 80% as a result of lower pharmacodynamics protection for heterosexual 
individuals (see Chapter 4, 4.2.2.7). The estimates also use two sets of assumed ARV costs 
(see Chapter 4, 4.2.6) that capture the funds needed to deliver PrEP and ART. Briefly, the 
higher costs are as observed in a clinic in Uganda in 2012 U.S. dollars, and lower costs are 
ideal estimates, primarily as a result of a negotiated reduction in drug costs and task-shifting 
[351]. The overall costs include funds for antiretroviral and other medications, start-up of the 
program, transportation, salaries for healthcare workers, office supplies, and monitoring. 
 
 
 
 
ART Initiation at
CD4 Counts <500 cells/μl
ART Initiation at
CD4 Counts <350 cells/μl Universal ART(A) (B) (C)
Stable partner
External partner
Stable partner to external partner
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(A) 
Cost Per Infection Averted ($US) 
ART Initiation Threshold <350 cells/µl <500 cells/µl Universal ART 
Assumed 
Costs 
ART 
$740/PY 
PrEP 
$335/PY 
Maximum 
PrEP 
Efficacy 
$10,418 $13,736 $2,354 
Reduced 
PrEP 
Efficacy 
$16,373 $20,123 $11,051 
ART 
$336/PY 
PrEP 
$138/PY 
Maximum 
PrEP 
Efficacy 
$3,897 $5,361 $318 
Reduced 
PrEP 
Efficacy 
$6,321 $8,056 $3,824 
 
 
 (B) 
Cost Per DALY Averted ($US) 
ART Initiation Threshold <350 cells/µl <500 cells/µl Universal ART 
Assumed 
Costs 
ART 
$740/PY 
PrEP 
$335/PY 
Maximum 
PrEP 
Efficacy 
$5,217 $2,693 $933 
Reduced 
PrEP 
Efficacy 
$6,174 $3,771 $2,742 
ART 
$336/PY 
PrEP 
$138/PY 
Maximum 
PrEP 
Efficacy 
$1,952 $1,050 $126 
Reduced 
PrEP 
Efficacy 
$2,384 $1,510 $949 
Table 5.1: ICERs over the lifetime of the cohort for the cost per infection averted (A) and the 
cost per DALY averted (B) at the end of a PrEP intervention for different ART initiation 
thresholds, cost assumptions, and maximum pharmacodynamics efficacy of PrEP 
(“maximum PrEP efficacy” = 100% protection with perfect adherence; “reduced PrEP 
efficacy” = 80% protection with perfect adherence). In (B), green shading indicates scenarios 
in which a PrEP intervention could be cost-effective according to a cost-effectiveness 
threshold of $500/DALY averted. 
 
A PrEP intervention for this population would only be cost-effective if ARV costs are 
lowered and PrEP is used in conjunction with immediate and universal ART initiation. In the 
	  
	  
198 
simulations, most infections averted are during the first year of PrEP use, as partners with 
high SPVLs infect their stable partners early in the baseline scenario. This is the riskiest time 
for within-couple transmissions. The greatest number of infections averted by PrEP is in the 
lowest ART initiation scenario (CD4 counts <350 cells/µl), due to increased time for PrEP to 
be used by the HIV-uninfected partner. Cumulative infections averted decrease slightly over 
time in all scenarios, as infections may occur following cessation of PrEP. Reduced PrEP 
efficacy (as a result of the pharmacodynamics of tenofovir-based PrEP) makes a substantial 
difference in terms of impact, particularly if PrEP is used for longer when ART is initiated at 
CD4 counts <350 cells/µl. For cost-effectiveness, PrEP is used for less time with higher ART 
initiation thresholds, and seroconversions occurring due to reduced PrEP efficacy are more 
influential over the resulting cost per infection and cost per DALY averted. PrEP is therefore 
most advantageous when used for a shorter amount of time, efficacy is high, and costs are 
low. For a PrEP intervention to be cost-effective in this setting, PrEP needs to be less 
expensive and used when risk is highest for the shortest period of time possible. 
 
5.3.2  Sensitivity Analyses 
 
I conducted a multivariate sensitivity analysis to evaluate the influence of a number of 
factors on the resulting cost per DALY averted (Figure 5.3). Costs are assumed to be 
$740/PY of ART and $335/PY of PrEP in all scenarios, and PrEP is assumed to have 100% 
efficacy with perfect adherence. 
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Figure 5.3: Multivariate sensitivity analysis for alternative scenarios of PrEP use, compared 
to identical scenarios with no PrEP use. Results presented are for the median cost per DALY 
averted over the lifetime of the cohort when holding the respective parameter fixed and 
varying the others. Couples with “high-risk behaviours” have more external partners and 
more unprotected sex with both their stable and external partners. “Younger couples” are 
couples in which the HIV-uninfected partner is younger than 35 years old at the beginning of 
the simulation. “Lower adherence to ART” indicates that ART is 75% effective at preventing 
HIV, due to assumed lower adherence among HIV-infected individuals. “Decline in PrEP 
adherence over time” assumes a yearly decrease in mean adherence per person. If “PrEP 
adherence is negatively correlated with unprotected sex,” PrEP doses are more likely to be 
missed on days when condomless sex occurs. PrEP is assumed to have maximum efficacy 
and ARV costs are assumed to be $740/PY and $335/PY for ART and PrEP, respectively. 
 
In default scenarios, couples have relatively low incidence (approximately 2.0/PY, 
with an average number of monthly condomless sex acts less than one [50,369]), which limits 
the effect of PrEP. If annual incidence were approximately 5.0/PY, as a result of targeting 
PrEP to high-risk couples (as a function of increased frequency of condomless sex and 
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external partnerships in the model), a PrEP intervention would be cost-saving with universal 
ART and cost-effectiveness would be improved for ART at CD4 counts <500 cells/µl or 
<350 cells/µl. In keeping with this benefit, targeting PrEP for younger couples (i.e. the HIV-
uninfected partner is <35 years old when first prescribed PrEP) could increase the cost-
effectiveness of the intervention, as younger couples exhibit more risk behaviours than do 
older couples. 
There are several other notable trends in the results. A moderate decline in PrEP 
adherence over time would not substantially affect cost-effectiveness, as the majority of 
individuals do not spend enough time on PrEP to increase risk, and the most important period 
of risk is early in the intervention. If PrEP non-adherence were correlated with instances of 
condomless sex, cost-effectiveness would be reduced substantially and the intervention 
would not be cost-effective in any scenario. Finally, a delay in finding couples improves cost-
effectiveness with ART at CD4 counts <500 cells/µl or <350 cells/µl, due to individuals 
taking PrEP for a shorter period of time. With universal ART, however, the intervention is no 
longer cost-effective, as the vast majority of couples never use PrEP at all. Additionally, the 
total number of averted infections and DALYs are severely reduced in all ART scenarios, 
with a substantial proportion of simulations resulting in a negligible effect of PrEP and a very 
high ICER. 
5.3.3  Varying PrEP Cost and Adherence 
 
The cost per DALY averted can also be evaluated with respect to adherence, cost, and 
the risk behaviours of couples. In Figure 5.4, the cost of PrEP is measured against the 
percentage of PrEP users above a threshold of 70% mean adherence in order to determine 
their influence over the cost-effectiveness of the intervention, with an ART initiation 
threshold of CD4 counts <500 cells/µl. As the percentage of users above the threshold 
changes, the distribution of adherers below and above 70% is scaled to remain proportional to 
that in the default scenario. For example, if 100% of users are assumed to have adherence 
above 70% (a higher percentage than observed in the data), the proportion of users in each 
10% adherence category above 70% is multiplied by a factor greater than 1, while the 
proportion of users in each category below 70% is multiplied by a factor less than 1. PrEP 
costs are varied between $138 and $335 per person per year, with the cost of ART remaining 
stable at $740 per person per year. 
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Figure 5.4: Cost per DALY averted over the lifetime of the cohort (for ART initiation at 
CD4 counts <500 cells/µl) with respect to the cost of PrEP and PrEP adherence for (A) 
Partners PrEP couples and (B) high-risk couples. Partners PrEP couples are identical to those 
observed in the trial, while high-risk couples have more frequent condomless sex and more 
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external partnerships. Cost per DALY averted depends on the cost of PrEP per person per 
year (ranging from $US 138-335) and the percentage of PrEP users with adherence greater 
than 70% (ranging from 0-100%). ART is assumed to cost $740 per person per year in all 
scenarios. The dashed black line represents the cost-effectiveness threshold ($500/DALY 
averted) and the solid black line represents the cost-saving threshold ($0/DALY averted). 
 
In both scenarios, the cost of PrEP relative to ART influenced the resulting cost per 
DALY averted to a greater extent than did the proportion of PrEP users above a 70% 
threshold of adherence. As PrEP becomes cheaper, the percentage of PrEP users that are 
highly adherent has less influence over whether or not the intervention is cost-effective for 
Partners PrEP couples. If all PrEP users have mean adherence >70%, the intervention could 
be cost-effective if the cost of PrEP is below $244/PY. For high-risk couples, the intervention 
is cost-saving across many scenarios of cost and adherence, and ceases to be cost-effective if 
the proportion of users with high adherence is low (<30%) while the cost of PrEP is high 
(>$278/PY). The intervention can be cost-saving for all adherence scenarios, and when risk is 
high, the cost of PrEP has less influence over the cost-effectiveness of the intervention 
compared to Partners PrEP couples. 
 
5.3.4  Indicators of Adherence 
 
Finally, a comparison of the usefulness of different indicators of adherence in 
predicting the risk of seroconversion on PrEP in the model is presented in Table 5.2. The 
outcome variable – whether or not the HIV-uninfected partner in the couple seroconverted 
while on PrEP during the modelling simulation – is compared to different measures of 
adherence. Adherence is evaluated by mean adherence over the first year of PrEP use, the 
single longest consecutive sequence of non-adherence while the individual is using PrEP, 
whether or not a PrEP dose was ever missed on a day of condomless sex, and the mean 
number of days per month on which a condomless sex act occurred but the corresponding 
PrEP dose was not taken. The approximate projected cost per DALY averted over the 
lifetime of the cohort for ART initiation at CD4 counts <500 cells/µl is calculated using 
default costs ($740/PY for ART and $335/PY for PrEP). No confidence intervals or p values 
are included, as the regression analysis is conducted on a simulated population of couples in 
which confidence intervals would only indicate the size of the cohort modelled.  
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Category Adjusted Odds Ratio† Pseudo R
2 
Cost per DALY Averted 
(ART Initiation at CD4 
Counts <500 cells/µl) 
Mean adherence during first year of PrEP use 
90-100% 1.00 0.0889 $1,800 
80-90% 1.89 -- $2,900 
70-80% 3.03 -- $3,100 
60-70% 4.66 -- $6,900 
50-60% 6.11 -- $8,000 
40-50% 7.22 -- $8,500 
30-40% 8.24 -- $9,900 
20-30% 10.50 -- $18,500 
10-20% 12.93 -- $53,000 
0-10% 15.09 -- $1,500,000 
Longest consecutive sequence of non-adherence to PrEP 
0-1 1.00 0.0522 $1,500 
2-6 2.17 -- $4,200 
>7 5.63 -- $17,800 
Ever missed a PrEP dose on a day of condomless sex 
No 1.00 0.0527 $1,200 
Yes 6.71 -- $8,000 
Mean number of missed doses on days of condomless sex per month of PrEP use 
0 1.00 0.1070 $1,200 
<0.5 4.70 -- $4,900 
0.5-1 23.01 -- $15,800 
1-1.5 40.81 -- $38,000 
1.5-2 86.04 -- $100,000 
>2 107.92 -- $4,700,000 
† Adjusted for age, sex, and viral load of stable partner 
Table 5.2: Multiple logistic regression for factors affecting HIV seroconversion while the 
HIV-uninfected partner is on PrEP. N.B. the variable “longest consecutive sequence of non-
adherent days” may be confounded by cessation of PrEP if seroconversion occurs. The higher 
the value in the “Pseudo R2” column, the better the model predicts the outcome. The column 
“Cost per DALY Averted” gives the approximate anticipated cost per DALY averted at an 
ART initiation threshold of CD4 counts <500 cells/µl with ART costs of $740/PY and PrEP 
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costs of $335/PY if all individuals in the population behaved according to the relative 
adherence metric. 
 
The logistic regression informs both the usefulness of the indicator overall (according 
to the pseudo R2 value) and the change in individual risk with different categories of 
adherence (the adjusted odds ratio). Based on the pseudo R2, which comparatively evaluates 
how each one model explains the resulting outcome, the mean number of missed doses on 
days of condomless sex per month of PrEP use best predicts the risk of seroconversion out of 
all of the adherence metrics investigated. The longest consecutive sequence of non-adherence 
to PrEP is the least useful, as “breaks” in adherence may not correspond with risk behaviour. 
Decreasing mean adherence to PrEP results in substantial increases in the risk of infection. In 
addition, increasing consecutive sequences of non-adherence and ever missing a dose on a 
day of condomless sex both result in higher odds of infection while taking PrEP. The metric 
that most strongly predicts infection in the model is the frequency of the interaction of missed 
doses with unprotected sex; more than two missed doses occurring on days of condomless 
sex acts per month results in an approximately 100-fold increased risk of infection. The odds 
ratio is likely so high because individuals in the model with frequent missed doses on days of 
condomless sex will necessarily have a combination of low adherence and high-risk 
behaviour. In evaluating PrEP programs, this indicator would be the best way to check the 
resulting impact of PrEP, as it is more indicative of adherence and risk, as opposed to the 
metric “ever missed a PrEP dose on a day of condomless sex” which indicates risk better than 
it does adherence. 
The cost per DALY averted for each adherence level may also be useful for indicating 
the likely cost-effectiveness of an intervention if a PrEP program observes a given category 
of adherence within the intervention population. The values could be used by PrEP programs 
to assess if the program is “on course” to be cost-effective, given data on the level of a 
particular indicator and a relevant willingness-to-pay threshold. 
 
5.4 Discussion 
 
Serodiscordant couples have been identified as a major target for an oral PrEP 
intervention in sub-Saharan Africa [14,137]. Couples have repeated exposure to risk [14], 
low condom use in long-term partnerships [134,370], fertility intentions [138], and have 
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demonstrated willingness to use PrEP [102] and high overall adherence [103,215]. A 
previous modelling study by Hallett et al. demonstrated that PrEP could be cost-effective 
(with estimates ranging from cost-saving to US $1,600 per QALY gained if PrEP was 80% 
effective) if used strategically among couples in serodiscordant partnerships in South Africa 
[125]. However, this analysis was completed before any data on the efficacy of oral PrEP was 
available. In this study, we have included much more data in the modelling analysis, which 
has substantially refined our conclusions about the use of PrEP for serodiscordant couples. 
Firstly, we incorporated a PK/PD model, daily adherence profiles, and an efficacy 
relationship between the two. This yields reliable projections of impact, including over the 
long-term, and also shows which indicators of adherence will be most useful in evaluating 
programs. Secondly, we incorporated HIV-1 transmission according to set-point viral load 
variation, which improves the description of risk in couples and highlights the imperative to 
protect serodiscordant couples from HIV-1 acquisition early in the relationship. Thirdly, we 
track the risks and benefits among couples and any external partners they may have during 
their lives. Finally, we have included empirical cost estimates of PrEP and ART to assess the 
realistic cost-effectiveness of an intervention for serodiscordant couples in East Africa. 
In this analysis, I found that in specific cases, a PrEP intervention could be cost-
effective, even if impact is low at a population-level. For couples with low annual incidence 
yet high adherence, such as the total cohort represented in the Partners PrEP Study, a PrEP 
intervention as a bridge to ART can be cost-effective in East Africa only if current ARV costs 
are lowered (to $336/PY for ART and $138/PY for PrEP) and ART is initiated immediately 
for all HIV-infected individuals. In order to improve cost-effectiveness, couples must be 
identified early, be at high risk of seroconversion, use PrEP for a short time before their 
partner’s ART initiation, and have high adherence while taking PrEP, especially surrounding 
times of sexual activity. However, if the dose-response relationship between TFV 
concentration and efficacy were substantially different to what is predicted, the cost-
effectiveness of the intervention would be substantially reduced in all cases. Of the many 
ways to evaluate adherence, the metric of days in which condomless sex occurs on days of 
missed PrEP doses may be the best, and is much better at capturing risk than traditional 
metrics such as “average adherence.” 
According to the 2012 WHO guidelines regarding antiretroviral use for HIV 
prevention, all HIV-infected partners in a serodiscordant couple should initiate ART 
immediately in order to prevent transmission within the couple [137]. However, scale-up of 
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early ART is still on-going in many sub-Saharan African countries, and some individuals in 
serodiscordant couples in Kenya and Uganda have chosen to delay ART initiation even when 
eligible according to national guidelines [61]. Our analysis shows that PrEP can be most cost-
effective when used for a short duration of time during periods of highest risk (i.e. early in 
the relationship and before viral suppression has occurred). Limited duration of time on PrEP 
or a targeted duration of PrEP is achievable and realistic, according to preliminary 
experiences in the Partners Demonstration Project [121]. Furthermore, lower adherence in the 
Partners PrEP trial was associated with a longer duration of time on PrEP [215]; limiting the 
window of time for PrEP use would also prevent a significant drop in adherence over time. 
Even if all HIV-infected partners in serodiscordant couples initiated ART as soon as possible, 
PrEP could still play an important role in preventing transmission during an initial period (six 
months to one year) of ART use. PrEP could also provide a useful additional benefit to early 
ART, given that somewhere between 10-30% of infections within serodiscordant couples are 
estimated to originate from external partnerships [111,130,371]. If PrEP averts an infection 
within the partnership, this could also prevent an onward sequence of transmission to an 
external partner, their other partners, and so forth. 
Several contributing factors investigated in this analysis would be relevant for a 
potential PrEP intervention among serodiscordant couples. It would be imperative to recruit 
those couples who are at the highest risk of transmission, potentially by using a metric such 
as a risk score [145] or younger age – an approach that is being used and seems possible in 
the context of the Partners Demonstration Project [121]. Furthermore, two central underlying 
factors that drive pre-ART transmission in the model are the SPVL of the HIV-infected 
partner and the number of condomless sex acts occurring each month. Cost-effectiveness of 
the intervention is inherently limited if couples exhibit less risky behaviour (i.e. condomless 
sex and sex with external partners), as observed using data from the cohort enrolled in the 
Partners PrEP Study. However, couples in the trial received regular counselling regarding 
other HIV prevention methods, as well as provision of free condoms [50]. In a real-world 
setting, couples are likely to be less intervened upon, and could be recruited based on such 
high-risk factors. In addition, PrEP must be prioritized not only according to the most at-risk 
couples, but also at the right time. Our results show that the window of opportunity for PrEP 
use among serodiscordant couples is narrow, and PrEP must be used for a short period of 
time prior to viral suppression for the HIV-infected partner, to be most cost-effective. 
Couples in which the HIV-infected partner has a high viral load are more likely to infect their 
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partner early in the relationship; in later years of the intervention, the couples available to 
utilize PrEP are already at a manifestly lower risk of transmission. 
In this modelling study, several simplifying assumptions were made, and there are a 
number of important model limitations. First, adherence to PrEP as measured in the trial 
could be less representative of true behaviour than we assume. Participants in the Partners 
PrEP Study AAS experienced an intensive counselling intervention if adherence fell below 
80%, and which significantly improved later adherence [216]. Alternatively, adherence could 
be better than observed in the trial, as PrEP users may benefit from knowing efficacy and 
therefore having a greater desire to use PrEP within the relationship. Adherence monitoring 
by MEMS and a similar adherence intervention will not be feasible within the scale of a PrEP 
intervention. In addition, participants in the adherence sub-study could have been subject to 
social desirability bias, and unmonitored adherence in a real-world setting could be lower. 
Long-term dosing patterns on PrEP may also be different than assumed in the model, and 
could potentially affect results, particularly in ART initiation scenarios at CD4 counts <350 
cells/µl. Lastly, the timing of sex acts and adherence were assumed to be independent of each 
other, as no data surrounding this issue was collected in the Partners PrEP Study. As the 
logistic regression analysis showed, the degree to which non-adherence coincides with 
condomless sex strongly predicts the risk of seroconversion, and so results could be affected 
in either direction if the true prevalence of such behaviour is less or more frequent than 
assumed in the model. 
Secondly, the pharmacokinetic model used to calculate drug concentrations based on 
PrEP dosing history is a simplified representation of the pharmacokinetics of tenofovir for a 
real-life population. I assumed no difference in drug concentration over time based on age, 
sex, body weight, creatinine clearance, or any other forms of inter- or intra-individual 
variability. In reality, individual differences can affect the single-dose and steady-state 
pharmacokinetics of tenofovir in plasma substantially, with estimates ranging from 
approximately 25-60% [223,343]. While inter-individual variability could affect the 
individual-level risk of acquiring HIV-1, minor differences are unlikely to drastically alter the 
number of infections averted on a population level. 
Thirdly, the relationship between drug concentration and protective efficacy is not 
well established for heterosexual couples. The adapted pharmacodynamics model used in this 
analysis is based on a crude dose-response curve assimilating results from trials among other 
populations (MSM, IDU, young women) and including results from TDF gel studies in 
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addition to oral PrEP [226]. One assumption underlying the dose-response curve is that the 
maximum intrinsic efficacy of tenofovir is 100%, which is supported by modelling studies 
from the iPrEx trial and the open label extension that have predicted efficacy >99% in the 
context of daily dosing [120,228]. However, pharmacokinetic studies of tenofovir have also 
demonstrated that tenofovir accrues in the rectum in higher concentrations than in vaginal 
tissue [349]; as most sex acts between heterosexual couples are assumed to be vaginal, this 
could result in less protection for this population, even with daily dosing. Importantly, there 
are no models of efficacy available for heterosexual men acquiring HIV-1. Finally, protection 
afforded at lower levels of adherence is not yet well understood, and could also influence 
these results substantially. 
A number of additional factors could influence the estimated cost-effectiveness of the 
PrEP intervention. Firstly, couples have been shown to delay ART initiation even after 
becoming eligible according to national guidelines [61]. Regardless of the advised ART 
initiation threshold, delaying treatment for the HIV-infected partner would decrease the cost-
effectiveness of a PrEP intervention, as it would entail HIV-uninfected partners remaining on 
PrEP for a longer period of time. Secondly, logistical challenges and costs not included in the 
model would be relevant to the cost-effectiveness estimates presented here, including finding 
and retaining serodiscordant couples in the program. In particular, seeking out couples with 
high risk factors prior to seroconversion could be challenging and expensive, and warrants 
further investigation. Results from this analysis also showed that delayed PrEP initiation, due 
to potential difficulties in identifying couples, greatly limited the overall impact of the 
intervention and particularly decreased cost-effectiveness when ART initiation for partners 
was earlier. Thirdly, all analyses do not account for any potential drug resistance that may 
occur among individuals with low adherence to PrEP, which could lessen the cost-
effectiveness of the intervention. However, as low adherence is uncommon in this population 
(6% of individuals had adherence lower than 50% in the AAS data), drug resistance is 
unlikely to be a pervasive issue. Additionally, modelling studies have indicated that 
insufficient adherence to PrEP is likely to have a minimal contribution to rates of drug 
resistance in comparison to non-adherence to ART [232,233]. Finally, it is not clear whether 
the results presented here would be generalizable to other populations. Modelling analyses 
for PrEP including detailed adherence patterns would be useful for other key populations 
targeted for PrEP use, such as MSM or single heterosexual men and women. 
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As more data becomes available, these projections can be refined further. Data from 
the Partners Demonstration Project, which has been on-going since November 2012, will 
resolve many of the factors addressed in this analysis. In the Demonstration Project, 
serodiscordant couples were recruited based on high-risk factors, such as high partner viral 
load, younger age, and risk behaviour (see Appendix D). Based on an interim evaluation, 
HIV-uninfected partners have had high adherence to PrEP and the demonstration project has 
thus far reduced an estimated 96% of anticipated new infections [121]. The behaviour of 
couples in the Demonstration Project may also be more indicative of couples in the “real 
world,” as the cohort had less frequent monitoring and no adherence intervention. However, 
preliminary data show that overall adherence in the cohort was lower (by approximately 
10%) than in the Partners PrEP Study (see Chapter 3, section 3.3.2). Couples with 
characteristics such as those recruited in the demonstration project could provide a highly 
specified population in which a PrEP intervention is cost-effective or cost-saving in more 
scenarios, but is unknown whether lower adherence could also compromise cost-
effectiveness. These questions, among others, will be fully explored in Chapter 6. 
In summary, a PrEP intervention could be cost-effective or potentially cost-saving for 
serodiscordant couples in East Africa. However, this is highly dependent on both targeting 
couples at high risk of transmission at the right time, as well as the cost of PrEP. For 
individuals on PrEP, risk behaviour (i.e. condomless sex) must be aligned with PrEP use 
consistently in order to provide protection. This analysis provides a realistic estimate of the 
potential of PrEP to contribute to combination prevention for serodiscordant couples in sub-
Saharan Africa, given the behaviours observed in a clinical trial setting. 
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6      Evaluating the cost-effectiveness of a PrEP 
intervention for high-risk serodiscordant couples 
 
Abstract 
Background: Pre-exposure prophylaxis (PrEP) has been shown to be an effective and 
scalable HIV prevention as a “bridge” to antiretroviral therapy (ART) use among 
serodiscordant couples in the Partners Demonstration Project. 
Aims: The objective of this chapter was to evaluate the likely cost-effectiveness of a PrEP 
intervention for serodiscordant couples, given targeted recruitment of high-risk couples using 
a risk score and adherence to open-label PrEP. A secondary objective was to investigate the 
effect of the potential cost of finding high-risk couples on the resulting cost-effectiveness. 
Methods: Using a microsimulation model of serodiscordant couples in Africa, a PrEP 
intervention was simulated for three different ART initiation scenarios: ART at CD4 counts 
<350 cells/l, <500 cells/l, and universal ART for all HIV-infected persons. Cost-effectiveness 
was assessed by measuring disability-adjusted life-years (DALYs) averted against the total 
cost of the intervention over the lifetime of the couples. A robust multivariate sensitivity 
analysis was conducted in order to construct a cost-effectiveness acceptability curve (CEAC) 
to estimate the probability that the intervention will be cost-effective. 
Results: PrEP is estimated to be cost-saving in all scenarios of ART initiation, and potential 
spending on identifying couples could range between $192-336 per couple for the 
intervention to remain cost-effective. The CEAC estimates that the probability of the 
intervention being cost-saving is 34%, and the probability of the intervention being cost-
effective is between 43-78%, contingent on the willingness-to-pay threshold. 
Conclusion: PrEP as a bridge to ART for the HIV-infected partner could be a cost-effective 
or cost-saving method of HIV prevention for high-risk serodiscordant couples, particularly 
when couples are found early, ART effectiveness is high, and the cost of PrEP is low relative 
to ART. 
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6.1 Background 
 
In light of the positive results from the Partners PrEP Study [50], and other trials 
reporting the efficacy of oral PrEP [49,51,52], the Partners Demonstration Project was 
conducted in order to assess both the feasibility and effectiveness of a PrEP intervention as a 
bridge to ART use among serodiscordant couples in Kenya and Uganda [327]. The 
Demonstration Project differed from the trial in that couples were recruited based on high-
risk characteristics and in the use of overlapping strategies of antiretroviral-based HIV-1 
prevention. In an interim analysis, two individuals became infected over 858 PY of follow-up 
time, which translates to incidence of 0.2/100 PY and a 96% reduction in transmission from a 
simulated counterfactual model with no intervention [121]. 
The couples recruited for the Partners Demonstration Project were chosen based on 
criteria defined by a risk score specifically intended to identify couples at high risk of HIV-1 
transmission [145]. The risk score assigns numeric scores to couples for six component 
characteristics (age of HIV-uninfected partner, number of children, male circumcision status, 
cohabitation, recent unprotected sex, and plasma viral load of the HIV-infected partner), for a 
maximum total score of 13 (see Appendix D). Couples with risk scores ≥5 had annual 
incidence of approximately 5.0/100 PY or greater and were responsible for 67% of observed 
HIV-1 seroconversions, despite making up only 28% of the population [145]. These couples 
are at significantly higher risk of HIV-1 infection than those recruited for the Partners PrEP 
Study and additionally exhibit different behavioural characteristics and frequency of risk 
behaviour. 
Results from Chapter 3 comparing adherence patterns in the trial to those in the 
demonstration project showed that mean adherence was significantly lower in the context of 
open-label PrEP use (85% versus 75%, respectively). In addition, a greater proportion of 
participants in the demonstration project took extended “breaks” (i.e. one week or longer). 
However, adherence among PrEP users in the trial declined significantly over time while 
remaining stable in the demonstration project. Importantly, while no data was available about 
the concurrence of missed doses and condomless sex in the trial, an SMS sub-study as part of 
the demonstration project revealed that the frequency of such behaviour was minimal, with 
condomless sex occurring on 7% of days on which a PrEP dose was missed. 
In Chapter 5, modelling results using characteristics of couples in the Partners PrEP 
trial demonstrated that a PrEP intervention for serodiscordant couples with incidence of 
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approximately 2.0/100 PY was not cost-effective except if ART was universal and the cost of 
providing antiretrovirals was substantially reduced from current estimates. However, in a 
sensitivity analysis with higher risk couples, the intervention was cost-saving with universal 
ART and cost-effectiveness was improved for other ART initiation scenarios. The work in 
Chapter 5 also showed that the time of finding couples could drastically reduce the number of 
infections averted and could affect the cost-effectiveness, depending on the threshold for 
ART initiation. 
This work prompted several questions: first, what would be the projected impact and 
cost-effectiveness of a PrEP intervention as a bridge to ART for high-risk couples recruited 
based on the risk score? Second, how would adherence to PrEP – in the context of known 
efficacy and among younger couples with less adherence support – affect the strength of the 
intervention? Thirdly, which factors are most influential in determining the outcomes of a 
PrEP intervention? Fourthly, to what degree would the costs of finding high-risk 
serodiscordant couples affect the cost-effectiveness of an intervention? Finally, how can we 
contextualize the likely costs and benefits of a PrEP intervention in order to aid health 
policymakers? In this chapter, I investigate these questions by re-parameterizing the model 
described in Chapter 4 using characteristics and adherence patterns of couples participating in 
the Partners Demonstration Project. In the context of a scalable PrEP intervention used as a 
bridge to ART use among serodiscordant couples in Kenya and Uganda, I explore potential 
impact and cost-effectiveness and determine which factors are most important for the 
outcomes of an intervention. 
 
6.2 Methods 
 
6.2.1 Model Description 
	  
 A full description of the model structure and parameters can be found in Chapter 4. In 
brief, the model tracks a cohort of HIV-serodiscordant couples throughout their lives until 
they die, while tracking HIV-1 progression, new infections, pregnancies, PrEP and ART use, 
external partnerships, and DALYs accumulated over time. In this chapter, the model was re-
parameterized using characteristics of couples participating in the Partners Demonstration 
Project. As no data on HIV-1 incidence in the absence of PrEP and ART was available in the 
	  
	  
213 
demonstration project, only demographic characteristics (e.g. age distribution and joint CD4 
count/SPVL distribution), adherence patterns, and sexual behavior characteristics (see 
Chapter 4, section 4.2.3.2) were changed in the model. The trial calibration (see Chapter 4, 
section 4.2.5) was used to produce results. Modelled incidence from our model, using 
Partners Demonstration Project parameters and in the absence of PrEP, was 6.4/100 PY, as 
compared to 5.3/100 PY (95% CI 3.2-7.6/100 PY) in the counterfactual model developed by 
the Partners Demonstration Project team (see Chapter 3, 3.3.2). However, true background 
incidence, without the use of ARVs for prevention, is unknown for these couples. 
As in Chapter 5, three scenarios of ART initiation were modelled – at CD4 counts 
<350 cells/µl, <500 cells/µl, and universal ART. A PrEP intervention is modelled in which 
the HIV-uninfected partner begins using PrEP immediately after being identified, and 
continues using PrEP until the HIV-infected partner initiates ART and for six months 
thereafter – i.e. as a “bridge” to ART. Results compare PrEP intervention scenarios to 
counterfactual “baseline” scenarios with no PrEP use and an equivalent threshold of ART 
initiation. 
 Cost-effectiveness is calculated over the lifetime of the couples from the perspective 
of the health system, in which funds for a PrEP intervention are drawn from the same budget 
that supplies money for ART programs. Two sets of costs are used to evaluate the cost-
effectiveness of the intervention: default costs (in 2012 USD) are $740/PY for ART and 
$335/PY for PrEP, and “ideal” costs are $336/PY for ART and $138/PY for PrEP, which 
include medication costs (ARVs and others), start-up costs, personnel salaries, office 
supplies, transportation, and monitoring (see Chapter 4, section 4.2.6 for the full breakdown 
of cost components). All cost calculations and DALYs are discounted annually by 3%. This 
means that HIV-1 infections averted by PrEP not only prevent the accumulation of DALYs, 
but also avert future ART costs. The timescale of the cost-effectiveness calculation takes 
place over the lifetime of the couples because many of the benefits of a PrEP intervention (in 
terms of DALYs averted by years spent living without HIV, prevention of early death, and 
averted costs from years of ART use) are not reaped until the end of the simulation. A PrEP 
intervention was deemed cost-effective if it fell below $500/DALY averted, which represents 
a realistic willingness-to-pay threshold for sub-Saharan African countries [367], and cost-
saving if it fell below $0/DALY averted. WHO-recommended willingness-to-pay thresholds 
of GDP per capita (very cost-effective) and three times GDP per capita (cost-effective) [315] 
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are also explored for both Uganda and Kenya [368] in order to determine cost-effectiveness 
from a range of perspectives.  
 
6.2.2 Multivariate Sensitivity Analysis 
 
 A degree of uncertainty surrounds a number of key parameters in the model. In order 
to explore the credible parameter space fully, a global multivariate sensitivity analysis was 
conducted using Latin Hypercube Sampling (LHS) [317,372]. LHS is described in detail in 
Chapter 2, section 2.2.3. Briefly, LHS is a form of Monte Carlo sampling in which each 
parameter range is separated into equiprobable intervals and every interval is sampled once, 
without replacement. Parameters are varied simultaneously with each parameter value used 
exactly once, which leads to greater efficiency at exploring uncertainty in parametric space. 
Eleven parameters were varied across credible ranges (Table 6.1). The model was then 
simulated using five hundred parameter sets that were specified using LHS. 
 
Parameter Default Value Range 
Time of finding couplesa Immediate Immediate or at time of couple’s first pregnancy 
Multiplicative factor for monthly frequency 
of condomless sex, compared to 
baselineb 
1 0.5-1.5 
Proportion of PrEP users with mean 
adherence >70%c 70% 0-100% 
Proportion of condomless sex acts 
occurring on the same day as a missed 
PrEP dosed 
7% 1-82% 
Effectiveness of ART for reducing HIV-1 
transmissione 92% [46,79] 75-99% [47,373,374] 
Discount ratef 3% 3-12% [375] 
Hill coefficientg 2.3 [226] 1.5-3.5 
EC50h 43 ng/ml [226] 20-80 ng/ml 
Annual dropout rate from ART programsi 0% 0-5% [294] 
Annual cost of providing ART $740/PY $336-$740/PY [351] 
Annual cost of providing PrEP $335/PY $138-$335/PY [351] 
Table 6.1: Model parameters varied in the multivariate sensitivity analysis. 
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aThe default model assumption is that couples are found shortly after seroconversion, but this 
may be unrealistic. Given that HIV-1 testing occurs at antenatal clinics, and this is one 
channel through which couples are found, an alternative assumption is that couples are not 
identified for PrEP until the woman becomes pregnant [142,376]. 
bReports  of the frequency of condomless sex acts among couples have been shown to vary 
between studies and are potentially subject to recall or social desirability biases [169]. A 
lower estimate would be similar to reported condomless sex in the Partners PrEP Study, 
while a higher estimate account for biases.  
cComparative parameter adjusting the proportion of users with high adherence. In the 
Partners Demonstration Project, approximately 70% of PrEP users had adherence >70%. As 
real world PrEP use is unknown, this parameter was varied across a full range. 
dThis parameter was varied by changing the parameter α (see Chapter 4, section 4.2.5) which 
weights condomless sex acts towards days of adherence or non-adherence. As there is little 
data surrounding the frequency of condomless sex on days of non-adherence, α was varied 
between -1 (more likely for condomless sex acts to fall on days of non-adherence) and 30 
(more likely for condomless sex acts to fall on days of adherence), leading to a calculated 
range of 1-82%. 
eART effectiveness for HIV-1 prevention may vary based on adherence. Changes in 
effectiveness represent credible effectiveness for low adherence and high adherence 
scenarios. 
fChoice of discount rate is variable in health economics analyses. A higher discount rate 
implies that health benefits accrued in the future are less valuable than those gained in the 
present. Common discount rates used in health economics are 3%, 6%, and 12%. 
gThe Hill coefficient describes the slope of the dose-response curve. A low value results in 
shallower slope while a high value produces a steeper slope (see Chapter 4, section 4.2.2.7). 
hEC50 is the concentration at which a drug (in this case tenofovir) demonstrates 50% of the 
maximal response (see Chapter 4, section 4.2.2.7). 
iThe default assumption of 0% dropout from annual ART programs is generous to ART, 
while realistic dropout rates may be higher in sub-Saharan Africa [294,377]. 
 
Given that all parameters were varied simultaneously, it was also important to 
evaluate each parameter’s influence over the resulting outcomes. Partial rank correlation 
coefficients (PRCCs) were used to compare the independent effect of each variable on both 
DALYs averted and the cost per DALY averted. PRCC is a statistical technique that 
measures the monotonic relationship between input variables and outcome variables by 
assessing the correlation between each input parameter and the outcome, while holding all 
other variables constant [317]. PRCC is particularly useful when parameters are 
interdependent, as is the case here (e.g. adherence to PrEP and the frequency of condomless 
sex acts occurring on days of non-adherence). The correlation coefficients allow parameters 
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to be ranked in order of their influence over the outcomes of the analysis, thereby providing 
insight into which parameters are most likely to affect the results substantially. 
Lastly, a cost-effectiveness acceptability curve (CEAC) is constructed in order to 
estimate the probability of a PrEP intervention being cost-effective according to a range of 
willingness-to-pay thresholds [378]. CEACs are increasingly being used to aid policymakers 
in decisions regarding the introduction of a new health intervention [378]. As point estimates 
of cost-effectiveness inevitably contain multiple sources of uncertainty, a CEAC allows for 
the construction of a confidence interval for modelled results using results from a 
probabilistic sensitivity analysis. The curve shows the probability than an intervention will be 
cost-effective according to a given willingness-to-pay threshold by calculating the percentage 
of simulations in a multivariate analysis that fall beneath that threshold. 
 
6.3 Results 
 
6.3.1  Impact and Cost-Effectiveness 
 
 Infections averted and DALYs averted are shown cumulatively over a 10 year time 
horizon for all three ART initiation scenarios and two PrEP efficacy assumptions in Figure 
6.1. PrEP averts the greatest number of infections in an ART initiation scenario at a threshold 
of CD4 counts <350 cells/µl, as PrEP is used by HIV-uninfected partners for a longer period 
of time, on average (~3 years). With ART initiation at CD4 counts <500 cells/µl, PrEP is 
used for a mean time ~1.5 years, and with universal ART, PrEP is used for 6 months within 
each partnership. As PrEP non-adherence rarely coincides with condomless sex, PrEP is 
highly protective throughout this initial period and averts up to 80% of new infections in the 
first year. 
The cumulative number of infections averted declines over time, particularly with 
earlier ART initiation, as PrEP may only postpone – rather than permanently avert – a small 
percentage of infections. This effect is seen to a greater extent when ART initiation takes 
place at lower CD4 cell counts, as more infections have been "averted" prior to ART 
initiation and therefore proportionally more individuals are susceptible to seroconversion 
once the HIV-infected partner is on ART. Fewer DALYs are averted at higher ART initiation 
thresholds not only because a smaller number of infections are averted, but also because 
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individuals starting ART at high CD4 counts do not experience such a high burden of 
"disability" as do individuals with lower CD4 counts.  
In all scenarios, reducing maximum intrinsic PrEP efficacy to 80% (dashed lines in 
Figure 6.1) limits the number of infections averted by the intervention. Reduced intrinsic 
efficacy also has a more deleterious effect when PrEP is used for a longer period of time, as 
repeated risk exposures are less protected by PrEP use and therefore lead to proportionally 
more infections. 
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Figure 6.1: Cumulative infections averted (A) and DALYs averted (B) for three ART 
initiation scenarios and two PrEP efficacy assumptions (solid lines: maximum intrinsic 
efficacy of 100%; dashed lines: maximum intrinsic efficacy of 80%). Results are shown per 
100,000 couples over a 10-year time horizon. 
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 ICERs for the PrEP intervention for three ART initiation scenarios are presented in 
Table 6.2. The ICER is listed as “cost-saving” if the cost of providing a PrEP intervention 
results in a final cost lower than that of the baseline (i.e. the ICER is <$0/DALY averted). An 
exact cost per DALY averted is not listed for point estimates that are cost-saving, as a more 
negative cost per DALY averted does not necessarily represent the ICER with the greatest 
savings and the most DALYs averted. In all scenarios – except those in which ART is 
initiated at <350 cells/µl and PrEP has reduced intrinsic efficacy due to a maximum dose-
response protection of 80% – a PrEP intervention for high-risk couples would be cost-saving 
(Table 6.2), i.e. the overall cost of the intervention is offset by savings in later ART costs and 
the net cost of the intervention is less than that of the baseline. When PrEP is used for a 
longer period of time with lower efficacy, risk is not high enough for the entire time period 
and not enough infections are averted to generate cost savings. 
 
(A) 
Cost Per Infection Averted ($US) 
ART Initiation Threshold <350 cells/µl <500 cells/µl Universal ART 
Assumed 
Costs 
ART $740/PY 
PrEP $335/PY 
Maximum PrEP 
Efficacy Cost-saving Cost-saving Cost-saving 
Reduced PrEP 
Efficacy $2,281 Cost-saving Cost-saving 
ART $336/PY 
PrEP $138/PY 
Maximum PrEP 
Efficacy Cost-saving Cost-saving Cost-saving 
Reduced PrEP 
Efficacy $1,941 Cost-saving Cost-saving 
 
 
 (B) 
Cost Per DALY Averted ($US) 
ART Initiation Threshold <350 cells/µl 
<500 
cells/µl Universal ART 
Assumed 
Costs 
ART 
$740/PY 
PrEP 
$335/PY 
Maximum 
PrEP Efficacy Cost-saving Cost-saving Cost-saving 
Reduced PrEP 
Efficacy $858 Cost-saving Cost-saving 
ART 
$336/PY 
Maximum 
PrEP Efficacy Cost-saving Cost-saving Cost-saving 
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PrEP 
$138/PY 
Reduced PrEP 
Efficacy $730 Cost-saving Cost-saving 
Table 6.2: ICERs over the lifetime of the cohort for the cost per infection averted (A) and the 
cost per DALY averted (B) at the completion of a PrEP intervention for different ART 
initiation thresholds, cost assumptions, and the pharmacodynamics efficacy of PrEP 
(maximum PrEP efficacy = 100% maximum efficacy; reduced PrEP efficacy = 80% 
maximum efficacy). In (B), green shading indicates scenarios in which a PrEP intervention 
could be cost-effective according to a willingness-to-pay threshold of $500/DALY averted. 
 
6.3.2  Comparison to Partners PrEP Study Couples 
 
 
 A PrEP intervention for high-risk couples, such as those enrolled in the Partners 
Demonstration Project, would avert a greater number of infections among than among 
couples like those in the Partners PrEP Study (Figure 6.3). In addition, PrEP is estimated to 
be cost-saving for demonstration project couples in all but two scenarios, whereas no 
scenarios were cost-saving in analyses with lower risk “trial couples,” and only one scenario 
was cost-effective according to a willingness-to-pay threshold of $500/DALY averted. By the 
end of the simulation, PrEP for “Partners Demonstration Project couples” will have averted 
1.2 times, 1.5 times, or 1.8 times as many infections as it would for the same population 
consisting of “Partners PrEP Study couples”, for ART initiation at CD4 counts <350 cells/µl, 
<500 cells/µl, or universal ART, respectively. 
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Figure 6.2: Comparison of infections averted over 10 years among “Partners PrEP Study 
couples” versus “Partners Demonstration Project couples” for three thresholds of ART 
initiation (CD4 counts <350 cells/µl, <500 cells/µl, and universal ART). 
 
6.3.3  Costs of Finding Serodiscordant Couples 
 
 
 As the default calculations of cost-effectiveness do not take into account the potential 
additional costs needed to find high-risk serodiscordant couples, I also examined how much 
the health system could afford to pay to find and recruit each couple for the intervention 
(Figure 6.3). These additional costs might include screening, home-based or self-testing, 
funding for promotional campaigns, clinic time involved in administering the risk score, HIV 
and pregnancy testing and re-testing, and staff salaries, among other costs. 
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Figure 6.3: Influence of the potential cost of finding each serodiscordant couple on the 
resulting cost per DALY averted over the lifetime of the cohort. The black dashed line 
represents a willingness-to-pay threshold of $500/DALY averted. 
 
For an ART initiation threshold at CD4 counts <350 cells/µl, the cost of finding each 
couple could reach $192 for the intervention to remain cost-saving, or a maximum of $296 to 
stay cost-effective. With an ART initiation threshold at CD4 counts <500 cells/µl, a cost 
below $265 and $336 to find each couple would make the intervention cost-saving and cost-
effective, respectively. Finally, for universal ART, the cost of finding a couple would have to 
be below $160 to remain cost-saving, and below $192 to be cost-effective. The steepness of 
the slope of the line is determined by the number of DALYs averted. If more DALYs are 
averted by the intervention (as in the scenario with ART initiation at CD4 counts <350 
cells/µl), an additional increase in cost is less influential over the resulting cost-effectiveness 
of the intervention. 
 
6.3.4  A Cost-Effectiveness Acceptability Curve 
 
 A cost-effectiveness acceptability curve for a PrEP intervention was constructed using 
cost per DALY averted estimates from multivariate sensitivity analysis simulations (Figure 
6.5). If the willingness-to-pay threshold is $0/DALY averted (i.e. the “break-even” point), 
34% of realizations fall below this threshold (and are therefore cost-saving). A PrEP 
intervention in this scenario has a 43% probability of being cost-effective for a willingness-
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to-pay threshold of $500/DALY averted. According to the highest WHO cost-effectiveness 
threshold of three times GDP per capita, the intervention is between 67-78% likely to be cost-
effective in Uganda and Kenya, respectively. 
 
	  
Figure 6.4: Cost-effectiveness acceptability curve for a PrEP intervention in conjunction 
with ART initiation at CD4 counts <500 cells/µl, given a range of willingness-to-pay 
thresholds. The x-axis starts at willingness-to-pay threshold of $0/DALY averted, with the y-
axis value indicating the proportion of simulations equivalent to or below the relevant 
threshold. 
 
The individual results of a multivariate sensitivity analysis consisting of 500 
combinations of eleven parameters (with ART initiation at CD4 counts <500 cells/µl) are 
shown in Figure 6.6. Five willingness-to-pay thresholds are displayed, with the lowest 
$500/DALY averted and higher thresholds – GDP per capita and three times GDP per capita 
– according to WHO guidelines for cost-effectiveness for both Uganda and Kenya. In 
Uganda, GDP per capita from 2000-2014 was $677 [368] (with three times GDP per capita 
equivalent to $2,031), while in Kenya, GDP per capita over the same period of time was 
$1,338 [368] (with three times GDP per capita equal to $4,014). Estimates that fall below 
each willingness-to-pay threshold are deemed cost-effective, according to the respective 
threshold. Compared to the majority of simulations, the point estimate is optimistic, with 
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14,325 DALYs averted at a savings of $26 million for 100,000 couples over the lifetime of 
the cohort. 
 
	  
Figure 6.5: Scatter plot of incremental costs and DALYs averted over the lifetime of the 
cohort from 500 parameter sets in a multivariate sensitivity analysis. Each blue point 
represents the change in DALYs averted and change in cost from baseline simulations 
(equivalent parameters with no PrEP) and the pink point represents the point estimate from 
the default analysis. Linear lines represent different willingness-to-pay thresholds. 
 
6.3.5  Relative Importance of Parameters 
 
 
 From the multivariate analysis simulations, partial rank correlation coefficients were 
calculated in order to determine the relative importance of varied parameters in determining 
outcomes in the model. Tables 6.3 and 6.4 show the PRCCs for the number of DALYs 
averted and the cost per DALY averted over the lifetime of the cohort, respectively. PRCCs 
are presented on a scale of -1 to 1. The sign of the coefficient indicates the direction of the 
association – i.e., negative coefficients result in a lower outcome value as the parameter value 
increases and positive coefficients results in a higher outcome value as the parameter value 
increases. A higher absolute value of a parameter indicates the relative importance of the 
parameter in determining the outcome.  
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Parameter Partial Rank Correlation Coefficient 
Timing of finding couplesa 0.9218 
Discount rate -0.7280 
Background incidence in the absence of PrEP 0.5088 
Effectiveness of ART for HIV prevention 0.4216 
Proportion of condomless sex acts occurring on 
the same day as a missed PrEP dose -0.3092 
ART dropout rate -0.1489 
Proportion of PrEP users with mean adherence 
>70% 0.1365 
Cost of PrEP relative to cost of ART -0.0586 
Hill coefficient -0.0212 
EC50 0.0079 
Table 6.3: Partial rank correlation coefficients for DALYs averted. N.B. p values not 
included because results are derived from model simulations. 
aThe time of finding couples is binary, with a parameter value of 0 equivalent to couples 
being found immediately and a parameter value of 1 equivalent to couples being found at the 
time of the couple’s first pregnancy. 
 
Parameter Partial Rank Correlation Coefficient 
Background incidence in the absence of PrEP -0.2601 
Effectiveness of ART for HIV prevention -0.2221 
Cost of PrEP relative to cost of ART 0.2034 
Proportion of condomless sex acts occurring on 
the same day as a missed PrEP dose 0.1799 
Discount rate 0.1415 
Timing of finding couplesa -0.0901 
Hill coefficient 0.0747 
EC50 0.0459 
ART dropout rate 0.0245 
Proportion of PrEP users with mean adherence 
>70% -0.0042 
Table 6.4: Partial rank correlation coefficients for cost per DALY averted. N.B. p values not 
included because results are derived from model simulations. 
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aThe time of finding couples is binary, with a parameter value of 0 equivalent to couples 
being found immediately and a parameter value of 1 equivalent to couples being found at the 
time of the couple’s first pregnancy. 
	  
Overall, the input parameters are more strongly associated with the number of 
DALYs averted than the ICER, as both the parameters determining cost and those 
determining impact influence the cost per DALY averted. In scenarios in which couples are 
found at the time of their first pregnancy, the average cost is 65% lower, infections averted 
are 77% lower, and the resulting ICER is 32% higher. In terms of DALYs averted, finding 
couples later also severely limits the number of DALYs averted. For couples in which the 
HIV-uninfected partner ever initiates PrEP, this delay is ~2 years on average. With ART 
initiation at CD4 counts <500 cells/µl, 80% of couples never use PrEP as the HIV-infected 
partner initiates ART and achieves viral suppression before a pregnancy occurs. However, 
this postponement of PrEP use has a lesser effect on the cost-effectiveness of the 
intervention; in these scenarios, many fewer years of PrEP are paid for, and even though only 
a small number of infections are averted, the benefit of saving on many future years of ART 
for those averted infections outweighs the very small impact. 
 Four parameters were highly significant for both the number of DALYs averted and 
the cost per DALY averted. The discount rate had a highly significant effect on the number of 
DALYs averted and the cost per DALY averted, as higher discount rates place less weight on 
infections and DALYs averted in the future. Expected background incidence in the absence 
of PrEP also influences the number of DALYs averted and the cost-effectiveness of the 
intervention. When incidence among the couples is high, PrEP has more scope to prevent 
new infections, which results in a greater number of averted DALYs and consequently more 
savings on future years of treatment. The effectiveness of ART for prevention – due to 
assumed differences in adherence – was also highly influential for determining the impact 
and cost-effectiveness. This is important in the years after PrEP use has ceased; if ART is less 
effective at preventing transmission, a proportion of individuals whose infections were 
“averted” by PrEP will later seroconvert while the HIV-infected partner is on ART, thereby 
reducing the number of DALYs averted and the cost-effectiveness by the end of the couples’ 
lifetimes. Finally, the relative frequency of missed PrEP doses on days of condomless sex 
was important as lower adherence around times of sex results in less protection, and therefore 
more seroconversions.  
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6.3.1  One-Way Sensitivity Analysis 
 
 Finally, a number of the most significant parameters from the PRCC tables were 
varied in one-way sensitivity analyses, with a tornado plot of relative costs and DALYs 
averted shown in Figure 6.7. The greatest savings are observed when the cost of PrEP is 
$138/PY and ART costs $740/PY (~20% of the cost relative to ART) and the most DALYs 
are averted when ART effectiveness is 99%. However, the ability of the intervention to be 
cost-saving is compromised particularly if the discount rate is much higher than assumed or if 
the relative cost of PrEP and ART are similar. 
	  
Figure 6.6: One-way sensitivity analysis of important parameters from PRCC analysis. 
Green bars and blue bars represent the incremental change in cost (in millions of $US) and 
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change in DALYs averted associated (in thousands), respectively, for a PrEP intervention 
among 100,000 serodiscordant couples over the lifetime of the cohort. The dashed lines 
represent the estimated change in cost and change in DALYs averted from the default model 
simulation. “Background incidence” indicates HIV-1 incidence in the absence of PrEP. 
 
6.4 Discussion 
 
For high-risk couples in East Africa, a PrEP intervention as a bridge to ART for the 
HIV-infected partner would be a cost-saving method for preventing new HIV-1 infections 
under three different scenarios of ART initiation. Compared to results from the Partners PrEP 
Study, PrEP would have much greater utility when specified for couples with annual HIV-1 
incidence of at least 5.0/100 PY, as specified by a validated risk score [145,379]; among this 
population, PrEP could avert up to 1.8 times as many infections among individuals in the 
cohort over the lifetime of the cohort. The principal determinants of the cost-effectiveness of 
the intervention were HIV-1 incidence in the absence of PrEP, effectiveness of ART for HIV 
prevention, relative cost of providing PrEP and ART, the discount rate, and the frequency of 
PrEP non-adherence occurring simultaneously with condomless sex acts. 
One of the key uncertainties in the model is the cost of finding each high-risk couple 
for the purposes of a PrEP intervention, as our default assumption is that the couples are 
readily available through pre-existing channels (e.g. antenatal clinics, voluntary counselling 
and testing [VCT], or referral through ART programs [142,376]). Evidence from screening of 
couples, using the risk score and identified through these channels, showed that 77% of 
couples scored ≥5 during recruitment for the Partners Demonstration Project, indicating that 
high-risk couples are common among all serodiscordant couples [379]. A number of 
interventions have been shown to improve access to partners of couples, which might be 
viable ways to recruit stable couples for a PrEP program. For example, a study assessing the 
effect of an invitation letter to male partners of antenatal clinic attendees found a 10% 
increase in joint couple attendance and willingness to be tested for HIV [380]. Other studies 
have investigated couples testing, home-based VCT and have found such programs to have 
high uptake, acceptability, and cost-effectiveness in sub-Saharan Africa [381,382]. However, 
such approaches may inherently target lower-risk couples, as those willing to test together 
may already be more likely to use other HIV prevention methods. Given this, other methods 
of identification of high-risk couples (e.g. presumptive PrEP for HIV-negative women 
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engaging in partnerships with men of unknown serostatus) could be necessary. As the PrEP 
intervention is estimated to be cost-saving, our analysis indicates that the program could 
feasibly afford an additional one-time cost up to $192-336 to recruit each couple and the 
intervention would remain cost-effective. 
While adherence to PrEP remains important for the effectiveness of the intervention, 
our results show that adherence need not be perfect in order to generate substantial reductions 
in the number of new infections among couples, provided that risk of acquiring HIV-1 is 
high. Although mean adherence according to MEMS in the demonstration project was 
significantly lower (by approximately 10% overall) than in the idealized setting of the trial, 
this difference was strongly outweighed by the increased risk behaviour and high 
infectiousness (as a consequence of set-point viral load) of the couples in the Demonstration 
Project. Interestingly, in the PRCC analysis, the proportion of PrEP users with mean 
adherence greater than 70% was not as influential for the DALYs averted as other 
parameters, and was the lowest ranked parameter for determining cost per DALY averted, 
though it was varied over a smaller range than the more influential parameters. This is also 
because, in most cases, a small number of condomless sex acts occur on days of non-
adherence, and thus average adherence does not capture the extent to which adherence is 
“prevention-effective” [200]. In keeping with analysis from the Partners PrEP Study, the 
conjunction of condomless sex and missed PrEP doses is a stronger predictor of impact and 
cost-effectiveness than is overall adherence. However, if periods of non-adherence tend to 
occur on or around days of condomless sex, the impact and cost-effectiveness of the 
intervention would be compromised, and the frequency of such behaviour would be a clear 
indicator for PrEP programs of the likely cost-effectiveness of the intervention. Importantly, 
these results show that adherence to PrEP outside of a clinical trial setting is sufficient to 
generate substantial reductions in HIV-1 incidence and be a cost-effective HIV prevention 
strategy within a large cohort of couples. Notably, individual-level risk differs from cohort-
level risk, and instances of low adherence have more influence over outcomes for single 
couples than for the entire cohort. Adherence counseling will continue to be important for 
individuals taking PrEP. 
The strength of the association between ART effectiveness and the cost-effectiveness 
of the PrEP intervention indicates that the strategy of using PrEP as a bridge to ART use for 
the HIV-infected partner is only viable if ART has very high effectiveness for prevention. In 
the model, the parameter for the effectiveness of ART is generalized to take into account 
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imperfect adherence, but the model would benefit from additional resolution concerning ART 
adherence. During periods of non-adherence, HIV-infected individuals may have increased 
infectiousness due to viral rebound, which may not necessarily be constant over time or 
across individuals [383-386]. This analysis is also generous to ART, as no dropout is 
assumed and HIV-infected individuals experience a constant reduction in transmission after 
initiating treatment. In reality, some proportion of HIV-infected partners are likely to be lost 
to the healthcare system or experience dynamic changes in viral load due to adherence. More 
work on related patterns of adherence to ART as well as PrEP would be useful to analyse the 
contribution of ART adherence to the success of PrEP over long time horizons. Nevertheless, 
the overall strength of the association indicates that a combination intervention of PrEP and 
ART should stress high adherence for both partners. 
This analysis has several notable limitations. First, modelled background incidence in 
our baseline scenarios was higher than predicted by simulations conducted by the Partners 
Demonstration Project team [121], which could have led to potentially more optimistic 
estimates of impact and cost-effectiveness. However, a one-way sensitivity analysis in which 
the frequency of condomless sex was adjusted to produce cohorts with different levels of 
incidence found that a PrEP intervention could remain cost-saving with background 
incidence as low as 3.0/100 PY. This suggests that any potential over-estimate of incidence in 
the absence of PrEP did not wholly determine the cost-saving ICER point estimates, though 
reduced incidence in combination with other factors such as lower adherence could 
negatively affect the overall cost-effectiveness. 
A second limitation in the model is the assumption that the couples in the modelled 
cohort remain together for the duration of their lives, which may be unrealistic. For example, 
a study of 469 serodiscordant couples in Kenya found that 24% of the cohort had separated 
within two years of follow-up [387]. This could potentially affect the estimates of impact and 
cost-effectiveness in the sense that the HIV-infected partner’s future partners would either be 
unknown to the PrEP program or would need to be recruited (which could involve additional 
costs). However, if the HIV-uninfected partner remained uninfected at the time of the 
relationship dissolution, PrEP would still have played an important role in preventing 
seroconversion. PrEP programs intended for stable couples should nevertheless seek to 
recruit those couples with the intention to remain together in the future, as a PrEP 
intervention for single heterosexuals could be substantially different in a multitude of ways. 
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While the focus of this work is serodiscordant couples, it will also be important to address the 
issues raised here for other partnerships with higher turnover as well as single individuals. 
Another important caveat to these results is the WHO-recommended guidelines for 
immediate ART initiation for any HIV-infected partner in a serodiscordant couple, regardless 
of CD4 cell count [131]. Firstly, even if the HIV-infected partner in each couple initiates 
ART immediately, PrEP would still be useful and cost-saving during the initial six months of 
viral suppression for the HIV-infected partner. However, our model also assumes that HIV-
infected individuals initiate ART immediately after their CD4 cell counts drop below the 
relevant ART initiation threshold, which is likely to be unrealistic for settings in sub-Saharan 
Africa. For example, a study of East African couples showed that only 50% of adults in a 
serodiscordant couple had initiated ART six months after becoming eligible, and that delays 
in ART initiation were associated with younger age and higher CD4 cell counts [61,388]. 
Such delays in ART initiation, regardless of the threshold, could cause PrEP to be used 
within the couple for a longer time, which would potentially reduce cost-effectiveness. 
On a larger scale, the data collected in the Partners Demonstration Project may not be 
representative of true “real world” conditions and its external validity may not be 
substantially better than a RCT. While demonstration projects are billed as prospective 
feasibility studies, and do have less clinical oversight than RCTs, they also include some 
features that are reminiscent of a rigorous trial. For example, all PrEP users in the Partners 
Demonstration Project used MEMS pill bottles that closely monitored daily adherence and 
attended regular clinic visits. In addition, smaller subsets of individuals responded to daily 
SMS surveys regarding recent PrEP adherence and sexual behaviour and had blood samples 
drawn for analysis of tenofovir detection. Though necessary for the assessment of PrEP 
implementation, such features of the demonstration project could lead to substantial biases in 
reported data. 
PrEP is also only one element of a combination prevention program needed to reduce 
HIV-1 transmission [389], and one step towards the maximization of health and quality of 
life. As PrEP is best utilized during short periods of high risk, lifelong HIV prevention will 
necessarily depend on the strength of other additional methods of prevention, such as male 
circumcision, condoms, and treatment as prevention. Furthermore, while prioritizing PrEP for 
high-risk couples would result in the greatest cost-effectiveness, other factors may and should 
contribute to health policy decision-making [390]. For example, equitable access for all 
serodiscordant couples wishing to use PrEP – regardless of risk score – would need to be 
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ensured, and access to ART for HIV-infected partners in serodiscordant couples should also 
be a priority. Additionally, the preferences of couples themselves would need to be taken into 
account, as the long-term consequences of early ART initiation could lead to reduced quality 
of life, or poorer adherence and retention in ART programs [390]. Finally, our results were 
generated using parameters from low-resource African settings, and they would only be 
generalizable to populations in contexts with similar attributes. 
In summary, a daily oral PrEP intervention could be cost-saving or very cost-effective 
for high-risk serodiscordant couples in East Africa. This intervention has the potential to 
substantially reduce HIV-1 transmission in partnerships where risk of seroconversion is 
elevated, overall adherence is high enough to be “prevention-effective,” and in a setting 
where such couples are easy to identify and willing to use PrEP as at least one strategy for 
HIV prevention. A PrEP intervention for serodiscordant couples merits consideration by 
health policymakers as part of a combination HIV prevention package, particularly because 
other options may be less desirable or of lesser benefit to couples, and PrEP could effectively 
prevent new HIV-1 infections and save costs for this key population. 
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7      Discussion 
 
7.1 Introduction 
 
At the end of the twentieth century, the HIV pandemic sparked an international health 
crisis and, in turn, a global response. In the absence of a vaccine or a cure, researchers and 
policymakers struggled to find effective ways to address the pandemic for both those living 
with HIV and those at risk of acquiring the infection. Now, fifteen years into the twenty-first 
century, optimism about the end of the epidemic [57,86,391] feels warranted, if not 
somewhat premature. Life-saving HIV treatment, which has significantly reduced morbidity 
and mortality, has been extended to over 15 million people, achieving a UNAIDS rollout 
target nine months ahead of schedule [28]. The pace of scaling up male circumcision and 
PMTCT programs has also increased over recent years, though challenges to implementation 
– low demand, insufficient financial resources, and health service barriers, among others – 
have impeded their progress [392-394]. Despite these advancements, HIV-1 incidence 
remains disappointingly high in some populations. New prevention options are desperately 
needed, particularly those suited for key populations (e.g. MSM and FSW) that continue to 
drive new infections in concentrated epidemics and high-risk groups in generalized epidemics 
(e.g. young women and serodiscordant couples). Many of these key populations have faced 
stigma, structural barriers to HIV prevention, or low acceptance of available HIV prevention 
options. 
Promising evidence from RCTs regarding the efficacy of antiretroviral-based HIV 
prevention began to emerge in 2010. After observational studies showed reduced rates of 
HIV-1 transmission individuals taking ART, the HTPN 052 Study demonstrated that ART for 
HIV-infected individuals reduced transmission by 93% over ten years [88]. This discovery 
heralded a shift from the previously competitive priorities of treatment and prevention to 
treatment as prevention [395]. In addition, trials of oral tenofovir-based pre-exposure 
prophylaxis to prevent HIV-1 infection have shown that PrEP is efficacious for MSM, single 
heterosexual men and women, serodiscordant couples, and IDUs [49-52]. Much attention has 
now turned towards investigating the real-world effectiveness and scalability of 
implementing antiretroviral-based prevention through demonstration projects. Early results 
have indicated that PrEP is highly effective when used daily and intermittently among MSM 
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[53,54,242], and has contributed to a 96% reduction in new HIV-1 infections for 
serodiscordant couples when used as a bridge to ART initiation for the HIV-infected partner 
[121]. In addition, new formulations of antiretroviral drugs –including maraviroc [396], 
dapivirine [397,398], and cabotegravir [399]– are being tested in phase I-III clinical trials for 
use as PrEP, in combination with alternative methods of PrEP delivery – such as long-acting 
injectables, vaginal rings, and multipurpose prevention technologies (MPTs) that combine 
contraceptive needs with HIV/STI prevention [400]. 
The development of a suite of diverse HIV prevention tools has become a key step 
towards “bending the curve” of new infections downwards [401]. The global response to the 
epidemic has undergone a substantial transformation since the early uniform prescriptions of 
abstinence, behaviour change, and condoms. This approach has become further specified over 
time, with studies projecting substantial reductions in HIV incidence by tailoring 
combinations of interventions to the needs different geographical “hotspots” [30], 
emphasizing the need for a range of prevention options to fit the preferences of key 
populations [402], and increasing personalization of risk-reduction and adherence counselling 
[60]. Part of this change may be explained by the expanded inventory of the tools available, 
but HIV prevention is also situated in the midst of a broader global health trend towards the 
specialization and personalization of health treatments and programs [403]. Narrowing the 
focus of combination prevention packages to fit specific microepidemics promises to be a key 
strategy for curbing new infections globally [30]. 
Enthusiasm about advances in biomedical prevention has also led to ambitious targets 
of an AIDS-free generation [57] and the end of the HIV/AIDS epidemic through the scale-up 
of ARV-based prevention [29]. Mathematical models have predicted that the HIV epidemic 
could reach an “elimination” phase (i.e. incidence below 0.1%) with rapid scale-up of ART 
through a “universal test-and-treat” approach [92,404]. In 2014, UNAIDS also proposed a 
new “Fast-Track” strategy to end the epidemic by 2030, starting with the goal of getting 90% 
of individuals living with HIV-1 diagnosed, 90% of those who know their HIV-status onto 
ART, and 90% of those on treatment virally suppressed by 2020 [29]. A flood of articles, 
including a cover-page story in the Economist [86], have focused on the prospect of ending 
the epidemic with tools already at hand [405-407], rather than waiting for a “silver bullet.” 
However, some caution should be urged about placing too great of an emphasis on 
biomedical prevention. Current strategies rely on those individuals at highest risk of HIV-1 
infection possessing accurate risk perception and a willingness to engage in HIV prevention 
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strategies. In reality, not all high-risk individuals will want to take PrEP, nor will all HIV-
infected individuals be eager to spend additional years on ART when they are asymptomatic. 
Evidence from two failed studies of PrEP among young African women (FEM-PrEP [94] and 
VOICE [95]) showed that although incidence was shockingly high in these populations, 
many women still elected not to take PrEP, either due to a lack of risk perception, stigma, and 
other health priorities such as contraception [408,409]. In addition, transferring millions of 
individuals onto ART will also result in heavy burdens being placed on healthcare systems of 
resource-poor countries in sub-Saharan Africa [410], which will necessitate increased 
financial backing from governments and international donors. 
In order to optimise the HIV prevention programs to generate maximum impact for 
the lowest cost, policymakers will increasingly need to consult and understand models of 
potential intervention. Mathematical, statistical, and health economics models have become 
increasingly valuable to health policymakers for their assistance with decision-making, when 
faced with a collection of competing, hypothetical interventions. In the process of evaluating 
the 2013 WHO guidelines for ART initiation [23], mathematical modelling was used for the 
first time to inform policy decisions [244]. In addition, model comparison exercises have 
demonstrated broad consistency between separate models, particularly for short-term results, 
which has reinforced their reliability as one aspect of the decision-making process [404,411].  
In this thesis, I have used statistical analysis and mathematical modelling to provide a 
detailed investigation of the ways in which ARV-based prevention can be used and optimised 
among one specific group at high risk of HIV infection in Africa. By bringing together the 
threads of antiretroviral-based HIV prevention, serodiscordant couples, and health 
economics, we can evaluate the optimal uses of ART and PrEP for a key population within 
Africa, and provide important public health considerations concerning the strengths and 
weaknesses of PrEP implementation.  
 
7.2 Key Themes 
 
 From the investigations in this thesis, three central themes have emerged. First, 
prioritizing PrEP use for high-risk couples is important for both increasing impact and cost-
effectiveness (chapters 5 and 6). This can be accomplished by using a risk score to identify 
couples with factors placing them at an elevated risk of transmission [145], or more simply 
by directing interventions to couples under the age of 30. Young heterosexuals in sub-
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Saharan Africa, particularly women in their teens and twenties, have been shown to have 
staggeringly high annual HIV-1 incidence of up to 17.2/100 PY in some high-prevalence 
locations like urban KwaZulu-Natal in South Africa [229]. Likewise, young serodiscordant 
couples have also demonstrated higher incidence than their older counterparts, partly due to 
greater frequency of unprotected sex [153]. The comparison between modelling results from 
Chapters 5 and 6 showed a substantial difference in the absolute number of infections averted 
as well as the cost-effectiveness of a PrEP intervention, which was largely driven by 
prioritizing PrEP for younger couples. Averting one HIV infection among a young individual 
is also of greater benefit to the health system over a long time horizon, as more years of ART 
use are averted. These results are also in keeping with findings from other studies 
highlighting the importance of HIV-1 incidence for determining the cost-effectiveness of a 
PrEP intervention among other populations such as MSM and FSW. As modelling results in 
Chapter 2 demonstrated, the small additional benefit of PrEP for reducing the risk of HSV-2 
acquisition was partially limited due to saturation of HSV-2 among both partners in the 
couples modelled. Given that HSV-2 prevalence is highly age-specific [321], younger 
individuals in serodiscordant couples would be less likely to both be infected with HSV-2, 
and PrEP would therefore might greater scope to prevent new HSV-2 infections in addition to 
HIV-1 infections, though this is still unlikely to affect the cost-effectiveness of a PrEP 
intervention for serodiscordant couples substantially. 
 A second emerging theme is that the relationship between adherence to PrEP and 
cost-effectiveness is complex, and the importance of adherence is dependent on many co-
related factors. When the risk of seroconversion is high, modelling results (Chapter 6) 
showed that a PrEP intervention could be cost-saving, even in light of somewhat lowered 
adherence; i.e., elevated incidence outweighed moderately decreased adherence. This result 
emphasizes the importance of a “prevention-effective” paradigm of adherence for PrEP, 
rather than the uniformly high adherence required for patients on ART [200]. Chapter 5 
confirmed this by showing that the most important indicator of an individual’s risk of 
seroconversion was the number of times that condomless sex occurred with missed PrEP 
doses; in other words, non-adherence is most detrimental when aligned with exposures to 
risk. IPERGAY, a recent study of “on demand” intermittent PrEP among MSM has also 
demonstrated effectiveness of 86% for reducing HIV-1 acquisition, highlighting that 
adherence can be imperfect during periods of abstinence while still providing protection if 
taken around times of sexual activity [53]. It is also important to note that this relationship is 
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dependent on high intrinsic efficacy of PrEP (i.e. efficacy with perfect adherence) and a short 
amount of time needed to reach efficacy, as cost-effectiveness would be compromised if 
PrEP does not have near-perfect protection. Furthermore, the acceptable boundaries of lower 
adherence or the effectiveness of “on-demand PrEP” for heterosexual couples are not clear 
yet. The Partners Demonstration Project may also not be the “moment of truth” for PrEP 
adherence among heterosexual serodiscordant couples; though it has been used as a proxy for 
“real world” adherence in this thesis, true adherence to PrEP may yet be lower. 
The third major theme is that the window of opportunity for PrEP use among 
serodiscordant couples is narrow, both temporally and in regards to the type of couples 
indicated for PrEP. Current WHO guidelines advocate immediate treatment for the HIV-
infected partner in a serodiscordant couple [131]; while our analyses show that PrEP can still 
be a worthwhile and cost-saving intervention during a six-month period of viral suppression, 
PrEP interventions must be considered for near-term use, before current serodiscordant 
couples have fully transitioned onto ART and achieved viral suppression. Our results also 
show that a potential PrEP intervention would be of greatest cost-effectiveness when couples 
are recruited based on a risk score indicating those at highest risk of acquiring HIV-1 [145]. 
Recruitment of such couples may be difficult and add supplementary costs to the estimates 
provided in this thesis, particularly if couples with specific risk characteristics are being 
sought and a large number of couples need to be screened. In previous studies, channels for 
the recruitment of serodiscordant couples included centres for voluntary HIV-1 testing, 
through community promotion of joint couples testing, antenatal clinics, prevention of 
mother-to-child transmission programs, and referral from HIV care for individuals with HIV-
uninfected partners [376,412]. It may be possible that couples naturally present themselves to 
the healthcare system through these channels [351] – and therefore at a low additional cost 
for a potential PrEP intervention – but the resources needed for identifying serodiscordant 
couples are not yet well understood, and will be critical for determining accurate cost-
effectiveness. Most of the results presented in Chapters 5 and 6 take the generous assumption 
that couples are found instantaneously and at no extra cost to the healthcare system. If 
couples are found later, cost-effectiveness is only somewhat modulated (as individuals spend 
less time on PrEP overall), but the magnitude of the benefits of an intervention is 
considerably diminished. It could therefore be valuable to pay an additional cost 
(approximately $300 or less per couple) in order to identify high-risk couples early.  
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7.3 Comparison to Other Work 
 
 Other health economics studies of antiretroviral-based HIV-1 prevention have also 
estimated the potential impact and cost-effectiveness of PrEP for key populations. A number 
of studies predicted the cost-effectiveness of an oral PrEP intervention in combination with 
ART in settings including generalized epidemics among heterosexual men and women in 
southern Africa and concentrated epidemics among key populations in settings across the 
globe [124,125,127,254-260]. 
Assumptions about the effectiveness of PrEP (particularly in studies published before 
all trial results were released), adherence, behavior changes, drug resistance, and 
measurements of costs and cost-effectiveness varied widely between studies [126]. Because 
of these differences in settings and model assumptions, cost-effectiveness estimates are often 
difficult to compare between different models. However, broad themes and consistencies can 
emerge from such a comparison. Overall results from modeling studies showed that PrEP has 
the potential to be cost-effective or cost-saving for serodiscordant couples [125,127], young 
women [258], MSM and transgender women [254,257], and IDUs [413] as well as using 
other strategies of prioritizing PrEP for individuals with the greatest level of sexual-activity 
[124] or by providing time-limited PrEP [414]. 
 The findings in this thesis correspond with other work concluding that, despite the 
high cost of providing PrEP, an intervention could be cost-effective for populations at high 
risk of acquiring HIV-1. In Chapter 5, a PrEP intervention was not cost-effective for couples 
when incidence was 2.0/100 PY, except when ART was universal for infected partners. 
However, when used only among couples recruited using a validated risk score, the 
intervention became cost-saving over the lifetime of the cohort for all ART initiation 
thresholds. Our results provide evidence that a bridge strategy of PrEP can potentially save 
health systems substantial costs and prevent considerably more HIV-1 infections than ART 
alone. For serodiscordant couples, periods of risk are well-defined and may be anticipated in 
advance (e.g. prior to ART initiation for the partner). Furthermore, couples of all ages have 
shown commitment to taking PrEP both within and outside of a clinical trial setting (see 
Chapter 3), which makes them substantially different from the young single women observed 
in southern Africa [95,409]. Notably, the criteria determining what constitutes a “high-risk” 
couple are important and may not be consistent between individuals with similar 
characteristics or over time, which could affect the results presented in this thesis. Couples 
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categorized as “high-risk” according to the risk score could additionally experience variations 
in risk, potentially due to the concentration of the sexual risk period, the type of sex the 
couple engages in (e.g. anal sex versus vaginal sex), or the balance of risk between stable and 
external partnerships. Dynamic fluctuations in risk may be an important consideration for 
future PrEP studies. 
 Several important messages can be gleaned from this group of cost-effectiveness 
modeling studies. One, PrEP has the greatest opportunity to be cost-effective when targeted 
to specific populations with an elevated risk of acquiring HIV-1, rather than to a general 
population of HIV-susceptible individuals. Importantly, even some high-risk populations may 
not benefit adequately from PrEP use, as the population may have already been heavily 
intervened upon by other HIV prevention programs [260]. Two, when PrEP is considered 
alongside other potential HIV prevention interventions, it is not typically the most cost-
effective strategy alone, meaning that in the context of combination prevention, PrEP 
potentially should be prioritized after the scale-up of interventions like male circumcision and 
ART. Three, cost-effectiveness is often limited by the considerable expense of providing 
PrEP, and initial outlays may prevent PrEP from being introduced until patents on ARVs 
expire and generic drugs may be used in their place. 
 
7.4 From Demonstration to Implementation 
 
Evidence thus far has shown that oral PrEP is safe, effective when adherence is high, 
and a desirable prevention option for some groups. The most pressing challenge will now be 
transitioning from evidence to implementation, which will include developing guidance about 
how to roll out PrEP and how to prioritize initial distribution. In particular, resource-limited 
countries will require support in deciding how to allocate PrEP based on geographic hotspots, 
key populations, or individuals at highest risk of infection. The 2012 WHO guidelines on 
PrEP recommended implementation within the context of demonstration projects for 
serodiscordant couples and key populations [137]. Now, in light of the strong evidence of the 
efficacy of oral PrEP and its effectiveness in demonstration projects, revised guidelines have 
been put in place for its use. As of 2015, the WHO has recommended oral PrEP as an 
additional prevention option offered to all individuals at high risk of HIV-1 acquisition (those 
with expected annual incidence >3/100 PY), showing a strong shift towards backing PrEP as 
a prevention option for key populations [24]. In addition, the United States and Kenya 
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currently both recommend offering PrEP as one prevention option for serodiscordant couples 
[243,415] (though PrEP is currently unavailable in practice in Kenya). In light of the backing 
of PrEP from the WHO, the next hurdles will be addressing regulatory issues and barriers to 
implementation.   
 Recent results have allayed many of the behavioural concerns about a potential PrEP 
rollout. Initially, there was apprehension about key populations achieving the high adherence 
necessary to ensure HIV protection, and concern that low adherence could lead to drug 
resistance. Though some populations – particularly young women – had low adherence in 
clinical trials, studies among other key populations (MSM and serodiscordant couples in 
particular) showed substantial reductions in incidence by means of PrEP and commitment to 
remaining HIV-uninfected. In 2015, results from the PROUD Study and IPERGAY, two 
studies of oral PrEP among MSM, showed that adherence was sufficiently high to generate 
an 86% reduction in new infections, easing concerns that adherence would be too low to 
generate impact [53,54]. Furthermore, as oral PrEP has the most evidence for protection of 
any biomedical prevention intervention currently available, strategies to increase acceptance 
of and adherence to PrEP among young women should still be explored [402]. A second 
concern about the introduction of PrEP is risk compensation (i.e. reduced condom use as a 
result of anticipated protection via PrEP), which, theoretically, could outweigh the prevention 
benefits afforded by PrEP [416]. However, no study thus far has shown any evidence of 
increased behavioural disinhibition after beginning PrEP use [99,369]. Furthermore, condom 
use is already low in many key populations, and part of the very rationale behind PrEP is to 
provide an HIV prevention option for individuals for whom pre-existing prevention options 
are insufficient. 
 Nevertheless, implementation of PrEP will need to overcome political and economic 
barriers to rollout. Regulatory issues must be addressed; Truvada (TDF/FTC) is currently 
only licensed for use as HIV prevention in the United States [115], though Truvada’s 
manufacturer, Gilead, has filed applications for the regulatory approval of oral PrEP for 
prevention in Australia, Brazil, South Africa, and Thailand [118]. In addition, uptake of PrEP 
in the United States has been frustratingly slow [128,417,418], with some potential users 
expressing anger about lack of awareness that such a drug existed [129]. Other issues, like 
stigma, cost, and inadequate access to health care have been additional barriers to uptake in 
the United States. In sub-Saharan Africa, past experience with the struggles of scaling up of 
other HIV prevention interventions, such as male circumcision, PMTCT, and PEP, suggest 
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that the challenges facing PrEP implementation may be formidable in resource-limited 
settings [419]. 
The high cost of PrEP could also be a substantial impediment to implementation, 
particularly in the context of settings with competing health interventions and restricted 
budgets [420]. Drug prices are an important barrier to access, and delivery costs associated 
with PrEP use (e.g. allocating resources or task-shifting) could slow the introduction of PrEP 
in some settings. In the current context, a hypothetical PrEP intervention faces competing 
pressures: on the one hand, as this work has shown, the window of opportunity for PrEP use 
is narrow, and on the other, PrEP use could be unsustainable due to expense, while 
potentially displacing funds needed for treatment. Cost-effectiveness analyses also do not 
consider the affordability of introducing an intervention in a given setting. The cost-
effectiveness paradigm is best suited for identifying small tweaks to be made to a health 
system (as a comparison between health benefits gained and costs displaced and the status 
quo), but does not necessarily provide the tools to determine if a new program can be 
introduced in the context of a fixed or restricted budget. A potential PrEP intervention would 
be an entirely new prospect for the health system (as opposed to scale-up of a pre-existing 
program, like ART) and will have a large upfront expense associated with its introduction. In 
order for decision-makers to assess the worth of introducing PrEP, further analyses of 
affordability may be necessary to determine if it would be feasible to introduce, even in light 
of the significant benefits and estimated costs saved in the analysis presented here. 
Relevant principles of ethical allocation of resources may also pose issues for 
prioritizing PrEP for some at-risk individuals above others [421]. An argument can be made 
that serodiscordant couples in which the HIV-infected partner is not virally suppressed satisfy 
the principles of utility (i.e. the greatest gain for the lowest cost) and urgent need (i.e. 
individuals at immediate risk), as an intervention is predicted to be highly cost-effective and 
couples require an alternative prevention solution to those currently available [421]. 
However, such ethical decisions are complex, and policymakers will need to consider which 
principles to apply in order to determine how the resources are allocated efficiently and 
ethically. Additionally, the research presented in this thesis has focused extensively on the 
importance of cost-effectiveness, but this is only one aspect of the decision-making process 
for introducing a new health intervention. For high-income countries considering PrEP, 
willingness-to-pay thresholds will be higher, and an intervention might be introduced on the 
grounds that it provides health benefits to individuals in need. Furthermore, those individuals 
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that qualify as “high-risk” may differ depending on local context, potentially due to 
geographic variations in prevalence, the primary mode of transmission of the epidemic, or the 
goals and budgets of specific governments. In addition, the utility of PrEP for serodiscordant 
couples as a bridge to ART for the HIV-infected partner may change if the now-
recommended goals of universal “test-and-treat” are achieved. 
 Ultimately, oral PrEP is one element of a combination prevention package; it is not 
intended to be used by everyone at risk of acquiring HIV, nor is it intended for lifelong use or 
as a replacement for condoms. Offering oral PrEP to specific populations provides an 
important additional HIV prevention option, and with greater diversity of options, more 
individuals at risk can be reached. A number of alternative forms of PrEP – both new drugs 
and methods of delivery – are in the development pipeline [422]. These include the vaginal 
ring, with results expected in 2016 [397,398], injectable drugs that will provide long-lasting 
doses (1-3 months) of slow-release ARVs, such as cabotegravir [399] and rilpivirine [423], 
and MPTs that combine contraceptives with PrEP. If they demonstrate efficacy, new 
prevention technologies could further expand the options available for at-risk individuals, 
potentially expanding the reach of PrEP to some individuals for whom daily oral PrEP was 
not acceptable. As attention and excitement turns towards new prevention technologies, 
however, the ground-breaking gains of PrEP should not be forgotten, as oral PrEP will still be 
preferable for some individuals and populations. 
For now, future studies of antiretroviral-based prevention should focus on specific, 
concrete steps to take towards the scale-up of oral PrEP. As PrEP is intended for use in 
specific settings, modelling work like that presented in this thesis will be necessary to assess 
likely contributions to impact and cost-effectiveness within a combination prevention 
package. In addition, wider social and political issues raised by PrEP programs – e.g. 
sustainability, scalability, and equal access – will need to be addressed [424]. For couples, 
studies should also investigate the accessibility of couples through different channels, such as 
VCT, antenatal clinics, and referral through ART programs, including the costs associated 
with finding the couples and administering the risk score. More work is also needed on the 
social marketing of PrEP, including optimising campaigns for joint couples testing and for 
increasing awareness about the benefits of PrEP for couples at high risk of HIV transmission. 
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7.5 Future Work 
 
A number of questions regarding the use of antiretrovirals for prevention remain 
unanswered. I intend to continue work on this topic to answer some of these questions in 
several distinct ways. First, the microsimulation model described in Chapter 4 will continue 
to be updated with new adherence data from the Partners Demonstration Project after the 
study has been completed at the end of 2015. This will include incorporating data from 
additional participants in the Partners Demonstration Project’s SMS sub-study of daily 
adherence and sexual behavior (see Chapter 3, section 3.3.2.6), as well as pharmacokinetic 
measurements of tenofovir in plasma at times of risk exposure and measurements of inter-
individual variability. The model will also be adapted to include future work on the dose-
response curve for tenofovir-based oral PrEP among heterosexuals. These additions will 
improve the accuracy of the model and allow further confidence in the results. 
Secondly, detailed patterns of adherence to ART among the HIV-infected partners in 
serodiscordant couples are not considered in this thesis. Representing adherence to treatment 
on the same level as adherence to PrEP is important, and would provide a more balanced 
representation of behavior for both individuals in the couple, as well as insight into the 
optimal strategies of PrEP and ART use for different types of couples. 
Thirdly, I intend to adapt the model here for a population of high-risk young women 
in South Africa in order to compare the resulting impact and cost-effectiveness of several 
different measures of PrEP. The model will be revised to include daily pharmacokinetics and 
pharmacodynamics for cabotegravir, which has a half-life of 21 to 50 days in humans [425] 
and is proposed for quarterly injections [399]. Core components of the model will be varied 
across a range of different measures (i.e. thresholds for ART initiation, plausible PK/PD 
representations, behaviour change, missed doses, duration of time on PrEP, and the costs of 
providing PrEP) in order to explore the full potential of cabotegravir PrEP within this 
population. These analyses will provide insight into the real-world challenges that would 
accompany such an intervention for a different geographic setting and another key 
population. 
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7.6 Conclusion 
 
The research contained in this thesis has shown that antiretroviral-based HIV 
prevention for heterosexual serodiscordant couples in Africa can substantially reduce 
incidence and be cost-effective - or even cost-saving - when targeted to high-risk couples as a 
bridge to partner ART initiation. Evidence from both the Partners PrEP Study and the 
Partners Demonstration Project has shown that adherence to PrEP is high both in the context 
of a clinical trial with unknown PrEP efficacy and a demonstration project with open-label 
use. When PrEP is targeted to couples with high annual HIV-1 incidence (>5.0/100 PY), 
particularly younger couples, an intervention is predicted to be cost-saving despite 
moderately lower adherence. For future PrEP programs for serodiscordant couples, studies 
should investigate the costs of finding and recruiting such high-risk couples in order to ensure 
cost-effectiveness. A daily oral PrEP intervention, in combination with treatment as 
prevention for the HIV-infected partner, would be a useful option for HIV prevention for 
serodiscordant couples in sub-Saharan Africa. 
More broadly, daily oral PrEP fills a specific niche for HIV-1 prevention. For couples, 
using PrEP during a brief period of time prior to partner ART initiation can provide a 
protected transition to a treatment as prevention strategy. For HIV prevention on the whole, 
recent advances in biomedical prevention, compounded with political will and evidence-
based programming, provide reason to believe that the epidemic can be brought under control 
in the decades to come if action is taken swiftly and prevention is directed towards the right 
populations. 
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Abstract
Objective
To estimate the cost-effectiveness of daily oral tenofovir-based PrEP, with a protective ef-
fect against HSV-2 as well as HIV-1, among HIV-1 serodiscordant couples in South Africa.
Methods
We incorporated HSV-2 acquisition, transmission, and interaction with HIV-1 into a microsi-
mulation model of heterosexual HIV-1 serodiscordant couples in South Africa, with use of
PrEP for the HIV-1 uninfected partner prior to ART initiation for the HIV-1 1infected partner,
and for one year thereafter.
Results
We estimate the cost per disability-adjusted life-year (DALY) averted for two scenarios, one
in which PrEP has no effect on reducing HSV-2 acquisition, and one in which there is a 33%
reduction. After a twenty-year intervention, the cost per DALY averted is estimated to be
$10,383 and $9,757, respectively – a 6% reduction, given the additional benefit of reduced
HSV-2 acquisition. If all couples are discordant for both HIV-1 and HSV-2, the cost per
DALY averted falls to $1,445, which shows that the impact is limited by HSV-2 concordance
in couples.
Conclusion
After a 20-year PrEP intervention, the cost per DALY averted with a reduction in HSV-2 is
estimated to be modestly lower than without any effect, providing an increase of health ben-
efits in addition to HIV-1 prevention at no extra cost. The small degree of the effect is in part
PLOS ONE | DOI:10.1371/journal.pone.0115511 January 23, 2015 1 / 11
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due to a high prevalence of HSV-2 infection in HIV-1 serodiscordant couples in South
Africa.
Introduction
Pre-exposure prophylaxis (PrEP) has been demonstrated to be 44–75% effective at reducing ac-
quisition of HIV-1 among uninfected individuals [1–5]. Two recent PrEP trials found that top-
ical tenofovir gel and oral co-formulated tenofovir/emtricitabine (TDF/FTC) also decreased
the acquisition of herpes simplex virus-2 (HSV-2) [1,4]. The CAPRISA 004 trial, which tested
coitally-dependent use of a 1% tenofovir vaginal gel for HIV-1 prevention, found that the gel
decreased HIV-1 incidence by 39% (95% confidence interval [CI] 6–60%), and HSV-2 inci-
dence by 51% (95% CI 22–70%) [1]. Subsequently, the Partners PrEP Study found that daily
oral TDF/FTC decreased acquisition of HIV-1 by 75% (95% CI 55–87%) and HSV-2 by 33%
(95% CI 2–54%) in heterosexual HIV-serodiscordant couples [4,6,7]. HIV-1 serodiscordant
couples have emerged as a potential key population for implementation of a PrEP intervention,
given their sustained exposure to risk, need for additional prevention strategies in addition to
condoms, and high adherence to PrEP [8].
In sub-Saharan Africa, high prevalence of both HIV-1 and HSV-2 infections has long been
considered a factor in facilitating the transmission of the HIV epidemic [9–11]. HIV-1 and
HSV-2 interactions are synergistic; the presence of one facilitates both the acquisition and on-
ward transmission of the other [12,13]. Persons infected with HSV-2 are two to three times
more susceptible to acquiring HIV-1, and HSV-2/HIV-1 co-infection is associated with higher
HIV-1 infectiousness and faster HIV-1 disease progression [11,14]. Aside from the use of con-
doms, there are few effective primary prevention interventions to lower the risk of HSV-2 ac-
quisition. Suppressive therapy for HSV-2 reduces the recurrence of genital ulcers and decreases
transmission of HSV-2 in HIV-1 uninfected, HSV-2 serodiscordant couples by 48% [15], but
the same effect was not observed in HIV-1 serodiscordant couples [16]. No HSV-2 vaccine has
demonstrated efficacy in reducing HSV-2 acquisition [17]. Contracting HSV-2 can also have
serious consequences for pregnant women; if acquired during the last trimester, the infection
can be transmitted to the neonate during birth, and subsequently result in high rates of disabili-
ty or the death of the infant [18]. This is particularly a concern in populations with high fertility
rates in young women who are also susceptible to HSV-2 infection. The additional findings of
the Partners PrEP Study on the HSV-2 effect therefore generated further enthusiasm that a
PrEP intervention could increase health benefits for the same cost and potentially provide an
unanticipated dual benefit by protecting against both HIV-1 and HSV-2.
We had previously modeled the impact and cost-effectiveness of oral PrEP for HIV-1 in
South Africa, with no assumed effect on HSV-2 transmission [19]. This study found that a
PrEP intervention among HIV-1 serodiscordant couples could be a cost-effective HIV-1 pre-
vention strategy in South Africa. Given the observed efficacy of daily oral TDF/FTC PrEP
against HSV-2, it is important to reassess the cost-effectiveness of PrEP in terms of disability-
adjusted life-years (DALYs) based on both HIV-1 and HSV-2 efficacy. We provide revised esti-
mates of the cost-effectiveness of PrEP for HIV-1 serodiscordant couples by incorporating the
additional benefit of the protective effect of PrEP against HSV-2 acquisition.
Methods
An existing microsimulation model [19] was revised to incorporate HSV-2 transmission, neo-
natal HSV-2 infection, and the interactions between HIV-1 and HSV-2 (Figure S1 in S1 Text),
and was parameterized for South Africa [20]. Briefly, the model follows a set of heterosexual
Cost-Effectiveness of PrEP for HIV-1 and HSV-2 in Couples
PLOS ONE | DOI:10.1371/journal.pone.0115511 January 23, 2015 2 / 11
content is the responsibility of the authors and does
not necessarily represent the official views of the
National Institutes of Health. The funders had no role
in the study design and analysis, decision to publish,
or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
	  
	  
272 
 
 
 
 
 
 
HIV-1 serodiscordant couples, and tracks progression of HIV-1, ART initiation, transmission
of HIV-1 and HSV-2 within the couple–including to and from any external partners–and
HSV-2 transmission from a woman to her infant at birth [18]. HSV-2 infection is assumed to
have a constant low-level infectiousness that is not attenuated by ART [21]. The model is pa-
rameterized using data from the Partners in Prevention HIV/HSV Transmission trial, which
took place among HIV-1 serodiscordant couples in 7 countries, including 3 sites in South
Africa, from 2004–2008 [20,22]. In the trial, only couples in which the HIV-1 infected partner
was also infected with HSV-2 were enrolled, and in 69% of trial couples, both partners were al-
ready infected with HSV-2. The model simulates only the trial couples, potentially neglecting a
small sub-section of South African couples in which the HIV-1 infected partner is HSV-2 unin-
fected, in order to fit to the sex-specific HIV-1 and HSV-2 prevalence and incidence observed
in the trial.
An intervention was simulated. From the time that the HIV-1 serodiscordant couple is
“identified,” the HIV-1 infected partner in each couple initiates ART when their CD4 cell
count falls below 350 cells/μl and the HIV-1-uninfected partner takes daily oral PrEP until
their partner initiates ART and is assumed to achieve HIV-1 viral suppression (i.e. for one year
following ART initiation), an approach which is consistent with current ART guidelines in
South Africa. Intervention scenarios were compared to a baseline scenario of ART initiation at
CD4 counts below 350 cells/μl, with no PrEP. DALYs were used to summarize health loss and
gain, and can accrue through different stages of HIV-1 infection, HSV-2 infection, and the dis-
ability or death of infants as a result of neonatal HSV-2 [23,24]. A summary of key assumptions
are available in Table 1, with further information about the model structure and parameters,
including DALY weights, available in the online technical appendix (Tables S2-S3 in S1 Text).
If an individual was infected with both HIV-1 and HSV-2, DALY weights for the respective
stage of each disease were summed. The HIV-1 uninfected partner in the couple is assumed to
be 90% adherent to PrEP, and TDF/FTC PrEP is assumed to be 90% efficacious against HIV-1
and 33% efficacious against HSV-2, giving an overall protective effect similar to that observed
in the trial (Figure S2 in S1 Text). We assumed that efficacy of PrEP against HIV-1 was very
high, given that PrEP efficacy with consistent adherence has been estimated at close to 100% in
the iPrEx and Partners PrEP trials [3,25–27]. Serodiscordant couples observed in an adherence
sub-study of the Partners PrEP trial also demonstrated very high adherence overall, and thus
the functional effectiveness of PrEP in the model reflects observations from the trial [26].
The calculation of the cost per DALY averted takes the perspective of the health care system
(unless stated otherwise), in which gains from averted HIV-1 infections benefit the system by
saving on later years of ART. Each result is the mean from a set of 100,000 simulated couples,
and all costs and impacts are discounted at an annual rate of 3%.
Results
Fig. 1 shows the cost per DALY averted for the same PrEP intervention over a 20-year time ho-
rizon; the only difference is the effect of TDF/FTC PrEP on HSV-2 acquisition (0% or 33% effi-
cacy). The cost per DALY averted after 20 years for a PrEP intervention with no assumed effect
against HSV-2 is estimated at $10,383, and a 33% protection against HSV-2 yields an estimate
of $9,757–a reduction of $626 (6%). Over the first seven years of the intervention, the cost per
DALY averted drops dramatically for both scenarios, due to the accumulation of averted HIV-
1 and HSV-2 infections. For PrEP with a 33% protective effect against HSV-2, the intervention
is cost-effective according to the WHO’s cost-effectiveness threshold for three times GDP per
capita after seven years, and for one times GDP per capita after 17 years [28]. DALYs related to
neonatal HSV-2 make up less than 1% of total DALYs, and the benefit of reduced HSV-2
Cost-Effectiveness of PrEP for HIV-1 and HSV-2 in Couples
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Table 1. Key assumptions and parameters used in the model.
Parameter Values Source
Infectiousness of untreated individuals (relative to those with CD4
count ! 500 cells/μl
CD4 350–500: 1.00 Cohort of stable serodiscordant couples [34]
CD4 200–350: 1.59
CD4 0–200: 4.99
Mean time spent in CD4 cell count category (y)a Infection to CD4 of 500:
2.4
Pooled analysis of African observational cohort studies
[38]
CD4 350–500: 2.4
CD4 200–350: 4.6
CD4 0–200: 2.6
Relative infectiousness of those on ART (relative to those
untreated with CD4 cell count <350 cells/μl)
0.08 Cohorts of stable serodiscordant couples [34,35]
Mortality rates on ART (per year) Multiple observational cohort studies [39–41]
First year:
ART initiation at CD4 500+ 1.3%
ART initiation at CD4 350–500 2.5%
ART initiation at CD4 200–350 5%
ART initiation at CD4 0–200 10%
Subsequent years:
ART initiation at CD4 500+ 1.3%
ART initiation at CD4 350–500 1.3%
ART initiation at CD4 200–350 2.5%
ART initiation at CD4 0–200 5%
Drop-out from ART (per year) First year: 10%;
subsequent years: 5%
Observational data from programs in Zambia [42]
PrEP efﬁcacy against HIV-1 90% Consistent with the range of efﬁcacy reported in PrEP
trials after taking adherence into account [3,4,26]
PrEP efﬁcacy against HSV-2 33% Partners PrEP trial [7]
PrEP adherence 90% Consistent with overall adherence reported in a sub-
study of adherence in the Partners PrEP trial [26]
Multiplicative factor for increased susceptibility to HIV-1 if HSV-2
infection >1 year (prevalent HSV-2 infection)
3.0 Systematic review and meta-analysis of longitudinal
studies [11]
Multiplicative factor for increased susceptibility to HIV-1 if HSV-2
infection <1 year (incident HSV-2 infection)
6.0 Assumed increase in susceptibility due to frequency of
ulcers during primary HSV-2 infection [43–46]
Multiplicative factor for increased susceptibility to HSV-2 among
those with HIV-1 infection
3.7 Cohort of adults in Uganda [13]
Multiplicative factor for increased transmission of HIV-1 among
those with HIV-1/HSV-2 co-infection
3.0 Systematic review and meta-analysis of longitudinal
studies [11]
Multiplicative factor for increased transmission of HSV-2 among
those with HIV-1/HSV-2 co-infection
4.0 Cross-sectional study of HIV-1/HSV-2 co-infected
women [47]
Relative reduction of acquisition of HIV-1 due to condoms per sex
act, with respect to baseline transmission probabilityb
100% Assumed
Relative reduction of acquisition of HSV-2 due to condoms per sex
act, with respect to baseline transmission probabilityb
75% [48]
Relative reduction of acquisition of HIV-1 due to circumcision per
sex act, with respect to baseline transmission probabilityb
65% [49]
Relative reduction of acquisition of HSV-2 due to circumcision per
sex act, with respect to baseline transmission probabilityb
28% Cohort of HIV-1 and HSV-2 uninfected men [50]
Probability of acquisition of neonatal HSV-2 if mother acquires
HSV-2 in last trimester
33% Cohort of pregnant women with HSV-2 infection [18]
(Continued)
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incidence averts 8% of DALYs related to neonatal HSV-2 compared to PrEP with no effect on
HSV-2. The inset shows the difference in the number of averted DALYs between the two PrEP
scenarios over time, with a greater differential towards the end of the hypothetical 20-year in-
tervention period due to the accumulated benefit of averted HSV-2 infections and clinical
Table 1. (Continued)
Parameter Values Source
Probability of acquisition of neonatal HSV-2 if mother’s HSV-2 is a
reactivation
3% Cohort of pregnant women with HSV-2 infection [18]
Probability of child death with neonatal HSV-2 65% [51]
Given child survival, probability of child disability with neonatal
HSV-2
80% [51]
Full cost per year of ART US $515 [52,53]
Full cost per year of PrEP US $250 [19,54]
aMean time elapsed between entering category (CD4 cell count reaching value of upper bound) and exiting category (CD4 cell count drops below value of
lower bound).
bBaseline transmission probability is from an asymptomatic, non-pregnant woman to an uncircumcised man.
doi:10.1371/journal.pone.0115511.t001
Figure 1. Difference in cost per DALY averted for two PrEP scenarios. The discounted cost per DALY averted for a 20-year PrEP intervention with no
assumed protection against HSV-2 acquisition and with 33% protection (both relative to a baseline scenario of no PrEP and ART initiation at a CD4 count of
350 cells/μl). The inset is the difference between the two scenarios in the mean number of DALYs averted per couple over the intervention period. The
horizontal lines represent WHO thresholds for cost-effectiveness at three times GDP ($34,320) and one times GDP ($11,440) for South Africa.
doi:10.1371/journal.pone.0115511.g001
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consequences thereof. At the end of the 20-year intervention, however, the vast majority of the
DALYs averted by the intervention originate from preventing new HIV-1 infections, and the
overall added benefit of averting HSV-2 infections makes a minimal contribution.
Fig. 2 shows univariate sensitivity analyses for several factors that contribute to uncertainty
in the cost per DALY averted estimates, in which each factor is compared to a baseline cost of
PrEP with an HSV-2 protective effect of 33%. The degree of the protective effect of PrEP
against HSV-2, using the 95% confidence intervals from the Partners PrEP trial, has a minor
additional impact on overall cost-effectiveness compared to other factors. Varying the protec-
tion against HSV-2 acquisition yields a range of $8,853–$10,355, for 54% and 2% efficacy, re-
spectively. A lower cost per DALY averted are associated with increased thresholds for ART
initiation, due to individuals spending less overall time on PrEP and greater ART savings from
averted HIV-1 infections. PrEP can also be more cost-effective in scenarios in which all couples
are dually discordant for HIV-1 and HSV-2–i.e. one partner has both infections and one has
neither–or if the couples engage in higher-risk behaviors, e.g. reduced condom use and more
unprotected sex. If PrEP is only taken during 50% of unprotected sex acts, the cost per DALY
averted more than doubles, as the same number of person-years of PrEP are being used, but
Figure 2. Sensitivity analysis for factors affecting the cost per DALY averted.Univariate sensitivity analysis for factors affecting the cost per DALY
averted at the end of a 20-year PrEP intervention, with a baseline assumption of a 33% protection against acquisition of HSV-2 (the vertical line at $9,757).
The bars titled ART Initiation CD4<500 and ART Initiation Immediately assume increased thresholds for ART initiation. The bar titled PrEP Adherence
assumes HIV-uninfected individuals are 50% adherent to PrEP. The bar titled PrEP Protection Against HSV-2 explores the confidence intervals of the
protective effect of HSV-2 from the Partners PrEP Study. The bar titled All Couples HIV-1 & HSV-2 Discordant simulates the same intervention among a set
of couples in which one partner is dually infected with HIV-1 and HSV-2 and the other partner has neither infection. The bar titled Higher-Risk Couples
assumes men are equally as likely to be the HIV-1 infected partner, condom use is reduced by 75%, 50%more couples have external partners, and the
frequency of unprotected sex in external partners is doubled, in comparison to the demographic and behavioural characteristics of the South African HIV-1
serodiscordant couples who were enrolled in the Partners in Prevention HSV/HIV Transmission Study. The bar titled Cost of PrEP Per Year explores the cost
per DALY averted if PrEP costs $150/PY or $350/PY, and the PrEP Program Cost Perspective bar assumes that the cost of the PrEP intervention is separate
from funding for treatment, and does not include savings from reduced ART need due to averted HIV infections.
doi:10.1371/journal.pone.0115511.g002
Cost-Effectiveness of PrEP for HIV-1 and HSV-2 in Couples
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the impact is greatly reduced. Finally, if the intervention is funded separately to ART programs,
the program is less cost-effective, and if PrEP costs are lower or higher than assumed, the cost
per DALY averted changes linearly with respect to the price of PrEP. A multivariate sensitivity
analysis was also carried out using Latin Hypercube Sampling, in which 400 parameter sets
varying adherence to PrEP and the efficacy of PrEP on HSV-2 were evaluated in 24 different
scenarios. This analysis yielded a spectrum of the cost per DALY averted ranging from a low of
$486 per DALY averted to a high of $5.6 million per DALY averted (Table S4 in S1 Text). The
highest costs per DALY averted resulted from extremely low adherence (2%), in which funds
are being spent on PrEP with a negligible impact in terms of averted HIV-1 and HSV-2 infec-
tions. This wide interval suggests that the true cost per DALY averted for a hypothetical PrEP
intervention in this population is uncertain.
Discussion
Over a 20-year period, the efficacy of TDF/FTC PrEP to prevent new HIV-1 infections domi-
nates the combined impact of PrEP on reducing HIV-1 and HSV-2 infections. The protective
effect against HSV-2 has useful public health advantages, particularly given the lack of effective
prevention strategies for HSV-2, but will not materially affect the cost-effectiveness of PrEP in
HIV-1-serodiscordant couples. This is in part due to the relatively mild health consequences of
HSV-2 in comparison to HIV-1; preventing HSV-2 incidence does not avert early death or
years of severe morbidity in the same way that preventing acquisition of HIV-1 does. However,
HSV-2 prevention is a potentially valuable supplementary benefit of PrEP, particularly in pop-
ulations with lower HSV-2 prevalence than HIV-1 serodiscordant couples. Averting HSV-2
infections in women may also be especially valuable for the health system, given the risk of neo-
natal HSV-2 for pregnant women in their last trimester and the risk of serious morbidity and
mortality for infants with primary HSV-2 infection. However, neonatal HSV-2 infection is a
rare occurrence in itself, and the reduction in HSV-2 acquisition due to PrEP only protects a
small fraction of women and their children from such an occurrence in a setting where HSV-2
prevalence is already high. Although HSV-2 treatment was not explicitly modeled in this analy-
sis, the reduction in new HSV-2 infections may additionally benefit the health system by de-
creasing the need for HSV-2 treatment medications, such as acyclovir and valacyclovir.
In South Africa, as well as throughout sub-Saharan Africa, dual infection with HIV-1 and
HSV-2 is high and acquisition of HSV-2 often occurs early in sexual activity, regardless of
HIV-1 status [29,30]. HIV-1 serodiscordant couples are often identified after HSV-2 infection
has already occurred (Table S1 in S1 Text) [22,31]; therefore, oral PrEP that provides partial ef-
ficacy against both HIV-1 and HSV-2 could demonstrate greater impact and improved cost-ef-
fectiveness in other populations. Primary prevention interventions like PrEP would have
greater potential impact in reducing HSV-2 incidence in younger populations who have lower
HSV-2 prevalence than serodiscordant couples. In the CAPRISA 004 trial among young
women in South Africa, for example, incidence of HSV-2 was very high at 20.2 per 100 PY in
the placebo arm [32], suggesting a greater opportunity for effective prevention of HSV-2 than
in HIV-1 serodiscordant couples. A modelling study of the impact and cost-effectiveness of
tenofovir gel among young women in Gauteng province in South Africa has also predicted that
introducing coitally-dependent microbicide PrEP would be highly cost-effective, at less than
$300 per DALY averted [33]. This intervention may be of more benefit in a population of
young women simultaneously susceptible to HSV-2 and HIV-1 infection, and also at high risk
of pregnancy. Although our analysis did not demonstrate a large effect in the cost-effectiveness
of PrEP for HIV-1 serodiscordant couples, further modelling of oral PrEP is needed to investi-
gate impact and cost-effectiveness in other populations, such as young women.
Cost-Effectiveness of PrEP for HIV-1 and HSV-2 in Couples
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The cost per DALY averted is also dramatically reduced if the threshold for ART initiation
is raised to CD4 counts<500 cells/μl or to immediate ART initiation upon a positive HIV-1 di-
agnosis. In these scenarios, HIV-1 uninfected partners in the couples spend less time on PrEP
overall, and averted HIV-1 infections save a greater number of years of costly ART treatment.
As early ART demonstrates greater cost-effectiveness than PrEP, earlier ART initiation may be
preferable to a PrEP intervention in this population from a cost-effectiveness point of view.
However, an important consideration for interventions in serodiscordant couples is the extent
to which they can be considered “stable,” given that 25–30% of HIV transmission among cou-
ples has been shown to originate from an unlinked source [34,35]. If a substantial proportion
of HIV-1 infections do indeed come from external partnerships, PrEP would be a preferable
option to earlier ART. The preferences of couples themselves should also be taken into consid-
eration, and some couples might choose to have the HIV-1 uninfected partner take PrEP, rath-
er than earlier ART for the HIV-1 infected partner [36], especially if the couple is dually
discordant for HIV-1 and HSV-2.
In South Africa, PrEP prioritized for serodiscordant couples could also make a useful contri-
bution to HIV-1 prevention for less overall budgetary impact than early ART. In the South Af-
rican sites in Partners in Prevention HIV/HSV Study, 27.4% of couples tested were HIV-1
serodiscordant [37], which may indicate hundreds of thousands of individuals for short-term
PrEP use. Unlike early ART initiation, PrEP can be used as a prevention mechanism during
“seasons of risk” only–e.g. during brief intervals of time during which the couple is trying to
conceive and cannot use other prevention measures such as condoms–and does not necessarily
require provision of costly medication for years. PrEP might be a useful addition to the combi-
nation prevention options currently available in South Africa, particularly in scenarios when
earlier ART initiation means that fewer years of PrEP use are necessary. As with all cost-effec-
tiveness analyses, our analysis does not consider affordability and it is not clear whether the
WHO-recommended threshold represents the opportunity cost of displaced resources
for health.
Ultimately, the additional benefit reaped by averting a small percentage of HSV-2 infections
in HIV-1 serodiscordant couples leads to a modest decrease in the cost per DALY averted over
a 20-year PrEP intervention. The magnitude of this benefit does not suggest a substantial de-
parture from our previous understanding of the impact and cost-effectiveness of an oral PrEP
intervention in this population, but may make such an intervention more appealing for HIV-1
serodiscordant couples–particularly those who are discordant for both HIV-1 and HSV-2–
given this secondary beneficial effect.
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Appendix B – Additional Results for Chapter 3 
 
	  
	  
Figure 1: Distribution of maximum consecutive days of non-adherence in the Partners PrEP 
Study AAS, including cessation of PrEP. The light blue shaded area represents the 
cumulative distribution function (CDF) of the data. 
 
	  
	  
Figure 2: Distribution of maximum consecutive days of non-adherence in the Partners 
Demonstration Project, including cessation of PrEP. The light blue shaded area represents the 
cumulative distribution function (CDF) of the data. 
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Appendix C – Additional Figures for Chapter 4 
 
	  
	  
Figure 1: Data-model comparison of adherence distribution for each age- and sex-specific 
category. A = Females 15-24, B = Females 25-34, C = Females 35-44, D = Females 45+, E = 
Males 15-24, F = Males 25-34, G = Males 35-44, H = Males 45+. 
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Figure 2: Data-model comparison (orange bars = data; red bars = model) of the mean 
number of consecutive days of adherence by age and sex category, with 1 lapsed day 
considered a “break” in the sequence. 
 
 
Figure 3: Data-model comparison (orange bars = data; red bars = model) of the mean 
number of consecutive days of adherence by age and sex category, with a lapse of 2 or more 
days considered a “break” in the sequence. 
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Figure 4: Determination of number of couples needed to simulate to reduce stochastic noise. 
k=1,000; m=million. 
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Appendix D – Components of the Risk Score 
 
Reference 
Kahle EM, Hughes JP, Lingappa JR, et al. An empiric risk scoring tool for identifying high-
risk heterosexual HIV-1 serodiscordant couples for targeted HIV-1 prevention. Journal of 
acquired immune deficiency syndromes (1999). 2013; 62(3):339-347. 
doi:10.1097/QAI.0b013e31827e622d. 
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Figure 1: HIV-1 acquisition risk score worksheet. 
 
(1) Age of HIV-1 uninfected partner
20 years or less
21-30 years
More than 30 years
4
1
0
(2) Number of children
0
1-2
3 or more
2
1
0
Yes
No
1
0
(3) Male HIV-1 uninfected partner uncircumcised
Yes
No
1
0
(4) Married and/or cohabiting
Yes
No
2
0
(5) Unprotected sex within partnership, prior 30 days
(6) HIV-1 plasma viral load, HIV-1 infected partner
50,000 copies or higher
10,000-49,999 copies
Less than 10,000 copies
3
1
0
TOTAL SCORE
